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Abstract
Macrophage inflammatory protein-1 alpha (MIP-la) is a member of the chemokine 
superfamily and has been observed to inhibit the proliferation of transiently engrafting 
stem cells, namely the colony forming unit-agar (CFU-A) stem cells. This study was 
initiated to investigate how M IP-la exerts its inhibitory effect on these cells at the 
genetic level and, to examine whether altering the growth factors required for CFU-A 
colony formation could interfere with the inhibitory activity of M IP-la.
The results presented in this thesis indicate that growth factor alteration has minimal 
effects on the inhibition of CFU-A colony formation. However, low levels of M IP-la 
in the presence of high levels of SCF or M-CSF have been observed to stimulate 
colony formation. This stimulatory activity of M IP-la has been previously observed 
on progenitor cells however, it has never been reported on stem cells. Furthermore, 
alternatively shaped CFU-A colonies have been observed in assays containing high 
levels of both GM-CSF and MIP-la. These results indicate that although the growth 
factors in the context of this assay can not interfere with the inhibitory signal of MIP- 
l a  they may however interact with the other M IP-la signalling pathways.
Although in the CFU-A assay SCF and IL-11 could not interfere with the inhibition of 
CFU-A colonies by M IP-la, it was observed that upon the ex-vivo expansion of bone 
marrow, with SCF and IL-11, that the inhibitory activity of M IP-la was reduced. 
This effect was observed to be specific for M IP-la, as TGF-p inhibition of CFU-A 
colony formation was not affected, and was proposed to be due to the down regulation 
of the M IP-la inhibitory receptor. Indeed analysis of M IP-la receptor expression 
indicated that CCR-1 was up-regulated whereas CCR3 and D6 were both down 
regulated, however neither CCR-3 nor D6 proved to be involved in M IP-la inhibition 
of CFU-A colony formation. Therefore this study observed that in the context of the 
CFU-A assay that M IP-la inhibitory signalling pathway is robust and minimally 
interacts with SCF, M-CSF, GM-CSF, IL-11 and LIF signalling pathways.
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CHAPTER 1 : INTRODUCTION
i
i
i
| 1.1 The Haemopoietic System : An Overview
i
I The haemopoietic system is a complex cellular system, which is essential for the
maintained viability of an individual. It consists of at least eight, phenotypically and
I functionally distinct mature cells with an overlapping set of more immature cell types
(figure 1.1). All immature cells and mature blood cells are ultimately derived from 
the self-renewing pluripotent stem cell through the processes of commitment, 
proliferation and differentiation. The mature blood cells have well characterised 
morphologies and functional properties. Indeed, erythrocytes are responsible for 
oxygen and carbon dioxide transport, megakaryocytes generate platelets necessary for 
clotting the blood; T and B cells contribute to immune surveillance and 
responsiveness; and macrophages and granulocytes aid in the disposal of invading 
micro-organisms and damaged tissue. A necessary property of the haemopoietic 
system is the capacity to regenerate mature cells and therefore maintain steady state 
levels. It has been estimated that to maintain homeostasis in humans, the 
haemopoietic system must replace approximately 2.4 xlO8 red blood cells and 4 xlO6 
neutrophilic lymphocytes cells each day (Erslev 1983, Dancey et al 1976). Such 
demands necessitate strict control over haemopoietic progenitor proliferation and this 
is regulated by the various factors produced in the bone marrow microenvironment 
(section 1.7). These PHSC cells reside within the bone marrow and are defined as 
being able to self renew and give rise to all lineages of blood cells (Till and 
McCulloch 1960). This definition can be applied to a number of cells within the 
haemopoietic system, thus allowing one to refer to the primitive end of the system as 
the stem cell compartment (section 1.2 and figure 1.2). Stem cells only make up a 
tiny proportion of the cells in the haemopoietic system, probably between 0.01-0.1 % 
of the total bone marrow and the majority of these stem cells are quiescent (Hodgson 
et al 1982). Under steady state conditions, the quiescent stem cells play a minimal 
role in haemopoiesis and constitutive haemopoiesis is thought to be maintained by the 
more mature stem and progenitor cells. However, under haematological stresses such 
as blood loss, infection and exposure to cytotoxic chemicals, the stem cells can be 
rapidly induced into cell cycle to replenish the mature cell compartment and this is
1
Figure 1.1 Overview of Haemopoiesis
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Fig 1.1 Overview o f haemopoiesis
A schematic representation o f  the haemopoietic system, depicting a few o f  the precursor cells that are 
involved in the production o f  the mature blood cells. CFU-GM Colony Forming Unit-Granulocyte 
macrophage, BFU-E Blast Forming Unit-Erythroid, CFU-E Colony Forming Unit-Erythroid, CFU- 
Meg Colony Forming Unit M egakaryocyte, NK Natural Killer .
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known as inducible haemopoiesis. Following the replenishment of the system, these 
stem cells once again become quiescent.
These observations suggest that the HSC is under both positive and negative 
proliferative regulation and that the overall proliferative state of the HSC is dependent 
upon the levels of these two opposing activities (sections 1.7 and 1.9).
1.2 The Stem Cell Compartment
The variation in cell cycling properties, and self renewal capacity of the CFU-S stem 
cells, lead Rosendaal et al (Rosendaal et al 1976) to suggest that the stem cell 
compartment is organised in a hierarchical structure. Young stem cells that have 
undergone few divisions having extensive self-renewal capacity and a lower 
differentiation drive are near the primitive end of the system, whereas, the older stem 
cells that are more mature, have the opposite properties of the young stem cells in that 
they are limited in their self-renewal capacity, and have a greater tendency to 
differentiate.
Using various in-vivo and in-vitro assays, it has been demonstrated that at the 
primitive end of the haemopoietic system are a range of overlapping cell types that 
display the characteristics of stem cells, but differ in their relative abilities to self 
renew and differentiate. These findings have lead to the definition of the primitive 
end of the system as the stem cell compartment and one can imagine the stem cell 
compartment represented as a pyramidal structure (figure 1.2). At the top of the 
triangle are the most primitive cells, the pluripotent haemopoietic stem cells, these 
cells display a high self-renewal capacity, repopulating ability and are most resistant 
to differentiation and proliferation stimuli. As one goes further down the stem cell 
compartment, the cells display a reduced tendency to self-renewal with a concurrent 
increase in capacity to differentiate, and the mature blood cells are found at the base 
of the pyramid. Therefore, the stem cell compartment is a heterogeneous 
compartment consisting of cells displaying varying degrees of self-renewal capacity 
and/ or differentiation potential (Graham et al 1992a).
3
Figure 1.2 : The Stem Cell Compartment
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Fig 2.1 The Stem Cell Compartment
A schematic representation o f  the stem cell compartment. The LTC-IC and LTR have the greatest self­
renewal and long term repopulating abilities, whereas the stem cells downstream  o f these have more 
proliferative potential and have lower self-renewal capacities. The progenitor assays depicted under 
the triangle also have high proliferative capacity and give rise to mature cell colonies in agar or 
m ethylcellulose, from where they get their name. The traingle is split into two parts, which define the 
long (grey triangle) and short term repopulating potential o f these parts o f  the stem cell com partm ent, 
both o f  which are needed for long term survival after marrow ablation by chemotherapy.
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The stem cell compartment can be further simplified within the murine system based 
on the abilities of the members of the stem cell compartment to confer engraftment of 
the haemopoietic system after lethal irradiation. Lethal irradiation of a mouse will 
ensure death as a result of the ablation of the haemopoietic system due to the 
attendant bone marrow failure. However, it is possible to rescue these irradiated mice 
by giving them a bone marrow transplant, during which the transplanted bone marrow 
cells replenish the damaged system, allowing the mouse to survive.
The stem cell compartment can be divided into 1) very primitive stem cells or long 
term repopulating cells and 2) less primitive stem cells or short term repopulating 
cells, that display distinct functional roles following transplantation (figure 1.2). 
Following irradiation of a mouse, the administration of only the less primitive stem 
cells rescue the mouse from radioactive insult, however, the mouse will die after 4-6 
weeks from bone marrow failure. This indicates that the less primitive stem cells are 
only capable of transiently engrafting the murine haemopoietic system and can only 
protect against the initial radioactive insult. These cells are known as the transient 
engrafting cells, short term repopulating cells or radio-protective stem cells and 
typically have only limited differentiation potential (Jones et al 1990). In contrast, the 
administration of the very primitive stem cells following irradiation fails to rescue the 
mouse. The very primitive stem cells have no short term repopulating ability and do 
not protect the mouse against the radioactive insult. Therefore, to rescue a mouse and 
allow for haematological recovery, the combination of these two populations is 
needed. The less primitive stem cells act initially to allow the mouse to recover from 
the radioactive insult and during this time the very primitive cells seed within the 
bone marrow, and after a period of 4 to 6 weeks start to contribute to the 
haemopoietic system of the transplanted mouse. Thus the long-term repopulating 
stem cells allow the mouse to survive long term and as they are pluripotent, they are 
capable of generating both lymphoid and myeloid cells (Jones et al 1990, Uchida et al 
1994).
1.3 Isolating Haemopoietic Stem Cell
There are numerous separation techniques used to enrich for haemopoietic stem cells, 
for example, stem cells can be enriched by their physical properties using density 
gradient centrifugation. This was demonstrated by Boyum et al (Boyum 1968) who
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produced a one step centrifugal technique for isolation of various leukocytes 
(LymphoPrep™), this was modified in 1983 to isolate mononuclear cells from species 
other than humans. Both LymphoPrep™ and NycoPrep™ remove erythrocytes by 
sedimentation and the majority of mononuclear cells can be found separated at the 
interface of the plasma layer and the NycoPrep™ solution (Boyum 1983). Counter 
flow centrifugal elutriation (CCE) is another centrifugation method used for 
separating different cellular populations and separates large numbers of cells, 
primarily on the basis of size and density. The cells are placed in a rotating chamber, 
and as they reach equilibrium, the smaller cells migrate to the centre of the chamber 
while the larger ones sediment towards the outer end and, with alterations in flow rate 
of the elutriation, cells of different sizes can be collected (Jones et al 1990).
Alternatively, the isolation of stem cells can be performed by examining the cell 
surface expression of various markers, such as lectins or cellular antigens via 
antibodies conjugated to fluorescent markers or, by the incorporation of vital dyes 
such as Rhodamine 123 or DNA binding dyes such as, Hoechst 33342. The basis of 
fluorescence activated cell sorting (FACS), is to label cells with one or a number of 
fluorescent markers and to use these to select a specific cellular population. Using a 
flow cytometer, this is performed on the basis of size and granularity and the 
heterogeneity of the fluorescent intensity of the population. Although there are no 
monoclonal antibodies available yet that exclusively recognise HSCs, these cells have 
been enriched by capitalising on multiple cell surface characteristics such as 
expression of c-kit (Okada et al 1991), Thy-1 (Muller-Seiburg et al 1986), Sca-1 
(Spangrude et al 1988), CD34 (Sutherland et al 1992) or binding to wheat germ 
agglutinin (WGA) (Ploemacher et al 1988).
Although the use of various antibodies to surface antigens has allowed the separation 
of cellular populations that display stem cell characteristics, the relevant functional 
role of the expression of some of these antigens on PHSC is not so obvious. In an 
attempt to examine the function of these antigens, several groups have produced mice 
that do not express these various antigens.
Sca-1 or Ly-6A is expressed on most peripheral lymphocytes, as well as haemopoietic 
stem and progenitor cells (Shevach et al 1989), and surprisingly, analysis of Sca-1 
null mice by flow cytometer demonstrated that these animals had normal levels of all
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haemopoietic lineages in bone marrow, spleen, lymph node, and thymus, thereby 
demonstrating that Sca-1 is not necessary for haemopoietic development. However, it 
was observed that the T cells from these animals proliferate at an increased level 
compared to that of wild type cells, thereby suggesting that Sca-1 may be essential for 
regulation of T cell proliferation (Stanford et al 1997).
CD34, another supposed marker of PHSC activity, has been observed to be expressed 
on a heterogeneous population of haemopoietic cells which include primitive 
haemopoietic stem cells and committed progenitors of the myeloid, lymphoid and 
erythroid lineages (Sutherland et al 1992). The analysis of the function of CD34 in- 
vivo was performed by generating CD34 null mice by homologous recombination. 
These mice were observed to have a delay in myeloid and erythroid development and 
a reduced colony forming ability of their progenitor cells from the yolk sac and fetal 
liver. Furthermore, the colony forming potential of the haemopoietic progenitors 
from these mice (CFU-GM, CFU-GEMM and BFU-E) is reduced and these 
progenitor cells could not be expanded by the combination of SCF, FL, EPO and GM- 
CSF treatment however, in spite of these haemopoietic abnormalities the adult mice 
still display normal levels of mature blood cells. These results suggest that CD34 is 
involved in the proliferation and the maintenance of haemopoietic progenitor cells in 
the embryo and the adult mouse (Cheng et al 1996), however, the normal levels of 
mature blood cells in CD34 null mice suggest that CD34 may not be essential for the 
development of all haemopoietic lineages. Several other reports have observed PHSC 
activity in a CD34' cellular population, and upon stimulation of this CD34' population 
with growth factors, these cells become CD34+, suggesting that CD34 may be a 
marker of activation in these PHSCs (Osawa et al 1996, Morel et al 1998).
Naturally occurring mutations in mice resulting in the lack of the stem cell factor SCF 
receptor (c-kit) have rendered the production of c-kit null mice by homologous 
recombination unnecessary. The absence of c-kit in these mice, results in death in 
utero as a result of severe anaemia and analysis of non-lethal mutations within the c- 
kit or W locus have indicated a further role for c-kit in the fertility and pigmentation of 
these mutant mice. On further examination of the bone marrow of W /W  mice 
(Russell 1979), it was observed that these mice had fewer colony forming units spleen 
(CFU-S), burst forming unit erythroid (BFU-E), colony forming unit granulocyte 
macrophage (CFU-GM), and colony forming unit erythroid (CFU-E) than their litter
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mate controls (Barker 1994). The reduction in progenitor cells and the lethal anaemia 
in the various c-kit mutant mice, indicate that c-kit as well as being a marker for 
PHSC may also play an important role in the survival and regulation of various 
haemopoietic cells and therefore, may be a more functionally relevant marker of 
PHSC than CD34 or Sca-1. However, more recent studies in the human and murine 
systems have observed that PHSC activity can also be isolated in a cellular population 
that is c-kit' (Sogo et al 1997, Doi et al 1997, Ortiz et al 1999). Therefore, although 
Sca-1, CD 34 and c-kit have been historically accepted as markers for isolating PHSC 
activity, it may be that their expression is not needed for the functional activity of 
these cells. It may even be possible that a definitive marker for the PHSC does not 
exist. However, following the intravenous introduction of haemopoietic stem cells, 
they find their way to the bone marrow with great accuracy. Therefore, it seems that 
these HSC carry certain cell surface molecules that are specific for counter 
receptors/ligands within the bone marrow stroma, thus indicating that there may be an 
as yet, unknown surface molecule that could be used as a marker for PHSC.
1.4 In-vitro Assays
Due to the difficulty in distinguishing stem cells on the basis of their morphology, 
much of what we know about stem cells has been learnt through the development and 
use of in-vitro assays. The basis of these in-vitro assays, is the fact that clonogenic 
bone marrow cells cultured in the presence of appropriate growth factors give rise to 
colonies in semi-solid culture, without the addition of supporting stromal cells. The 
precise combinations of cytokines and their concentrations vary from assay to assay, 
as does the size, morphology and cellular composition of these colonies, and these 
colony characteristics can be used to give an indication of the level of primitiveness of 
the cell from which they were derived. A number of in-vitro assays have been 
reported that detect a range of cells within the haemopoietic stem cell compartment. 
However, the precise relationship between these cells and the roles they play in 
normal steady-state haemopoiesis in-vivo is still uncertain. These assays have 
however, enabled identification of several primitive stem cell types and haemopoietic 
regulatory factors, a number of which are described in sections 1.41, 1.42 and 1.43 
also see figure 1.2.
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1.4.1 High Proliferative Potential-Colony Forming Cells (HPP-CFC) Assays
In 1979, Bradley and Hodgson described an in-vitro clonogenic assay, which detected 
a primitive stem/progenitor cell population termed, High Proliferative Potential 
Colony Forming Cells (HPP-CFC). These HPP-CFC cells form large macrophage 
colonies in agar culture that have diameters greater than 0.5 mm and contain 
somewhere in the region of 50000 cells per colony. The formation of HPP-CFC 
colonies was initially observed to be produced by synergistic interactions between M- 
CSF and crude conditioned media (CM) sources of other factors (Bradley and 
Hodgson 1979). However, with the use of recombinant growth factors, HPP-CFC 
stem cells could be subdivided into HPP-CFC-1, 2 and 3 (McNiece et al 1986). HPP- 
CFC-1 is the most primitive HPP-CFC sub-population, as indicated by their 
quiescence, their resistance to 5-FU and their ability to generate HPP-CFC-2 sub­
population upon stimulation with SCF and M-CSF (McNiece et al 1986). These 
HPP-CFC-1 cells correlate closely with pre-CFU-S cells (Hodgson and Bradley 1984) 
and have been reported to generate CFU-S dl2, cells of the megakaryocyte and 
granulocyte/macrophage lineages (McNiece et al 1987). Unlike HPP-CFC-1, that 
require IL-1, M-CSF and IL-3 for growth (McNiece et al 1987, HPP-CFC-2 and 3, 
colonies can be produced upon stimulation with only IL-3 / M-CSF and M-CSF 
respectively. Furthermore, HPP-CFC-2 and 3 numbers are depleted with 5-FU 
treatment, indicating that they are more mature and less quiescent than HPP-CFC-1 
stem cells (McNiece et al 1987,1988).
1.4.2 Colony Forming Unit-Agar (CFU-A) Assay
In 1988, Pragnell et al first described an in-vitro clonogenic assay that detects a 
transiently engrafting cell with similar characteristics to the CFU-S day 12 (Pragnell 
et al 1988). In this assay, bone marrow cells were grown in agar and medium 
supplemented with horse serum and a source of synergistic growth factors. These 
growth factors were, initially in the form of conditioned media (CM) from L-929 cells 
and AF-19T cells that produced M-CSF and GM-CSF respectively. The assay was 
further refined using recombinant growth factors, alongside M-CSF and GM-CSF, a 
further inclusion of SCF was required to produce similar numbers of CFU-A colonies 
seen with CM. This assay is incubated for 11 days, and under these conditions
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macroscopic colonies of between 2-5 mm in diameter are produced, each of which 
contained on average 1-4 xlO4 cells. The incidence of CFU-A stem cells in normal 
bone marrow is 150-220/105 cells, although this varies slightly depending on the 
strain of mice (Lorimore et al 1990). Lorimore and colleagues characterised the 
CFU-A cell by comparing its properties with those of multipotential CFU-S dl2 cells 
and the lineage restricted progenitor cells, GM-CFC. They observed that CFU-A and 
CFU-Sdl2 cells displayed an identical recovery profile after a single dose of 5-FU, 
and that CFU-A and CFU-S cells derived from bone marrow were found to be out of 
cycle (<10% in S phase), and those derived from regenerating bone marrow were 
actively cycling (30% in S phase). Both CFU-A and CFU-Sdl2 cellular populations 
responded identically when they were exposed to a proliferation inhibitor or 
stimulator and also displayed similar responses to ionising radiation. The similarity 
of CFU-A and CFU-Sdl2 was further evident in experiments examining the cell 
separation of these cells on the basis of their density distributions and of their radial 
distribution in the femur (Lorimore et al 1990). Thus, the murine CFU-A and CFU-S 
d l2  were shown to detect a similar transiently engrafting stem cell within the stem 
cell compartment, and interestingly, the CFU-A assay has also been reported to detect 
cells that can be detected by the more mature HPP-CFC assays. The CFU-A assay 
has been useful in the investigation into growth stimulators and inhibitors, indeed 
Graham et al used this assay to isolate and characterise the stem cell inhibitor, MEP- 
la , and is routinely used in our laboratory (Graham et al 1990).
1.4.3 Long Term Culture Initiating Cells (LTC-IC)
In human and murine long-term bone marrow cultures, it has been observed that 
clonogenic progenitors rapidly undergo terminal differentiation (Sutherland and Eaves 
1993, Kerk et al 1985). As a result, the initially present primitive progenitors 
disappear within the first 4 weeks, and the clonogenic progenitors detected at later 
times represent the progeny of more primitive precursors cells called long term 
culture initiating cells (LTC-IC). LTC-IC are present in normal bone marrow at a 
frequency of about 1/ 2xl04 nucleated cells and represent the most primitive stem cell 
detected in-vitro. A unique feature of the LTC, is its ability to better support the 
maintenance and proliferation of haemopoietic cells with stem cell characteristics, 
than standard colony assays. This is not only due to the production of growth factors 
needed for the extended haemopoiesis which is characteristic feature of LTCs, but
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also to the supportive function provided by the feeder layer. Irradiated adherent 
layers from LTC, established with previous samples of normal (allogenic) bone 
marrow cells or alternatively murine fibroblast cell lines, can be used as a source of 
feeder layers in LTC. Human LTC-IC have a limited life span of approximately 2-5 
weeks in long term bone marrow culture, however, a more recent study by Verfaillie 
observed that diffusable stromal factors from a stromal non contact assay, and the 
addition of M IP-la and IL-3, allowed these human LTC-IC cells to survive for up to 
2 months (Verfaillie et al 1995).
1.5 In-vitro Progenitor Assays
Progenitor cells are more lineage restricted cells and are capable of forming colonies 
that contain single or multiple cell types, and are named according to the type of cell 
that they give rise to in in-vitro colonies. Within the myeloid lineage, there are a 
number of progenitor cell assays that recognise the progeny produced by various 
progenitor cells in semi-solid assays. These include granulocyte, erythrocyte, 
megakaryocyte, macrophage colony forming unit (CFU-GEMM), granulocyte/ 
macrophage colony forming unit (CFU-GM), macrophage CFU (CFU-M), 
megakaryocyte CFU (CFU-Meg), the burst forming unit erythroid (BFU-E). A more 
recent study by Akashi et al, for the first time, described a method for isolating 
multipotential progenitors and committed progenitors from long term and short term 
repopulating stem cells. Indeed, they isolated a common myeloid progenitor (CMP) 
that can mature into two further committed progenitors, namely a granulocyte/ 
macrophage progenitor (GMP) and a megakaryocyte/ erythrocyte progenitor (MEP). 
These committed progenitors can terminally differentiate and produce granulocytes, 
macrophages, megakaryocytes and erythrocytes respectively (Akashi et al 2000). 
This study may lead to the further identification of the progenitor cells, such as BFU- 
E and CFU-M, whose existence has only been known due to their ability to produce 
colonies in semi-solid media, and to a better understanding of lineage commitment 
and the role each of these progenitors plays in haemopoiesis.
1.6 Bone Marrow Microenvironment
Mechanisms that govern induction of the quiescent state, proliferation and 
differentiation of primitive haemopoietic progenitors are not well understood. In-vivo
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haemopoiesis takes place in close proximity with the bone marrow microenvironment 
where haemopoietic stem cells reside. This process is mimicked relatively closely in- 
vitro by the stroma-dependant long term bone marrow cultures (LTBMC), which were 
initially described by Dexter et al (Dexter et al 1977), and for human cells by 
Mergenthaler and Dormer (Mergenthaler and Dormer 1990). Initial evidence 
suggested that stem cells and progenitors bind to the stroma, whereas more mature 
cells are found as non-adherent cells in the supernatant (Coulombel et al 1983). 
However, Verfaillie indicated that although contact between HSC and stromal was 
observed to be initially needed, this dependency on contact can be replaced by 
diffusable soluble stromal factors and the addition of growth factors in a stroma non 
contact assay (Verfaillie et al 1994).
The long-term bone marrow cultures (LTBMC) have proved useful for modelling the 
structure of the stromal microenvironment, and the various interactions between the 
stromal cells and the haemopoietic stem cells. Indeed, within the bone marrow, the 
stem cells reside in regulatory niches consisting of various cell types such as 
endothelial cells, fibroblasts, adipocytes and macrophages. Stromal cells not only 
produce growth factors, they also produce a wide range of extracellular matrix 
molecules (ECM) such as, collagens, fibronectin, tenascin and cellular adhesion 
molecules (CAMs) e.g. I-CAM-1, VCAM-1, and integrins (VLA-4) which provide a 
supportive milieu for the stem cells allowing them to function.
The extracellular components of the multiple cell types such as fibronectin, collagen 
and tenascin-C are reported to play a role in the interaction of the HSC and the 
stroma. Indeed, antibodies specific for fibronectin have been observed to inhibit the 
formation of CFU-S dl2  in LTBMC (Williams et al 1991c), and tenascin-C specific 
antibodies have the ability to block the adhesion of HPCs to stroma (Klien et al 1993). 
Fibronectin has also been observed to increase the production of CFU-E, BFU-E and 
CFU-GEMM colonies derived from human bone marrow, and can further increase 
their formation in the presence of IL-3 (Zhou et al 1993). Further evidence for the 
role of these ECM proteins was observed upon the analysis of their respective null 
mice. Fibronectin null mice are unable to form blood islands in the embryo and are 
therefore embryonic lethal (George et al 1993) whereas, Tenascin-C null mice are 
viable and have a reduced level of haemopoiesis, suggesting that Tenascin C may play 
a role in the interactions between the haemopoietic stem cells and the stromal cells
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(Ohta et al 1998). These studies indicate that the interaction of stem cells and stromal 
cells via ECM molecules may be important in the regulation of stem cell functions, 
and are reviewed by Whetton and Graham (Whetton and Graham 1999).
Glycosaminoglycans such as heparin, heparan sulphate and chondroitin sulphate are 
expressed on stromal cells and the various populations of stem/ progenitor cells, and 
are thought to be involved in interactions between these cells. Indeed, heparan 
sulphate (HS) has been observed to be involved in the adhesion of primitive 
haemopoietic progenitor cells (Siczkowski et al 1992), and has been observed to bind 
both growth stimulating and inhibiting factors, such as IL-3, GM-CSF and TGF-p, 
(Roberts et al 1988a, Lopez-Casillas et al 1993). Furthermore, a report by Gupta et al 
indicated that the HS in combination with cytokines could maintain levels of human 
LTCIC cells in long-term bone marrow cultures (Gupta et al 1996). Therefore, these 
reports suggest that HS may regulate stem cell activity by being involved in co- 
localising progenitors with heparin binding cytokines in the ECM or alternatively they 
may act as a presentation molecule for various growth factors such as fibroblast 
growth factor (Omitz et al 1992, Faham et al 1998).
A further type of molecule involved in interactions between the stem cells and the 
stromal cells within the bone marrow microenvironment are adhesion molecules. 
Both stromal cells and HSCs have been observed to express large number of CAMs, 
including members of the integrin superfamily (VLA-4, 5), the sialomucin family 
(CD34, CD45RA, CD43 and CD164) and immunoglobulin family (CD31 and CD50), 
as well as ligands for selectins (Simmons et al 1997). Evidence for the role of these 
adhesion molecules in regulating haemopoiesis was initially observed by the fact that 
antibodies to VLA-4 added to LTBMC abrogated lymphopoiesis, reduced CFU-S dl2 
cell production and the level of myelopoiesis (Williams et al 1991c, Miyake et al
1991). Antibodies to VLA-4 have also been observed to mobilise stem cells to the 
peripheral blood (Craddock et al 1997), and B cell precursors have been shown to 
adhere to bone marrow fibroblast through the interaction of VLA-4 and VCAM-1 
(Ryan et al 1991). Furthermore, the disruption of the a4-integrin gene was observed 
to lead to impaired T and B lymphopoiesis in mice (Arroyo et al 1996). These results 
suggest that VLA-4 plays a major role in the interaction between HSC and stromal 
cells. Other studies have also indicated a role of adhesion molecules in the bone 
marrow microenvironment. Indeed, Bazil and colleagues suggested that mucin like
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molecules may function as negative regulators of haemopoiesis. They observed that 
antibody mediated cross linking of the mucin CD43 induced apoptosis in the CD34+ 
haemopoietic progenitor cells, and that the multipotential (CFU-GEMM) and 
erythroid progenitors (BFU-E) were more sensitive than committed progenitors 
(CFU-M) (Bazil et al 1995). Furthermore, another member of the mucin family 
CD 164 is also involved in adhesion of HSC to stroma (Watt et al 1998) and was 
found to induce apoptosis and suppress the recruitment of quiescent haemopoietic 
stem cells into cell cycle (Zannettino et al 1998). Thus, these various studies indicate 
the important role of adhesion molecules in the regulation of stem cell function within 
the bone marrow microenvironment.
In addition to providing an adherent surface for the stem cell to sit down on, the stem 
cell niche produces a range of soluble and transmembrane localised growth factors 
and their receptors, such as SCF, M-CSF, c-kit and c-fins. The interaction of these 
growth factors and their receptors is not only involved in stem cell function, they also 
display a range of activities on a number of additional cell types and these are 
discussed in the next section.
1.7 Growth Factors
The continual production of blood cells during an individuals lifetime, is mediated by 
the co-ordinated effects of a number of cytokines and growth factors acting on the 
haemopoietic stem and progenitor cells within the bone marrow. The small number 
of haemopoietic stem cells can proliferate and differentiate into lineage committed 
progenitors which eventually generate all the different kinds of mature terminally 
differentiated blood cells. Among such growth factors, SCF and FL are involved in 
survival of early haemopoietic stem cells, interleukin-3 and GM-CSF stimulate multi­
lineages of haemopoietic cells while M-CSF, G-CSF and EPO stimulate more 
restricted lineages of the haemopoietic system. Each of these growth factors and their 
actions within haemopoiesis are described in the sections below, as SCF, M-CSF and 
GM-CSF are involved in CFU-A colony growth these have been described in more 
detail.
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1.7.1 Tyrosine Kinase Signalling Growth Factors
1.7.1.1 Stem Cell Factor (SCF)
Stem Cell Factor (SCF) is the gene product of the murine Steel (SI) locus and the 
ligand for the c-kit tyrosine kinase receptor, the product of the dominant white 
spotting locus (W). Despite the SI locus being localised to chromosome 10 and the W 
locus on chromosome 5 defects at these genetic loci result in similar phenotypes. 
These are characterised by white spots on the bellies of pigmented mice, which is due 
to the inability of the melanocytes to migrate to the hair follicle. Furthermore, these 
mice have reproductive difficulties and are anaemic, due to the ineffective migration 
of the germ cells and the reduction in the number of erythrocytes respectively. Due to 
similar phenotypes produced by these separate mutations researchers hypothesised 
that there was a relationship between these two loci. Indeed, in 1988 two groups 
found that the W locus encoded a tyrosine kinase receptor known as c-kit (Chabot et 
al 1988, Geissler et al 1988), and subsequently the cDNA corresponding to SCF was 
isolated from different sources, this lead to the protein being named in accordance to 
its source, mast cell growth factor (MGF), stem cell factor (SCF) and c-kit ligand 
(Huang et al 1990, Martin et al 1990, Williams et al 1990b). Within this thesis this 
protein will be referred to as SCF. Although the mouse and human proteins are 82 % 
identical at the amino acid level they show varying degrees of species specificity 
indeed, the full-length mouse protein is active on human cells whereas, the human 
SCF has limited activity on murine cells (Martin et al 1990). As a results of 
alternative splicing there are two major isoforms of SCF in mice and humans, a 
membrane associated glycoprotein of 248 amino acids (aa) which is rapidly cleaved to 
release a biologically active soluble protein of 164 aa and a glycoprotein of 220 aa 
which lacks the proteolytic cleavage site encoded in exon 6, and thus remains 
predominantly membrane associated. Interestingly, this isoform can also be slowly 
released from the cell surface through the use of an alternative proteolytic cleavage 
site (Flanagan and Leber 1990). More recent studies have indicated that proteolytic 
enzymes from mast cells can cleave SCF thus producing alternative SCF products of 
various lengths. This was hypothesised to be a possible method of regulating the 
activity of SCF on the mast cells or may even allow the production of another SCF
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isoform that has distinct activities on these mast cells (Longley et al 1997, dePaulis et 
al 1999).
Stem cell factor can be expressed by various different cell types such as fibroblasts, 
stromal cells, keratinocytes, gut endothelial cells and the cells of the central nervous 
system (Longley et al 1993, Linenberger et al 1995, Klimpel et al 1995, Zhang et al 
1998a). Interestingly, Huang et al observed that there is tissue specific expression of 
the different SCF isoforms and thus hypothesised that SCF function may differ 
depending upon whether the target cell expressing the SCF receptor interacts with the 
soluble or membrane bound isoforms (Huang et al 1992). The analysis of the 
phenotypic abnormalities of Steel-Dickie (Sf)  mice together with analysis of the 
biological activity of the soluble and membrane forms of SCF have indicated that the 
membrane form of SCF is necessary for normal phenotype in these mice (Toksoz et al
1992). Furthermore Toksoz et al also observed that membrane associated SCF 
supported long term production of primitive haemopoietic progenitors in-vitro, 
whereas only a transient maintenance of haemopoiesis was observed with soluble 
SCF (Toksoz et al 1992). Further evidence for the distinct roles of membrane bound 
and soluble forms of SCF was reported in transgenic Sl/S? mutant mice expressing 
either soluble or membrane restricted SCF. Indeed, the membrane restricted SCF 
isoform could partially correct the anaemia associated with these mice whereas the 
soluble form could not, however, in contrast the soluble SCF isoform and not the 
membrane restricted form was observed to restore the myeloid progenitor cell 
numbers (Kapur et al 1998,1999).
SCF is a multifunctional cytokine that displays activities on mast cells, melanocytes 
germ cells, and a whole number of haemopoietic cells such as stem cells, progenitor 
cells and mature cells. SCF has the ability to act as a survival factor in the absence of 
other growth factors. Indeed, SCF inhibits apoptosis in NK cells, murine myeloid and 
mast cell lines (Carson et al 1994, Gommerman et al 1998) and also allows the 
survival of both murine and human primitive haemopoietic stem cells (Keller et al 
1995, Borge et al 1997). SCF is widely expressed in embryogenesis and along with 
its receptor c-kit they play a role in the migration and the correct tissue localisation of 
primordial germ cells, melanocytes and hematopoietic stem cells (Matsui et al 1990, 
Keshet et al 1991). Although SCF acts alone in the survival of stem and progenitor 
cells there are numerous studies that indicate that SCF acts in combination with
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various growth factors in a wide range of functions. Indeed, SCF can act together 
with IL-3 to expand the numbers of progenitor cells, such as BFU-E, CFU-GM and 
colony forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU- 
GEMM) by 200 fold in liquid culture (Brugger et al 1993). Furthermore, culturing of 
murine marrow cells in a cytokine cocktail (SCF, IL-3, IL-6 and IL-11) expanded the 
number of progenitor cells, low proliferative potential colony forming cells (LPP- 
CFC) and HPPCFC, but impaired the long term repopulating ability (Peters et al 
1996). As well as SCF synergy with various growth factors in the expansion of cell 
numbers, SCF also synergises with EPO, IL-3, GM-CSF, TPO, IL-6, IL-7 and G-CSF 
to increase both size and number of BFU-E, CFU-GM, CFU-GEMM and CFU-Meg 
colonies in semisolid media. However, alone SCF has only modest effects on colony 
growth (Avarham et al 1992, Briddell et al 1991, Tanaka et al 1992, Fahlman et al
1994).
A further important function of SCF is its ability to induce adhesion and migration 
and, these functions are important for determining the correct tissue localisation of 
cells. Indeed, SCF is a potent stimulator of the adhesion of mast cells, haemopoietic 
progenitor cell lines and CD34+ progenitors to fibronectin and vascular cell adhesion 
molecule-1 VCAM-1 (Levesque et al 1995, Dastych et al 1994, Kodama et al 1994). 
Membrane bound SCF may also act as an adhesion molecule for mast cells and 
haemopoietic cells and may explain why the incubation of these cells with antibodies 
to c-kit reduces their homing efficiency (Broudy et al 1996). Furthermore, SCF has 
been observed to mobilise human and murine haemopoietic stem cells from the bone 
marrow to the peripheral blood and also displays chemotactic and chemokinetic 
properties on various HPC in Sca-1+ / Lin' cells (Okumura et al 1996).
SCF activities are not restricted to haemopoietic cells indeed, membrane bound SCF 
has been observed to be involved in the maintenance and proliferation of liver stem 
cells and the expression of soluble SCF and its receptor have been observed during 
liver regeneration in rats (Fuijo et al 1994). Furthermore, Zhang et al also observed 
that both soluble and membrane associated SCF can be expressed by neurones and it 
appears that the membrane form is more important for microglial cell survival in 
neuron-microglia mix cultures (Zhang and Fedoroff 1997).
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As is the case with SCF, c-kit the SCF receptor, also exists as different isoforms one 
of which is lengthened by four amino acids (glycine-asparagine-asparagine-lysine). 
Both receptors are ligand-induced protein tyrosine kinase (PTK), which belong to the 
receptor subfamily III, members of which include the receptors for EGF, PDGF, c-fms 
and flt3/FLK2 (Hanks et al 1988). As well as these isoforms, a soluble c-kit receptor 
has been found at high levels in human serum and in the culture medium of some 
haemopoietic cell lines (Turner et al 1995, Wypych et al 1995). The observation that 
c-kit, like SCF, has differing isoforms indicates that the various interactions between 
these isoforms may be a further method for regulating the various functions of SCF at 
the cellular level. Interestingly, the smaller of the c-kit isoforms has been reported to 
be constitutively active producing a low level of auto-phosphorylation. This basal 
level of activation may be enough to promote survival of some cell types and higher 
levels produced when SCF is present may produce an alternative signal (Reith et al
1991).
SCF receptor, c-kit, can be detected on a host of cell types such as mast cells, 
promyelocytes, myelocytes, eosinophils, monocytes, microglial and primordial germ 
cells (Metcalf 1991a, Fukada et al 1995). Within the haemopoietic stem cell 
compartment c-kit was initially observed to be expressed by all the in-vitro clonogenic 
cells with the exception of pre-B progenitor colony forming cells responsive to IL-7 
(Ogawa et al 1991). However, more recent studies on human haemopoietic 
progenitor cells have indicated that there is a population of cells that display a c-kit ' 
phenotype. This c-kit' cellular population were observed to possesses long term 
repopulating activity and upon growth factor stimulation became c-kit+ cells, thus 
suggesting that the expression of c-kit on c-k it' cells may be the first maturational 
step of haemopoiesis for these primitive human progenitor cells (Sogo et al 1997). 
Two further studies in the mouse also isolated a ckit stem cell population that 
displays long term repopulating activity (Doi et al 1997, Ortiz et al 1999). Thus 
collectively, these studies suggest that although human and murine LTRC were 
initially observed to express high levels of cell surface c-kit, it seems that they coexist 
with a less frequent sub population of LTRC with undetectable c-kit expression and it 
is therefore, possible that the expression of c-kit on these LTRC cells is the first step 
in maturation of this population of long term repopulating cells. Therefore, the 
expression of c-kit receptor whether it is an increase in PHSC or a decrease in
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progenitor cells indicates that stem cell factor and its receptor play an important role 
in the maturation of cells at various stages of the haemopoiesis.
1.7.1.2 Macrophage Colony Stimulating Factor (M-CSF)
Macrophage colony stimulating factor (M-CSF), or colony stimulating factor-1 (CSF- 
1) as it was originally known, was initially identified as a haemopoietic growth factor 
that stimulates haemopoietic precursors to form colonies containing mononuclear 
phagocytes in-vitro (Stanley and Heard 1977). Unlike the granulocyte/macrophage- 
colony stimulating factor (GM-CSF) and Interleukin-3 (IL-3), which also directly 
induce mononuclear phagocyte proliferation, M-CSF is a lineage specific growth 
factor which plays an essential role in the survival and maturation of the mononuclear 
phagocytic lineage (Stanley et al 1983).
Biologically active, secreted and membrane bound forms of M-CSF (Rettenmeir et al 
1988, Wong et al 1987, Manos et al 1988) are encoded by alternatively spliced 
messenger RNA’s translated from a single unique gene which is located on 
chromosome 3 in mouse and chromosome 5 in humans (Kawasaki et al 1985, Morris 
et al 1991). Combining differential splicing and complex co and post-translational 
modifications the M-CSF mRNA species generates different mature M-CSF isoforms: 
a homodimeric secreted M-CSF glycoprotein of 85 kDa (Kawasaki et al 1985) which 
is the main form of M-CSF detected in body fluids (Suzu et al 1994), a membrane 
associated homodimeric 68 kDa form (Uemura et al 1993) which can also be slowly 
released as a soluble molecule of 44 kDa, and a homodimeric or heterodimeric M- 
CSF proteoglycan (PG-M-CSF) of anything up to 150 kDa (Suzu et al 1997). 
Different cell types under various stimuli have been observed to produce different 
ratios of soluble and membrane associated M-CSF and thus may suggest differences 
in the functions of these M-CSF isoforms.
M-CSF has been observed to be detected in blood and bone marrow plasma (Suzu et 
al 1994) and in-vitro M-CSF can be produced by a variety of cell types such as 
endothelial cells, thymic epithelial cells, monocytes-macrophages, marrow stromal 
cells, B and T cells, osteoblasts, astrocytes, microglia, neurones and keratinocytes 
(Seelentag et al 1987, Horiguchi et al 1986, Oster et al 1987, Fixe et al 1997, Praloran 
1991, Alterman et al 1994, Hallet et al 1991). Furthermore, these cells can be
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induced to express M-CSF by various factors such as interferon gamma (IFN-y), 
tumour necrosis factor (TNF a), IL-1, and GM-CSF (Praloran et al 1991, Hashimoto 
et al 1997).
As stated earlier, M-CSFs main activities are observed on the various cells of the 
mononuclear phagocytic lineage, indeed M-CSF can enhance the differentiation of 
monocytes to macrophages and this can be observed by the induced expression of 
surface antigens such as HLA-DR, Fc-receptor and CD l ib  (Hashimoto et al 1997). 
M-CSF potentiates the ability of macrophages to kill infectious microorganisms 
(Karbassi et al 1987, Lee et al 1987) and tumour cells (Wing et al 1982). 
Furthermore, M-CSF enhances these functions by the induction of macrophage 
cytokines such as interferon, TNF, IL-1, GM-CSF (Moore et al 1980, 1984, Warren 
and Ralph 1986, Motoyoshi et al 1982) as well as other inflammatory mediators, such 
as prostaglandins and chemokines (Kurland et al 1978, Hashimoto et al 1996, Lyberg 
et al 1987). Thus M-CSF not only activates macrophage directly it also primes these 
cells so that they can respond to other stimuli. A further interesting function of M- 
CSF was observed by Sakurai et al, they demonstrated that a single injection of M- 
CSF into mice produced an increase in the number of natural killer (NK) cells in the 
spleen, and subsequent injections of M-CSF increased the NK activity of these 
mononuclear cells (Sakurai et al 1997). Further evidence to suggest that M-CSF is 
involved in regulating the cytoxicity of mononuclear cells was obtained when Jadus et 
al observed that the expression of M-CSF on the cell surface of tumour cells inducing 
macrophages to recognise and kill these tumour cells bearing the M-CSF (Jadus et al 
1996). This suggested that M-CSF may have a role in cancer treatment however, 
contradictory reports indicated that M-CSF has no benefits in the treatment of cancer 
(Dorsch et al 1993)
M-CSF activities are not only restricted to mature cell populations in the mononuclear 
phagocytic lineage. M-CSF can stimulate the formation of murine macrophage 
monocytic progenitor colonies (CFU-M), and in combination with other growth 
factors it can also stimulate the formation of colonies from primitive cells such as 
high proliferative potential colony forming cells (HPP-CFCs) (Bartlemaz 1989) and 
colony forming unit-agar (CFU-A) cells (Pragnell et al 1988, Holyoake et al 1993). 
Further evidence for the role of M-CSF in haemopoietic stem and progenitor colony 
growth was observed by the inhibition of the formation of CFU-A and day 12 colony
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forming unit spleen CFU-S d-12 colonies by neutralising antibodies to the M-CSF 
receptor, c-fms (Gilmore et al 1995). Furthermore, Muench et al observed that M- 
CSF can stimulate colony growth of primitive fetal liver colony-forming stem cells, 
CD34+ / CD38+/ Lin (Muench et al 1997).
M-CSF has activities outwith the haemopoietic system indeed, Kawada et al reported 
that M-CSF as well as G-CSF stimulated the proliferation of human keratinocytes 
(Kawada et al 1997). Michaelson et al also provided data to suggest that M-CSF is an 
important factor in CNS development (Michaelson et al 1996). Further biological 
roles of M-CSF have been observed in the mutant osteopetrotic (op/op) mice, a 
natural occurring M-CSF mouse knockout. These op/op mice have a reduced level of 
macrophages and osteoclasts, they are infertile and are osteopetrotic due to a reduced 
level of bone remodelling (Wiktor-Jedrzejczak et al 1990, 1991, Pollard et al 
1987,1991). These conditions are a direct consequence of the loss of M-CSF, as the 
addition of recombinant M-CSF can correct these abnormalities which are also 
progressively corrected as the mice age (Begg and Bertoncello 1993). The 
characteristic defects of the op/op mice can also be reversed by the addition of GM- 
CSF or IL-3 (Myint et al 1999). This correction of macrophage deficiency on the 
treatment of op/op mice with GM-CSF and IL-3 indicates that there is an overlap in 
the functions with these growth factors. On further analysis of these op/op, 
Michaelson et al observed that the loss of M-CSF lead to abnormal brain development 
in these mice thus, suggesting a role of M-CSF in the central nervous system 
(Michaelson et al 1996).
The various actions that M-CSF exerts on the numerous target cell types is mediated 
through its interaction with its receptor, c-fms which is alternatively known as CD 115 
(Sherr et al 1985). Like c-kit, c-fms is a member of the receptor subfamily III that 
exhibit ligand-induced tyrosine kinase activity (Hanks et al 1988). The c-fms proto­
oncogene maps near the M-CSF locus on the human chromosome 5 at band 5q33.3 
(Roussel et al 1983, Groffen et al 1983), and is linked in tandem with the type (3 
PDGF-receptor gene (Roberts et al 1988b). In this location there are several other 
growth factor genes that play important roles in haemopoiesis, these include GM- 
CSF, IL-4 and IL-5 genes (Le Beau 1986, Sutherland et al 1988a, b). Both human 
and mouse M-CSF receptors are integral transmembrane glycoproteins and share 74% 
overall homology, the greatest sequence homology occurring in the intracellular
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kinase domains. Within the haemopoietic system c-fms has been observed to be 
expressed on macrophages, blast cells, myeloid precursors, lymphocytes and on cells 
of the megakaryocyte or erythroid lineage (Byrne et al 1981). Furthermore, the level 
of c-fms expression is thought to be dependant on the maturation state of the cell as 
suggested by the observation that c-fms mRNA is induced in the HL60 cell line after 
the induction of differentiation by phorbol myristate acetate (Biskobing et al 1993, 
Stone et al 1990, Perkins and Kling 1995). The M-CSF receptor expression is not 
restricted to the cells of the haemopoietic system as it has been observed to be 
expressed on placental trophoblasts (Regenstrief and Rossant 1989), osteoclasts 
(Hofsetter et al 1992) and on macrophage-like microglial cells in the nervous system 
(Sawada et al 1990, Brosnan et al 1993). Indeed, Raivich et al demonstrated that the 
macrophage like cells of the CNS, the microglial cells, express low levels of c-fms. 
The level of c-fms expression is induced upon CNS injury therefore, suggesting that 
the level of c-fms expression may have a role in preparing the microglial to take part 
in the cellular response involved in CNS injury (Raivich et al 1998).
1.7.1.3 Fit Ligand (FL)
Fit ligand (FL) appears to play a role in the functions of the haemopoietic stem and 
progenitor cells, and similar to SCF it also displays various synergistic activities with 
other growth factor on a range of haemopoietic cells.
Due to alternative splicing FL exists as a membrane bound and a soluble form, both of 
which exhibit similar biological activities (Lyman et al 1995a). FL is not species 
specific and this is thought to be due to the high degree of homology shared between 
the human and murine FL proteins, 72 % identity at the amino acid level (Lyman et al 
1993, Broxmeyer et al 1995). In normal individuals the plasma levels of FL are low 
and can only be detected by sensitive ELISA however, these levels have been 
observed to be increased in haemopoietic disorders such as acquired aplastic anaemia 
(Lyman et al 1995b) and thus is thought to play a role in this disorder.
In-vitro studies have indicated that, like SCF, FL can support maintenance of stem 
and progenitor cells (Hudak et al 1995, Muench et al 1995). Initially it was observed 
that FL alone had no significant colony stimulating activity however, subsequent 
studies indicated that FL alone or in combination with GM-CSF, M-CSF, IL-3, IL-6,
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IL-11, IL-12 and SCF enhanced the proliferative response or colony forming potential 
of purified human and murine stem and progenitor cells (Muench et al 1995, Jacobsen 
et al 1995a, Rasko et al 1995). Further reports have indicated that FL functions are 
not restricted to the myeloid lineage as FL in combination with IL-7 acts on the 
lymphoid lineage (Muench et al 1995). FL has also been observed to be an effective 
replacement for SCF in ex-vivo expansion protocols as it has been observed to expand 
CD34+ progenitors (Mckenna et al 1995) namely CFU-GM and CFU-GEMM 
progenitors (Broxmeyer et al 1995).
Flt-3 ligand (FL) induces its haemopoietic growth factor activities through interaction 
with its specific receptor, fins-like tyrosine kinase 3 (Jlt3) also referred to as fetal liver 
kinase 2 (FLK-2). While expression studies have indicated that FLK2/ flt3  ligand 
(FL) is ubiquitously expressed (Lyman et al 1995a) it seems that its receptor is more 
restricted to primitive haemopoietic progenitors (Small et al 1994). FLK-2//W is a 
member of the tyrosine kinase receptor family, which includes M-CSF receptor and 
SCF receptor and is, located on mouse chromosome 5 and human chromosome 13 
(Rosnet et al 1993).
Targeted disruption of the flt3l FLK2 or FL gene produces normal healthy mice that 
have reduced levels of B cell progenitors (Mackarehtschian et al 1995, McKenna et al 
1996, 2000) and further studies have also reported that FL deficient mice have 
reduced levels of dendritic and NK cells (McKenna et al 2000). These studies 
indicate that although FL is involved in various lineages, other growth factors can 
compensate for the loss of FL activity. Interestingly mice that lack both Jlt3fFLK2 
and c-kit die after birth, and on analysis of their haemopoietic systems it was observed 
that these animals had a severe reduction in their overall size of the haemopoietic 
system, particularly in the myeloid and lymphoid lineages and a reduction in all 
progenitor cells. These results indicate that FL may play a role in haemopoietic 
development (Mackarehtschian et al 1995) and that FL is part of a network of 
cytokines that regulate the growth and survival of early haemopoietic stem and 
progenitor cells.
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1.7.2 Beta Common (pc) Signalling Growth Factors
1.7.2.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Granulocyte macrophage colony stimulating factor (GM-CSF) is a haemopoietic 
growth factor that derives its name from the ability to stimulate the formation of in- 
vitro macroscopic colonies containing neutrophils, eosinophils, and macrophages, or a 
mixture of these cell types. Historically growth factors such as GM-CSF were 
purified from conditioned medium that displayed the ability to stimulate the growth of 
colonies from immature bone marrow derived progenitors (Broxmeyer et al 1990, 
1999). Indeed, murine GM-CSF was no exception as it was first identified and 
purified from mouse lung conditioned medium (Burgess and Metcalf 1977). Around 
the same time Weisbart et al identified a factor that could inhibit the migration of 
neutrophils and named it NIF-T (Weisbart et al 1979). Human GM-CSF was 
subsequently purified from a human T-cell leukaemia virus type II (HTLV-II)- 
infected T-lymphoblastoid cell line, Mo. However, it wasn’t until 1985 that Wong et 
al cloned human GM-CSF and NIF-T and GM-CSF were observed to be identical and 
are now known as GM-CSF (Wong et al 1985).
The GM-CSF gene has been mapped to the long arm of chromosome five between 
5q21-32, in an area containing several other haemopoietic growth factors and their 
receptors. The full length human GM-CSF is 127 amino acids in length and has a 
molecular mass of approximately 22 kDa (DiPersio et al 1988) and although human 
and murine GM-CSF share 60 % identity they are not cross reactive.
There are a number of different cell types that produce GM-CSF following various 
kinds of stimuli. Indeed, GM-CSF production has been demonstrated in 
monocyte/macrophages, neutrophils, B-lymphocytes, eosinophils, mast cells, 
keratinocytes, osteoclasts as well as different epithelial cells. Further expression 
studies have reported that the constituent cells of the bone marrow microenvironment 
produce GM-CSF (Kita et al 1991, Baldwin et al 1992, Jung et al 1995). However, 
most of the GM-CSF expressing cells under resting conditions are not significant 
sources of GM-CSF, but rapidly and transiently can be stimulated by factors such as 
phorbol esters, interferon-y, LPS, IL-1 and TNF-a to produce GM-CSF (Kothori et al
1995). Therefore, it seems that the activation state of the cells is the major factor in
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determining whether the cells that have the potential to express GM-CSF actually do. 
In contrast to other members of the CSF family such as G-CSF, GM-CSF cannot be 
detected in the circulation by ELISA, and this may be due to GM-CSF being 
sequestered by the extracellular matrix (Modrowski et al 1998).
GM-CSF was the first human colony stimulating factor to be purified, cloned and 
expressed using recombinant DNA technology. This allowed vast amounts of GM- 
CSF to be synthesised which lead to the further investigation into the functions of 
GM-CSF. There is evidence to suggest that GM-CSF plays a role in immune 
responses, GM-CSF can stimulate the cytotoxic capacity of neutrophils and 
monocytes (Masucci et al 1989), expand and activate antigen presenting cells (APCs), 
induce the differentiation of monocytes to macrophages (Inaba et al 1992, Sallusto 
and Lanzavecchia 1994), activate immune functions in eosinophils and basophils 
(Fabian et al 1992, Negata et al 1995) and increase natural killer cell function. 
Furthermore, GM-CSF can induce the expression of growth factors and cytokines 
such as M-CSF, G-CSF, IL-12 and IL-15 and other pro-inflammatory agents such as 
prostaglandin’s, plasminogen activators, interferon-y, TNF and IL-8 from the above 
cells (Takahashi et al 1993, Bendall et al 1995). GM-CSF can therefore directly or 
indirectly affect the functions of various mature cells (Yong and Linch 1993, Weiser 
et al 1987, van Pelt et al 1996). GM-CSF not only stimulates the growth of various 
mature cell types such as granulocytes, dendritic cells, Langerhans cells, eosinophils, 
megakaryocytes, it can also stimulate the proliferation of progenitors such as CFU-G, 
CFU-M, CFU-E and CFU-GM from human and murine bone marrow or human 
peripheral blood (Broxmeyer et al 1990,1999, DeWynter et al 1998).
The high affinity receptor for GM-CSF is composed of two sub-units, the a  and p 
sub-unit (Hayashida et al 1990, Tavemier et al 1991, Kitamura et al 1991). The a  
sub-unit is specific for GM-CSF and binds it with low affinity whereas the beta (pc) 
sub-unit is shared between GM-CSF, IL-3 and IL-5 (Matsuguchi et al 1997). To date, 
there are at least six isoforms described for the GM-CSFR alpha (Chopra et al 1996). 
Humans have only one p sub-unit (pc), which has no binding capacity by itself but 
can form a high affinity IL-3, IL-5 and GM-CSF receptors with their respective a  
sub-units. Both sub-units belong to the cytokine receptor family, which includes the 
receptors for many haemopoietic growth factors and cytokines such as growth
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hormone, erythropoietin (EPO), thrombopoietin (TPO), IL-2 and IL-6 (reviewed by 
Mui 1994). Members of this family are characterised by an extracellular cytokine 
receptor module (CRM) of about 200 amino acids containing several conserved 
motifs, including the hallmark WSXWS (Trp-Ser-Xaa-Trp-Ser) motif and a 
cytoplasmic domain that lacks any intrinsic enzymatic activity associated with signal 
transduction (Bagley et al 1997). Although only the (3c sub-unit has the potential to 
produce a signal, truncation studies have indicated that the interaction between the a  
and the pc sub-unit is neeeded for the activation of JAK/STAT signalling pathways 
(Scott et al 1998, Doyle et al 1998). Neither the a  or p sub-unit have intrinsic kinase 
domains or are linked to G-proteins, instead the receptor produces a signal by 
associating with and activating a number of cytosolic tyrosine kinases including lyn, 
fes  and JAK2 (Thompson et al 1995, Linnekin et al 1995, Al-Shami et al 1997, 1998). 
GM-CSFRa can exist in both a transmembrane form and a soluble form indeed, 
naturally occurring soluble forms of sGM-CSFRa can be detected in the supernatants 
of human neutrophils and in human plasma and may allow GM-CSF to interact with 
cells that do not express the membrane form of the GM-CSFRa sub-unit (Sayani et al 
2000).
There is some debate about the expression of the GM-CSF receptor in the primitive 
cells of the haemopoietic system. Several studies have suggested that primitive 
progenitors lack the receptor for GM-CSF (Wognum et al 1994, Jubinsky et al 1994, 
Berardi et al 1995). Indeed, McKinstry et al observed that GM-CSF receptor could 
not be found on primitive populations but could be detected on committed progenitors 
cells that were defined as Sca-l+/c-kit+ (McKinstry et al 1996). In contrast, a study by 
Lund-Johansen et al observed that a primitive human haemopoietic progenitor 
population, which is defined by the expression of CD34hi CD381o, expresses both the 
alpha and beta sub-units of the GM-CSF receptor and that GM-CSF displayed 
minimal effects on the survival or proliferation of these primitive progenitors. 
However, in combination with the SCF, GM-CSF can enhance the survival and 
growth of these cells (Lund-Johansen et al 1999). These differences may be due to 
the isolation of different primitive cell types in these reports.
The in-vivo effects of GM-CSF have been examined in a number of ways in murine 
models; by injecting GM-CSF (Metcalf et al 1987), by generating hGM-CSF receptor
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transgenic mice (Nishijima et al 1997), by reconstituting mice with bone marrow cells 
that over produce GM-CSF (Lang et al 1987) or examining GM-CSF or GM-CSFR 
null mice. Indeed, Stanley et al produced GM-CSF null mice and on examining these 
animals they observed that there was no perturbation of the major haemopoietic 
populations in blood or bone marrow (Stanley et al 1994). Thus indicating that other 
regulators can replace GM-CSFs activity in its absence however, GM-CSF is not 
totally redundant as indicated by the formation of the abnormal lung pathology, 
pulmonary alveolar proteinosis (PAP). This lung pathology is due to the 
malfunctioning of alveolar macrophages and can be cured by a bone marrow 
transplant (Nishinakamura et al 1996). A similar pulmonary phenotype was observed 
on the examination of mice lacking the Pc receptor sub-unit of the GM-CSF receptor, 
which is also common to the IL-3 and IL-5 receptors. These mice also displayed a 
reduction in eosinophils, which was consistent with the loss of IL-5 activity, one of 
the major growth factors necessary for eosinophil development and response 
(Nishinakamura et al 1995, Stanley et al 1994). This pulmonary alveolar proteinosis 
(PAP) condition has also been observed in humans, however, on analysis of their 
bone marrow cells it was observed that they have both the GM-CSFRa and pc sub­
units of the GM-CSF receptor. Furthermore, GM-CSF administration could not 
reduce the disease, suggesting that the GM-CSF signalling system is not wholly 
responsible for the pathology of this disease (Carraway et al 2000)
1.7.2.2 Interleu kin-3 (IL-3)
IL-3 is a multipotential haemopoietic growth factor capable of stimulating the 
survival, proliferation and development of multipotent stem cells and myeloid 
progenitor cells. In contrast to many other growth factors, IL-3 expression is restricted 
to only a few cell types. Furthermore, Gibson et al indicated that IL-3 appeared not to 
be produced in normal animals however, IL-3 expression can be observed but only 
with the use of sensitive technique such as RT-PCR (Gibson et al 1995). In 
peripheral blood the predominant IL-3 expressing cells are antigen or mitogen 
stimulated T cells. Other reports have also observed that NK cells, megakaryocytic 
cells, epithelial and mast cell lines can express IL-3 (Gibson et al 1995, Cuturi et al 
1989, Wickenhauser et al 1995, Nimer et al 1995, Wodnar-Filipowicz et al 1989, 
Dalloul et al 1991). The restricted production of IL-3 and the inability to detect levels 
of it in serum and bone marrow with out the aid of sensitive techniques has lead to the
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proposal that IL-3 may not be involved in the day to day control of haemopoiesis 
(constitutive haemopoiesis), and that it may only be needed in times of stress or 
infection (inducible haemopoiesis). This is supported by the need for activation of T 
cells, mast and megakaryocytic cell lines before they express IL-3 (Gibson et al 1995, 
Nimer et al 1995).
In-vitro IL-3 has been observed to support the proliferation of CD34+ bone marrow 
and myeloid progenitors cells and also supports the development of these cells down 
the megakaryocytic and erythroid lineages however, terminal differentiation only 
occurs in the presence of TPO or EPO (Banu et al 1995, Saeland et al 1988). 
Furthermore, IL-3 has been observed to be involved in the differentiation of 
eosinophils (Saito et al 1988) and can interact with other growth factors such as SCF 
to promote mast cell proliferation (Rennick et al 1995). IL-3 activities are not only 
restricted to supporting growth and differentiation as in conjunction with SCF, M- 
CSF or the CXC chemokine SDF-1, IL-3 has been observed to display chemotactic 
and chemokinetic responses on murine haemopoietic progenitors (Okumura et al 
1996, Aiuti et al 1997). Other reports have also suggested that IL-3 may also be 
involved in regulating adhesion of stem cells to the stromal cells. Indeed, IL-3 can 
reduce integrin mediated adhesion and promote migration of CD34+ cells (Schofield 
et al 1997) and this may explain the enhanced mobilisation of peripheral blood 
progenitors by IL-3 in the presence of G-CSF (Huhn et al 1996). A further activity of 
IL-3 was observed using a multipotential progenitor cell line, FDCP-Mix, these cells 
depend on IL-3 for growth and upon its removal these cells undergo apoptosis, 
indicating that IL-3 acts as a survival factor for this cell line (Williams et al 1990a, 
Fairbaim et al 1993). These reports indicate that in-vitro IL-3 can regulate the 
functions of various cell types at different stages of maturation.
As alluded to in section 1.7.2.1, IL-3 induces its activities through a common 
signalling sub-unit shared by IL-5 and GM-CSF, the pc sub-unit (Mui et al 1994). In 
mice IL-3 can also signal through an IL-3 specific beta sub-unit namely pIL'3 (Hara et 
al 1992, 1996). The pc and pIL'3 sub-units are expressed on myeloid progenitor cells, 
macrophages, mast cells, B cells and endothelial cells whereas, the expression of the 
alpha sub-unit is more restricted suggesting that IL-3 responses are regulated by the 
level of IL-3 a  sub-unit expression. Mice that completely lack IL-3 have been
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observed to display no aberrant phenotype suggesting that other growth factor can 
compensate for the loss of IL-3 function (Nishinakumura et al 1996). Furthermore, 
the observation that there are certain strains of laboratory mice that have no IL-3Ra 
expression and have no alteration in their haemopoietic system, indicates that the IL-3 
system is not essential for normal haemopoiesis and the role IL-3 plays in 
haemopoiesis in-vivo has yet to be defined (Nicola et al 1996).
1.7.3 Glycoprotein 130 (gpl30) Signalling Growth Factors
1.7.3.1 Interleukin-6 (IL-6)
Interleukin-6 (IL-6) was originally identified as a factor that induces B cell terminal 
differentiation into antibody producing cells (Hirano et al 1986). It was subsequently 
observed to display numerous activities, which include growth promotion, 
haemopoietic colony formation, differentiation of macrophages and T cells, neural 
differentiation and induction of acute phase proteins (Simpson et al 1997). The 
human IL-6 gene encodes a polypeptide precursor of 212 aa which is cleaved and 
secreted as a 184 aa mature glycoprotein of between 21-28 kDa in mass, the range in 
mass is due to various levels of glycosylation (van Snick et al 1988).
Unlike GM-CSF and IL-3, IL-6 can be detected in serum and other body fluids, e.g. in 
synovial fluids of patients with arthritis. IL-6 can be expressed by a number of cell 
types including; monocytes/macrophages, stromal cells, fibroblast, endothelial cells 
and keratinocytes (Kupper et al 1989, Richards et al 1991). IL-6 expression can be 
further induced upon stimulation with LPS, phorbol esters and the cytokines IL-1 and 
TNF (Zhang et al 1990) whereas, IL-4 has been observed to act as potent inhibitors of 
IL-6 production (Denizot et al 1999).
In-vitro Musashi and colleagues have shown that IL-6, similar to IL-11 and LIF, 
enhances IL-3, IL-4 and SCF dependant proliferation of primitive blast cell colonies 
in methylcellulose cultures (Musashi et al 1991a, b). This activity is thought to be 
due to the growth factors shortening the time the cell spends in Go, and this 
observation lead to the inclusion of IL-6 in stem cell expansion protocols. Indeed, 
Bodine et al observed that IL-6 in combination with SCF was capable of stimulating 
the expansion of CFU-S stem cells and maintaining a significant amount of
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repopulating ability after 6 days in liquid culture (Bodine et al 1994). Furthermore, 
Sui et al demonstrated that stimulation of gpl30 by IL-6 and soluble IL6R, resulted in 
superior ex -vivo expansion of primitive human haemopoietic progenitor cells when 
compared to IL-6 alone (Sui et al 1995). More recently a fusion protein of IL6 and 
IL-6R was observed to be fully active at concentrations of 100-1000 fold less 
compared to that of unlinked IL-6 and IL6R (Fischer et al 1997) in expansion 
protocols (Chebath et al 1997). Other reports have indicated that IL-6 is involved in 
the development of erythroid, megakaryocytic, myeloid and lymphoid lineages 
(Kimura et al 1990, Hirano et al 1996, Sui et al 1999). Indeed, Sui et al also 
demonstrated that soluble IL-6R and IL-6 in combination with SCF is involved in 
megakaryopoiesis and this activity is independent of TPO induced megakaryocyte 
production (Sui et al 1999). The IL-6/sIL-6R complex mimics not only the activity of 
IL-6 on cells expressing gpl30 but also the other members of the IL-6 family of 
cytokines. For instance, pluripotentiality of ES cells can be maintained by 
simultaneous addition of IL-6 and sIL-6R but not IL-6 or sIL-6R alone (Yoshida et al 
1994).
Interleukin-6 exerts these various functions through its receptor which consists of two 
sub-units, the ligand binding a  sub-unit which has a mass of 80 kDa and the 
signalling gpl30 sub-unit which is 130 kDa and both belong to the type I cytokine 
receptor family. The gp 130-signalling sub-unit is also shared with IL-6, LIF, 
Oncostatin M and CNTF and this results in these cytokines sharing partly overlapping 
activities. Although gpl30 is widely expressed (Saito et al 1992) the ligand specific 
receptor components display a more limited expression, suggesting that cellular 
responsiveness is largely determined by the regulated expression of the ligand specific 
receptor chains. The IL-6Ra sub-unit has a short cytoplasmic domain of 82 amino 
acids and this domain is not needed for signalling as indicated by IL6Ra truncation 
studies (Taga et al 1989). The finding that IL-6a sub-unit exists as a membrane 
associated and a soluble form indicated that maybe these different isoforms regulate 
different functions (Narazaki et al 1993). Indeed, upon isolation of CD34+ cells it 
was observed that these could be subdivided into IL-6R expressing and non­
expressing cells however, both populations express gpl30. It was demonstrated that 
IL-6Ra expressing cells can be stimulated to form granulocyte macrophage colonies 
whereas, IL-6Ra negative cells upon stimulation with IL-6 and soluble IL6Ra form
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various types of colonies including erythroid bursts, granulocyte macrophage 
colonies, megakaryocytes and mixed colonies (Sui et al 1999). This phenomenon of 
sIL-6 and sIL6Ra inducing signalling through cells that express gpl30 is referred to 
as transignalling, and as observed by Hirano et al it allows cells that do not express 
IL-6Roc sub-units to respond to IL-6 (Hirano et al 1997). The IL-6Ra chain exhibits 
low affinity for IL-6 however, upon stimulation of cells with IL-6 a high affinity 
receptor was identified which contained gpl30. The high affinity IL-6 receptor has 
been observed to consist of a hexameric complex containing two IL-6 molecules, two 
IL-6 alpha sub-units and a homodimer of gpl30 (Baumann et al 1996). McKinstry et 
al demonstrated that the number of IL-6R on haemopoietic progenitors cells increases 
significantly with the maturation of these cells (McKinstry et al 1997).
IL-6 null mice exhibit a severe impairment in antibody production and acute phase 
protein production following viral infection and mineral oil injection and they also 
have a decreased ability to deal with bacterial infections (Kopf et al 1994, Dalrymple 
et al 1995). Furthermore, another group examining IL-6 null mice observed that there 
was a reduced level of leukocyte recruitment, which they suggested was due to the 
reduced ability of these cells to produce chemokines (Romano et al 1997). The 
various functions of the interleukin-6 family of cytokines on the haemopoietic and 
lymphoid cell systems, and their ability to function extensively outside these systems 
is thought to be due to the ubiquitous expression of the gpl30 sub-unit (Saito et al
1992).
1.7.3.2 Interleukin-11 (IL-11)
An activity that was observed in conditioned media from a primate cell line, PU34 
was reported to support the proliferation of an IL-6 dependent plasma cell line. 
Subsequent studies demonstrated this activity was due to another gpl30 signalling 
cytokine namely IL-11 (Paul et al 1990). IL-11 like all the gpl30 signalling
cytokines is pleiotropic and displays diverse effects such as stimulation of myeloid, 
erythroid and megakaryocyte differentiation, modulation of macrophage and T cell 
inflammatory functions and induction of acute phase response proteins, such as 
fibrinogen and C reactive protein (Baumann 1991). The coding region of Interleukin- 
11 (IL-11) predicts a polypeptide of 199 amino acids in length which contains a 21 
amino acid signal peptide and upon cleavage produces a secreted protein of IL-11 that
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has a molecular mass of 19 kDa. Human and murine IL-11 share 88% identity at the 
primary amino acid level (Morris et al 1996), and interestingly IL-11 is unlike the 
other human gpl30 proteins in that it does not have any cysteine residues in its 
primary aa sequence and has no glycosylation sites.
IL-11 has been detected in fibroblasts from various tissues and can also be produced 
by bone marrow stromal cells, chondrocytes and osteoblasts and cytokines such as IL- 
la , TNF-a, TGF-P and EGF can further induce these cells to produce IL-11 (Elias et 
al 1994a, b).
In the context of the haemopoietic system, Musashi et al observed that IL-11 could 
induce the formation of blast cell colonies in-vitro but only in combination with other 
early acting growth factors such as IL-3, IL-4 or SCF (Musashi et al 1991a, b). IL-11 
in combination with SCF or IL-3, not only maintains the levels of primitive 
progenitors in liquid culture it also promotes their growth in methylcellulose (Neben 
et al 1994). IL-11 like IL-6, in the presence of SCF, can also induce primitive 
quiescent stem cells to exit Go and enter the Gl/S phase of the cell cycle and this 
function has been exploited by several groups in ex-vivo expansion protocols (Neben 
et al 1994, Holyoake et al 1996). As well as displaying activities on primitive parts of 
the haemopoietic system, IL-11 alone has been observed to have direct effects on 
more mature cells. Weich et al observed that IL-11 can not only enhance the 
formation of megakaryocyte colonies (Weich et al 1997), it can also induce the 
differentiation and maturation of megakaryocytes and their precursors in combination 
with IL-3. In-vivo administration of rhIL-11 was observed to increase the number of 
platelets in animals (Neben et al 1993) and more importantly in humans and myelo- 
suppressed patients (Tepler et al 1996), further suggesting the role for IL-11 in 
megakaryopoiesis. These observations lead to the approval of rhIL-11 as a treatment 
for chemotherapy induced thrombocytopenia (Gordon 1996). The megakaryocyte 
lineage is not the only lineage that IL-11 is involved in, it has also been observed that 
IL-11 plays a role in erythropoiesis as IL-11 in combination with SCF and EPO can 
stimulate the growth BFU-E and CFU-E colonies (Quesniaux et al 1992, Lemoli et al 
1993, Rodriguez et al 1995). The administration if IL-11 to mice resulted in an 
increase in the number of CFU-GM progenitors within the bone marrow and an 
increase in the cycling rate of these progenitors and that of the CFU-GEMM 
progenitors (Hangoc et al 1993).
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Similar to the IL-6 receptor the IL-11 receptor consists of two sub-units. The ligand 
specific non-signalling sub-unit IL-1 IRa, which can exist in a membrane, bound form 
or a soluble form, and the signal transducing sub-unit gpl30 (Taga et al 1997). The 
IL-1 IR a sub-unit consists of an extracellular domain, which contains two N linked 
glycosylation sites, a transmembrane domain and a small non-signalling cytoplasmic 
tail (Hilton et al 1994). Studies that knockout the IL-1 IR a sub-unit have indicated 
that these animals are healthy and have normal levels of peripheral blood 
lymphocytes, erythrocytes, platelets, multipotential stem cells (CFU-S) and 
committed progenitors (CFU-GM, BFU-E and CFU-Meg) (Nandurkar et al 1997). 
Thus suggesting that IL-11 is not essential for regulating haemopoiesis and in its 
absence its functions are replaced by other growth factors. A further study Robb et al 
observed a similar non-effect in haemopoiesis however, these mice did have an 
obvious phenotype in that the removal of the IL-1 IR a sub-unit renders the female 
mice infertile (Robb et al 1998).
1.7.3.3 Leukaemia Inhibitory Factor (LIF)
Leukaemia inhibitory factor (LIF) was previously known as differentiation inducing 
factor (D-factor or DIF) and macrophage/granulocyte inducer type 2 (MGI-2) 
(Tomida et al 1984, Hilton et al 1988). LIF, like the other gpl30 cytokines, is 
multifunctional and has been observed to inhibit the differentiation of embryonic stem 
cells, promote the survival and proliferation of primitive haemopoietic precursors and 
primordial germ cells; induce the expression of acute phase proteins; and is involved 
in adipocyte differentiation, bone formation and survival of neuronal and muscle cells 
(Piquet-Pellorce et al 1994, Hamilton et al 1993, Marshall et al 1994, Thaler et al 
1994, Austin et al 1992). LIF is a 180 amino acid glycoprotein whose molecular 
weight ranges from 38-67 kDa and this heterogeneity has been ascribed to extensive 
glycosylation (Gough et al 1989).
Although LIF is almost undetectable in-vivo it has been reported to be expressed by a 
number of cell types but only after induction with various stimuli. Indeed, the 
expression of LIF in human bone marrow stromal cells can be induced by phorbol 
esters, LPS, epidermal growth factor, interleukin-la and p, TNF, TGF-P and SCF but
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not by M-CSF, G-CSF and GM-CSF (Lorgeot et al 1997, Gollner et al 1999). LIF 
was originally defined by its ability to induce monocyte differentiation and suppress 
the differentiation of the murine monocytic leukaemia cell line Ml (Gearing et al 
1987). On its own LIF has little or no effect on the proliferation or differentiation of 
primitive haemopoietic progenitors however, in combination with IL-3 or M-CSF, 
LIF can enhance the proliferation of blast-CFCs, megakaryocyte colonies and CFU-M 
colonies (Metcalf et al 1988, Warren et al 1993, Keller et al 1996). Furthermore, LIF 
acts in combination with IL-3, GM-CSF, M-CSF and SCF to promote the colony 
formation of partially purified lineage negative (Lin*) bone marrow progenitors 
(Keller et al 1996). However, the most interesting function of LIF is its ability to 
prevent differentiation commitment of murine embryonic stem cells (ES). These ES 
cells are normally totipotent and can give rise to all tissues of a mature mouse when 
injected into the blastocyst, however, in the absence of LIF these ES cells differentiate 
and lose their totipotency. This activity of LIF in particular has allowed the 
development of ES based methods such as those used in the production of transgenic 
and knockout animals (Capecchi 1994). Interestingly, this ability of LIF to inhibit the 
differentiation has also been observed for some of the other gp 130 signalling 
molecules such as IL-6, IL-11 and CNTF (Yoshida et al 1994).
The receptor for the cytokine leukaemia inhibitory factor (LIF) comprises of a 
transmembrane protein with low affinity for the cytokine known as gpl90 and the gp 
130 signal transducing chain (Taga et al 1997). Upon LIF binding to gp 190, gp 130 
can now interact with this complex and produces a fully functional signalling 
complex. OSM, CNTF and CT-1 also use gpl90 (LIFR) as part of their high affinity 
receptor complexes. Both sub-units of the LIFR are members of the haemopoietin 
receptor family however, unlike IL-6 and IL-11R alpha sub-units the low affinity 
LIFRa chain contains 2 haemopoietin domains separated by an immunoglobulin 
domain and three fibronectin domains. Recent studies have elucidated that the 
membrane distal haemopoietin domain along with the Ig domain is essential for LIF 
binding (Taupin et al 1999). Similar to other members of the gp 130 cytokine family, 
the LIF receptor also has a soluble isoform (Layton et al 1992). On examining cross 
species reactivity it can be observed that murine LIF does not bind to human LIFR 
whereas, human LIF can bind to murine LIFRa and interestingly human LIF has a 
higher affinity for murine LIFR complex than murine LIF.
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LIF null mice were produced to examine the in-vivo role of LIF, these null mice 
initially appeared to develop and behave normally however, upon further examination 
they were shown to have a reduced number of stem and progenitor cells in their 
spleens and bone marrow. Furthermore, it was observed that female mice are unable 
to produce pups, this was due to the inability of the blastocyst to implant into the 
uterus. Other LIF null mice have been reported and these mice have been observed to 
reduce levels of CFU-S stem cells (Escary et al 1993). These various reports indicate 
that LIF is involved in regulating differentiation, haemopoiesis and also plays a role in 
implantation of the developing blastocyst.
1.7.4 Homo-Dimerising Signalling Growth Factors
1.7.4.1 Granulocyte Colony Stimulating Factor (G-CSF)
Granulocyte colony stimulating factor (G-CSF) is a growth factor that acts on the 
neutrophil lineage to stimulate the proliferation of committed progenitor cells and 
functionally activates mature neutrophils. The human gene is located on chromosome 
17 whereas, the murine gene is clustered on chromosome 11 with the genes for GM- 
CSF and IL-3 (Nagata et al 1989, Platzer 1989).
The G-CSF protein is approximately 18.6 kDa in size and can be produced by a 
variety of cell types including; macrophages, fibroblasts, endothelial cells and stromal 
cells, and this expression is further enhanced by IL-1, LPS and phorbol esters 
(Kothari et al 1995).
In-vitro G-CSF has been observed to induce the formation of neutrophilic colonies 
from the CFU-G progenitors, and enhance the formation of CFU-GM colonies but 
only at high concentrations (Metcalf and Nicola 1993). In synergy with other growth 
factors G-CSF can stimulate the survival and proliferation of human myeloid and 
erythroid progenitor cells (McNiece et al 1991). Furthermore, G-CSF can enhance 
the differentiation and activation of mature neutrophils it also primes these cells to 
release cytokines and increases their cytotoxicity (Begley 1986).
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G-CSF exerts these activities through a single, high affinity, specific receptor which 
has an approximate mass of 140 kDa and is a member of the haemopoietin receptor 
family or the cytokine receptor type I superfamily (Demetri and Griffin 1991).
The in-vivo role of G-CSF was investigated by Lieshcke et al who produced mice that 
were homozygous for a null mutation of G-CSF. These mice are fertile, viable and 
have a 70% reduction in the numbers of circulating neutrophils. This indicated that 
G-CSF is an important regulator of neutrophil production under steady state 
conditions and emergency situations. Interestingly, these mice also were observed to 
have a reduced level of progenitors from all lineages suggesting that G-CSF may play 
a direct role in regulating progenitor levels (Lieshcke et al 1994). Indeed, G-CSF and 
SCF have been observed to enhance the formation of progenitor cells of multiple 
lineages in developing blast cell colonies (Metcalf et al 1991a) and this action may 
also explain the elevation of multiple lineage elevation of stem and progenitor cells in 
the blood after G-CSF administration (Roberts and Metcalf 1994). Alternatively, the 
loss of lineage progenitors may be linked to the decrease in neutrophil levels, as it is 
possible that neutrophils produce growth factors that are needed for the survival 
and/or the proliferation of these progenitors.
Numerous reports indicating that G-CSF is the major growth factor involved in 
neutrophil differentiation lead to the analysis of recombinant G-CSF as a candidate 
therapy of the neutropenia associated with chemotherapy and radiotherapy. Indeed, 
G-CSF or Filgrastim as it is clinically known has been observed to decrease the 
incidence, severity and duration of neutropenia and this has allowed the increase in 
dose of certain chemotherapy regimes. A further clinical utility of G-CSF was 
discovered when G-CSF alone or in combination with chemotherapy or chemokines 
was reported to mobilise progenitors to the peripheral blood. Interestingly these 
mobilised progenitor cells were observed to be more effective than bone marrow in 
accelerating platelet and neutrophil recovery in lymphoma patients (Schmitz et al 
1996).
1.7.4.2 Thrombopoietin (TPO)
Thrombopoietin affects all levels of megakaryocyte development, it not only 
stimulates haemopoietic stem cells into cycle, it can also support the proliferation of
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multipotent and committed megakaryocytic progenitors and induces the expression of 
various molecules that are needed for platelet formation (Ku et al 1996, Broudy et al 
1995, Papayannopoulou 1996 a, b). Thrombopoietin (TPO) was cloned by a number 
of groups and was observed to be the ligand for the c-mpl receptor. Thrombopoietin 
mRNA has been detected in the liver, the kidney and to a lesser extent in the bone 
marrow and spleen (Kuter et al 1994, Kaushansky et al 1995).
TPO functions primarily as a differentiation factor with limited ability to promote 
CFU-Meg formation however, in combination with SCF or IL-3, TPO can enhance 
the formation of these colonies in semisolid media (Broudy et al 1995). Further 
evidence for the role of TPO in megakaryopoiesis was observed in-vivo, as the 
administration of TPO to various animals and humans was shown to increase the 
number of bone marrow megakaryocytes and peripheral blood platelets (Harker et al 
1996). As well as TPOs activity on the megakaryocyte lineage, TPO has also been 
observed to expand cell numbers in mouse long-term cultures and these cells can 
competitively repopulate a lethally irradiated recipient (Yagi et al 1999). 
Furthermore, the numbers of granulocyte macrophage progenitors (Kaushansky et al 
1996) and neutrophils is increased upon TPO administration (Sawai et al 2000). In- 
vitro in combination with erythropoietin TPO can stimulate the growth of erythroid 
progenitor cells (Kaushansky et al 1995).
These activities of TPO are mediated through its receptor c-mpl, which is a member 
of the cytokine receptor type I superfamily of receptors and requires homo- 
dimerisation for activation (Bazan 1990). The cytoplasmic domain of Mpl is 121 
amino acid in length and contains two membrane proximal motifs (box 1 and box 2), 
these domains are conserved among most members of the cytokine receptor 
superfamily and are critical for receptor function and signalling via JAKs (Drachman 
et al 1997). A more recent study also provided evidence that TPO is involved in early 
haemopoietic events, this group isolated early haemopoietic stem cells and further 
subdivided this population by the expression of c-mpl. Upon examining the 
repopulating ability of these cells it was observed that the c-m p t population 
essentially contained all of the haemopoietic activity as assessed at 24 week (Solar et 
al 1998).
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Although TPOs main function is in the megakaryocyte lineage the haemopoietic 
defects in mice lacking TPO or its receptor are not restricted solely to cells of the 
megakaryocyte lineage. In-vitro assays have revealed that these TPO null mice 
display a modest effect on multi-lineages within the haemopoietic system, as 
indicated by the decrease in the number of CFU-Meg, CFU-GM and BFU-E 
progenitor cells (Alexander et al 1996, Gurney et al 1994). Examination of c-mpl-! - 
mice indicated that they have almost no CFU-S stem cells and a reduced level of blast 
colony forming cells further suggesting a role for TPO in early haemopoiesis as well 
as regulating megakaryopoiesis (Kimura et al 1998).
Platelets are necessary for blood clotting and when numbers are very low individuals 
are at risk of death from haemorrhage. In-vivo data has suggested that the Mpl ligand 
can ameliorate the thrombocytopenia associated with chemotherapy and clinical trials. 
Indeed, the administration of a pegylated megakaryocyte growth and development 
factor (PEG-MGDF), which consists of the N terminal region of TPO conjugated to 
polyethylene glycol, reduces the time the patient is thrombocytopenic and also 
induces leukocyte and erythrocyte recovery, further suggesting a role for TPO as an 
adjuvant in transplantation, chemotherapy or radiotherapy. However, care must be 
taken as TPO receptor c-mpl is expressed in some disorders such as acute myeloid 
leukaemia (AML), and cells from these patients have been observed to proliferate in 
response to TPO (Matsumura et al 1995, Bouscary et al 1995).
1.7.4.3 Erythropoietin (Epo)
Erythropoietin promotes the growth, differentiation and survival of erythroid 
progenitors and is essential for the terminal stages of erythrocyte development. EPO 
is an approximately 30 kDa glycoprotein and animal studies have indicated that EPO 
is primarily produced in the kidney during adult life and in the liver in fetal 
development (Krantz 1991). Further evidence for the kidney being the primary 
source of EPO in humans was observed as individuals with renal disease are generally 
anaemic and this anaemia can be reversed by the administration of EPO. EPO has 
been observed to be produced by murine bone marrow macrophages (Rich et al 1982) 
however, a more recent report indicated that EPO could not be detected in CFU-GM 
colonies derived from human bone marrow and human peripheral blood macrophages 
(Stpoka et al 1998).
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EPO acts mainly on the erythroid progenitor cells, it prevents apoptosis, stimulates 
proliferation and induces the differentiation of these cells into mature erythrocytes 
(Kirby et al 1996, Liboi et al 1993, Kelley et al 1993). In addition to erythropoietic 
activities, EPO has been observed to be involved in the megakaryocyte lineage, and 
can increase the production of CFU-Meg progenitors from CD34+ bone marrow cells 
in conjunction with TPO (Papayannopoulou et al 1996a). Further evidence for EPOs 
role in the megakaryocyte lineage in mice was indicated by the increase in platelets 
and their precursor, megakaryocytes, after EPO administration (Tsukada et al 1990). 
Evidence to suggest that EPO plays a role out with the haemopoietic system was 
described by Carlini et al, they observed that EPO could induce endothelial cell 
proliferation and protect these cells from LPS induced apoptosis (Carlini et al 1999). 
Furthermore, a previous report also indicated that EPO receptors are expressed in 
human umbilical vein endothelial cells (HUVEC) (Anagnostou et al 1990, 1994) and 
neurones (Morishita et al 1997).
The ability of erythroid cells to respond to EPO is due to their expression of the EPO 
receptor. The EPO-R is a member of the cytokine receptor type I superfamily and 
like most of its members require homo-dimerisation for activation (Livnah et al
1996). Further evidence for the need for homo-dimerisation for activation of EPO 
signalling was observed by Schneider et al, they indicated that monoclonal antibodies 
could mimic the homo-dimerisation of the EPO-R and induce proliferation and 
differentiation of erythroid precursors (Schneider et al 1997). The initial steps in the 
signalling transduction process upon activation of the EPO-R are the activation of 
JAKs (JAK2) and STAT phosphorylation (STAT5) and this is similar to the other 
members of the cytokine receptor type I superfamily (Wojchowski et al 1999).
The in-vitro role of EPO in erythropoiesis was confirmed in-vivo as mice lacking the 
EPO gene or its receptor fail to develop beyond day 13 in utero, due to failure of 
erythropoiesis at the CFU-E stage in the fetal liver. These mice die of a severe 
anaemia due to the absence of red blood cells, thus indicating that EPO is crucial for 
survival, proliferation and differentiation of the late committed progenitors (CFU-E) 
but not the early progenitors (BFU-E) (Wu et al 1995). Further examination of EPO 
and EPOR null embryos have indicated that these embryos also have a heart defect
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and therefore, it seems that EPO signalling system may be involved in heart 
morphogenesis (Wu et al 1999).
The observation that EPO is essential for the terminal differentiation of red blood 
cells has lead to it being used as a therapy in a number of conditions that are 
associated with blood loss. Indeed, EPO is used to treat anaemia in renal failure, 
cancer and HIV patients. It also has also been used to increase platelet number in 
patients with chronic liver disease (Goodnough et al 1997).
1.8 Growth Factor Signal Transduction
1.8.1 Protein Tyrosine Kinase Receptor Signalling
The SCF receptor c-kit is a tyrosine kinase receptor (RTK) which is closely related to 
the receptors for platelet derived growth factor, macrophage colony stimulating factor 
and Fit ligand. As there is a plethora of data on signalling pathways activated by the 
numerous tyrosine kinase receptors it was decided to provide a brief overview of the 
role of c-kitlSCF signalling as an example of how intricate and intertwined the protein 
tyrosine kinase signalling pathways are.
The c-kit receptor contains five Ig like domains in its extracellular domain the first, 
three of which are involved in SCF binding. The fourth Ig domain may play a role in 
receptor dimerisation and the function of the 5th Ig domain has yet to be discovered. 
The organisation of the cytoplasmic domain of c-kit is similar to c-fins, in that both 
cytoplasmic domains contain a catalytic domain, which is separated by a kinase insert 
domain. The first catalytic domain contains the ATP binding site and the second site 
has potential autophosphorylation sites. Before examining the signalling pathways it 
is worth realising that there are two isoforms of SCF, a soluble and a membrane 
associated form, and that each has a different effect on the tyrosine kinase activity of 
c-kit. The membrane anchored form induces a prolonged autophosphorylation of c-kit 
compared to the soluble SCF, and this may be due to a slower rate of down regulation 
via receptor internalisation (Miyazawa et al 1995).
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Fig 1.3 An overview o f  tyrosine kinase receptor signalling pathways
Brief summary o f  the multiple signalling pathways activated by SCF. SCF induces homodimerisation and 
auto-phosphorylation o f  c-kit on various tyrosine residues. Various proteins which contain SH2 domains bind 
to these phosphotyrosines and lead to the recruitment and activation o f  a number o f  other proteins e.g. src 
family members, PI3 K, Grb-2, Ras, Raf-1, MAP kinases, JAKs and STATs. Interaction between different 
components o f  these pathways occurs at multiple points and the negative regulators such as SHP-1,
2 and PKC play a role in controlling the signalling pathways.
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SCF activates multiple signalling components. Upon ligand binding auto 
phosphorylation of various tyrosine residues occurs within the c-kit molecule and this 
allows various signalling adapter molecules to interact with these phosphotyrosine via 
their SH2 domains, such as Crkl and c-Cbl, (Sattler et al 1997). Indeed, a number of 
kinases have been observed to bind to these phosphotyrosines on the c-kit receptor 
such as PI-3 kinase, JAK-2 and members of the src family of kinases such as lyn, c- 
Src and Fyn (Lev et al 1992, Serve et al 1994,Weiler et al 1996, Deberry et al 1997, 
Blume-Jensen et al 1994, Linnekin et al 1997).
Through the actions of these kinases SCF can activate signalling pathways such as the 
Ras-RAF-MAP kinase cascade and the JAK/STAT pathway (Tsai et al 1993). These 
various SCF stimulated pathways need to be controlled, and this may be down to 
negative regulators such as SHP-1. SHP-1 and SHP-2 are SH2 containing protein 
tyrosine phosphatases that have been observed to act as negative regulators of SCF 
activity in haemopoietic cells (Kozlowski et al 1998). Although it may be easier to 
examine each of these pathways individually one needs to remember that many of 
these signalling components can interact with multiple pathways induced upon SCF / 
c-kit interaction and therefore, the end results of c-kit activation is a result of various 
signalling pathways.
1.8.2 Glycoprotein 130 (gpl30) Signalling
The first step in signalling by members of the IL- 6  cytokine family is the specific 
binding of the particular cytokine to the soluble or transmembrane receptor a  sub­
unit. The alpha sub-unit is inert in terms of signalling and requires the interaction 
with the gpl30 sub-unit to produce a signal. Ligand binding stimulates homo or 
hetero dimerisation of gpl30 (Timmerman et al 2000) and although gpl30 possesses 
no intrinsic tyrosine kinase activity, the dimerisation of gpl30 leads to the 
phosphorylation of gpl30. This phosphorylation of gpl30 occurs through the 
activation of a number of the Janus kinase (JAK) family members e.g. JAK1, JAK2 
and TYK which have been observed to be associated with gpl30 via the membrane 
proximal box 1 motif in the cytoplasmic domain of gpl30 (Tanner et al 1995). The 
tyrosine phosphorylation of gpl30 provides a docking site for the SH2 containing 
proteins such as STAT3 and PI-3 kinase (Zhong et al 1994, Minami et al 1996, Chen
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Fig 1.4 Gp 130 signalling pathways
Brief summary o f  the multiple signalling pathways activated by gp 130 family members e.g. IL-6. IL-6 induces 
heterodimerisationof the IL -6a and g p l3 0  receptor sub-units, this in turn leads to the phosphorylation o f  the 
g p l3 0  sub-unit by associated tyrosine kinases. Various proteins which contain SH2 domains bind to these 
phosphotyrosines and lead to the activation o f  src family members, PI3 K,the Ras-Raf-MAP kinase cascade 
and the JAK/STAT pathway. Interaction between different components o f  these pathways occurs at multiple 
points and the negative regulators such as SHP-1 and 2 and PKC play a role in controlling the signalling pathways. 
Interaction between different components o f  these pathways occur at multiple points and the negative regulators 
such as SHP-1 and 2, PKC and SOCS play a role in controlling the signalling pathways.
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et al 1999). Besides using the JAK/STAT signalling pathway, several lines of 
evidence have been observed that suggest that gpl30 stimulation can activate the 
RAS/MAPK signalling pathway. Indeed, IL- 6  can increase the proportion of GTP- 
bound RAS compared to GDP-bound RAS (Nakafuku et al 1993), c-Raf-1 a serine 
threonine kinase known to interact with RAS is also activated by tyrosine 
phosphorylation (Boulton et al 1994). Furthermore, mitogen activated protein kinase 
(MAPK) becomes hyperphosphorylated thus activating its serine / threonine kinase 
activity that can then induce phosphorylation of NF-IL6  that can lead to transcription 
(Nakajima et al 1993).
1.8.3 Beta Common (pc) Sub-Unit Signalling
The mechanism of activation of the GM-CSF/ IL-3/ IL-5 receptor system exhibits 
features that are similar to other members of the cytokine superfamily. Indeed, the pc 
sub-unit is functionally analogous to the gpl30 and IL2Ry and the common sub-unit 
of the IL-4 and IL-13 receptors (Zurawski et al 1993, Bagley et al 1997).
The receptors for IL-3, GM-CSF and IL-5 all lack any intrinsic tyrosine kinase 
activity (Watanabe et al 1996, Itoh et al 1996) however, they can upon stimulation via 
their respective ligands produce a rapid tyrosine phosphorylation of various cellular 
proteins, these include PI-3 kinase, She and the pc sub-unit itself. This is through the 
action of a number of kinases, which have been reported to be associated with the Pc 
sub-unit lyn, fes  and JAK2 (Thompson et al 1995, Linnekin et al 1995, Brizzi et al 
1996, Al-Shami et al 1997, 1998). JAK-2 is a member of the Janus kinase family 
(Quelle et al 1994) and has been observed to be associated with Pc sub-unit via the 
membrane proximal box 1 motif in the cytoplasmic domain of the cytoplasmic tail of 
the Pc sub-unit. Upon activation, JAK2 phosphorylates the membrane distal region of 
pc and STAT 5 a member of the signal transducer activated transcription family of 
DNA binding proteins. Phosphorylation of STAT 5 induces dimerisation, which 
results in translocation to the nucleus where it is involved in gene transcription (Ihle 
1996, Itoh eta l 1998).
As well as tyrosine phosphorylation of Pc allowing the activation of the JAK/ STAT 
pathway it also allows binding of adapter proteins containing src homology 2 (SH2)
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Fig 1.5 Beta common signalling pathways
Brief summary o f  the multiple signalling pathways activated by GM-CSF. GM-CSF induces heterodimerisation 
o f  the a  and Pc GM-CSF receptor sub-units, this in turn leads to the phosphorylation o f  the Pc sub-unit by associated 
tyrosine kinases. Various proteins which contain SH2 domains bind to these phosphotyrosines and lead to the activation 
o f  src family members, PI3 K, the Ras-Raf-MAP kinase cascade and theJAK/STAT pathway. Interaction between differei 
components o f  these pathways occurs at multiple points and the negative regulators such as SHP-1 and 2 and PKC play a 
role in controlling the signalling pathways. Interaction between different components o f  these pathways occurs at multiple 
points and the negative regulators such as SHP-1 and 2 and PKC play a role in controlling the signalling pathways.
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domains. She is one such example and it has been observed to recruit grb2 (Gale et al
1998), the further recruitment of SOS forms a complex, which activates p21 ras 
nucleotide exchange. This leads to the activation of ras and downstream partners on 
the mitogen activated protein (MAP) kinase pathway, including Raf (Okuda et 
a/1997). Other studies have demonstrated that it is not only the tyrosine 
phosphorylation that is important for GM-CSF signalling. Indeed, a serine 
phosphorylation sequence was found in the pc sub-unit that can be serine 
phosphorylated on activation with GM-CSF and can interact with an adapter protein 
14-3-3 £ therefore, serine phosphorylation may also play a role in regulating the 
signalling of GM-CSF (Stomski et al 1999).
1.9 Growth Inhibitors
As well as positive growth regulators there are also negative growth regulators that 
may interact with stem and progenitor cells within the bone marrow to control the 
proliferation of these cells. The major inhibitors of stem cell proliferation include the 
tetrapeptide (AcSDKP), the pentapeptide (pEEDCK), TNF-a, IFN-y, M IP-la and 
TGF-P (Bonnet et al 1995, Frindel and Guigon 1977, Laerum and Maurer 1973, 
Zhang et al 1995, Snoeck et al 1994, Graham et al 1990, Keller et al 1994). A brief 
description of each of these inhibitors and the part of the stem cell compartment that 
they exert their inhibitory effect on is outlined below however for further information 
on these inhibitory molecules see Graham and Wright 1997a, Graham 1997b.
1.9.1 The Tetrapeptide (AcSDKP)
The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) was initially isolated from 
fetal calf bone marrow and is now chemically synthesised and known as Goralatide 
(Lenfant et al 1989). The AcSDKP sequence has been found in a number of larger 
proteins such as Thymosin-p4 (Tp4) and TNF-a (Grillon et al 1990) and has been 
observed to be present in human plasma from healthy individuals (Ezan et al 1994). 
AcSDKP has been observed to be constitutively produced in-vitro by bone marrow 
cells in murine long-term cultures (Wdzieczak et al 1990) and a more recent report 
indicated that the macrophage is the major AcSDKP producing cell (Li et al 1997).
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In-vitro AcSDKP can reversibly inhibit the proliferation of CFU-GM, CFU-Meg and 
BFU-E progenitor cells, it can also inhibit the proliferation of more primitive 
haemopoietic cells such as HPP-CFC and human LT-CIC. Furthermore, AcSDKP 
has been observed to inhibit the proliferative response of purified human CD34+ cells 
to a cocktail of growth factors (Jackson et al 1996, Aidoudi et al 1998, Robinson et al 
1992, Bonnet et al 1993). Although, the sequence SDKP has been observed in TNF- 
a  both these molecules regulate the proliferation of human CD34+ cells differently 
(Bonnet et al 1995) and unlike TGF-p, TNF-a, M IP-la and pEEDCK all of which 
exhibit bi-directional growth activities, AcSDKP has never been observed to exert any 
positive growth signals.
These inhibitory activities of AcSDKP in-vitro were confirmed in-vivo as 
administration of AcSDKP was observed to prevent the recruitment of the colony 
forming unit-spleen (CFU-S) into S-phase and increase the rate of survival of mice 
which have been treated with cytosine-arabinoside (Ara-C) (Bogden et al 1991). As 
well as protecting cells from Ara-C, AcSDKP has also been observed to protect stem 
cells and progenitor cells from various agents such as cyclophosphamide, 5- 
fluorouracil (5-FU), doxorubicin, ionising radiation and hypertherapy or phototherapy 
(Bogden et al 1991, Aidoudi et al 1996, Masse et al 1998, Watanabe et al 1996, 
Wierenga et al 1997, Coutton et al 1994). The inhibitory properties of AcSDKP as 
well as its inability to inhibit leukaemia cells (Bonnet et al 1992) suggested that it 
may have a therapeutic role as a myeloprotective agent during chemotherapeutic 
treatment of cancer. This was confirmed as AcSDKP in association with a 
chemotherapeutic regimen in cancer patients reduces the period of neutropenia (Carde 
et al 1992). However, its use is limited due to its short half-life and this was observed 
to be due to its breakdown by an enzyme normally associated with regulating blood 
pressure, angiotensin-converting enzyme (ACE). A potential role for angiotensin 
converting enzyme (ACE) in the regulation of haemopoiesis was observed as 
administration of Captopril, an inhibitor of ACE, was observed to increase the plasma 
concentrations of AcSDKP by 5-6 fold (Azizi et al 1996, Rousseau et al 1995, Li et al 
1997). These studies indicate that the tetrapeptide (AcSDKP) displays inhibitory 
properties on a range of cells in the stem cell compartment from mature progenitor 
cells to immature progenitor/stem cells.
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1.9.2 The Pentapeptide (pEEDCK)
The pentapeptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) is produced in granulocytes, 
(Paukovitis et al 1983) and its sequence has been observed in the alpha sub-units of 
G-proteins (Pfeilstocker et al 1996). pEEDCK has been observed to reversibly inhibit 
the proliferation of bone marrow progenitor cells and has been reported to protect 
mice from the myelotoxicity associated with Ara-C (Paukovitis et al 1990). 
Paukovitis also observed that pEEDCK could not only inhibit the formation of CFU- 
GM colonies, it could also inhibit the proliferation of CFU-S stem cells in-vivo 
(Paukovitis et al 1993). Furthermore, the addition of pEEDCK to long term bone 
marrow cultures inhibits progenitor production from LTC-ICs (Paukovitis et al 1995).
Interestingly, the oxidation of the thiol group of pEEDCK leads to the formation of a 
disulphide bonded dimer which has been observed to increase the production of CFU- 
GM in long term bone marrow cultures and has no inhibitory activity (Laerum et al 
1998, Paukovitis et al 1995). Activated granulocytes can rapidly oxidise monomeric 
pEEDCK to the dimeric form in-vitro (Paukovitis et al 1998) and the administration 
of (pEEDCK)2 to mice lead to an increase in myeloid progenitors, megakaryocytes, 
mature leukocytes and platelets (Paukovitis et al 1995). The growth promoting and 
inhibitory activities of this pentapeptide suggest this one molecule alone could control 
the regulation of stem cell proliferation.
1.9.3 Tumour Necrosis Factor-alpha (TNF-a)
TNF-a is a member of a family that consists of TNF-p or lymphotoxin alpha (LT-a) 
and lymphotoxin beta (LT-p). Although there are several cell types that produce 
TNF-a, the main source of the cytokine are the monocytes and macrophages and 
these cells can be further induced to produce TNF-a by LPS and IL-1. TNF-a is a 
pleiotropic cytokine and has a number of functions on a variety of cell types; it can 
induce cytokine expression in T cells, fibroblasts, monocytes and endothelial cells; 
TNF-a can induce the express of adhesion molecules on endothelial cells and it can 
also induce the expression of antibodies in B cells and acute phase protein production 
in hepatocytes.
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TNF-a is a bi-directional cytokine as it can stimulate or inhibit cell growth (Backx et 
al 1990). Indeed, TNF-a has been observed to potentiate human progenitor cell 
growth in conjunction with IL-3 and GM-CSF and inhibit the same cells grown in 
SCF, M-CSF or G-CSF (Caux et al 1990, Rusten et al 1994a, b). The inhibitory 
activity of TNF-a is not restricted to committed progenitors as TNF-a has been 
observed to inhibit HPP-CFC colony formation and colony formation of primitive 
haemopoietic cells (Sca-1+/ Lin') (Jacobsen et al 1994).
TNF-a exerts these various functions through interaction with, two distinct TNF-a 
receptors a 55 kDa (TNFR55) and a 75 kDa (TNFR75) both of which exist as soluble 
forms (Aderka et al 1992). TNF-a has been observed to induce distinct functions 
depending on which receptor it interacts with, indeed upon activation of signalling 
through TNFR55, TNF-a induces proliferation of fibroblasts and prostaglandin 
synthesis, whereas, signalling through TNFR75 by TNF-a has been reported to 
mediate T cell, mononuclear, fibroblast and NK proliferation and induction of GM- 
CSF in T cell lines (Naume et al 1991). Furthermore, TNF-a signalling through 
TNF-75 (75 kDa TNF-Receptor) has been observed to inhibit primitive cells whereas, 
the signal through TNF-55 (55 kDa TNF-Receptor) inhibits more committed 
progenitors isolated from bone marrow from mice and humans (Rusten et al 1994b, 
Jacobsen et al 1995b). These observations were confirmed by using specific antibody 
agonists to the two different receptors and studies examining the different activities of 
hTNF-a and mTNF-a, i.e. hTNF-a can not bind to TNFR 75 and thus can not inhibit 
primitive cell proliferation (Rusten 1994b). However, a contradictory report 
examining TNFR55 null mice observed that primitive haemopoietic stem cells, Sca-1+ 
/Lin' /ckit+ cells, are increased in number and TNF could not inhibit the proliferation 
of these cells, suggesting that TNFR55 is the major receptor involved in regulation of 
these HSC (Zhang et al 1995). This contrasting data may be due to the use of two 
different types of primitive progenitors i.e. Sca-1+ /Lin' in the previous study 
compared to Sca-1+ /Lin' /ckit+. These studies indicate that signalling via TNF is 
complex and although each receptor has been observed to signal separately for many 
TNF responses, Tartaglia proposed that signalling through one of the receptors can 
only be obtained through the interaction with the other (Tartaglia et al 1993).
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1.94 Transforming Growth Factor-beta (TGF-P)
Transforming growth factor beta (TGF-P) belongs to a large superfamily of growth 
factors that all share varying degrees of homology with TGF-p. This family can be 
subdivided into four groups the TGF-p family, the bone morphogenic protein (BMP) 
family, the inhibin/activin family, and the MIS (Mullerian inhibiting substance) 
family. TGF-p(l-3) can all inhibit the growth of epithelial, endothelial, keratinocytes 
and haemopoietic cells and although TGFpl was initially shown to be the most potent 
isoform, further studies have indicated that TGF-p3 is in fact the most potent isoform 
(Alexandrow et al 1995, Heimark et al 1986, Sitnicka et al 1996, Hatzfeld et al 1996). 
TGF-P 1, 2  and 3 are located on chromosome 19, 1 and 14 in humans and on 
chromosome 7, 1 and 12 in mice (Fujii et al 1986, Guron et al 1995). TGF-p 
expression has been observed to be ubiquitous and it is secreted from the cell of origin 
in a latent form. This latent form consists of a mature dimer plus two pro-region 
peptides called latency-associated proteins (LAP) and the removal of this produces an 
active TGF-P homodimer.
In-vitro TGF-P has been observed to inhibit the formation of CFU-GEMM, CFU-GM 
and CFU-M colonies in the presence of GM-CSF from human long term bone marrow 
cultures, and similarly TGF-p also inhibited the formation of these progenitor 
colonies in the presence of IL-3 in murine long term bone marrow cultures (Ohta et al
1987). TGF-p inhibitory properties have also been observed in the erythropoietic and 
megakaryocytic lineages as TGFP-1 can inhibit the formation of BFU-E, CFU-E and 
CFU-Meg colonies. TGF-p has also been observed to induce apoptosis of primitive 
haemopoietic progenitor cells (Jacobsen et al 1995a). TGF-p also displays positive 
growth properties as Keller et al have observed that TGF-p 1 can augment GM-CSF 
supported CFU-GM colony formation and also inhibit the formation of these same 
colonies that are stimulated by IL-3 (Keller et al 1991). The inhibitory or stimulatory 
activity of TGF-p is determined by the context in which it is acting i.e. the specific 
nature of the target cells or the presence of growth factors (Keller et al 1994).
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Apart from TGF-p's ability to inhibit and stimulate haemopoietic stem and progenitor 
cells it also plays other important roles in the bone marrow microenvironment that 
may effect the proliferative state of these cells. Indeed, TGF-P 1 has been observed to 
regulate the adhesiveness of cells by increasing the synthesis of extracellular matrix 
protein expression, control of matrix degrading proteases and protease inhibitors and 
increased expression of cell surface receptors for cell adhesion such as integrins. It 
can also regulate the expression of various growth factors and their receptors as 
indicated by the reciprocal interaction between TGFp and M IP-la in bone marrow 
macrophages (Maltman et al 1996). A possible mechanism for TGF-P inhibition or 
stimulation of cell growth is via the down regulation of various growth factor 
receptors.e.g. TGFP can downregulate EGF (Takehara et al 1987), SCF, GM-CSF and 
IL-3 receptors (Jacobsen et al 1993) and up regulate the expression of CCR-1, 3, 5, 6  
and CXCR-4 on dendritic cells (Sato et al 2000).
The in-vivo functions of TGFP-1 were initially examined by injecting mice with TGF- 
p l. TGFp-1 administration was observed to inhibit the proliferation of CFU-S and 
this inhibition was reversible as the growth of these progenitor cells began to recover 
after 24 hours after the withdrawal of the treatment (Migdalska et al 1991). TGFp-1 
was also observed to accelerate the recovery of mice after a dose of 5-FU 
(Grzegorzewski et al 1994) furthermore, TGF-p 1 could also inhibit intestinal 
epithelial cells. These functions of TGF-P 1 indicate that it can play an important role 
in controlling the proliferation of stem and progenitor cells. A further examination of 
TGF-P 1 in-vivo function was observed by disrupting the TGF-p 1 gene. In doing so it 
was observed that approximately 50 % of these TGF-p 1 -/- embryos died before birth 
and the other 50 % survived however, these mice died after 2-3 weeks due to a rapid 
wasting syndrome (Kuilkami et al 1993). Further studies have indicated that the 
survival of some of the TGF-/- embryos was due to the maternal transfer of TGF-P 1 
via the placenta (Letterio et al 1994). The wasting disorder observed in these TGF-p 1 
-/- mice is characterised by the infiltration of various tissues such as heart, lung and 
liver by inflammatory cells and an increase in pro-inflammatory cytokines such as 
TNF-a and M IP-la, which eventually leads to cell death and tissue necrosis. 
However, this can be reversed by the administration of an immuno-suppressing agent, 
Rapomycin (Borkowski et al 1996). A further TGFp-1 null mice study indicated that 
the reason for the death of these embryos prior to birth was due to defects in
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haemopoiesis and blood vessel formation in the yolk sac (Dickson et al 1995). 
Therefore, these TGF-p 1 null mice studies indicate that TGF-P 1 has a role to play in 
early haemopoiesis, vasculogenesis and in inflammation
1.95 Macrophage Inflammatory Protein-1 alpha (MIP-la)
A more detailed description of M IP-la and its various activities can be found in 
section 2.52. Briefly, M IP-la is a member of the pro-inflammatory CC chemokine 
family that has been observed to reversibly inhibit the short term repopulating 
components of the stem cell compartment. Furthermore, it also displays various 
functions from inflammatory activities on mature cells to inhibition of keratinocytes 
and stem cell proliferation. M IP-la or stem cell inhibitor (SCI) as it was previously 
known has been observed to inhibit the transiently engrafting stem cells such as the 
CFU-A and CFU-S stem cells (Pragnell et al 1988, Lord et al 1992). However unlike 
the previously described inhibitors, it has no inhibitory activity on mature progenitors 
or on long term repopulating stem cells or other primitive cell types such as HPP-CFC 
progenitors (Bonnet et al 1995, Broxmeyer et al 1990, 1999, Graham et al 1990, 
Quesniaux et al 1993, Keller et al 1994). M IP-la can protect CFU-S and CFU-A 
stem cells following treatment with the cytotoxic drug cytosine arabinoside (ARA-C) 
by preventing these stem cells from entering S phase of the cell cycle (Dunlop et al 
1992). This ability lead to M IP-la being examined as a myeloprotective agent in 
cancer treatment however, contradictory results have been observed on its efficiency 
to act as a myeloprotective agent (Broxmeyer et al 1998, Bemsteain et al 1997, 
Clemons et al 1998). Under steady state conditions, it is likely that the majority of 
haemopoietic function is regulated at the level of the transiently engrafting stem cells 
with little input from the primitive long term repopulating cells. Therefore, it is likely 
that the transient engrafting cells, the target of M IP-la, may be more in need of 
regular growth control. This may partially explain the relatively restricted pattern of 
M IP-la function within the stem cell compartment. Interestingly, M IP-la null mice 
have no reduction in their short term repopulating stem cells when compared to wild 
type animals suggesting that M IP-la is not essential for the negative regulation of 
stem cell proliferation. However it may be possible that in the absence of M IP-la 
some other growth inhibitor fulfils the inhibitory function of M IP-la.
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CHAPTER 2 : INTRODUCTION
2.1 M IP-la and the Chemokine Super Family : An Overview
The role of macrophage inflammatory protein-1 alpha (M IP-la) as a haemopoietic 
stem cell regulator was initially identified by Graham et al in 1990. They purified a 
reversible inhibitor of CFU-A and CFU-S stem cell proliferation from a murine 
macrophage cell line J774.2 (Graham et al 1990). Sequence analysis demonstrated 
that this protein, which they referred to as Stem cell Inhibitor (SCI), was indeed 
identical to a previously described molecule Macrophage inflammatory protein -1 
alpha (Wolpe et al 1988). M IP-la is a member of a rapidly expanding family of pro- 
inflammatory mediators known as chemokines, the various members of which are 
involved in multiple processes, which include development, haemopoiesis (Graham et 
al 1990), angiogenesis (Streiter et al 1995) and regulation of specific leukocyte 
trafficking (Sozzani et al 1997). The chemokine field has recently become the focus 
of much attention after the major discovery that chemokines and their receptors have 
a role to play in HIV pathogenesis.
The initial members of the chemokine family were identified by biochemical 
purification of biological activities in cell supernatants and subsequent cloning. More 
recently, molecular biologists have identified chemokines by constructing cDNA 
libraries from subtractive hybridisation (Schall et al 1988) and signal sequence trap 
cloning (Tashiro et al 1993) techniques, and screening these libraries against various 
databases such as expressed sequence tags (EST) databases (Rossi et al 1997). This 
has lead to the expansion of chemokine numbers in recent years, from a handful of 
proteins, to in excess of 40. The name chemokine was proposed to convey the 
combined chemoattractant and cytokine properties that had been identified for many of 
these peptides. Chemokines in general are monomeric and constitute a superfamily of 
small 7-18 kDa basic, heparin binding, inducible and secreted pro-inflammatory 
cytokines that can be identified by their sequence homology and the arrangement of 
conserved cysteine residues (Baggolini et al 1994, Rollins et al 1997, Zlotnik et al 
1999). Until recently, the chemokine superfamily was divided up into two subgroups, 
however, there is now evidence to support the existence of a further two subgroups 
within the chemokine superfamily. The two major chemokine subgroups are the CXC
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and the CC subgroup. The CXC subgroup are so called because the two cysteine 
residues nearest the N terminus of these proteins are separated by a single amino acid 
(Baggolini et al 1997), whereas, the CC subgroup have their first two cysteines 
adjacent to one another (see section 2.41, 2.42 and 2.51, 2.52 for a detailed description 
of two CXC and CC respectively). The two newest subgroups of the chemokine 
superfamily are the “C” and the “CX3C” subgroups. The chemokines that belong to 
these subgroups have either a lone cysteine in the N terminal domain or have three 
amino acids separating their two N-terminal cysteine residues, and these will be 
discussed in sections 2.2 and 2.3. (Kennedy et al 1995, Kelner et al 1994, Pan et al 
1997, Bazan et al 1997). For further information on chemokine nomenclature and 
recent discoveries the reader is referred to a review by Zlotnik (Zlotnik et al 1999).
2.2 The C Superfamily
Lymphotactin (Ltn) was cloned from an activated mouse pro-T cell (Kelner et al 1994) 
and its human homologue single cysteine motif chemokine 1 (SCM-1) was 
subsequently isolated (Yoshida et al 1995). Lymphotactin is similar to members of 
the CC and CXC super families, however, it only retains the 2nd and 4th cysteines 
therefore, Ltn can only make one of the two di-sulphide bonds that are characteristic 
features of the quaternary structure of the chemokines (Kennedy et al 1995). In 
humans there are two homologous genes localised on chromosome 1 that encode two 
SCM-1 proteins, SCM-1 a  and SCM-1 P, and these differ by only two amino acids 
(Yoshida et al 1996). Interestingly, both the murine and human genes are found on 
chromosome 1, an unusual location for chemokine genes (Kelner et al 1994, Kennedy 
et al 1995). Lymphotactin expression has been detected in activated pro-T cells, CD8 + 
T cells, NK cells (Hedrick and Zlotnik 1997 a, b), dendritic epidermal T cells 
(Boismenu et al 1996) and mast cells (Rumsaeng et al 1997). Although, Ltn can act as 
a chemotaxin for lymphocytes and NK cells, but not monocytes or neutrophils, the 
exact role of Ltn is as yet unclear (Kelner et al 1994). An orphan receptor first 
identified by Heiber et al, which is now known as XCR1, has been observed to be a 
functional receptor for Lymphotactin and SCM-1 p. Interestingly XCR1 has been 
observed to be highly expressed in placenta, with low levels in spleen, thymus and 
peripheral blood cells (Heiber et al 1995, Yoshida et al 1998). Lymphotactin and 
SCM-1 p are important chemokines not only because of their unusual structure,
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expression pattern and chromosomal location, but also because they are one of the 
growing numbers of chemokines that can induce chemotaxis of lymphocytes 
(Loetscher et al 1996).
2.3 CX3C Superfamily
One of the more interesting observations in the chemokine field was the identification 
of an atypical chemokine, fractalkine or neurotactin (Bazan et al 1997, Pan et al 1997). 
To date, this is the only member of a fourth chemokine subgroup, which contains the 
CX3C fingerprint. This molecule was identified from non haemopoietic cells and has 
been shown to be a 373 amino acid glycoprotein that carries the chemokine domain on 
top of an extended mucin like stalk domain. Fractalkine can exist in two forms, either 
a membrane anchored moiety, as predicted by a stretch of 18 hydrophobic residues 
making this domain the likely transmembrane domain, or a soluble glycoprotein of 95 
kDa. These two forms of fractalkine have different functions, the soluble form has a 
potent chemoattractant activity for monocytes and T cells (Bazan et al 1997, Imai et al 
1997), whereas, the expression of the membrane bound form, which can be actively 
induced on primary endothelial cells by IL-1 and TNF-a, promotes leukocyte 
adhesion. Studies have indicated that the chemotactic activity of fractalkine can be 
inhibited by pertussis toxin, whereas, the direct adhesion of cells to tethered 
fractalkine cannot. Thus indicating that signalling through a pertussis toxin sensitive 
receptor is needed for the chemotactic activity of fractalkine, but not its adhesive 
function (Imai et al 1997, Haskell et al 1999). Pan et al alternatively cloned 
Fractalkine as neurotactin in 1997, and its messenger RNA is predominantly expressed 
in mouse brain. Both groups identified the chromosomal location to be distinct from 
the majority of other chemokine families, human chromosome 16 (Bazan et al 1997) 
and chromosome 8  in the mouse (Rossi et al 1998). However more recently, two CC 
chemokines genes for monocyte-derived chemokine (MDC) and thymus and 
activation-regulated chemokine (TARC) have been shown to be located on 
chromosome 16 (Imai et al 1998, Nomiyama et al 1997). The exact function of this 
fourth chemokine subfamily has yet to be defined however, fractalkine is a versatile 
molecule that can regulate both cell-cell interactions as the membrane bound form and 
directed cell migration by the soluble form. A more recent report indicates that 
fractalkine may well be involved in leukocyte trafficking within the central nervous 
system (CNS), as expression of both fractalkine and its receptor CX3CRI have been
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detected in the CNS (Nishiyori et al 1998). Interestingly, CX3CRI has been observed 
to be an HIV co receptor in-vitro (Combadiere et al 1998), however, the relevance of 
this in-vivo has still to be recognised. Thus, further investigation is needed to uncover 
the functions of fractalkine and CX3CRI in vivo.
2.4 The CXC Superfamily
The CXC superfamily consists of at least 15 chemokines and there may be more to be 
found. Platelet factor-4 (PF4) was the first CXC protein to be characterised. Its 
sequence was reported in 1977, 10 years before the discovery of IL- 8  (Walz et al 
1977). CXC chemokines with biological activities similar to PF-4 and IL- 8  were 
discovered e.g. GRO-a, p and y, ENA-78, IP-10 and Mig (For an up to date list of the 
members of the chemokine families see figure 2.1). The CXC chemokines can be 
further subdivided into chemokines that contain the motif ELR prior to their first 
cysteine residue and those that do not contain the ELR motif. Interleukin-8 , GRO-oc, 
p, y, ENA-78, and GCP-2 are a few of the CXC chemokines that contain the ELR 
motif, and they generally all have the ability to chemoattract and activate neutrophils 
(Clark-Lewis et al 1993 1994, Rollins et al 1997), whereas, the non ELR CXC 
chemokines, IP-10, Mig, SD F-la /p, I-TAC and BCA-1 have little or no effect on 
neutrophils and attract activated T lymphocytes (Taub et al 1995). The introduction of 
the ELR motif into PF-4, a non-ELR containing CXC chemokine, enables this 
chemokine to chemoattract and activate neutrophils, however, this is not always the 
case, as the introduction of the ELR motif into IP-10, Mig or the CC chemokine MCP- 
1 has no effect on their activities (Clark-Lewis et al 1993). A full discussion of the 
CXC chemokine members is beyond the scope of this work, therefore, only two CXC 
chemokines will be discussed in more detail below, IL- 8  (an ELR CXC chemokine) 
and SDF-1 (a non-ELR CXC chemokine). These chemokines are of particular interest 
as both have activities that are involved haemopoiesis.
2.4.1 Interleukin -8 (IL-8)
The prototypic CXC chemokine IL- 8  was purified and originally described as 
MDNCF (monocyte derived neutrophil chemoattractant factor), (Schroeder et al 1987) 
and NAP-1 (neutrophil activating protein-1) due to its ability to chemoattract
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neutrophils in-vitro (Walz et al 1987). The cDNA corresponding to Interleukin- 8  was 
cloned shortly after by Matsushima et al in 1988 (Matsusihima et al 1988).
Human IL- 8  can be synthesised and secreted by a host of cell types including 
monocytes/macrophages (Schroeder et al 1987, Yoshinumra et al 1987), T cells 
(Gregory et al 1988), neutrophils (Streiter et al 1990a) and endothelial cells (Streiter et 
al 1989, Utgaard et al 1998) and can be further induced by IL-1, TNF-a and LPS. 
Two distinct forms of human IL- 8  have been identified (Van Damme et al 1990, 
Yoshimura et al 1989), the most abundant form being the naturally occurring one 
which is 72 amino acids in length. The alternatively spliced form of IL- 8  is 77 amino 
acids in length and is produced by endothelial cells, and therefore is sometimes 
referred to as endothelial IL-8 . This larger protein is 10 fold less potent at attracting 
and activating neutrophils in-vitro (Gimbrone et al 1989). However, in-vivo there is 
no apparent difference in neutrophil attraction or activation by either of these proteins 
and this is thought to be due to N terminal processing that occurs in-vivo and not in- 
vitro.
Although IL- 8  is an inflammatory cytokine that is known to function as a neutrophil 
chemoattractant and activating factor (Baggolini et al 1992), it can also act as a 
chemotaxin for monocytes, NK cells (Morohashi et al 1995), T cells (Bacon et al 
1995) and mast cells (Nilsson et al 1999). Other properties attributed to IL- 8  include 
induction of oxidative burst and lysosomal enzyme release in neutrophils (Baggolini et 
al 1992), histamine release by basophils (Dahinden et al 1989) and IL- 8  may also have 
a role to play in angiogenesis (Koch et al 1992, Strieter et al 1995). Upon injection of 
IL- 8  into mice, the entire inflammatory process of neutrophil recruitment can be 
observed in tissues, and this was initially thought to be due to the diffusion of IL- 8  
between the pericellular space of the endothelial cells of the blood vessels (Swensson 
et al 1991). However, a more recent study observed that IL- 8  produced in tissues was 
transcytosed across the endothelial cells (EC) and presented at the lumenal surface. 
Furthermore, this study also suggested that the interaction of IL- 8  with the 
promiscuous chemokine receptor DARC and heparan sulphate were involved in this 
process (Middleton et al 1997).
A role for IL- 8  in the haemopoietic system was postulated by Broxmeyer et al, who 
observed that IL- 8  could suppress colony formation of mature progenitor cells from
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unfractionated bone marrow grown in SCF and GM-CSF (Broxmeyer et al 1993). A 
later study by Graham et al using growth conditions that induce the proliferation and 
differentiation of a more primitive population of cells, transiently engrafting stem cells 
referred to as colony forming unit-agar CFU-A, indicated that IL- 8  could not inhibit 
the formation of these CFU-A colonies (Graham et al 1993). This may indicate that 
IL- 8  like M IP-la has a restricted inhibitory role in haemopoiesis. A further possible 
role of IL- 8  in haemopoietic system was observed by Laterveer et al, who described 
that IL- 8  alone or in combination with SCF could mobilise progenitor cells to the 
peripheral blood (Laterveer et al 1996). A further study by Liu et al reported that IL- 8  
was unable to induce mobilisation of these stem and progenitor cells in G-CSF null 
mice, and they therefore suggested that IL- 8  indirectly mobilises these cells by the 
possible increase in expression of G-CSF (Liu et al 1997). However, a further study 
by Pruijt et al observed that antibodies to the 02 integrin LFA inhibited the 
mobilisation of progenitor and stem cells in mice injected with IL- 8  (Pruijt et al 1998). 
From this observation, they suggested that IL- 8  may alter the adhesiveness of these 
progenitor cells and this may be an important step in mobilisation of these cells to the 
peripheral blood.
IL- 8  has been observed to induce its various activities by binding to two specific 
receptors; these receptors were originally called IL-8 RA and B but are now referred to 
as CXCR1 and CXCR2. CXCR1 is more selective in respect to ligands than CXCR-2, 
as CXCR1 can only interact with IL- 8  and GCP-2 with high affinity, whereas, CXCR2 
has high affinity for IL- 8  and all other ELR containing CXC chemokines e.g. growth 
related oncogene (GRO) proteins, epithelial neutrophil attractant-78 (ENA-78), 
neutrophil activating protein-2 (NAP-2) and granulocyte chemotactic peptide-2 (GCP- 
2). Human CXCR1 cDNA was first isolated by Holmes et al in 1991, and a year later 
Lee et al isolated the cDNA for the human CXCR2 receptor (Holmes et al 1991, Lee 
et al 1992). These receptors are 78 % identical to one another and the genes were 
found on chromosome 2. Expression of both receptors have been identified on various 
mature blood cells neutrophils, monocytes/macrophages and on cytokine activated 
eosinophils, basophils, T lymphocytes, mast cells and dendritic cells (Morohashi et al 
1995, Heath et al 1997, Ochensberger et al 1999, Nilsson et al 1999, Sozzani et al 
1997). Although there are 2 forms of human IL-8 , there has yet to be identified a 
mouse or rat homologue. The existence of such a rodent counterpart is suggested by 
inhibition of lung inflammation in rats with neutralising antibodies to human IL- 8
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(Mulligan et al 1993). Cacalano identified a reputed mouse gene with close homology 
to CXCR1 and CXCR2, and on the examination of IL-8 R null mice they observed an 
expansion in neutrophilic myeloid cells, B cells and enhanced myelopoiesis in the 
bone marrow (Cacalano et al 1994). This lead to the suggestion that the signalling 
through the murine IL- 8  receptor was involved in the negative regulation of B cells 
and neutrophil production and this is consistent with the negative regulatory effects 
that human IL- 8  has on myeloid cells in-vitro (Lu et al 1993). A further study by 
Broxmeyer et al also indicated that murine IL- 8  receptor knockout myeloid 
progenitors were insensitive to human IL- 8  or MIP-2 providing further evidence for 
the negative regulatory role of mIL-8 R (Broxmeyer et al 1996).
2.4.2 Stromal Derived Factor 1 (SDF-1)
Stromal derived factor (SDF-1) or pre-B cell growth stimulatory factor (PBSF) was 
originally cloned from bone marrow stromal cell lines using a signal sequence trap 
technique (Tashiro et al 1993). Alternative splicing produces two isoforms of SDF-1, 
SDF-1 a  and SDF-1 p, which differ by four C-terminal amino acids (Shirozu et al 
1995). Similarly to Mig and IP-10, SDF-1 a  and P do not contain the ELR motif prior 
to the first cysteine residue and thus do not induce neutrophil migration (Liao et al
1995). SDF-1 a  and p have been reported to chemoattract lymphocytes, macrophages 
and as the original name pre-B cell growth stimulatory factor suggests, they can 
stimulate B cell progenitor proliferation in-vitro (Bleul et al 1996). SDF-1 has proved 
to be unique among the chemokines, in that it is constitutively expressed by many 
tissues and it is highly conserved between species e.g. human and mouse SDF-1 are 
99% identical in sequence (Shirozu et al 1995).
In-vitro studies observed that SDF-1 is a chemotaxin for CD34+ haemopoietic cells 
and cells of the megakaryocyte lineage, isolated from the bone marrow and peripheral 
blood (Wang et al 1998). Although SDF-1 has been observed to induce migration of 
haemopoietic progenitor cells, SDF-1 alone or in combination with IL-3 and SCF 
displays no enhancement of colony formation. However, SDF-1 has been observed to 
decrease the colony formation of a myeloid progenitor cell line, 32D cells (Sanchez et 
al 1997) suggesting that it may play a role in regulation of myeloid progenitors in- 
vivo. Further work has also indicated that SDF-1 can induce adhesion of
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megakaryocytes to bone marrow endothelial cells and enhance megakaryocyte 
progenitor migration (Wang et al 1998). Furthermore, Campbell et al also 
demonstrated that SDF-1 could induce adhesion of lymphocytes to endothelial cells 
(Campbell et al 1998). These various studies indicate that SDF-1 may be involved in 
trafficking of mature blood cells and, migration or homing of CD34+ progenitors to 
different niches during the differentiation and maturation of haemopoietic progenitor 
cells. A further activity of SDF-1 is its ability to inhibit HIV-1 from infecting their 
target cells (Bleul et al 1996) this will be discussed later in section 2.10. In an attempt 
to further examine the role of SDF-1, inactivation of the PBSF/SDF-1 gene and 
examination of the resultant embryos was reported by Nagasawa et al (Nagasawa et al
1996). These SDF-1 null mice died perinatally and were observed to have a reduced 
level of B cell progenitors in both the liver and bone marrow and a reduction in 
myelopoietic progenitors in the bone marrow. These SDF-1 null mice also displayed 
major defects of the heart, the large blood vessel supplying the gastrointestinal tract, 
and the brain. Upon further examination of earlier developing embryos from these 
SDF-1 null mice, it was observed that these embryos had normal fetal liver 
myelopoiesis, suggesting that the decrease in bone marrow myelopoiesis is possibly 
due to the impaired migration of myeloid stem/ progenitor cells from the fetal liver to 
the bone marrow (Nagasawa et al 1996).
These multiple functions of SDF-1 are induced through its interaction with its receptor 
CXCR-4. CXCR4 was previously known as LESTR and Fusin (Loetscher et al 1994, 
Feng et al 1996) however, subsequent work identified SDF-1 as the ligand for both of 
these receptors and therefore, this receptor was formally renamed CXCR4 (Bleul et al 
1996, Oberlin et al 1996). CXCR4 is widely expressed in the various mature cell 
types of the haemopoietic system e.g. neutrophils, monocytes, T and B cells and 
expression has also been observed in less mature cell types such as B cell precursors 
and CD34+ progenitor cells (Zaitseva et al 1997, 1998). Outwith the haemopoietic 
system, CXCR4 has been observed to be expressed on vascular endothelial cells, in 
both microglia and astrocytes in the brain and neurones in the peripheral and central 
nervous system (Gupta et al 1998, He et al 1997). Interestingly CXCR4 null mice 
display a similar phenotype to SDF-1 null mice, suggesting that the interaction of 
SDF-1 and CXCR4 is unique and non promiscuous in-vivo, and that their interaction is 
involved in homing of stem cells to their niches.
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Figure 2.1 An up-to-date list of the Human and Murine Chemokines
CC Chemokines CXC Chemokines
Human Mouse Human Mouse
1-309 TCA-3 GRO-a GRO/KC?
MCP-1 JE GRO-P GRO/KC?
M IP-la MIP-la GRO-8 GRO/KC?
MIP-lp MIP-lp PF-4 PF-4
RANTES RANTES ENA-78 LIX?
Unknown Cl 0/MRP-1 GCP-2 CKa-3
MCP-3 MARC? NAP-2 Unknown
MCP-2 MCP-2? IL-8 Unknown
Unknown MRP-2/MIP-18 Mig Mig
Eotaxin Eotaxin IP-10 IP-10
Unknown MCP-5 I-TAC Unknown
MCP-4 Unknown SDF-1 a/p SDF-1
HCC-1 Unknown BCA-1 BCA-1
HCC-2 Unknown BRAK BRAK
HCC-4 Unknown Unknown Lungkine
TARC TARC
PARC/DC-CK1 Unknown CX*C Chemokines
ELC/MIP-3p ELC/MIP-3p Human Mouse
LARC/MIP-3a LARC/MIP-3a Fractalkine Neurotactin
SLC SLC
MDC ABCD-1 C Chemokines
MPIF-1 Unknown Human Mouse
Eotaxin-2 Unknown Lymphotactin/SCM-1 a Lymphotact
TECK TECK SCM-lp
Eotaxin-3 Unknown
CTACK/ILC/ CTACK/ILC/Eskine
Figure 2.1 An up-to-date list o f  the Human and Murine Chemokines
? Possible murine equivalent, if one exists
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2.5 The C-C Chemokines
The C-C chemokine superfamily is by far the largest chemokine subfamily containing 
somewhere in the region of 28 members. The first C-C chemokine was isolated by 
differential hybridisation from human tonsillar lymphocytes and was known as LD78 
(Obaru et al 1986). Several cDNA isoforms of a closely related protein Act-2 were 
later identified (Lipes et al 1988). Due to the amino acid identity of more than 70%, 
the murine proteins M IP-la and MIP-lp were considered as the homologues of LD78 
and Act-2 (Sherry et al 1988), and recently the names M IP-la and p have been used 
to describe both the murine and human forms of the proteins. Like the a  chemokines 
(CXC), the p chemokines (CC) can be further divided into inducible pro-inflammatory 
chemokines such as M IP-la and RANTES which can be produced in response to 
microbial, inflammatory or immune signals, and account for the increased leukocyte 
recruitment under these conditions, and constitutive homeostatic chemokines such as 
HCC-1, SLC and ELC, which are hypothesised to control the normal trafficking of 
leukocytes under physiological conditions. Other examples of CC chemokines are 
RANTES (Regulated on activation normal T expressed and secreted) (Schall et al
1988), 1-309 (Miller et al 1989), HCC-1 (Schulz-Knappe et al 1996) and MCP-1 
(Yoshimura et al 1989 a,b,). Due to the use of techniques referred to earlier the 
expansion in numbers of CC chemokines has been more dramatic in recent years; 
TARC (Imai et al 1996), TECK (Vicari et al 1997), Eotaxin-2 (Forssmann et al 1997), 
MCP-4 (Uguccioni et al 1996), secondary lymphoid chemokine (SLC) (Nagira et al
1997), Epstein-barr virus 1 chemokine (ELC) (Yoshida et al 1996), MPIF (Patel et al
1997), ESkine (Baird et al 1999) and for further examples of CC chemokines the 
reader is referred to a review by Zlotnik (Zlotnik et al 1999). Historically, the C-C 
chemokines were described as monocyte and macrophage chemotaxins, however, it is 
now accepted that C-C chemokines can induce chemotaxis of a variety of leukocyte 
populations. As was the case for the CXC chemokines, the discussion of only two CC 
chemokines relevant to this project is presented in more detail below.
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2.5.1 RANTES (Regulated upon Activation of Normal T cell Expressed and 
Secreted)
RANTES was isolated by Schall et al from a differential screen using T cells versus B 
cells (Schall et al 1988). RANTES is a basic protein composed of 69 amino acids 
which contains a 23 amino acid signal peptide and upon cleavage a mature protein of 
approximately 7.8 kDa is generated. The murine RANTES gene is localised on 
chromosome 11 (Danofif et al 1994), whereas, the human gene resides on chromosome 
17 (Nelson et al 1993). Murine and human RANTES share 85 % amino acid identity 
and this may explain the observed species cross reactivity of RANTES (Schall et al
1992).
RANTES is produced by a variety of cells such as T cells, natural killer (NK) cells, 
platelets (Klinger et al 1995), eosinophils (Lim et al 1996) and epithelial cells (Schall 
1991). RANTES expression has also been detected from synovial fibroblasts isolated 
from patients with Rheumatoid arthritis (RA) (Rathanswami et al 1993), and the 
expression of RANTES in these cells can be fiirther stimulated by TNF-oc and IFN-y.
RANTES was initially identified as a chemotaxin for monocytes and memory T cells 
but not neutrophils (Schall et al 1990), however, further studies indicated that 
RANTES can chemoattract a wide variety of leukocyte subsets e.g., eosinophils 
(Rot et al 1992), platelets (Kameyoshi et al 1992), basophils (Bischoff et al 1993), NK 
cells (Taub et al 1995), CD4+ and CD8 + T cells (Roth et al 1995) and memory T cells 
CD4+ CD45 RO+ (Schall et al 1990). RANTES may also play an important role in 
trans endothelial migration of leukocytes as RANTES has been observed to induce 
adhesion of monocytes and T cells (Vaddi et al 1994) to recombinant ICAM-1 and 
VCAM-1 (Lloyd et al 1996), and can regulate the secretion and activity of matrix 
metalloproteinase 2 and 9 (Xia et al 1996). RANTES induces its functions through 
the chemokine receptors CCR1, 3, 5 and D6  and these are discussed in section 2.6.1.
RANTES has been implicated in a number of auto-inflammatory diseases, e.g. 
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple 
sclerosis (MS), which is characterised by auto-reactive T cells infiltrating the CNS 
(Miyagishi et al 1997). Following antigen recognition, these cells become activated
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and secrete their pro-inflammatory cytokines TNF-oc and IL-1 which in turn lead to the 
induction of chemokines such as M IP-la and RANTES and the subsequent 
recruitment of additional inflammatory cells into CNS (Ranschoff et al 1996). 
RANTES has also been implicated in other inflammatory diseases e.g. Rheumatoid 
Arthritis (Kunkel et al 1996), asthma which leads to Allergic Airway inflammation 
(AAI) (Luckas et al 1996a), and skin inflammation (Schroder et al 1996). Further 
evidence for RANTES involvement in these inflammatory states was observed by the 
ability of a RANTES derivative Met-RANTES to reduce the onset of collagen induced 
RA, and also reduce the leukocyte infiltration in AAI (Plater-Zyberk et al 1997, 
Gonzalo et al 1998). These observations indicate that RANTES may be 
pathogenically responsible for the manifestations of these diseases.
2.5.2 Macrophage Inflammatory Protein 1 Alpha (MIP-la)
M IP-la was initially identified as a part of a complex known as macrophage 
inflammatory protein (MIP) which was released from a murine macrophage cell line 
after LPS stimulation. (Wolpe et al 1988). Subsequent fractionation proved MIP 
activity contained two closely related proteins, M IP-la and MIP-lp, and their cDNA 
clones were isolated by Sherry et al (Sherry et al 1988). Human M IP-la, previously 
known as LD78, is 92 amino acids in length and contains a 22 amino acid signal 
peptide (Obaru et al 1986). Upon cleavage, the secreted product is a 70 amino acid 
polypeptide, which has a molecular weight of about 7.8 kDa. Murine M IP-la is a 
single copy gene and is located on chromosome 1 1  clustered with the majority of the 
other members of the C-C chemokine family. In humans, unlike the mouse, there are 
three distinct isoforms of M IP-la (LD78 a, p and y). They are clustered with the 
majority of other p chemokines on chromosome 17 in the region q 11 -q21. The a  gene 
exists, as a single copy however, there can be anywhere between 0  and 6  copies of the 
p gene on chromosome 17 (Irving et al 1990). The product of the LD78a gene was 
initially thought to be the human homologue of mMIP-la. However, a recent study 
by Nibbs et al indicated that upon analysis of receptor binding, the product of the 
LD78p gene was more closely related to mM IP-la than LD78a (Nibbs et al 1999). 
Nibbs et al also observed that LD78p is a more efficient inhibitor of HTV infection 
compared to LD78a, and this was further confirmed by a study by Menten et al which 
indicated that LD78P was more potent at inhibiting HIV infection than LD78a, MIP-
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1 p or RANTES (Menten et al 1999). These studies therefore, suggested that LD78p is 
the human homologue of murine M IP-la and not LD78a as initially proposed. 
Furthermore, the observation that certain individuals have several copies or no copies 
of the LD78p gene suggests that these individuals may be less or more susceptible to 
becoming HIV positive. Unlike LD78 a  and P, LD78 y  cannot produce mRNA and is 
therefore an unexpressed pseudogene. It also differs from the a  and P forms by 
having its upstream control region and most of its first intron missing, this may 
explain why LD78y cannot be expressed. Similarly to LD78p, LD78 y  can be present 
in a various copies on chromosome 17ql l-q2 1  and interestingly in some individuals it 
is missing (Irving et al 1990).
Initial observations indicated that M IP-la and MIP-lp like other chemokines such as 
RANTES have the propensity to form high molecular weight aggregates in 
physiological buffers, and that these molecules could exist as multimers with 
molecular mass in excess of 100 kDa. This self aggregation is dependant on the 
protein concentration and the buffer in which the peptide is dissolved and is a 
consequence of non covalent, and electrostatic interactions as reversal of the
aggregation can be observed at high salt concentrations (Patel et al 1993, Graham et al
1993). Graham et al produced monomeric, dimeric and tetrameric forms of m M IP-la 
by sequentially neutralising carboxyl terminal acidic amino acid residues and observed 
that these variants, when compared to the wild type protein, have similar activities in 
CFU-A colony forming assays and monocyte shape change assays (Graham et al
1994). They therefore suggested that the active form of M IP-la must be the 
monomeric form and that the high molecular weight aggregates, dissaggregate in 
dilute solution. A similar study using human M IP-la indicated that disaggregation 
did not effect the activity of the molecule. Indeed, Czaplewski and colleagues 
produced a M IP-la mutant, by a single amino acid substitution Asp26 to Ala26, 
which they referred to as BB10010 and had an average native molecular weight of 19 
kDa (Czaplewski et al 1999).
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2.5.2.1 M IP-la Expression
In un-stimulated cells it is difficult to detect M IP-la mRNA and protein, however, 
with the use of sensitive PCR, M IP-la mRNA has been reported to be detectable at 
low levels within a wide variety of haemopoietic and non haemopoietic cell types and 
in the blood and bone marrow of healthy individuals (Cluitsman et al 1995). This 
suggests that there is a basal level of M IP-la in normal tissue in the absence of any 
overt inflammation and the probable source is monocytes and tissue macrophages.
A number of different stimuli such as LPS, IL-3, IFN-y, M-CSF, GM-CSF, adhesion 
molecules and antibodies can cause rapid and transient induction of M IP-la 
transcription and translation in numerous cell types which include macrophages 
(Maltman et al 1993, 1996, Jarmin et al 1999), neutrophils (Alam et al 1992), 
basophils (Li et al 1996), mast cells (Yano et al 1997), B cells (Sharma et al 1997), T 
cells (Marie et al 1997) and platelets (Klinger et al 1995). A more recent study by 
Majka et al also demonstrated that human CD34+ cells and CD34+/c-kit+ cells that are 
enriched for myeloid precursors can express and secrete M IP-la, MIP-lp and 
RANTES, and upon stimulation with IFN-y the level can be increased (Majka et al 
1999). Other studies have also detected M IP-la in non-haemopoietic cell types such 
as primary human fibroblasts (Nakao et al 1990), epidermal langerhan cells (Parkinson 
et al 1993), glioma cells and microglial cells (Hayashi et al 1995, Tanabe et al 1997). 
As well as inducing M IP-la expression, there are also a number of factors that have 
been observed to inhibit M IP-la production, indeed IL-10, IL-4 and IL-13 inhibit 
M IP-la production by inducing mRNA degradation in peripheral mononuclear cells, 
human blood monocytes and alveolar macrophages (Berkman et al 1995, 1996, 
Standiford et al 1993). A study by Maltman et al reported that TGF-p down regulated 
the expression of M IP-la (Maltman et al 1993), and on further analysis Maltman 
defined an endogenous reciprocal relationship between M IP-la and TGF-P in bone 
marrow macrophages whereby, elevation of M IP-la lead to the increase in TGF-p 
which in turn lead to the suppression of M IP-la. Thus, in the bone marrow where 
TGF-p levels are easily detected, TGF-p may act as a control element and keeps the 
level of M IP-la in check (Maltman et al 1996). Furthermore, Jarmin et al observed 
that IL-3 and GM-CSF can induce the expression of M IP-la in bone marrow
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macrophages and that the level of M IP-la expression is reduced in the presence of 
TGF-p (Jarmin et al 1999). Interestingly, TGF-p has been observed to down regulate 
the expression of GM-CSF and IL-3 receptors as well as CCR1, a M IP-la receptor. 
Therefore, TGF-p can interfere with M IP-la activity by reducing its expression, by 
down regulating the expression of its receptors and by down regulating the receptor 
expression of growth factors that up regulate M IP-la expression. In contrast to the 
above model of M IP-la regulation, McManus et al observed that expression of MIP- 
l a  and MIP-lp can be induced by LPS in human fetal microglia and that TGF-P could 
not modulate their expression (McManus et al 1998). Therefore the relationship 
between M IP-la and TGF-p demonstrated in-vitro might be more complicated in- 
vivo, where M IP-la expressing cells will ultimately be exposed to a wide range of 
interacting growth factors.
2.5.2.2 Inflammatory Effects of M IP-la
Historically, CC chemokines have not been observed to chemoattract neutrophils, 
however, the injection of high concentrations of MIP-1 into the footpads of mice was 
observed to induce neutrophil infiltration into the injection site (Wolpe et al 1988). 
Additionally, McColl et al indicated that human M IP-la had limited ability as a 
neutrophil chemoattractant (McColl et al 1993) and more recently murine M IP-la was 
observed to induce both chemotaxis and calcium release in murine neutrophils (Gao et 
al 1997). Furthermore, Zhang et al observed that human M IP-la can only induce a 
small release of calcium, and cannot induce chemotaxis in human neutrophils (Zhang 
et al 1999). The confusion in neutrophil chemoattraction by M IP-la may be 
explained if M IP-la does not play a role in neutrophil chemoattraction in humans but 
does in mice. IL- 8  in humans may have evolved to play a more specific role in human 
neutrophil chemoattraction than M IP-la, and as mice do not have a homologue of IL- 
8 , M IP-la may fulfil the role of IL- 8  in mice. These studies indicate that one has to 
be cautious in assuming that the functions of a chemokine in mouse are the same as in 
man.
M IP-la in common with other chemokines has multiple activities on a range of 
leukocytes. M IP-la has been observed to chemotax monocytes and CD8 + T 
lymphocytes (Fahey et al 1992, Taub et al 1993, Schall et al 1993), as well as being a
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chemotaxin for dendritic cells, NK cells, basophils and mast cells, it also activates 
these cells (Alam et al 1994, Luckas et al 1995a) and M IP-la can enhance the 
proliferation and activation of T lymphocytes (Taub et al 1996). Furthermore, MIP- 
l a  can also induce the expression of cytokines such as TNF-a, IL -la  and IL- 6  from 
macrophages (Fahey et al 1992). Antigen activation of the B cell receptor triggers the 
expression of M IP-la and MIP-lp and as B cell maturation is ultimately dependant on 
T cell help, it is possible that the expression of M IP-la and P two T cell 
chemoattractant agents (Tedla et al 1998) may be one mechanism that helps bring 
these two cell types together (Krzysiek et al 1999). These observations indicate that 
M IP-la has multiple activities on a range of leukocytes and that M IP-la acts at the 
onset of inflammation and can be clearly seen as an important immuno-regulatory 
cytokine.
In order to examine the biological role of M IP-la in-vivo, Cook et al (Cook et al
1995) generated M IP-la null mice. Mice homozygous for this disruption revealed no 
obvious abnormalities in development or haemopoiesis, thus suggesting that M IP-la 
is not required to maintain normal stem cell quiescence and other stem cell inhibitors 
must compensate, since the cycling rates of the stem cells from M IP-la null mice is 
comparable to that seen in wild type animals. However, these M IP-la null mice were 
shown to have a phenotype but only after infection with influenza or coxsackie 
viruses. M IP-la was observed to be essential for the effective control of the influenza 
infection, as M IP-la null mice infected with influenza were observed to have a 
reduced inflammatory response and a delayed clearance of the virus from their lungs 
(Cook et al 1995). Furthermore, the characteristic myocarditis observed in wild type 
mice infected by coxsackie B virus did not occur in M IP-la null mice. The 
observation that T cells are needed for the viral clearance from lungs and the possible 
involvement of cytotoxic T cells in the cardiac lesions associated with myocarditis 
indicates that M IP-la maybe the essential molecule needed for recruitment of these 
cells. A further study by Cook et al also observed the role of T cells and M IP-la in 
the clearance of the intracellular pathogen Listeria monocytogenes in-vivo (Cook et al
1999).
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2.52.3 M IP-la as a Haemopoietic Regulator
M IP-la has a number of other activities outwith the pro-inflammatory actions on the 
mature blood cell system. M IP-la can reversibly inhibit stem cell proliferation, 
however, its inhibitory properties are restricted to the transiently engrafting stem cells. 
Within the stem cell compartment, a range of in-vitro assays have demonstrated MIP- 
la 's  ability to inhibit the growth of cells detected in CFU-GEMM, BFU-E and CFU- 
S/A assays and its inability to inhibit proliferation of more primitive cell types such as 
long term repopulating stem cells and HPP-CFC 1 (Su et al 1997, Graham et al 1990, 
Quesniaux et al 1993, Keller et al 1994). Removing lineage positive cells from bone 
marrow and enriching the remaining lineage negative cells on the basis of expressing 
an antigen known as Thy-1, indicated that M IP-la could not inhibit the mature Thy-1+ 
Lin ' cells, however, M IP-la could inhibit the Thy-1 lo/" Lin' population (Keller et al 
1994). Su et al observed that M IP-la can inhibit the formation of BFU-E but not 
CFU-E from human bone marrow and suggested that this may be through the 
interaction with a known M IP-la receptor CCR1 as the observed inhibition could be 
reversed by anti CCR1 antibodies (Su et al 1997). However, Broxmeyer et al 
indicated that CCR-1 is not the dominant receptor for M IP-la suppression of myeloid 
progenitors such as CFU-GEMM, CFU-GM or BFU-E in mice (Broxmeyer et al 
1999). These contradictory results suggest that the interaction between M IP-la and 
CCR1 and the functional outcome may be different in the human and murine systems.
In-vivo studies have also indicated that M IP-la can function as an inhibitor of stem 
cell proliferation. Indeed, Dunlop et al observed that M IP-la could protect the CFU-S 
stem cells following treatment with the cytotoxic drug cytosine arabinoside (ARA-C) 
and furthermore, M IP-la was observed to inhibit the proliferation of dl2 CFU-S stem 
cells (Dunlop et al 1992). M IP-la suppression was further substantiated in-vivo in 
mice (Lord 1992) and was confirmed in breast cancer patients by an analogue of MIP- 
l a  with improved solubility properties, BB10010 (Broxmeyer et al 1998). However, 
data from other clinical trials have suggested that M IP-la, BB-10010, displays no 
myelosuppressive activities (Bernstein et al 1997, Clemons et al 1998). A further 
activity of M IP-la was observed upon systemic injections of BB-10010, which 
produced a mobilisation of progenitor cells to the peripheral blood in mice and
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humans (Lord et al 1995, Broxmeyer et al 1998). As well as the possibility of the 
myeloprotective activity of M IP-la being useful as a therapeutic in cancer treatment, 
the increased mobilisation of stem cells to the peripheral blood may also prove to be 
useful in leukopheretic protocols prior to ablative therapies. An additional therapeutic 
role for M IP-la lies in the treatment of some leukaemia’s. Eaves and colleagues have 
indicated that M IP-la does not inhibit the proliferation of primitive CML cells, but 
can inhibit the proliferation of normal primitive progenitors supported in long-term 
cultures (Eaves et al 1993, Chasty et al 1995). Chronic myeloid leukaemia (CML) is a 
clonal disorder of the pluripotent haemopoietic stem cell, which is characterised by the 
constitutively activated Bcr-Abl protein tyrosine kinase (PTK). A further study by 
Wark et al using FDCP-Mix cells transfected with a temperature sensitive v-abl PTK, 
indicated that M IP-la could inhibit these cells at the restrictive temperature and could 
protect these cells from death due to exposure of cytotoxic agents. However, at the 
permissive temperature for abl PTK activity, M IP-la treatment did not inhibit the 
proliferation of these cells and could not protect these cells from cell death induced by 
cytotoxic drugs (Wark et al 1998), thus providing further evidence for the possible 
treatment of CML with a regime of cytotoxic agents and M IP-la.
As well as growth inhibitory properties M IP-la has been observed to exert growth- 
promoting effects on some cells of the haemopoietic system. These growth- 
stimulating functions depend on the maturation state of the cellular population and the 
presence of specific growth conditions. Indeed, DeWynter et al isolated CD34+ cells 
from human bone marrow and cord blood and observed that M IP-la could inhibit 
CFU-GM from CD34+ human bone marrow and stimulate the growth of CFU-GM 
from cord blood (DeWynter et al 1998). Furthermore, Broxmeyer et al also reported 
that in-vitro M IP-la could enhance CFU-GM and CFU-M progenitor colony 
formation (Broxmeyer et al 1989, 1990 and 1999). In non stromal contact long term 
bone marrow cultures, M IP-la in the presence of IL-3 and diffusable soluble stromal 
factors has also been observed to maintain the numbers of long term repopulating 
cells, and it has been suggested that this may be due to the inhibition of differentiation 
(Verfaillie et al 1995). In addition to the inhibition of CFU-A/S stem cells, M IP-la 
has been observed to function as a potent and reversible inhibitor of human 
keratinocyte proliferation (Parkinson et al 1993). Epidermal langerhan cells and not 
keratinocytes are the source of M IP-la, and it is hypothesised that M IP-la regulates
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the proliferation of the stem cells within the skin (Graham et al 1992). High levels of 
M IP-la have been detected in and around wounds suggesting a possible role for MIP- 
l a  in wound healing (Dipetro et al 1998). These studies indicate that as well as MIP- 
l a  inhibiting cell proliferation of transiently engrafting stem cell it can also act as a 
growth stimulator.
2.5.2.4 M IP-la and Diseases
The wide range of biological functions of M IP-la indicates that its uncontrolled 
expression may play a role in inflammatory diseases. Indeed, M IP-la neutralising 
antibody studies have been used to demonstrate that M IP-la is involved in a number 
of autoimmune diseases. M IP-la antibodies can reduce the neutrophil infiltration in 
rats with LPS induced acute lung injury and also reduce the granuloma formation 
around the ova of the Schistosome parasite (Shanley et al 1995, Lukacs et al 1993). 
Furthermore, the administration of M IP-la antibody attenuated the influx of 
eosinophils in a mouse model of airway inflammation, suggesting an in-vivo role for 
M IP-la in eosinophillic inflammation (Rot et al 1992, Lukacs et al 1995).
Allergic inflammation is characterised by the presence of activated eosinophils, 
basophils and T cells and since M IP-la attracts and activates eosinophils, basophils, 
lymphocytes and monocytes it may play a role in the pathogenesis of allergic 
inflammation. Inflammatory lung disease can be induced experimentally in lab 
animals and it is associated with considerable up regulation of M IP-la expression. 
The exacerbation of asthma into allergic airway inflammation (AAI) is dependant on 
antigen challenge and the generation of inflammatory mediators. These inflammatory 
mediators and chemotactic factors can activate various populations of leukocytes and 
the recruitment and activation of eosinophils is thought to be responsible for the 
adverse effects in AAI. It has been shown that the CC chemokines M IP-la, 
RANTES, Eotaxin and MCP-3 are potent eosinophil chemotaxins in vitro (Jose et al 
1994, Rothenburg et al 1997, Dahinden et al 1994). However, the specific 
contribution of these chemokines in the pathology of AAI is not known. Luckas and 
Kunkel developed a murine model of AAI and they observed that antibodies against 
M IP-la and RANTES (Luckas et al 1995b) reduced eosinophil recruitment during the 
pathogenesis of the disease.
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M IP-la is also involved in Rheumatoid arthritis (RA). This autoimmune disease is 
characterised by a recruitment and activation of leukocyte subsets in the synovial fluid 
of joints. In patients suffering from RA, it has been shown that the synovial 
chondrocytes are an abundant source of M IP-la (Pulsatelli et al 1999, Borzi et al 
1999). In combination with other chemokines, M IP-la is known to play a role in the 
infiltration of leukocyte subsets into tissue and is thought to be involved in the 
pathogenesis of RA. An animal model of RA, Murine type 2 collagen induced 
arthritis, also shows an up regulation of M IP-la expression and this increases as the 
incidence and severity of the disease increases, and significantly the extent of the 
disease is reduced when the mice are treated with monoclonal antibodies to M IP-la 
(Thornton et al 1999)
There is evidence both in-vitro and in-vivo for the production of M IP-la in the CNS, 
Hayashi et al indicated that M IP-la expression was induced in microglial cells after 
stimulation with LPS and Miyagishi observed that M IP-la was present in the 
cerebrospinal fluid of MS patients (Hayashi et al 1995, Miyagishi et al 1995). MIP- 
l a  can also induce calcium release and chemo-attraction in astrocytes (Tanabe et al 
1997). Further evidence for the expression of M IP-la in brain was observed in HIV 
encephalitis and schizophrenia patients (Shmidtmayerova et al 1996, Ishizuka et al 
1997). Indeed, Experimental autoimmune encephalomyelitis (EAE) is an autoimmune 
disease of the CNS, which serves as a model for the human disease multiple sclerosis 
(MS). In both diseases circulating leukocytes penetrate the blood brain barrier, and the 
subsequent demyelination of neurones which is mediated by T cells results in impaired 
nerve conduction and paralysis (Macfarlin et al 1983, Karin et al 1993). In this 
condition it is the recruitment of inflammatory cells by M IP-la and MCP-1 that 
contributes to the pathogenesis of the disease. Further evidence for the role of M IP-la 
in EAE was demonstrated by Karpus et al, they indicated that antibodies to M IP-la 
could prevent the development of EAE (Karpus et al 1995).
2.6 Chemokine Receptors and Binding Proteins
Chemokine receptors belong to the seven transmembrane spanning family of G- 
protein coupled receptors. To date there are 20 human chemokine receptors, many of 
which exhibit multiple ligand specificity, indicating the redundancy and versatility of
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the chemokine system. Five human CXC chemokine receptors (CXCR1 through 
CXCR5), 11 human CC chemokine receptors (CCR1-11), one human CX3C and one 
human XCR1 have been identified thus far (Zlotnik et al 1999). An atypical human 
and murine receptor (D6 ) has been cloned by Nibbs et al. This receptor displays the 
greatest promiscuity of all the chemokine receptors, and thus far it has not been shown 
to signal in response to ligand binding (Nibbs et al 1997a, b). In addition to these 
receptors, there is a chemokine binding protein expressed on the surface of red blood 
cells and post capillary high endothelial cells known as Duffy antigen receptor for 
chemokine (DARC). This is a 7 transmembrane receptor that does not appear to 
signal upon interaction with various chemokines and thus may be coupled to different 
signalling transducing pathways. Although the chemokine/ ligand promiscuity does 
not usually cross the CC and CXC boundaries one exception to the rule is the Duffy 
Antigen Receptor for Chemokines (DARC) (Hadley and Peiper 1997).
Common features of chemokine receptors include; a conserved primary amino acid 
homology 36-77 % in CXC and 46-89 % with CC receptors, an acidic N terminus and 
a DRYLAIVHA sequence or a variation of it in the second intracellular loop. 
Furthermore, these receptors also have two conserved cysteines (Cys) residues in their 
primary amino acid sequence, one in the NH2 terminal domain and one in the third 
extracellular loop, and these cysteine residues form a disulphide bond which is critical 
for the conformation of the ligand pocket. The major shared biological function of the 
chemokine receptors is leukocyte trafficking and dependent processes such as immune 
surveillance, innate and adaptive immune responses (Foxman et al 1997). Within 
these areas each chemokine receptor appears to have a specific role, which is 
determined by their expression pattern on specific leukocytes and the temporal and 
spatial specificity of its ligand expression. The known chemokine receptors all appear 
to exhibit overlapping specificity, figure 2 .2 , albeit with variable affinities for their 
different ligands. As indicated above there is a number of chemokine receptors 
however, within the context of this project the relevant receptors are the receptors that 
interact with M IP-la and RANTES and these are described in more detail in section 
2.6.1. For further information on chemokine receptors the reader is referred to a more 
recent review on the chemokine receptors by Murphy et al (Murphy et al 2000).
Interestingly chemokine receptors are not the only proteins that chemokines can 
interact with. Chemokines are highly basic proteins and because of this a further
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property of most chemokines is their ability to interact with heparin and 
glycosaminoglycans (Koopman and Krangel 1997, Koopman et al 1999). Indeed, 
numerous studies have indicated that various chemokines such as IL-8, PF-4, M IP-la, 
MIP-lp and RANTES can interact with heparin (Mayo et al 1995, Koopman and 
Krangel 1997, Koopman et al 1999). The immobilisation of chemokines by the cell 
surface proteoglycans or components of the extracellular matrix is thought to be 
important for the maintenance of the immobilised or haptotactic gradient, which is 
needed for leukocyte activation, diapedesis and migration into the tissue (Rot et al 
1993). However, a further role for GAG binding was suggested by Kuschert et al, 
they observed that soluble GAGs could form complexes with chemokines and that 
these complexes could inhibit chemokine receptor binding and cellular responses of 
these chemokines (Kuschert et al 1999). Until recently, no data has been obtained to 
directly indicate a role for these interactions in-vivo however, a study by Middleton et 
al indicated that heparan sulphate can interact with IL-8 in-vivo (Middleton et al 
1997).
In an attempt to analyse the function of the heparin-binding site in M IP-la, Graham et 
al produced a variant of m M IP-la that had its stem cell inhibitory activity uncoupled 
from its ability to chemoattract monocytes. Graham and colleagues named this 
molecule HepMut, this molecule has a mutation of two basic amino acids in its 
proteoglycan binding domain which renders this molecule unable to bind to a range of 
proteoglycans. HepMut was observed to be as good as wild type M IP-la at inhibiting 
CFU-S / A cell proliferation, however, it was unable to induce monocyte shape change 
or bind to the M IP-la receptor CCR1 (Graham et al 1996), thus suggesting that the 
binding of proteoglycans is not essential for M IP-la induced stem cell inhibitory 
activity but may be involved in monocyte chemoattraction through its interaction with 
CCR1. A similar study by Koopman et al identified a single basic residue that is 
involved in the binding of human M IP-la to glycosaminoglycans (GAGs). They 
observed that the ability to bind to GAGs was not essential for receptor binding or 
signalling in-vitro by M IP-la and unlike HepMut this mutant could bind to CCR1. 
This may be due to species differences or due to the different nature of the 
mutagenesis (Koopman and Krangel 1997). This also suggests that GAG binding is 
not necessary for the activity of M IP-la, however, all chemokines can bind to heparin
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Figure 2.2 The Human Chemokine Receptor Family and Associated Ligands
Receptor Ligands
CXCR1 IL-8, GRO-a, GCP-2
CXCR2 IL-8, GRO-a, P and 8, NAP-2, ENA-78, GCP-2
CXCR3 IP-10, MIG, I-TAC
CXCR4 SDF-1 a  and p
CXCR5 BCA-1
CCR1 MIP-la, P, RANTES, MCP-3, HCC-1, 2 and 4, MPIF-1
CCR2 MCP-1,3 ,4
CCR3 Eotaxin, Eotaxin 2,3, RANTES, MCP-2,3, 4, HCC-2
CCR4 TARC, MDC
CCR5 M IP-la, MIP-lp, RANTES, MCP-2
CCR6 MIP-3a
CCR7 ELC, SLC
CCR8 1-309
CCR9 TECK
CCR10 CTACK
CCR11 SLC, TECK
D6 MIP-la, P, RANTES, MCP-1,2,3,4, Eotaxin, HCC-1
XCR1 Lymphotactin, SCM-ip
CX3C1 Fractalkine
Duffy RANTES, MCP-1, IL-8
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and it is possibly involved in the presentation of chemokines in sites of active 
inflammation (Hoogeworf et al 1997). A further study by Oravecz et al suggested that 
GAGs were important in the inhibitory activity of RANTES and M IP-la in HIV 
infection, as removal of these GAGs resulted in the inability of RANTES and M IP-la 
to inhibit HIV infection (Oravecz et al 1997). This result suggested that either the 
presentation of these chemokines to CCR5 or indeed, the increased local concentration 
produced by the interaction of the chemokine with the GAG is important in the 
mechanism of HIV inhibition. These studies indicate that chemokine binding to 
GAGs is not always necessary for their function, however, they do suggest that these 
molecules may have a role to play in some aspects of chemokine function.
2.6.1 The C-C Receptors used by M IP-la and RANTES
2.6.1.1 CCR1
CCR1 was originally designated MIP-la/RANTES receptor based on its high affinity 
for these ligands. The CCR1 gene is on human chromosome 3 clustered with several 
other chemokine receptors such as CCR3, CCR5, and several orphan receptors 
(Samson et al 1996). Human CCR1 can bind multiple inflammatory/inducible human 
CC chemokines with similar high affinities, M IP-la, RANTES, MCP-2 and 3, 
leukotactin-1/ MIP-5 and MCIF-1, and also bind other ligands such as MIP-lp, MCP- 
1 and HCC-1 with lower affinities, as indicated in figure 2.2. Mouse CCR1 displays 
an 80 % sequence identity to the human receptor and has been observed to bind both 
human and murine M IP-la with high affinity (Post et al 1995, Zhang et al 1999). 
CCR1 is expressed on monocytes, macrophages and T-lymphocytes, furthermore there 
is an increased expression of CCR-1 on CD45RO+ memory T cells compared to that 
on CD45 RO' T cells (Sallusto et al 1999). Pre-treatment of monocytes with IL-10 
leads to an increased expression of CCR1, as well as CCR3 and CCR5, and this is due 
to IL-10 prolonging the half-life of the mRNA (Sozzani et al 1998, Zella et al 1998). 
Furthermore, Graham et al have observed that both human and murine M IP-la do not 
induce the inhibition of proliferation of CFU-A /S stem cells through CCR1 (Graham 
et al 1996), these differences may be due to different functions of CCR1 in humans 
and mice.
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Further investigation into the role of CCR1 in-vivo was obtained by generating CCR1 
null mice. These CCR1 null mice are viable, indicating that CCR1 is dispensable for 
growth and development and there are also no apparent defects in the haemopoietic 
and reproductive systems. However, these mice are susceptible to Aspergillus 
infection, produce a reduced granulomatous response to schistosome egg challenge 
and reduced pneumonitis in a pancreatitis-induced pneumonitis model (Gao 1997, 
Gerard 1997), indicating that CCR1 is involved in various inflammatory responses.
The role of CCR1 in growth regulation within the stem cell compartment is not clear. 
Su et al reported that by using anti-CCR-1 antibodies, that human CCR1 is the 
receptor involved in the inhibition of BFU-E colony formation (Su et al 1997), 
however, Broxmeyer et al observed that murine CCR1 is not involved in inhibition of 
myeloid progenitors but is involved in growth promotion of more mature mouse 
progenitor cells (Broxmeyer et al 1999).
2.6.1.2 CCR3
The human cDNA for CCR3 was first identified by Combadiere et al and was 
identified as an eosinophil chemoattractant receptor, and maybe important in allergic 
responses such as asthma and antihelminthic host defences as in these conditions 
eosinophil numbers greatly out weigh the other leukocyte populations. The open 
reading frame predicts a polypeptide chain 355 amino acids in length and this displays 
closest homology to CCR-1, 62% identical at the aa level. Human CCR3 can interact 
with Eotaxin, Eotaxin 2 and 3, RANTES, MCP-3 and 4 and MIP-5 /Leukotactin-1. In 
contrast, the murine CCR3 receptor has been observed to bind MIP l a  and RANTES 
(Post et al 1995, Grimaldi et al 1999). CCR3 has been observed to be expressed on 
eosinophils (Kitaura et al 1996), basophils (Uguccioni et al 1997), mast cells, Th2 
lymphocytes (Sallusto et al 1997), dendritic cells and microglial cells. The expression 
of CCR-3 on human monocytes and macrophages can be further enhanced by 
treatment with IFN-y (Hariharan et al 1999). At present no CCR-3 knockout mouse 
has yet to be made available however, eotaxin gene disruption has been performed by 
two different groups who observed conflicting results. The first group Rotheburg et al 
observed that there was a 40% reduction in airway eosinophillia after ovalbumin 
challenge (Rothenburg et al 1997) and the second group reported that there was no 
reduction at all (Yang et al 1998). Thus although CCR3 and its expression on
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eosinophils may be involved in allergic airway pathologies further work is needed to 
confirm this. Interestingly, a modified form of the chemokine macrophage 
inflammatory protein 4 (MIP-4), Met-chemokine-P7 (CKp7), which has been 
alternatively known as pulmonary and activation-regulated chemokine (PARC), 
dendritic cell-derived C-C chemokine (DCCK-1), was observed to act as a potent 
specific antagonist for CCR3 (Nibbs et al 2000), further indicating the role of CCR3 in 
asthma and allergic airway inflammation. CCR3 has been observed to be able to act 
as an effective co receptor for several neurotropic strains of HIV-1 and thus may be 
involved in the dementia associated with AIDS (Price and Brew 1988). However, not 
all HIV-1 strains use CCR3 indicating that additional mechanisms may underlie the 
ability of HIV-1 to cause neurological impairment (He et al 1997, Shieh et al 1998).
2.6.1.3 CCR5
Human CCR5 was cloned by Samson et al in 1996 and is expressed on dendritic cells, 
CD34+ HPC, activated memory T cells and monocytes (Samson et al 1996, Alkahtib et 
al 1996, Bleul et al 1997, Ruiz et al 1998). Furthermore, the expression of CCR5 on 
human monocytes and macrophages can be further enhanced by treatment with IFN-y 
(Hariharan et al 1999). Outwith the haemopoietic system it has been observed to be 
expressed in neurones and astrocytes within the CNS, on capillary endothelial cells, 
epithelium and vascular smooth muscle cells. CCR5 ligands are M IP-la, RANTES, 
MIP-lp and MCP-2 and these bind with high affinity, their low affinity ligands are 
MCP-1, 3 and 4 and eotaxin (Combadiere et al 1996, Blanpain et al 1999). Mouse 
CCR5 has a similar ligand profile to the human receptor.
The role of CCR5 in-vivo was investigated by homologous recombination and on 
analysis of these CCR5 null mice it was observed that they develop normally, 
however, they do appear to have a reduced efficiency at clearing Listeria infection 
indicating a partial defect in macrophage function (Zhou et al 1998). Similarly the 
loss of CCR5 in humans has no obvious deleterious effects however, it does protect 
these individuals from infection by M-tropic HIV viral strains (Liu et al 1996, 
Benkirane et al 1997). A more recent study suggested a possible pathogenic role for 
CCR5 in multiple sclerosis (MS). T cells from MS patients have an increased level of 
CCR5 compared to that of healthy individuals. Furthermore, these T cells were
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observed to secrete high levels of IFN-y (Balashov et al 1999), which has been 
previously observed to induce the expression of CCR5 and various CC chemokines in 
monocytes and macrophages.
2.6.1.4 D6
Human and murine D6 were identified by Nibbs et al in 1997 and signalling studies 
indicated that D6 did not use similar signalling pathways to the other CC chemokines, 
and thus D6 has not been given a systematic name (Nibbs et al 1997a, b). Both 
proteins display an alteration in the highly conserved DRYLAIVHA motif observed in 
other chemokine receptors changing it to DKYLEIVHA in both human and murine 
D6. A further difference in D6 compared to other chemokine receptors is a single 
amino acid switch from an aspartic acid residue in the second transmembrane domain 
to asparagine. This aspartic acid residue is conserved in most chemokine receptors 
and Farzan et al observed that on mutating the aspartic acid residue in human CCR5, 
they can interfere with signalling processes but not ligand binding (Farzan et al 1999). 
Therefore, it is possible that these particular changes in the D6 receptors alter their 
ability to signal via the normal signalling pathways associated with the chemokine 
receptors. However, it may be possible to observe signalling through alternative 
signalling pathways in cell types that naturally express the D6 receptor e.g. lymphatic 
endothelial cells (Nibbs personal communication). Nibbs et al also observed that hD6 
does not act as a co receptor with CD4 for entry of M or T tropic isolates of HIV-1 or 
SIV into human cells however, less abundant viral strains use D6 as a co receptor. 
The gene has been localised to the gene cluster on human chromosome 3 (Bonini et al 
1997), human D6 has 71% sequence homology to murine D6 and the receptors display 
similar receptor ligand binding profiles.
Interestingly, all the ligands that bind D6 have a proline residue at position 2, this may 
be relevant in light of the discovery of an enzyme Di-peptidyl peptidase IV or CD26, 
which acts to remove the first two amino acids of proteins that have the N terminal 
sequence Xaa-Pro, where Xaa is a random amino acid. This has been hypothesised to 
alter the receptor binding of these chemokines and may also alter the repertoire of 
receptors that these chemokines interact with (Vanhoof et al 1995). Indeed, evidence 
supporting this hypothesis was reported by Proost et al who observed that CD26 
truncated RANTES is a chemotactic inhibitor and has increased anti-viral potency,
79
thus suggesting a role for CD26 in HIV infection and inflammatory processes (Proost 
et al 1998). CD26 digestion has also been observed to reduce the potency of SDF-1 
and M IP-la at inhibiting HIV-1 infection and reduces the chemotactic ability of 
eotaxin (Proost et al 1998, Nibbs et al 1999, Struyf et al 1999). These studies indicate 
that the removal of the first two amino acids has varying effects on the activities of 
different chemokines and it may be possible that CD26 digestion is a method of 
regulating chemokine interactions with D6.
2.7 Signalling of Chemokine Receptors
The signalling processes involved in the various functions of chemokines are both 
numerous and extremely complex and are not within the context of this project. 
Therefore, this section on signalling is only brief and introduces the general concepts 
involved in chemokine signalling, figure 2.3.
All chemokine receptors are members of the G-protein coupled receptor (GPCR) super 
family, which also contains rhodopsin receptors, other chemoattractant receptors such 
as C5a and the classic GPCR, the p adrenergic receptor. Classically the heterotrimeric 
GTP-binding proteins interact with the 2nd and 3rd intracellular loops of the various 
chemokine receptors and these G-proteins can either be members of the pertussis 
toxin-sensitive Gi or insensitive Gq families. Agonist binding to the receptor catalyses 
the exchange of GTP for the GDP that is bound to the G a sub-unit and this induces a 
dissociation /reassociation cycle of G a and Gpy sub-units. The GTP bound G a sub­
unit and the GPy sub-units then both independently activate downstream effectors such 
as adenylate cyclase, phospholipase C, PKC and PI-3 Kinase. Furthermore 
chemokines have been observed to signal through the activation of both the 
JAK/STAT and MAPK pathways (Myers et al 1995, Turner et al 1998, Mellado et al 
1998, Yen et al 1997, Wu et al 1993, Ganju et al 1998a).
In addition, although chemokine receptors lack tyrosine kinase activity, they can also 
stimulate the phosphorylation of the cytoskeletal protein paxillin (Dutt et al 1998), 
induce the activation of the related focal adhesion tyrosine kinases and various 
mitogen activated kinases (Ganju et al 1998 a, b, Mellado et al 1998), through the 
activation of small guanosine triphosphate-binding proteins of the Ras and Rho
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Figure 2.3 An Overview of Chemokine Signalling
PLD PLA-, PLC Ras PI3K Ser/Thr 
Kinases 
and
Phospholipases Phospholipases
Kinases
PA, DAG AA IP3, DAG MAPK 
C a 2+ PKC
PIP3
Figure 2.3 : An overview of chemokine signalling
Chemokine receptors are members o f  the serpentine G-protein coupled family 
and as indicated above stimulation o f  the receptor by ligand can induce various 
signalling pathways.
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families. Rho proteins are involved in cell motility through the regulation of actin 
dependant processes such as membrane ruffling, pseudopodia formation, and assembly 
of focal adhesion complexes. Indeed, Laudanna reported that the activation of RhoA a 
low molecular weight G-protein could induce integrin mediated adhesion on 
stimulation by IL-8 (Laudanna et al 1996). This indicates that chemokines can 
activate signalling pathways using both heterotrimeric and monomeric G-proteins e.g. 
Ras and Rho. Different cell types express varying combinations of trimeric G protein 
sub-units, consequently, there are cell type differences in the coupling of G proteins to 
receptors, which ultimately determine the signal transduction pathway activated in 
response to the chemokine. Furthermore, variable responses to one chemokine 
mediated through different receptors can produce differences in Ca mobilisation 
from intracellular versus extracellular stores and differences in downstream signalling 
events. Indeed, this is the case with the interaction of IL-8 and its receptors CXCR1 
and CXCR2 in neutrophils. CXCR-1/ IL-8 activation leads to an increase in Ca2+ from 
intracellular stores and the activation of Phospholipase C and phospholipase D (PLD), 
which in turn stimulates the release of neutrophilic granules and activates a number of 
serine/threonine and tyrosine kinases (L-Heureux et al 1995). In contrast, IL-8 
activation of CXCR-2 stimulates Ca2+ influx from outside the cell but does not activate 
PLD, or induce the release of neutrophilic granules (Damaj et al 1996). Thus the 
control of the signalling potential of a particular chemokine depends not only on the 
expression of the correct receptor on the surface of the cell, it also depends on the 
expression of the various types of G-proteins within the various cell types.
2.8 Leukocyte Trafficking
Immunosurveillance and host defence is dependent upon the movement of leukocytes 
to sites of inflammation, and the subsequent migration of these cells to the lymphoid 
tissue. Both these processes require the complex interplay between adhesion 
molecules and chemokines. The maintenance of leukocyte trafficking, whether it be in 
inflamed tissue or into lymphoid organs, is regulated by a multi step process involving 
a series of co-ordinated interactions between the leukocytes and the endothelial cells 
(Butcher 1991, Springer 1994). This process has been postulated to contain four steps: 
(a) primary adhesion and rolling of leukocytes; (b) activation and arrest; (c) firm 
adhesion; and (d) diapedesis. A considerable body of in-vitro evidence for the role of 
chemokines in the regulation of leukocyte emigration, from the vascular compartment
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to sites of inflammation exists, see review by Adams and Lloyd (Adams and Lloyd 
1997).
The majority of research in the chemokine field has indicated that the interaction 
between chemokines and their receptors induces chemoattraction and activation of 
myeloid and monocytic cell types whereas, comparatively little is known about 
chemokines that could interact with the lymphoid cells. However, more recent studies 
have indicated that there are several chemokines and their receptors that are involved 
in regulating the movement of lymphocytes and other immune cells. This lead to the 
chemokines being roughly divided into two functional groups inflammatory 
chemokines and homeostatic chemokines. The inflammatory chemokines are up 
regulated by inflammatory or immune stimuli in various cell types such as 
macrophages and endothelial cells, and function to attract appropriate effector cells 
into the tissue to respond to the particular pathogen or tissue damage. Whereas, the 
homeostatic chemokines are constitutively expressed in certain tissues or organs, and 
are involved in constitutive leukocyte trafficking as well as establishing the cellular 
compartments within these tissues or organs e.g. secondary lymphoid tissue.
Initial evidence for the role of chemokines in homeostatic trafficking to the 
compartments of secondary lymph nodes came from knockout studies of a receptor 
that is normally expressed on B cells, CXCR5. These mice displayed undeveloped B 
cell follicles in the spleen and Peyers patches, and transfer of these CXCR5 null B 
cells to wild type mice indicated that these cells could not migrate to splenic follicles. 
Furthermore, the ligand for CXCR5, B cell attracting chemokine /B lymphocyte 
chemoattractant (BCA-1/BLC) is expressed in stromal cells of secondary lymphoid 
organs (Gunn et al 1998), indicating a role for this interaction in trafficking of cells in 
LN. The identification of a further chemokine previously identified as Six-cysteine 
CC chemokine (6Ckine), Exodus-2, Thymus-derived chemotactic agent (TCA-4) or 
Secondary lymphoid tissue derived chemokine (SLC), indicated that this ligand was 
involved in trafficking of dendritic and T cells and the interaction of these cells in the 
secondary lymphoid tissue (Hedrick et al 1997b, Nagira et al 1997, Hromas et al 
1997, Tanabe et al 1997). CCR7, the receptor for SLC, is expressed on activated 
dendritic cells and its expression is higher on naive compared to activated T cells, 
further suggesting that the interaction between itself and its ligands may be involved in 
leukocyte trafficking. The role of SLC in leukocyte trafficking was shown in CCR-7
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null mice, where the naive T cells have a reduced ability to enter lymph nodes (Forster 
et al 1999). Furthermore, mice homozygous for a spontaneous mutation pit (paucity 
of lymph node T cells), lack SLC expression in lymphoid organs and have a defective 
T cell trafficking to lymph nodes (Gunn et al 1999). These are only a few examples of 
how recently identified chemokines are involved in normal haemopoietic cell 
migration and how this may affect the structure of lymph nodes. An interesting study 
by Foxman et al, indicated that neutrophils that are moving up one chemokine gradient 
can upon entering another gradient turn and migrate up the new gradient (Foxman et al 
1997), thus it seems that various leukocytes can respond to complex patterns of 
chemokine gradients, and these gradients guide these cells to their destinations in 
inflamed tissue or to lymphoid organs.
2.9 Viruses and Chemokines
Given the important roles of chemokines in diverse immune processes it is not 
surprising that viruses have exploited chemokine biology. In doing so these viruses 
can evade the immune system and increase their chances of survival. This 
phenomenon is emphasised by the large numbers of chemokines, chemokine receptors 
and general inhibitors and modulators of chemokine action that are encoded within 
different viral genomes. The chemokine receptors serve as co receptors for two 
important human pathogens, Plasmodium vivax and human immunodeficiency virus 
(HIV). The malarial parasite uses the DARC receptor to infect erythrocytes whereas, 
the HIV virus uses CD4 and several chemokine receptors as co factors to infect 
various cell types and these will be discussed in sections 2.10.
The Kaposi sarcoma associated Herpes vims (KSHV)/ Herpesvirus 8 encodes a 
number of viral chemokine homologues, vMIP-I, vMIP-II and vMIP-III, which show 
homology to M IP-la and have the ability to interact with CCR3 and CCR8 (Moore et 
al 1996, Kledal et al 1997, Endres et al 1999). Furthermore, Arvanitakis et al 
observed that KSHV also encodes a GPCR that can interact with both CC and CXC 
chemokines. This KSHC receptor has been observed to display angiogenic properties 
and more interestingly this receptor is constitutively active and can induce 
proliferation, without ligand activation, in transfected cells (Bais et al 1998, 
Arvanitakis et al 1997). The expression of this receptor has been observed in Kaposi
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sarcoma and primary lymphoma and the constitutive activation of this receptor may be 
involved in the regulation of these conditions.
Human cytomegalovirus (HCMV), (3-herpesvirus HHV-6, the Herpes virus saimiri 
(HVS) and Molluscum contagiosum virus (MCV) types 1 and 2 are further examples 
of viruses that encode chemokine like receptors and chemokine antagonists (Gao et al 
1994, Isegawa et al 1998, Ahuja and Murphy 1993, Krathwohl et al 1997). However, 
detailed descriptions of these are out with the scope of this project and the reader is 
referred to a number of recent reviews (McFadden et al 1998, Lalani et al 1999).
2.10 HIV/AIDS and the Role of Chemokine Receptors
HIV enters target cells by direct fusion of the viral and target cell membranes. This is 
mediated by the viral envelope protein (Env), which binds to CD4 on the target cell 
with high affinity. CD4 was observed to allow Env mediated fusion, entry and in 
human cells but not in non-human cells. Further experiments, performed using cell 
hybrids supported the hypothesis that a co-factor specific to human cells was involved 
in HIV fusion, rather than a fusion inhibitor in non-human cells. Thus the concept of 
co-receptor usage for HIV infection was hypothesised long before their discovery. A 
number of CC chemokines, RANTES, M IP-la and MIP-P produced by CD8+ T cells 
lines, can suppress infection of T cells by the M tropic, but not the T tropic, HIV-1 
strains (Cocchi et al 1995). This observation indicated that chemokines may 
determine the susceptibility to HIV-1 and that chemokine receptors may act as co­
receptors for the HIV-1 infection. Indeed, Feng et al showed that a 7 transmembrane 
receptor they termed Fusin could act in conjunction with CD4 to aid infection of T cell 
lines (Feng et al 1996). Fusin was subsequently observed to be identical to 
LESTR/CXCR4, and its ligand SDF-1 was observed to suppress infection by T tropic 
HIV-1 strains (Bleul et al 1996). The discovery of CXCR4 as a co-receptor for HIV 
infection and the suppressive properties of the CC chemokine RANTES, M IP-la and 
MIP-lp focused studies on the possibility that M-tropic HIV strains may use another 
chemokine receptor as an HIV co receptor. Indeed, several groups subsequently 
observed that CCR5, which binds RANTES, M IP-la and MIP-lp, is the co-receptor 
for M-tropic, but not T tropic, HIV-1 strains (Alkhatib et al 1996). Interestingly, it has 
become evident from the isolation of viral isolates over the progression of the disease,
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that HIV isolates change their in-vivo properties from M- to T-tropic. These studies 
indicated that M-tropic (CCR5 utilising) viruses are responsible for infection and that 
the T-tropic (CXCR4 utilising) viruses may be associated with the rapid CD4+ cell 
decline and the onset of the symptoms of AIDS (Conner et al 1994, Doranz et al
1996).
CCR-5 and CXCR4 are the predominant co-receptors used for HIV-1 infection 
however, more recent studies have also indicated that other CC chemokines, such as 
MDC and 1-309 can also inhibit some diverse strains of HIV-1 infecting T 
lymphocytes or monocytes. These results suggested that MDC and 1-309 receptors, 
CCR4 and CCR-8 can act as HIV co-receptors (Pal et al 1997, Horuk et al 1998). As 
well as CCR-4 and CCR8, there are a large number of alternative co-receptors that 
have been identified that support virus infection in vitro, these include CCR2b 
(Doranz et al 1996), CCR3 (Choe et al 1996), D6 (Choe et al 1998), CX3CR1 
(Combadiere et al 1998), a number of orphan receptors e.g. GPR15 (Farzan et al
1997), STRL33 (Liao et al 1997) and even some viral receptors, such as US28 from 
the human cytomegalovirus (Pleskoff et al 1997). Generally these receptors are used 
inefficiently relative to CCR5 or CXCR4 and their in-vivo relevance is uncertain 
(Ebinger et al 1998, Zhang et al 1998b).
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AIMS
The control of the haemopoietic system is ultimately articulated at the level of stem 
cell proliferation, and regulation of this proliferation is achieved through a balance of 
positive and negative regulatory signals. Much has been learned about positive 
growth molecules, but comparatively little is known about the negative regulators and 
what mechanisms are involved in their actions. Therefore, the characterisation of how 
one such negative regulator, Macrophage Inflammatory Protein-1 alpha (MIP-la), 
exerts its inhibitory effects will not only be central to an improvement in our 
understanding of haemopoietic regulation but may also shed light on cell cycle control 
in general. Thus, the aim of this thesis was to investigate the mechanisms involved in 
the inhibition of stem cell proliferation by the chemokine macrophage inflammatory 
protein-1 alpha (MIP-la). This was attempted firstly by using subtractive 
hybridisation and secondly by examining the effects of growth factor alteration on 
M IP-la inhibition of CFU-A colony formation.
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CHAPTER 3 : MATERIALS
3.1 Tissue Culture Supplies 
Suppliers Address
Beatson Institute Glasgow, UK
Central Services
R2 Beatson Institute 
Becton Dickinson, UK, Ltd 
Costar
Difco Laboratories 
Gelman Sciences
Gibco Life Technologies
Glasgow, UK 
Plymouth, UK 
Cambridge, MA, USA 
Detroit, Michigan, USA 
Northampton, UK
Paisley, UK
Sigma Chemicals Poole, UK
Sigma Chemicals Poole, UK
Sterile Phosphate Buffered Saline (PBS) 
Sterile Distilled H20 (DW)
Sterile Glassware and Pipettes 
L-Broth
L929 and AF-1.19T conditioned medium 
Falcon tubes 15 and 50 mis 
6 and 24 well culture plates 
Agar Noble
Sterile acrodisc syringe filters (0.2 mm & 
0.45mm)
MEM alpha stock 
L-glutamine (200 mM)
Sodium Pyruvate (100 mM)
Sodium Bicarbonate (7.5%)
MEM Non essential amino acids (100X) 
Fischers Medium (10X)
RPMI Medium (10X)
200mM Glutamine 
7.5% Sodium Bicarbonate 
Sodium Pyruvate 
Foetal Calf Serum 
Donor Horse Serum 
SLM
a  -Medium
Endotoxin-free Dulbecco’s PBS 
2-Mercaptoehanol (2mM stock in PBS) 
Donor Horse Serum 
Bovine Serum Albumin,
RPMI-1640 Medium 
Dulbecco’s MEM
8 8
3.2 Plastics 
Suppliers
Becton Dickenson 
(Falcon)
Address
Oxford, UK
3.3 Cytokines and Antibodies 
Suppliers Address
Beatson Institute, R2 Glasgow, UK
Dynal Bromborough, UK
Pharmingen San Diego, CA,USA
R & D Systems Abingdon, UK
FACSTAR Cell sorter
Tissue Culture Flasks
50ml & 15ml Centrifuge Tubes
5ml, 10ml, 20ml Plastipak Syringes
lml, 2ml, 5ml, 10ml, 25ml, 50ml Plastic
Pipettes
Cell Strainers
3 cm Dishes
2059 Tubes
mMIP-la (PM2) deletion was the form
of M IP-la used in these studies and was
as described in Graham et al 1994
Dynabeads (M-450 sheep anti-rat IgG)
Purified Rat Anti-Mouse Monoclonal
Antibodies
Gr-1
B220
Mac-1
CD4
CD5
CD8
Terll9
FITC Conjugated Sca-1
PE Conjugated Thy 1.1
FITC Conjugated IgG Isotype control
PE Conjugated IgG Isotype control
Anti-MIP-la antibody
rh & rm GM-CSF
rh & rm SCF
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3.4 Kits and Columns
Suppliers Address
Vector Labs Peterborough, UK
Invitrogen BV Leek, Netherlands
Applied Biosystems Warrington, UK
Pharmacia Biotech Ltd St.Albans, UK
Qiagen Inc. Chats worth, CA, USA
3.5 Membranes, Paper and X-ray Film
Suppliers
Amersham International pic.
Genetics research Ltd
Kodak Scientific Imaging Systems Ltd
Schleicher & Schuell
Technical Photo Systems
Vemon-Carus, Ltd
Whatmann International Ltd
Address
Amersham, UK 
Felstead Dumnow,UK 
Cambridge, UK 
Dassel, Germany 
Cumbernauld, UK 
Preston, UK 
Maidstone, UK
rm TGF-p 
rm RANTES 
rh & rm IL-11 
rh & rm IL-6 
rm & rh LIF 
rh M-CSF 
rm MCP-3 
rh HCC-1
Photobiotinylation Detection Kit 
Accessory Kit 
cDNA Copy Kit
Micro-Fast Track mRNA isolation Kit 
RnaseZap (RNase Inhibitor)
Gene Amp PCR Kit 
RT-PCR Kit
Microspin S 400 HR Columns 
Ready-To-Go DNA Labelling Kit 
NICK Columns Sephadex G-50 DNA 
grade
Qiagen Plasmid Preparation Kits 
Qiagen Gel Extraction Kits
Hybond N Nylon Membrane 
Saran Wrap
X-OMAT AR X-ray film 
3 MM Whatmann Filter paper 
Fuji RX Medical X-ray film 
Gauze swabs 
3 MM Blotting Paper
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3.6 Nucleotides, Polynucleotides, DNA Ladders
Suppliers
Amersham International pic.
Sigma Chemical Co Ltd. 
Gibco Life Technologies
Address
Amersham, UK
Poole, UK 
Paisley, UK
[a-32P]-dCTP: 3000 Ci/mmol 
[a-32P]-dUTP: 3000 Ci/mmol 
Salmon Sperm DNA 
1 Kb DNA Ladder 
100 bp DNA Ladder 
DNA Mass Ladder 
RNA ladder
3.7 Plasmids and Inserts
Suppliers
GE May 
Dr R Nibbs
Address
LRF, London, UK 
Glasgow, UK
PBSmCD34
pSKm(3-actin
CCR-1
CCR-5
CCR-3
D6
M Walker 
Beatson Institute
3.8 Gels 
Suppliers
Flowgen Instruments Ltd. 
Gibco Life Technologies
Glasgow, UK pCR2 GAPDH
Address
Sittingboume, UK
Paisley, UK
Agarose
Low Melting point Agarose (LMP) 
Agarose
3.9 Enzymes and Enzyme Buffers
All restriction endonucleases with buffer 
unless stated
Suppliers Address
Gibco BRL Paisley, UK
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NBL Gene Sciences Ltd Cramlington, UK T4 Polynucleotide Kinase 
DNA Ligase
3.10 Chemicals 
Suppliers
Boehringer Mannheim 
Coulter
DIFCO Laboratories 
Fisons Scientific Equipment
Gibco BRL
James Burrough Ltd. 
Northumbria Biologicals Ltd. 
Nycomed
Raymond A Lamb Lab 
Supplies
Sigma Chemical Co Ltd. 
Sigma Chemical Co Ltd
Address
Mannheim, 
Germany 
Luton, UK 
Michigan, USA 
Loughborough, UK
Paisley, UK
Witham, Essex, UK 
Cramlington, UK 
Sheldon, UK 
London. UK
Poole, Dorset, UK 
Poole, Dorset, UK
MOPS
Zapo-globin 
Bactoagar 
Acetic Acid 
Chloroform 
Dimethyl Sulfoxide 
Formaldehyde (38% w/v)
Formamide 
Glycerol 
Methanol 
Agarose 
TRIzol reagent
Phenol/Chloroform/Isoamyl alcohol 
(25 : 24 : 1, v/v pH 8)
Ethanol
BSA
Animal Nycodenz 1.077g/ml 
Napthalene Black
Ampicillin 
Bromophenol Blue 
Dithriothreitol (DTT)
Ethidium Bromide 
DNA samples (lOmg/ml)
RNA samples (1 mg/ml in DEPC treated 
water)
Fura-2AM
INT
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Thornton and Ross 
Fishers Scientific UK Ltd
Stem Cell Technologies
3.11 Animals 
Suppliers
Harlan Olac Ltd.
3.12 Solutions
3.12.1 Cell Culture Solutions
Alpha Stock
Alpha Medium (x2)
DMEM
DMEM
FDCP-Mix Medium (A4 Medium)
Streptavidin 
TRNA 
Tween 20 
Liquid Paraffin
All other chemicals not listed above 
Methyl-cellulose (# 3232 -EPO, - CSF)
Female B6D2F1 Mice
5 Litre pack of cc-MEM 
1500 mis DW
100 mg Gentamycin Sulphate 
50 mis MEM x 100 Vitamins 
Filter Sterilise 
25 mis DHS 
21 mis Alpha Stock 
3 mis 7.5% Sodium Bicarbonate 
1 ml L-Glutamine 
365 mis DW
50 mis lOx Dulbecco’s Medium 
50 mis FCS (10%)
25 mis 7.5% Sodium Bicarbonate 
5 mis Sodium Pyruvate 
5 mis L-Glutamine 
400 mis DW
45 mis lOx Fischers Medium 
100 mis DHS (20 %)
6.5 mis 7.5% Sodium Bicarbonate
Huddersfield, UK
Loughborough,
UK
Vancouver,
Canada
Address
Bicester, UK
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Fischers Medium
PBS/2 % FCS
RPMI Medium
Special Liquid Medium
Expansion Medium
4.5 mis L-Glutamine
87.5 mis DW
10 mis lOx Fischers Medium
1.5 mis 7.5% Sodium Bicarbonate
1 ml L-Glutamine 
8 mis FCS
400 mis PBS 
331 mis DW
50 mis 10 x RPMI Medium 
100 mis FCS (20%)
13.5 mis 7.5% Sodium Bicarbonate 
5 mis L-Glutamine
0.5 ml |3-mercaptoethanol 
Supplemented Modified Eagles Medium 
10% FCS
2 mM L-Glutamine 
290 mis DMEM 
100 mis DHS (25%)
10 mis Glutamine
3.12.2 Electrophoretic Solutions
Gel Loading Buffer 0.25 % Bromophenol Blue 
40 % w/v Sucrose in DW
lxTE Tris-HCl pH 8
1 mM EDTA
50 x TAE 0.4 M Tris Acetate
0.05 M Sodium Acetate (trihydrate) 
M EDTA
3.12.3 Southern Blotting and Hybridisation Solutions
Denaturation Buffer 1.5 M Sodium Chloride
0.5 N Sodium Hydroxide 
Neutralisation Buffer 1 M Tris (pH 7.4)
94
20 x SSC
Phosphate Wash Buffer (1)
Phosphate Wash Buffer (2)
1.5 M Sodium Hydroxide 
3 M Sodium Chloride 
0.3 M Tri-Sodium Citrate 
20 mM Di-Sodium Hydrogen 
Orthophosphate 
5 % SDS
20 mM Di-Sodium Hydrogen 
Orthophosphate 
1 % SDS
20 mM Di-Sodium Hydrogen 
Orthophosphate 
0.1 % SDS
0.25 M Sodium Dihydrogen 
Orthophosphate 
7 % SDS, pH 7.2
3.12.4 Northern Blotting and Hybridisation Solutions
Phosphate Wash Buffer (3)
Phosphate pre-hybridisation Buffer
50 X Denhardts
Denhardts pre-hybridisation Buffer
DEPC Water
10 X MOPS
RNA Loading Buffer
1 % (w/v) Ficoll 400
1 % (w/v) Polyvinylpyrolidone
1 % (w/v) Bovine Serum Albumin
6 x SSC
5 x Denhardts
0.5 % SDS
50 % Formamide
10 mg/ml Sonicated ss DNA
400 pis DEPC
400 mis DW
Shake briefly and Autoclave overnight
0.2 M MOPS
50 mM Sodium Acetate
10 mM Sodium-EDTA
50 % Glycerol
1 x MOPS
Bromophenol to colour made up in
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Wash Buffer 1
Wash Buffer 2
3.12.5 Calcium Signalling Assay Solutions
3.12.6 Bacterial Solutions
DEPC water 
2 x SSC 
0.05 % SDS 
0.1 x SSC 
0.1 % SDS
Tyrodes buffer
Beatson Institute 
Central Services 
L-Amp Broth
Glasgow, UK
SOC
Luria-Broth
0.5 % Yeast Extract 
1 % Bactotryptone
1 % Sodium Chloride
2 % w/v Bactotryptone 
0.5 % w/v Yeast Extract 
0.01 M Sodium Chloride 
0.0025 M Potassium Chloride 
0.01 M Magnesium Chloride 
0.01 M Magnesium Sulphate 
0.02 M Glucose
3.12.7 Subtractive Hybridisation Solutions
TBBS
0.1 M Tris pH 9.5 
0.15 M NaCl 
0.1 % Tween 20
3 x Hybridisation Buffer
Extraction Buffer
50 mM Tris pH 8.3 
lOmM EDTA pH 8.0 
0.3 % SDS 
50 mM Tris pH 8.3 
0.5 M NaCl
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5 mM EDTA
10 mM Hepes
HE 1 mM EDTA
3.13 Primers
RT-PCR Primers P-actin
5’ TCCATCATGAAGTGTGACGT 
3’ TACTCCTGCTTGCTGATCCAC
5’ G 173C
GCAAGAAATCTCTGTGGTGTTTTAGTT 
3’ 17RD
TTTTCACAGCACGTTTTTAGAGAC
D6
5’ D65F2
ACATGCCCACCGTTGCTTC 
3’ D632
GTGCAAGGTGATAAGCACT
Dr Nibbs CCR-3
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CHAPTER 4 : METHODS
4.1 Mice
For all work presented the strain B6D2F1, an FI hybrid of C57B1/6 (females) and 
DBA2 (male’s) strains, were used. All mice were housed within the animal facility of 
the Beatson Institute. Female mice were used at age 4-6 weeks for all experimental 
procedures.
4.2 Maintenance of Cell Lines
All cell lines were obtained from the frozen stocks of the Beatson Institute. The 
FDCP-Mix cell line is a primitive murine haemopoietic cell line, which is dependent 
on rm IL-3 for growth (Spooncer et al 1986). These cells were maintained in Fischers 
medium supplemented with 20 % DHS, Glutamine, Sodium Bicarbonate and 10 
jig/ml of IL-3. The human megakaryocytic progenitor cell line M 07e is also factor 
dependant (Hendrie et al 1991). These cells were maintained in Fischers medium 
containing, 10 % FCS, glutamine, sodium bicarbonate and 100 |ig/ml rh GM-CSF. 
THP-1 cells are a human monocytic cell line derived from a patient with acute 
monocytic leukaemia (Tsuchiya et al 1980), these cells were grown in RPMI 1640 
medium supplemented with 10 % FCS, glutamine, Sodium Bicarbonate and p- 
mercaptoethanol. RAW cells are murine monocytic cells which are maintained in 
special liquid medium (Gibco BRL) supplemented with 10 % FCS and 2 mM 
glutamine. J772.4 cells are a murine monocytic cell line and are maintained in special 
liquid medium (Gibco BRL) supplemented with 10 % FCS and 2 mM glutamine. Sub 
culturing of all cells was performed 2/3 times a week and the cells were seeded at 
1x10s cells /ml.
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4.3 Haemopoietic Cell Line Assays
4.3.1 FDCP-Mix Plating Assay
FDCP-Mix cells in mid log phase were counted on the CASY-1 counter and 
resuspended to give a cell concentration of 105 cells/ml. The FDCP-Mix cells were 
then diluted to 104 cells /ml. 100 pi of these cells were suspended in a-MEM, 
supplemented with 20 % DHS, rm IL-3 at lOpg/ml and 0.6 % agar in a total volume 
of 1 ml. The cells were plated in dishes and were incubated in the presence or 
absence of various concentrations of M IP-la (10, 50, 100, 250 and 500 ng/ml) in a 
humidified atmosphere containing 5 % CO2 , 10 % O2 and 85 % N2 for 7 days. The 
colonies could either be counted on day +7 or alternatively stained for 24 hours with 
INT and counted on day +8.
4.3.2 M 07e Plating Assay
Factor starved or normal M07e cells in mid log phase were counted on the CASY-1 
counter and resuspended to give a cell concentration of 105 cells/ml. They were then 
diluted to 104 cells /ml and 100 pi of these cells were suspended in a-MEM, 
supplemented with 20 % DHS, rm GM-CSF lOOpg/ml and 0.6 % agar to a total 
volume of 1 ml. The cells were then plated in dishes and incubated in the presence or 
absence of M IP-la at 100 ng/ml in a humidified atmosphere containing 5 % CO2 , 10 
% O2 and 85 % N2 for 7 days. The colonies could either be counted on day +7 or 
alternatively stained for 24 hours with INT and counted on day +8. For factor 
starvation, 18 hours prior to the experiment mid log phase M07e cells were washed 
and incubated in growth medium without rh GM-CSF.
4.3.3 Calcium Mobilisation Assay
Changes in intracellular Ca2+ were measured using the fluorescent label FURA-2AM. 
THP-1 or FDCP-mix cells were harvested and resuspended to 2-5 x 106 cells/ml. 
FURA-2AM (1 mg/ml in DMSO) was added to the cells (ImM) and incubated for 45 
minutes at 37 °C in an atmosphere of 5 % CO2, 10 % O2 and 85 % N2 . The cells were 
washed and resuspended in Tyrodes buffer to give 2-5 xlO6 cells/ml. FURA-2
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fluorescence emission intensity was measured at 37 °C using a Perkin-Elmer LS-50 
fluorimeter with a cell holder and built in magnetic stirrer. The samples were excited 
at 340 nm with a 10 nm band width and the emission was continuously recorded at 
500 nm with a 5 nm bandwidth. FURA-2-loaded cells (2 ml, 2-5 x 106cell/ml) were 
transferred to a 4.5 ml cuvette; CaCh was added to ImM and left to equilibrate for 2 
minutes. Recombinant murine M IP-la was added (20 pi, 100 X final concentration) 
and the increase in intracellular calcium was noted. After approximately 60 seconds, 
20 pi of 5 mM Tween 20 was added to lyse the cells to obtain the maximum 
fluorescence in 1 mM Ca2+ (F max). Once the fluorescence level had stabilised, 
EGTA (20pl, 1 mM pH 7.2) was added to obtain the background fluorescence (F 
min). The increase in intracellular calcium was calculated according to the equation 
[Ca2+]I nmol/L = 224[(F2-Fmin)/(Fmax-F2)] - 224[(Fl-Fmin)/(Fmax-Fl)], where FI 
is the intensity before the agonist addition, F2 is the peak intensity after the agonist 
addition, F max is the intensity after Tween 20 addition, and F min is the intensity 
after EGTA chelation, 224nm is the dissociation constant of calcium from FURA-2 at 
37°C.
4.4 Enrichment and Analysis of CFU-A Stem Cells
4.4.1 Harvesting of Bone Marrow
4-6 week old female B6D2F-1 mice were sacrificed either by cervical dislocation or 
by CO2 asphyxiation. Bone marrow cells were obtained from the femora and tibia of 
the mice. The bones were first cleaned of muscle tissue using a swab soaked in 70 % 
ethanol, then crushed in PBS/ 2 % FCS, using a mortar and pestle. After crushing, the 
cell suspension it was passed through a 70 pm cell strainer and collected in a 50 ml 
centrifuge tube. After one wash in PBS/ 2 % FCS, the bone marrow cells were 
resuspended in 5 mis of PBS/ 2 % FCS, to give a single cell suspension, and counted 
on a cell counter (CASY Counter) after lysing the red blood cells with Zapo-globin.
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4.4.2 Enrichment of Lin Negative (Lin~) Cells
Bone marrow was harvested from 10-20 female B6D2F1 mice as described in 4.41. 
The bone marrow cells were enriched by density gradient cell separation by layering 3
n
ml of cell suspension (2.5 x 10 / ml) on top of 3 ml Nycodenz mixture (density 
1.077g/ ml) and spun at 1000 g for 30 minutes at room temperature. The interface 
cells were harvested, washed once and resuspended in PBS/ 2 % FCS. These cells 
were further enriched for lineage negative progenitor content by using indirect 
immunomagnetic selection to remove mature cells according to previously described 
methods (Hirayama and Ogawa et al 1992). The antibodies used included Gr-1 to 
remove mature granulocytes, B220 to remove B cells and pre-B cells, Mac-1 to 
remove monocytes and macrophages, Ter 119 to remove erythroid cells and CD4, 
CD5 and CD8 to remove T cells. Antibody labelling was performed for 30 minutes 
on ice and agitated every 10 minutes. The labelled cells were washed three times and 
re-suspended in PBS/ 2 % FCS, mixed with Dynabeads (M-450 sheep anti -rat IgG) at 
concentration of 1 x 107 beads/ ml of cells and incubated at 4 °C for 30 minutes with 
end-over-end rotation. The tube containing the cells was then placed in a Dynal 
MPC-1 magnetic particle concentrator (DYNAL, Great Neck, NY, USA) for 2-3 
minutes. The non-rosetted cells were harvested using a pasteur pipette, washed once, 
re-suspended in PBS/ 2 % FCS and kept on ice for further enrichment by cell sorting. 
These cells were designated lineage negative. The Lin' cells were diluted and plated 
in a CFU-A assay alongside bone marrow cells.
4.4.3 Enrichment of Sca-1+/Lin' Cells
Lineage negative cells were isolated from bone marrow as described in section 4.4.2. 
Lineage negative cells were incubated with FITC-conjugated Sca-1 antibody, and a 
separate aliquot was also incubated with an FITC-conjugated IgG isotype control 
antibody. The cells were then washed three times in PBS/ 2 % FCS, added to a 70 
pm cell strainer and resuspended to give a final concentration of lxlO6 cells/ml. 
Cytometric analysis and cell sorting were performed on a FACStar (Becton 
Dickinson) with an argon-ion laser tuned to 488 nm at power of 200mW. FITC 
fluorescence was measured through a filter arrangement with peak transmittance at 
530 nm. Cells with high FITC labelling compared to that of the isotype control 
fluorescence were sorted into a 12 x 75 mm round bottom plastic tube containing
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PBS/ 2  % FCS, these cells were designated Sca-1+/Lin*. These cells were then spun at 
1000 g for 10 minutes, resuspended in 100 jllIs of PBS/ 2  % FCS and counted on a 
haemocytometer. The cloning efficiency of 100 Sca-1+/ Lin* cells was compared to 
500 Lin* cells and 5x10 bone marrow in a CFU-A assay, figure 4.1.
4.4.4 Enrichment of Sca-l+/T hyl.lIo/7Lin' Cells
Lineage negative cells were incubated with FITC-conjugated Sca-1 antibody and PE- 
conjugated Thy-1.1 at a concentration of 1 jug/ 1 x 106 cells. A separate aliquot was 
also incubated with two IgG isotype control antibodies, which are FITC-conjugated 
and PE-conjugated. The cells were then washed three times in PBS/ 2 % FCS, added 
to a 70 pm cell strainer and resuspended to give a final concentration of lxlO6 cells/ 
ml. Cytometric analysis and cell sorting were performed on a FACStar (Becton 
Dickinson) with an argon-ion laser tuned to 488 nm at power 200 mW. FITC 
fluorescence was measured through a filter arrangement with peak transmittance at 
530 nm and PE fluorescence was measured through a filter arrangement with peak 
transmittance at 585 nm. Cells with high FITC labelling and low PE labelling 
compared to that of the isotype control fluorescence were sorted into a 12 x 75 mm 
round bottom plastic tube containing PBS/ 2 % FCS. These cells were designated 
Sca-1+/ T hy l.llo/7 Lin*. These cells were then spun at 1000 g for 10 minutes, 
resuspended in 100 pi of PBS/ 2 % FCS and counted on a haemocytometer. The 
CFU-A colony formation of one hundred Sca-1+/ T hyl.llo/7 Lin* cells were compared 
to that of 500 Lin*, 100 Sca+/Lin* and 100 Sca-1+/ T hyl.l+/ Lin* cells and 5xl03 bone 
marrow cells, figues 4.2.
4.5 Colony Forming Unit -Agar (CFU-A) Assay
The protocol for the CFU-A assay has been described in detail previously (Pragnell et 
al 1988). Briefly, 5xl03 bone marrow cells were suspended in a-MEM, 
supplemented with 25 % DHS and 0.3 % agar to a total volume of 4 mis.
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Figure 4.1: Histograms of lin' cells labelled with Sca-1 FITC antibody or control
IgG FITC antibody
The bottom histogram depicts lin* cells stained with a control IgG antibody. Using 
this as a comparison, cells that were Sca-1+ and Sca-1* were selected and are depicted 
in the top histogram. The Sca-1+ cells are on the right hand side of the line whereas 
cells that are Sca-1* are on the left-hand side of the line. These cells are thus sorted 
and plated in a CFU-A assay.
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This suspension was seeded onto a 4 ml feeder layer consisting of 0.6 % agar in the 
same medium containing either 10 % L929-CM and 10 % AF1-19T-CM or rh M-CSF 
6 ng/ml, rm GM-CSF 0.2 ng/ml and 12 ng/ml rm SCF as a source of synergising 
growth factors. Dishes were incubated in a humidified atmosphere containing 10 % 
CO2, 5 % O2 and 85 % N2 for 11 days. The “cut-off’ for colonies to be included as a 
CFU-A colony was greater than or equal to 2 mm in diameter and this was not varied. 
This assay detects multi-potential progenitors with proliferative properties in common 
with CFU-S, and as such offers a means of measuring transient engrafting 
haemopoietic stem cell populations (Lorimore et al 1990, Pragnell et al 1988).
4.6 Viability of Cells
10 pi of Sca-1+/ T hy l.llo/' / Lin cells were spun down at 2000 rpm for 5 minutes in a 
microfuge. The medium was removed and the cells were resuspended in 2.5 pi of 
PBS/ 2 % FCS. 7.5 pi of Napthalene black was added and the cells were counted on a 
haemocytometer. The dead cells were identified by the uptake of the dye.
4.7 Cytospin of CFU-A Colonies
Briefly, 5xl03 bone marrow cells were suspended in methyl cellulose (#3230 : -CSF- 
1, -EPO). This suspension was seeded onto a 1 ml feeder layer, identical to the one 
described in section 4.5. Dishes were incubated in a humidified atmosphere 
containing 10 % CO2, 5 % O2 and 85 % N2 for 11 days. Using a dissecting 
microscope five colonies per control and 10 colonies per M IP-la treated plates were 
removed and pooled in 400 pi of ice cold PBS. The colonies were washed three times 
in 1 ml ice cold PBS, and resuspended in a further fresh 400 pi of PBS. The cells 
were placed in the sample chamber and spun in the cytospin centrifuge at 200 g for 5 
minutes. The sample slides were allowed to air dry and were then fixed by immersing 
in methanol for 2 minutes air dried again and stained with Giemsa.
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Figure 4.2. Histograms of lin' cells labelled with Sca-1 FITC antibody or control 
IgG FITC antibody and Thy 1.1 PE antibody or IgG PE control antibody
The bottom histograms depicts lin' cells stained with a control IgG FITC (FL1) and 
PE (FL2) antibodies and using this as a comparison the top histograms have gated 
cells that are Sca-1+ / Thy-1.1 lo/' and Sca-1+./ Thy-1.1 +. These cells are thus sorted 
and plated in a CFU-A assay.
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4.8 Alpha ( a) MEM (5 litres)
Alpha medium stock solution was made by adding alpha medium (Gibco 072-2000P 
10 litre pack), MEM Vitamin stock 100 x, Gentamycin 200 mg to 3 litres of pre­
heated ultra pure water with constant stirring. The media was then filtered through a 
pre filter, preventing the need to filter through stacked filters of 5, 1.2, 0,8, 0.45 and 
0.22 micron pore size. Finally the media was sterilised by passing it through a 0.2 
micron filter, aliquoted and frozen at -20 °C
4.9 Conditioned Medium
The L929 (Stanley and Heard 1977) and AF-19T (Franz et al 1985) cell lines were 
grown in roller bottles in SLM/ FCS to half confluence. The spent medium was then 
removed and replaced with fresh medium and the cultures were allowed to grow for a 
further three days. The CM was then removed and sterilised by passing it through a 
0.45 micron filter and then through a 0.22 micron filter. Finally the CM was 
aliquoted and stored at -20 °C. In the CFU-A assay, CM from the murine L929 cell 
line was used as a source of M-CSF and AF1-19T-CM was a source of GM-CSF.
4.10 Derivation of Bone Marrow Macrophages (BMM)
Bone marrow macrophage cells were produced by resuspending bone marrow cells at 
5 x 104 /ml in a modified MEM supplemented with 25 % DHS and 20 % L929 CM as 
a source of MCSF. Following incubation for 7 days at 37 °C in a dry atmosphere of 5 
% CO2, the remaining adherent cells consisted of a homogenous (>99%) population 
of bone marrow-derived macrophages (BMM), as determined by Jarmin et al.
4.11 Stimulation of Cell Lines and Bone Marrow Macrophages (BMM)
All reasonable precautions were taken to ensure contamination of experiments with 
endotoxin/ lipopolysaccharide (LPS) did not occur. This included the purchasing of 
endotoxin-free recombinant cytokines and PBS, as well as the use of sterile plastic 
tissue culture pipettes and aerosol plugged pipetteman tips. Bone marrow 
macrophages were made as in section 4.10. Recombinant SCF was reconstituted 
according to the manufactures guidelines in endotoxin free PBS/ 0.1 % BSA (v/v).
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The monocytic cell lines RAW cells and J774.2 cells can be stimulated to produce 
M IP-la by endotoxin. For this reason stem cell factor was reconstituted in endotoxin 
free PBS. PBS or 100 ng/ml of SCF was added to the cell lines and 250 pi of media 
was removed at 0,16, 24 and 48 hours.
4.12 M IP-la ELISA
M IP-la protein expression was analysed using a mouse M IP-la Quantikine M 
immunoassay from R&D Systems. Briefly, 50 pi of the assay diluent RD1-21 was 
added to each well in to which a further 50 pi of standard, control or sample was 
added. This was gently mixed and incubated at room temperature for 2 hours. Each 
well was then aspirated, washed 5 times with the wash buffer and 100 pi of m M IP-la 
conjugate was then added to each well and incubated for 2 hours. After a further 
aspiration and wash step as above 100 pi of substrate solution was added and this was 
incubated in the dark for 30 minutes. The reaction was stopped by the addition of 100 
pi of stop solution and the optical density of each well was determined within 30 
minutes using a micro-plate reader set to 450 nm.
4.13 Neutralising M IP-la Antibody Experiment
The CFU-A assay was set up as described in section 4.5. Recombinant murine GM- 
CSF and rh M-CSF were added to the assay at 0.2 and 6 ng/ml respectively with SCF 
at 1.2, 12 or 120 ng/ml. As well as the growth factors an anti-murine M IP-la 
neutralising antibody was added to the CFU-A assay at a concentration of 5 pg/ml. 
Dishes were incubated in a humidified atmosphere containing 10 % CO2, 5 % O2 and 
85 % N2 for 11 days and colonies were enumerated on a dissecting microscope. The 
same assay was performed with the rh M-CSF concentration altered to 0.6, 6 and 60 
ng /ml with the rm SCF and rm GM-CSF concentrations staying constant at 12 ng/ml 
and 0.2 ng/ml.
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4.14 Replating Assay
Briefly, 5 x 1 0  bone marrow cells were suspended in 1 ml of methyl cellulose (#3230 
: -CSF-1, -EPO). This suspension was seeded onto a 1 ml feeder layer, identical to 
the one described in section 4.5, the only difference being the addition of various 
concentrations of SCF, M-CSF or IL-6. Dishes were incubated in a humidified 
atmosphere containing 10 % CO2, 5 % O2 and 85 % N2 for 7 days. Using a dissecting 
microscope individual colonies were picked from each treatment type and placed in 
ice cold PBS, 10 in total. Each individual colony was then suspended in a-MEM, 
supplemented with 25 % DHS and 0.3 % agar to a total volume of 1 ml. This 
suspension was seeded onto a 1 ml feeder layer, identical to the one described in 
section 4.5. Dishes were incubated in a humidified atmosphere containing 10 % CO2, 
5 % O2 and 85 % N2 for 11 days and colonies were enumerated using a dissecting 
microscope.
4.15 Analysis of Numbers of Cells in CFU-A Colonies
Briefly, 5 x 1 0  bone marrow cells were suspended in methyl cellulose (#3230 : -CSF- 
1, -EPO). This suspension was seeded onto a 1 ml feeder layer, identical to the one 
described in section 4.5. Dishes were incubated in a humidified atmosphere 
containing 10 % CO2, 5 % O2 and 85 % N2 for 11 days. Using a dissecting 
microscope five colonies per control and 10 colonies per M DM a treated plates were 
removed and pooled in 400 (il of ice cold PBS. The colonies were washed three times 
in lml ice cold PBS, diluted and stained with methylene blue for counting on a 
haemocytometer.
4.16 IL-6, IL-11 and LIF CFU-A Assay
Dose responses of all cytokines were performed in the CFU-A assay (0.5, 1,5, 10, 50 
and 100 ng/ml) in the absence or presence of M IP-la at 1, 10 and 100 ng/ml. The 
CFU-A assay was set up as described in section 4.5.
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4.17 Ex-vivo Expansion
A B6D2F1 mouse was sacrificed either by cervical dislocation or by CO2 
asphyxiation. The femoral bones were cleaned of muscle tissue using a swab soaked 
in 70 % ethanol. The bone marrow cells were flushed from the bones using a 21- 
gauge needle containing PBS/ 2% FCS and were counted and diluted to 5 x 105 cells/ 
ml. These cells were then plated in expansion media in non tissue culture grade 3 cm 
petri dishes in the presence of various single cytokines or combinations of cytokines 
(SCF 18 ng/ml (KLS from CHO cells), rh IL-11 100 ng/ml, rm M IP-la 100 ng/ml) 
Dishes were incubated in a humidified atmosphere containing 5 % CO2, 10 % O2 and 
85 % N2 for 6 days. The cells were then harvested from the dishes, washed three 
times in expansion media and counted. Finally the cells were plated out in a CFU-A 
assay and incubated as previously described in section 4.5. The CFU-A colonies were 
scored using a dissecting microscope.
4.18 Photographing Colonies
To facilitate the photography, the colonies were stained with a solution of INT (2-(p- 
iodophenyl)-3-(p-nitrophenyl)-5-phenyl tetrazolium chloride hydrate). 200 pi of INT 
(1 mg/ml) was placed on each dish and the dishes were incubated in a humidified 
atmosphere containing 10 % CO2, 5 % O2 and 85 % N2 for 24 hours
4.19 Agar Films
All manipulations with glutaraldehyde were carried out in a fume hood. Briefly, 1 ml 
of 2.5 % glutaraldehyde solution was added to the CFU-A assays in the 3 cm dish and 
incubated at room temp for 10 minutes. The top layer of the agar was removed by 
running the end of a small spatula around the circumference of the top of the agar. 
The lower layer of agar was then carefully removed into a 9 cm petri dish containing 
20 mis distilled water. The (IH2O was changed several times over the next 48 hours to 
destain each agar film. The agar films were then transferred to a sandwich box 
containing fresh (IH2O water. Each agar film was removed from the water by placing 
a glass slide below the film and carefully lifting the film out of the water. The slides 
were then labelled and a piece of pre wet Whatman chromatography paper (DE81) 
was placed on top of the film and allowed to dry over night. The filter paper was
109
removed by running warm water over it and any excess fibers were removed by 
gently running a finger over the surface of the film. The slides were then placed in a 
slide rack and this was placed in a glass staining vessel ready to be stained by using 
May-Grunwald (MG) and Giemsa. MG and Giemsa should be made afresh by adding 
71 mis MG to 429 mis of buffer and by adding 6.6 mis of Giemsa to 495.4 mis of 
buffer. MG was added to the slide rack and incubated for 20 minutes at 37 °C. The 
MG was removed by running water into the staining vessel and the slides were 
subsequently stained with Giemsa for 40 minutes at 37°C. Once the stain was 
removed, the slides were dried and the agar films were mounted with a coverslip.
4.20 Molecular Techniques
4.20.1 Propagation of Plasmid DNA in Bacterial Cells
DH5a competent cells were transformed with the plasmid construct of interest. 
DH5a cells were removed from -70 °C and thawed on ice for 20 minutes. 20-50 pi 
aliquots of the cells were dispensed into pre-chilled sterile 2059 falcon tubes and 10- 
50 ng/ml of plasmid construct was added to the cells gently swirled and incubated on 
ice for 30 minutes. The cells were then “heat shocked” at 42 °C for 45 seconds 
exactly, returned to ice for 2 minutes and 90 pi of SOC medium was added. This 
mixture was shaken at 225 rpm for 1 hour at 37 °C to allow the expression of the 
ampicillin or tetracycline resistance gene. 100 pi and 50 pi of the transformed cell 
mixture was spread evenly onto LB Amp /Tetr plates using a glass spreader sterilised 
by flaming in ethanol. These plates were previously made by adding 7.25g of 
Bactoagar to 400 ml L-Broth. This mixture was then autoclaved and allowed to cool 
to 37 °C, 50 pg/ml Amp or Tetr was added to the mixture and 10 mis were poured 
into a 10 cm petri dish and allowed to set. The plates were left for 5-10 minutes and 
inverted and incubated at 37 °C overnight.
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4.20.2 Growth of Plasmids
A single bacterial colony was plucked from the L-Amp or the L-Tetr plates using a 
sterile eppendorf tip and added to 10 mis of L-Amp broth plus 50 pg/ml Amp or Tetr 
in a 2059 falcon tube. This was placed in a shaker and shook at 225 rpm for 16 hours 
at 37 °C. The mixture was added then to 400 ml of L-Amp or L-Tetr broth in a 2 litre 
conical flask and incubated under identical conditions for a further 16 hours. The 
suspension was then transferred to 250 ml centrifuge Sorvall bottle and spun at 3000 
rpm for 10 minutes in a Beckman J-6B centrifuge a GS-3 rotor using a Sorvall RC5B 
super-speed centrifuge. The supernatant was decanted and the pellet was then ready 
for plasmid preparation.
4.20.3 Plasmid Preparation (Maxi)
A plasmid preparation was performed using the commercially available Qiagen 
plasmid kit. Briefly, the bacterial pellets were resuspended in 10 mis of re-suspension 
buffer (PI: 100 pg/ml RNase A, 0.05 M Tris/HCL, 0.01 EDTA, pH 8.0) in a 50 ml 
centrifuge tube (Sorvall instruments). To this 10 mis of lysis buffer (P2: 0.2 M 
NaOH, 1 % SDS) was added, the solution was mixed gently by inversion and 
incubated at room temperature for 5 minutes. 10 mis of chilled neutralisation buffer 
(P3:3 M Potassium Acetate, pH 5.5) was added, mixed and incubated on ice for 20 
minutes. Tubes were spun at 4 °C for 30 minutes at 10000 rpm in a Sorvall RC-5B 
super-speed centrifuge containing SS-34 rotors. The supernatant was then poured 
through a double layer of gauze swab to remove particulate material. Qiagen-tip 100 
columns were equilibrated with 2 x 30 mis of equilibration buffer (QBT: 0.75 M 
NaCl, 0.05 M MOPS, 15 % Ethanol, 0.15 % Triton X-100, pH 7.0) and the filtered 
supernatant was applied to the column to purify the DNA. The column was then 
washed twice with 10 mis of wash buffer (QC: 1 M NaCl, 0.05 M MOPS, 15 % 
ethanol, pH 7.0) and the DNA was eluted from the column using 15 mis of elution 
buffer (QF:1.25 M NaCl, 0.05 M Tris/HCL, 15 % ethanol, pH 8.5). The DNA was 
precipitated with 0.7 volumes of isopropanol and centrifuged at 10000 rpm at 4 °C for 
30 minutes. The DNA pellet was allowed to air dry and then it was resuspended in 
300 pi of (IH2O. The DNA was transferred to a 1.5 ml microfuge tube and 
precipitated by the addition of 0.1 volume 3 M Sodium Acetate pH 5.2 and 2.5
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volumes of 100 % ethanol and incubated at -70 °C for 15 minutes. The pellet was 
washed with 70 % ethanol and spun at 13500 rpm for 5 minutes in a MSE bench top 
microfuge at 4 °C. To remove the ethanol the pellet was air dried and resuspended in 
distilled water. The DNA concentration was then measured by spectrophotometry.
4.21 Digestion of DNA
The appropriate amount of DNA to be digested, 10-50|ig, was added to a screw 
capped microfuge tube and 0.1 volumes (of the total reaction volume, normally 
lOOjil) of the appropriate 10 x Reaction buffer was added. Depending upon the 
restriction enzyme selected, the reaction buffer was chosen to optimise the enzyme 
activity. When two restriction enzymes are used, a compromise is reached and the 
buffer is chosen to enable the highest possible efficiency for both enzymes. The 
restriction enzyme is then added making sure the volume does not exceed 0.1 volumes 
of the final reaction volume in order to prevent inhibition of the reaction with glycerol 
within the enzymes. The digest reaction mix was then made up to the desired final 
volume of the reaction with distilled water, and incubated at 37 °C for 60 minutes. 
The DNA was either used for downstream applications or store at -20 °C.
4.22 Agarose Gel Electrophoresis
DNA derived from plasmid preps, restriction enzyme digests of plasmid DNA, 
quantitation of DNA probe fragments and visualisation of PCR products were 
routinely resolved on a non-denaturing agarose gel. 1 % agarose gels were made by 
adding 1.5 g agarose to 150 ml lx TAE and boiled in the microwave. Once the gel 
had cooled, 10 jil of ethidium bromide (stock 10 mg/ml) was added to the gel to aid 
visualisation of the DNA. The agarose was then poured into the casting tray and the 
gel was allowed to set. Loading Buffer (6x) was added to the DNA samples to be 
analysed to 1/6 of a final volume and the DNA samples were loaded into the gel. A 
size or mass ladder was always included in the gel. The gels were run at 100 volts 
until good separation of the molecular weight markers was obtained. Visualisation of 
ethidium bromide stained DNA bands on a trans-illuminator (A, = 312 nm) and a gel 
image recorded using an Ampligene imager. For derivation of probe fragments the 
appropriate bands were excised using a sterile scalpel, for southern blot analysis the 
image was recorded alongside a fluorescent ruler and excess agarose was trimmed off.
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4.23 Isolation of DNA Fragments for Radio-Labelling
Plasmid DNA encoding specific DNA probes was digested with the appropriate 
restriction enzymes and resolved by agarose gel electrophoresis and the appropriate 
sized band excised from the gel with a sterile scalpel. The gel fragment was placed in 
a 1.5 ml screw tap tube and the weight of the agarose was measured. The agarose was 
removed and DNA eluted, using a QIA quick gel extraction kit. Briefly, 3 volumes 
(0.1 g of agarose = approximately 100 pi = 1 volume) extraction buffer was added to 
the excised band in a microfuge tube. Heating to 55 °C for 10 minutes melted the gel 
and the mixture was added to the QIA quick spin column and spun at 13500 rpm for 1 
minute. The flow through was discarded and 750 pi of wash buffer was added to the 
column and spun at 13500 rpm for 1 minute. A further spin was needed to remove the 
additional wash buffer. The DNA was eluted into a new 1.5 ml eppendorf by adding 
30 pi of TE pH 8 to the centre of the column and spinning as above. The eluted DNA 
was visualised and quantified by agarose gel electrophoresis, 2-4 pi of DNA was 
added to a 1 % non-denaturing agarose gel and comparison against a known quantity 
of low DNA mass ladder.
4.24 RNase Free Environment
To reduce the possibility of degradation of the RNA by RNases several precautions 
were taken. Disposable, nuclease free, plugged pipetteman tips were used for 
handling RNA samples. The bench top surfaces and all non-disposable equipment 
were wiped with RNase-Zap a commercially available solution for inhibiting RNases. 
DEPC treated sterile water was used for making RNA samples and buffer, ethidium 
bromide and for resuspending RNA samples.
4.25 Isolation of Total RNA
Total RNA was isolated from the cells using Trizol™ (Gibco, Life Technologies, 
UK), a commercially available acid guanidinium thiocyanate-phenol-chloroform 
based extraction mixture (Chomcynski and Sacchi 1987), according to the 
manufacturer’s instructions. Briefly, for RNA isolation from adherent cells in 75cm2
113
flasks, growth medium was removed and 10 mis of Trizol™ was added to the flask. 
For isolation of RNA from cells grown in suspension, the cells were spun down at 
1000 rpm, the growth medium removed and 10 mis of Trizol™ was added to the cell 
pellet. RNA from adherent and suspension cells was then isolated in an identical way 
from this point. The flasks were swirled or the tube gently mixed to ensure complete 
coverage of the full cell area with Trizol™ and left at room temp for 5 minutes. The 
solution was pipetted up and down several times to ensure complete cell lysis and the 
solution was then transferred to a 15 ml snap cap Falcon 2059 tube where 2 mis of 
chloroform was added. Tubes were inverted several times and allowed to stand at 
room temp for 5 minutes and then spun in a Sorvall RC-5B supercentrifuge at 300 
rpm for 15 minutes using HB4 or HB6 swing out rotors. The resulting aqueous phase 
was then removed to a fresh 15 ml Falcon tube and to this 5 mis of isopropanol was 
added. The solution was mixed by inversion and left to stand at room temp for 10 
minutes. The iso-propanol supernatant was discarded and the pellet was resuspended 
in 10 mis of 70 % ethanol. The tubes were spun at 3000 rpm for 5 minutes, the 
ethanol was discarded and the tubes were inverted on the bench for 10 minute to drain 
off the excess ethanol, the pellets were then air-dried. The RNA was resuspended in 
50-100 pi of CIH2O (containing no RNases) and transferred to sterile tubes. The RNA 
was quantified by adding 3 pi of RNA to 297 pi of distilled water and measuring the 
OD 260 nm and RNA samples were stored at -70 °C until use.
4.26 Agarose Gel Electrophoresis of RNA
Total RNA was separated and visualised in a similar fashion to that used for DNA 
samples, the main difference being the usage of denaturing conditions. 5-20 pg of 
total RNA was added to a screw cap tube and frozen down in the speedi-vac. The 
pellet was then resuspended in 25 pi of RNA loading buffer and denatured in a water 
bath at 65 °C for 10 minutes and then placed on ice for 2 minutes to prevent 
renaturation of RNA strands. 1 pi of ethidium bromide (10 mg/ml) was then added to 
the RNA and the samples were loaded onto a denaturing agarose gel (1.4 % agarose, 1 
x MOPs, 2.2 M formaldehyde and made up to 150 mis with sterile distilled water). 
Gels were run at a constant 100 volts, until the bromophenol blue band had migrated 
2/3 of the distance of the gel (approximately 3 hours). At this time the integrity of the 
RNA was checked under UV transillumination and the gel image recorded alongside a
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fluorescent ruler to allow subsequent sizing of RNA species. Gels were then trimmed 
of excess agarose and northern blotted.
4.27 Detection of Specific DNA Sequences by Southern/Northern Blotting
Both methods are basically the same with only a few minor alterations. For southern 
blotting the gel was denatured by soaking in denaturation buffer for 3 x 15 minutes 
with constant agitation. After rinsing with dt^O, the gel was soaked in neutralisation 
buffer twice for 15 minutes. Following neutralisation, a glass tank partially filled 
with 500 ml 10 x SSC and a rectangular piece of glass was raised above the tank to 
form a platform. A larger rectangular piece of Whatmann 3 MM blotting paper was 
then soaked in 10 x SSC and placed on the platform with the ends of the paper in the 
tank of SSC thus forming a wick. The gel was inverted and placed on the 3 MM 
paper on a solid support over a reservoir of 10 x SSC. The edges of the 3MM paper 
were under the surface of the 10 x SSC solution. Four pieces of 3 MM paper and a 
piece of Hybond membrane, were cut to the size of the gel, soaked in 2 X SSC then 
placed on top of the gel with Hybond membrane adjacent to the gel. Rolling the side 
of a Pasteur pipette across the membrane before applying the 3MM paper expelled air 
bubbles. Unwanted, X-ray film was placed around the gel in such a way to ensure 
that the 20 x SSC from the reservoir would only diffuse through the gel. Paper towels 
were then stacked on top of the 3 MM paper, a glass plate was placed on top and this 
was weighed down with a filled 500 ml bottle. This was left overnight to allow 
capillary transfer of the DNA out of the gel and onto the membrane. The membrane 
was then carefully removed and washed in 6 x SSC and the DNA was fixed to the 
membrane by exposure to ultraviolet light (UV Stratalinker).
4.28 Preparation of Radioactive DNA Probes
Probe fragments generated by restriction digest were isolated as before and 
radiolabelled using a commercially available random priming kit Ready To Go™ 
according to manufacturer's instructions. Distilled water and 50 ng of DNA inserts 
were combined to give a total volume of 45 pi and denatured by boiling for 2 minutes 
and placed on ice for a further 2 minutes and added to Ready To Go ™ tube. All 
DNA probes used for hybridisation to southern blots were labelled for 15 minutes at 
37°C with 5 pi [a-32P]-dCTP, using a random priming kit according to the
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manufacturer’s instructions. After labelling, the radioactive probe was separated from 
the un-incorporated 32P-labelled nucleotides by passing through a NICK™ column, 
previously equilibrated with 1 x TE. The probes were then denatured by boiling for 2 
minutes, and placing on ice for 2 minutes before adding them to the blot.
4.29 Pre-Hybridisation and Hybridisation of Southern/Northern Blots
Pre-hybridisation and hybridisation of membranes was performed at 65 °C using 0.2 
M Na2H P(V  7 % SDS pH 7. These steps were performed using bottles and this was 
carried out in a rotary Hybaid oven. Briefly, the membranes were layered on top of 
Hybaid mesh and then rolled up and placed in bottles containing 10-20 mis of pre­
hybridisation buffer and incubated at 65 °C for at least 1 hour. Following pre­
hybridisation, the previously prepared radiolabelled probe was added with fresh 
hybridisation buffer to the bottle containing the blot and incubated overnight at 65 °C. 
The above process was performed similarly for northern blots, with the exception 
being the increase in temperature to 68 °C and the replacement of the pre­
hybridisation and hybridisation buffers with a commercially available solution, 
Express-Hyb from Clonetech.
4.30 Washing Southern/Northern blots and Exposing them to X-ray Film
Southern blots were washed with 2 x SSC/ 0.1% SDS for 30 minutes at room 
temperature followed by 20 minutes at 65 °C with the above fresh solution and then 
with 0.5 x SSC/ 1% SDS for 30 minutes at 65 °C. The membranes were monitored 
and additional washing performed if required, 20 minutes 65 °C 1 x SSC/ 0.1% SDS 
and finally 10 minutes 0.01 x SSC/ 0.1 % SDS at 65 °C. After the wash steps the 
membrane is wrapped in Saran Wrap and transferred to an exposure cassette 
incorporating an intensifying screen. The membranes were exposed to Kodak X-ray 
film (X-OMATAR) at -70 °C for 4 hours and longer exposures are performed if need 
be. In the case of northern blots the membranes were washed with 2 x SSC/ 0.1 % 
SDS for 4 x 10 minutes at room temperature followed by 2 x 20 minutes at 58 °C with 
0.5 x SSC/ 1 % SDS. The membranes were monitored and additional washing 
performed if required e.g. 20 minutes 58 °C 0.01 x SSC/ 0.01 % SDS.
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4.31 Stripping of Blots
The blots to be stripped were boiled in 0.1 % SDS for 5 minutes and allowed to cool 
to room temperature with continous agitation. They were then sealed in Saran Wrap 
and exposed to X-ray film at -70 °C to be certain that the blot was stripped.
4.32 Phenol/Chloroform Extraction and Ethanol Precipitation
An equal volume of phenol/ chloroform was added to the DNA. The mixture was 
inverted gently 2-3 times before spinning at 14000 rpm for 10 minutes. The top layer 
was aspirated and used for the next step in the same way. 1/10 th of the mixture 
volume of 3 M Sodium Acetate pH 5.2 and 2.5 volumes of absolute ethanol were 
added to the tube which was then inverted twice and incubated at -70 °C for 15 
minutes. The tube was then spun at 14 000 rpm for 15 minutes at 4 °C and the ethanol 
was carefully removed so as not to dislodge the pellet. The pellet was washed with 1 
ml 70 % ethanol and spun at 14000 rpm for a further 5 minutes. Finally the 70 % 
ethanol was removed, the pellet was air dried and resuspended in distilled water and 
store at -20 °C until needed.
4.33 Measurement of DNA/RNA Concentration by Spectrophotometry
The absorbance at 260 nm and 280 nm of DNA in solution was measured in a 500 jil 
cuvette and distilled water was used as a blank. An absorbance of 1 unit (i.e. one 
optical density (OD) is equivalent to 40 pg/ml of DNA and 50 pg/ml for RNA. The 
OD 260/ 280 nm ratio gives an estimate of the purity of the DNA/RNA. Pure 
preparations of DNA/RNA have an OD 260/ 280 nm ratio of 1.8. A 1/100 dilution of 
the DNA was performed and read in the spectrophotometer.
4.34 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
RT-PCR was performed using the commercially available Gene Amp RNA PCR Core 
Kit (Perkin Elmer). The manufacturer’s instructions were followed with minor 
adjustments. Briefly, reverse transcriptase reactions were set up as 20 pi reactions
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from a master mix (5 nM MgC12, lx  PCR buffer II, lU/ml RNase inhibitor, 2.5 mM 
Oligo d (T) 16, 1.75 mM random hexamers). lp l DNase I digested RNA (~lmg/ml) 
was added to 10 pi of master mix, mixed by pipetting and then incubated at 70 °C for 
5 minutes. Then 8 pi of dNTP mix (ImM each of dGTP, dATP, dCTP and dTTP) 
was added, followed by lpl of MuLV reverse transcriptase (2.5U/ ml) or 1 pi of 
DEPC-water. The reaction was then incubated for 10 minutes at room temperature to 
allow the Oligo d (T) 16 to be extended by the reverse transcriptase. The reaction 
tubes were then transferred to a Perkin Elmer Thermal Cycler 480, and incubated at 
42 °C for 20 minutes, followed by 5 minutes at 99 °C and 15 minutes at 5 °C. A PCR 
master mix was then prepared (0.5 nM MgCh, 1 x PCR buffer II, AmpliTaq DNA 
Polymerase (2.5U/100 pi) and 74 pi added to 20 pi of reverse transcriptase reaction 
from above. 3 pi each of 5’ and 3’ primers (200 ng/ml) were then added (see 
materials section for identity and sequences). The whole reaction mix was mixed by 
pipetting and then overlaid with 100 pi of liquid paraffin. Tubes were incubated in a 
Thermal Cycler for 1 minute at 94 °C and then for 30-35 cycles at the following 
conditions; 1 minute at 94 °C, 2 minutes at 60 °C, 2 minutes at 72 °C followed by a 
soaking at 4 °C. Samples were stored at 4 °C prior to visualisation of 20pl of 
amplified DNA product, by agarose gel electrophoresis on a 1% agarose gel.
4.35 Subtractive Hybridisation Techniques
4.35.1 Preparation of mRNA from Sca-1+/ Thy 1.1 ‘ n °  / Lin' cells
Sca+/ Thy 1.1 lo/7 Lin * cells were incubated with 100 ng/ml of rm RANTES or rm 
M IP-la for 4 hours, then washed in PBS at 4 °C and resuspended in 1ml Lysis Buffer 
(1 ml Stock Buffer, 20 pi RNase inhibitor). Messenger RNA was isolated from these 
cells by following the protocol in the Invitrogen mRNA kit. Briefly, the cells were 
washed in PBS and transferred to a sterile 1.5 ml microfuge tube and spun at 13500 
rpm for 15 minutes. The cells were resuspended in 1 ml of lysis buffer by passing 
them through a sterile syringe fitted with a 18-21 gauge needle and this was repeated 
three times. The suspension was then incubated for 20 minutes at 45 °C in a shaking 
water bath and the NaCl concentration was altered to 0.5 M NaCl by adding 63 ml of 
5 M NaCl solution and mixed thoroughly. The RNA was then sheared by passing the 
suspension through a syringe fitted with a 18-21 gauge needle. An Oligo-dT
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Cellulose tablet was added to the lysate, the tube was sealed and the tablet was left to 
swell and dispersed on a rocking platform for 20 minutes. The Oligo-dT was spun at 
10000 rpm for 10 minutes and was resuspended in 1.3 mis of binding buffer this was 
repeated a further twice and the eventual pellet was resuspended in 300 pis of binding 
buffer. The sample was added to a spin column and spun at 10000 rpm for 10 
seconds this was repeated until the entire sample was added to the spin column. The 
spin column was washed 3 times with binding buffer. The non-polyadenylated RNA 
was washed off by adding 200 pi of low salt wash buffer and spun as above. The spin 
column was then placed in a sterile RNase free 1.5 ml microfuge tube and the PolyA+ 
RNA was eluted by 2 x 100 pi of elution buffer. The RNA was then precipitated and 
finally resuspended in 10 pi of elution buffer (10 mM Tris pH 7.5) and stored at -70 
°C until needed.
4.35.2 Production of cDNA using Random Primers
Oligo dT priming was used to prime the first strand of cDNA synthesis from isolated 
Poly A+ RNA populations. Double stranded cDNA was synthesised using the 
Invitrogen COPY Kit by following the manufacturer’s instructions using the Gubler- 
Hoffman method of cDNA synthesis (Gubler and Hoffman 1983). Briefly, the 
method uses random priming and AMV reverse transcriptase to convert single 
stranded RNA into RNA-cDNA hybrids by reverse transcription. The second step 
utilises the activity of RNase-H to nick the RNA while the RNA-DNA hybrids form. 
The enzyme E.coli DNA Polymerase 1 then uses these fragments of nicked RNA as 
primers to synthesise the second strand of cDNA. Any nicks in the double stranded 
cDNA are repaired with E.coli DNA ligase. These enzymes produce a double 
stranded cDNA that retains the 3’ overhang at the end of the first strand of cDNA and 
a few RNA nucleotides of RNA sequence at the 5’ end of the converted strand. 
Finally, T4 DNA Polymerase is added to make the double stranded cDNA blunt 
ended. The cDNA is stored at -70 °C until needed.
4.35.3 Preparation of cDNA for Subtractive Hybridisation
The double stranded cDNA was digested completely with Alu 1 (this effectively 
produces smaller cDNA fragments and means that all the cDNA products will be
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equally represented when amplified with PCR). Three distinct double-stranded 
phosphorylated oligodeoxynucleotide linkers were designed and ligated onto each 
specific cDNA population.
RANTES
5’ [GGCCCTGCAGGATCGATCTATAGCG] and 
3’ [CCGGGACGTCCTAGCTAGATA]
M IP-la
5 ‘ [TAGTCCGAATTCAAGCAAGAGCACA] and 
3’ [CTTGCTTGAATTCGGACTA]
Bone Marrow
5’[GGCCCTGCAGGATCGATCTATAGCG] and 
3 ’ [ATAGATCGATCCTGCAGGGCC]
A Hind III, Not I and a Pst I site have been designed into the three primers 
respectively. Each linker has one blunt end and one 4-base 3’ protruding end. The 
three cDNA-linker mixtures were electrophoresed through a 2 % low-melting point 
agarose gel for a short distance to remove the un-ligated linkers. The linker ligated 
Alul cDNA fragments in the size range of 0.2-1Kb were cut from the gel and melted. 
Linker-ligated cDNA fragments in agarose were amplified directly by PCR. 1 pi of 
melted agarose was used for 100 pi PCR mixture (94°C, 1 min; 50°C 1 min; 72°C, 
lmin; Link 4°C Soak; 30 cycles). 10 such PCR reactions were performed for each of 
the samples. The amplified cDNA fragments were the starting material for 
subtractive hybridisation and were used for comparative southern blotting analysis 
with m CD34.
4.35.4 Photo-Biotinylation
10-40 pi of cDNA (0.01 mg/ml in TE) was added to an equal volume of 
PHOTOPROBEBlotin and mixed gently. For photo coupling, the reaction tube (cap 
open) was placed in an ice bucket 10 cm below a mercury vapour lamp and 
illuminated for 5 minutes. A further equal volume of PHOTOPROBE Bl0tin was added
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and this was again illuminated for 5 minutes under the lamp. The total volume of the 
reaction was brought to 80 pi with cffl^ O and a further 80 jil o f Tris pH 9.5 was added 
this facilitates the removal of the un-incorporated PHOTOPROBE Bl0tin. 160 pi of 2- 
butanol was then added to the mixture and mixed by inversion and this was spun in a 
micro-centrifuge at 13500 rpm for 5 minutes. The upper butanol phase was discarded 
and the process was repeated. The biotinylated cDNA was precipitated by the 
addition of 10 pi 10 M Ammonium Acetate, 2 pi 1 M MgCk, 1 pi of 20 mg/ml 
Glycogen and 125 pi of ethanol. This was mixed and incubated at -70 °C for 15 
minutes, the biotinylated cDNA was spun down at 13500 rpm for 15 minutes and 
washed with 70 % ethanol. The pellet was dried and resuspended in (IH2O.
4.35.5 Streptavidin Removal of Biotinylated DNA
Briefly, 10 pi of 3 x Extraction Buffer and 4 pi of streptavidin (1 mg/ml) was added to 
20 pi of biotinylated DNA and left at room temp for 5 minutes. This was performed 
to allow sufficient time for the biotin/avidin bond to form. 8 pi was removed for later 
analysis by PCR. An equal volume of TE Saturated Phenol/ Chloroform was added to 
the mixture and this was vortexed for 30 seconds and spun at 13500rpm for 5 minutes. 
The top layer was removed to a sterile eppendorf, and to this a further 50 pi of TEsat 
Phenol/Chloroform was added this again was vortexed 30 seconds and spun at 13500 
rpm for 5 minutes. The top layer was removed carefully trying not to transfer any of 
the bottom layer and this was repeated a further twice. The phenol was extracted 
from the DNA by adding 50 pi of chloroform, vortexing and spinning as above. A 
PCR reaction can be set up as a further check for the removal of the photobiotinylated 
cDNA. Using a master mix consisting of 20 pi Taq Buffer, 40 pi d NTPs (0.05 mM), 
20 pi Oligo (2 mM), 2 pi Taq Polymerase, 2 pi Template and 116 pi dH20. The PCR 
was set for 2 minutes at 94 °C, 1 minute at 55 °C, and 1 minute at 72 °C for 30 cycles 
followed by a soak of 4 °C.
4.35.6 Subtractive Hybridisation
Subtractive hybridisation was performed according to the protocol from Dr Ged 
Brady. Briefly, 400 ng of tracer cDNA, made from m M IP-la stimulated Sca-1+/ 
T hyl.l+/Lin' cells, 4 pg of photobiotinylated driver cDNA, made from RANTES
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stimulated Sca-1+/ T hyl.l+/ Lin" cells and 5 |Xg of tRNA were added to a sterile 1.5 ml 
microfuge tube and the volume was adjusted to 80 pi with HE. The mixture was 
vortexed for 30 seconds and spun briefly to ensure an even mixture was produced, 
this was then denatured by boiling for 2 minutes and then incubated on ice for a 
further 2 minutes. The DNA was precipitated by adding 8 pi 3 M Na Acetate, 200 pi 
100 % EtOH, vortexed briefly and chilled on ice for 20 minutes. This was then spun 
at full speed for 15 minutes and washed with 70 % EtOH and dried for 10 minutes. 
The pellet was carefully resuspended in 3 pi 3 x Hybridisation Buffer and 3 pi 5 M 
NaCl followed by 3 pi 40 % Polyethylene glycol 8000. The sample was then mixed 
and covered with 70 pi (1-2 drops) oil and transferred to a 0.5 ml microfuge tube. 
The hybridisation mixture was then placed in a PCR machine and set to run this 
following program: 5 minutes at 98 °C, 5minutes at 80 °C, 60 minutes at 68 °C then 
held at 68 °C. Once the program had reached the 68 °C end point 90 pi of extraction 
buffer (pre-heated to 68 °C to avoid cooling to reduce low stringency hybridisation) 
was added to the tube. The tube was then briefly spun at 13500 rpm in a bench top 
micro-centrifuge to ensure all the aqueous layers have combined. The mineral oil was 
removed from the top of the mixture and the tube was once again spun as above. The 
bottom 75 pi of hybridisation /extraction mixture was removed to a fresh tube and to 
this 21 pi of fresh extraction buffer plus 4 pi of 4 mg/ml streptavidin was added, 
mixed and then incubated at room temperature for 5 minutes. 100 pi of TE saturated 
phenol/chloroform was added and vortexed for 30 seconds and spun at 13500 rpm at 
room temperature for 5 minutes. The top three-quarters of the aqueous phase (~75 pi) 
was removed avoiding the interface and transferred to a fresh new tube. The 
transferred aqueous phase was extracted with 50 pi of chloroform, vortexed for 30 
seconds and spun at 13500 rpm at room temperature for 5 minutes. The above 
protocol consists of only one round of subtractive hybridisation it was therefore 
necessary to repeat the above step a further twice. Before doing so 10 pi of the first 
round of subtracted mixture was removed for further analysis and the remaining 60 pi 
of the mixture was then put through a further two rounds of subtraction. After a total 
of three sequential rounds of subtraction the final extracted 60 pi was ethanol 
precipitated using 2 pg glycogen (2 mg/ml, 2 pi) as a carrier protein, resuspended in 
10 pi of TE. 2 pi of each round of subtracted material was amplified using the tracer 
oligonucleotide as a primer. PCR conditions: 40 seconds 94 °C, 30 seconds 42 °C, 2
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minutes 72 °C for 25 cycles. PCR Set up: 53 pi CIH2O, 10 pi 10 x Buffer, 7 pi MgCL, 
10 pi Oligo (1-2 mM), 14 pi d NTPs (100 mM), 2 pi template, 2 pi Taq Polymerase.
4.35.7 Cloning, Sequencing and Analysis of Clones from the Subtractive Library
The final round of subtracted material and the PSK-bluescript vector were digested 
with Not 1 restriction enzyme. After PSK was treated with alkaline phosphatase, the 
cDNA fragments were ligated into the vector. DH5a competent cells were 
transformed with PSK-bluescript containing the cDNA inserts from the subtractive 
hybridisation. The only addition to the method described in 4.20.1 is the addition of 
IPTG and X-Gal to the Amp plates to provide blue/white selection. The plates were 
incubated at 37 °C overnight. On the next day any white colonies that formed, were 
picked and grown up as described in section 4.20.2 and plasmid preps were set up 
using the Quiagen mini prep kit. Each plasmid was digested to check for insert and 
then sequenced using the T3 primer. 50 clones were sequenced and were analysed for 
homologies with known genes and expressed sequence tags (EST’s) from non 
redundant and EST databases using the basic logical alignment search tool (BLAST) 
search program (Altschul et al 1990a, b).
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CHAPTER 5
RESULTS 1 : Enrichment of CFU-A stem cells and Subtractive 
hybridisation
5.1 Introduction
The primary aim of this work was to attempt to examine the molecular mechanisms 
involved in the inhibition of CFU-A stem cells by the chemokine macrophage 
inflammatory protein- 1 alpha (MIP-la). Over the years there has been an increasing 
number of studies examining how positive growth factors affect cell proliferation. 
Although there are now more studies examining how negative regulators such as 
M IP-la and TGF-p exert their function upon cell proliferation, comparatively little is 
known about how these negative regulators work. In an attempt to address this, a 
subtractive hybridisation method was used to examine how M IP-la exerts its 
inhibitory function on the transiently engrafting stem cells.
The heterogeneous nature of bone marrow cells and the very low incidence of 
haemopoietic stem cells have hampered studies of the mechanisms of haemopoietic 
regulation. The incidence of long term repopulating stem cells (LTRSC) has been 
estimated to be approximately lx l0 4 nucleated cells and the estimates vary depending 
on the assay techniques. Several investigators have employed both physical and 
immunological techniques in an attempt to enrich haemopoietic stem cells. These 
techniques have included, density gradient cell separation, centrifugal elutriation, 
immunomagnetic separation, immune adherence (panning) and fluorescence-activated 
cell sorting (FACS). The difficulty of enriching such a small stem cell population 
prompted us to initially attempt to find a cell line that not only displays stem cell 
characteristics but also can be inhibited by M IP-la. There are a number of primitive 
haemopoietic stem cell lines available and our group has examined the effects of 
M IP-la on two of these cells. The first cell line examined was a factor dependant cell 
line, Factor Dependant Cell Paterson- Mix (FDCP-Mix). FDCP-Mix cells were 
isolated from long term bone marrow cultures infected with a retrovirus carrying the 
src oncogene (Spooncer et al 1986). FDCP-Mix cells are unlike most other growth 
factor dependant haemopoietic cell lines in that they retain normal karyotype, they are
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non leukaemic and the rate of growth factor independent clones is less than 1 in 100 
million (Heberlein et al 1990). These FDCP-Mix cells are multipotent and are 
dependent on interleukin-3 (IL3) for growth and survival as the removal of IL-3 from 
these cells induces apoptosis within 24 hours (Williams et al 1990a). One attribute 
that distinguishes FDCP-Mix cells from other haemopoietic cell lines is their potential 
to differentiate along multiple haemopoietic lineages in response to regulatory 
molecules. The addition of IL-3, GMCSF and G-CSF can induce differentiation 
down the granulocyte lineage and culturing of FDCP-Mix cells with M-CSF or EPO, 
in the presence of IL-3, can induce macrophage or erythrocyte production 
respectively. On co-culturing FDCP-Mix cells with bone marrow stromal cells, the 
FDCP-Mix cells attach and grow on the stroma and undergo multi-lineage 
differentiation (Spooncer et al 1986, Heyworth et al 1990). It has also been observed 
that FDCP-Mix cells have similar properties to CFU-S stem cells in that they have the 
ability to produce colonies on the surface of spleens of irradiated mice following 
transplantation. The proliferation of CFU-S stem cells and their in-vitro counterparts, 
the CFU-A stem cells, can be inhibited by M IP-la. Therefore the similarities 
between the FDCP-Mix cells and the CFU-A/S stem cells makes this cell line an ideal 
candidate to examine the effects of M IP-la.
5.2 The Effect of M IP-la on FDCP-Mix Colony Formation
In the first experiment, the FDCP-Mix colony growth potential was examined in the 
presence or absence of increasing concentrations of M IP-la in soft agar assays. One 
thousand FDCP-Mix cells were incubated in the presence of varying concentrations of 
M IP-la for 7 days at 37 °C 5% CO2. An average of 60 FDCP-Mix colonies were 
produced after 7 days, FDCP-Mix colonies were defined as having between 20-40 
cells in a tight cluster of cells (figure 5.1). This represents a cloning efficiency of 6 % 
within the assay and this compares favourably with previously reported results. 
Indeed, Heyworth et al observed a cloning efficiency of 3.5- 5.3 %, and the variation 
was shown to be dependant on the time the cells were incubated in liquid culture 
before being transferred to the soft agar culture (Heyworth et al 1990). The addition 
of murine M IP-la (PM2, see materials) for the duration of the assay at 10, 50, 100 
and 500 ng/ml had no detectable inhibitory or stimulatory effect on the number of 
FDCP-Mix colonies in the soft agar assay. However, the addition of 250 ng/ml of
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8 0 -,
Figure 5.1 Colony Forming assay analysis of the effects of M IP-la on the production of 
FDCP-Mix colonies
FDCP-mix cells were cultured for 7 days in soft agar containing rm IL-3 at 10 jig/ml and 
M IP-la at 10, 50, 100, 250 and 500 ng/ml. FDCP-Mix colonies were defined as having 
between 20-40 cells in a tight cluster. The average colony production (+ SEM) is shown for 
10 plates. Results represent the mean of three replicate experiments. Students T-test were 
performed comparing control treatment to each concentration of M IP-la (* 1 = P < 0.05, *2 = 
P<0.01 and *3 = P <0.001)
I  Control Q  lOOng/ml M IP-la
■  500 ng/ml M IP-la ■  50 ng/ml M IP-la
0  250 ng/ml M IP-la I  10 ng/ml M IP-la
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M IP-la produced an 8.6 % reduction in the number of FDCP-Mix colonies, from 60 
to 53 colonies. Whilst the inhibition in FDCP-Mix colony formation at 250 ng/ml of 
M IP-la is statistically significant (P < 0.05), this reduction may be artefactual, as no 
further inhibition can be observed upon the further increase in M IP-la concentration. 
These results are in keeping with previous results within our group, which suggest 
that M IP-la does not induce inhibition of FDCP-Mix colony formation. Using [3H] 
Thymidine, we have been unable to show that M IP-la affects [3H] Thymidine uptake 
by these FDCP- Mix cells. These results observed within our group are at odds with 
the results produced by Heyworth et al. They observed that M IP-la can indeed 
inhibit the proliferation of FDCP-mix cells in soft agar assays and it can also reduce 
the uptake of [3H] Thymidine (Heyworth et al 1995, Wark et al 1998). However, it is 
possible that the degree of the inhibitory response is dependent on the particular cell 
isolate used, and this may explain these apparently contradictory results. This 
inability of M IP-la to inhibit FDCP-Mix cell proliferation, in our hands, may be 
explained in a number of ways: (1) There may be a signal transduction problem i.e. 
the FDCP-Mix cells may not have the ability to produce a signal in response to 
receptor ligand activation of its various chemokine receptors. (2) The FDCP-Mix 
cells may not express the appropriate receptor to produce the inhibitory property of 
M IP-la.
5.3 Calcium Mobilisation Experiments
The possibility of a signalling abnormality was addressed by analysing the signalling 
potential of these cells using a calcium mobilisation assay. This type of assay is 
normally used to study the signalling potential of chemokines in cell lines transfected 
with chemokine receptors, and is used by several groups to indicate the interaction 
between a receptor and the signalling mechanisms (Neote et al 1993, Myers et al 
1995, Wu et al 1993). Chemokine receptors are members of the 7 transmembrane G 
protein coupled family of receptors (GPCRs) (Murphy et al 2000). On stimulation of 
the receptor with its ligands, the beta isoform of phospholipase C (PLC-p) catalyses 
the breakdown of phosphoinositol (4,5) bis-phosphate (PtdInsP2) into two secondary 
messengers, namely diacylglycerol (DAG) and inositol tris-phosphate (InsPs) 
(Berridge and Irvine 1989). InsP3 is an intracellular secondary messenger, which can 
bind to a receptor on the endoplasmic reticulum and trigger the release of calcium
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from intracellular stores. Following this, a further increase in intracellular calcium 
comes as a consequence of the movement of calcium from outside to inside the cell, 
this may be due to the activation of InsP3 receptors in the plasma membrane (Khan 
1992). By using a fluorescent calcium binding molecule such as FURA-2AM, 
changes in the concentration of intracellular calcium can be followed (Sozzani et al 
1997). In figure 5.2, the results of two calcium assays can be observed. In assay A, 
the release of calcium is measured in THP-1 cells upon stimulation with 100 ng/ml of 
M IP-la. THP-1 cells are a human monocytic cell line and have a variety of 
chemokine receptors, principally CCR1 (Nibbs personal communication), expressed 
on their surface, and are routinely used to analyse chemokine signalling potential. It 
can be observed that there is an efficient uptake of the fluorescent dye, indicated by a 
baseline of approximately 208.7, and upon stimulation with 100 ng/ml of M IP-la a 
small calcium release shown by the height of the initial spike (230.6) can also be 
observed.
An estimation of the increase in intracellular calcium concentration was found to be 
166.6 nmol/L by using the equation:
[Ca2+]i = 224 [(F2-Fmta)/ (Fmax-F2)] - 224 [(F,-Fmin)/ G w -F ,)].
Where Fi is the intensity before the agonist addition, F2 is the peak intensity after the 
agonist addition, Fmax is the intensity after Tween addition, Fmin is the intensity after 
EGTA chelation and 224 is the dissociation constant in nM of calcium from FURA-2 
at 37 °C. When this experiment is compared to a similar one performed on the FDCP- 
Mix cells, (figure 5.2B) it can be observed that the FDCP-Mix cells have a lower base 
line than that of the THP-1 cells i.e. 50.5. On the addition of M IP-la, there is a small 
spike in calcium release indicated by the peak and the increase in intensity to 60.1. 
However, even with a low baseline of fluorescence, the increase in intracellular 
calcium concentration is equivalent to the THP-1 cells ([Ca]i = 157.5 nmol/L). Both 
results suggest that neither of these cell lines have a deficiency in signalling through 
their respective chemokine receptors. However, in both calcium assays the increase 
in calcium release upon stimulation with the agonist, 100 ng/ml of M IP-la, is very 
small and therefore further work is needed to examine the true signalling potential of 
both of these cell lines.
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Figure 5.2 Calcium mobilisation assay analysis of the ability of M IP-la to mobilise 
calcium in THP-1 and FDCP-Mix cells
Five million cells are assayed in a 2ml cuvette. The fluorescence is allowed to settle and then 
the 100 ng/ml of M IP-la is added as indicated by the arrow. This assay is a representative 
result from three replicate experiments.
A) Shows THP-1 cells as a positive control B) Shows FDCP-Mix cells
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Alternatively, it is possible that these cells do not express the unknown M IP-la 
inhibitory receptor. Although FDCP-Mix cells have been shown to express CCR1, 3, 
5 and D6 (Nibbs personal communication) there is some in-vitro data to suggest that 
these receptors are not involved in the inhibitory activity induced by M IP-la. 
However, further studies are needed to clarify the role of these receptors in-vivo. 
Finally, the inability of the FDCP-mix cells to show growth inhibition on incubation 
with M IP-la may be due to the dependence on IL-3. The IL-3 induced proliferative 
drive could be so powerful that any possible inhibition of proliferation by M IP-la 
may be hidden. A possible method of getting around this problem could be the 
removal the growth factor from the cells however, factor starvation of FDCP-Mix 
cells is not an option as on removal of growth factor these cells die by apoptosis 
(Williams et al 1990a). Therefore, the inability of M IP-la to inhibit the proliferation 
of FDCP-Mix cells, indicates that they are not a suitable cell line to use as a model for 
the inhibitory functions of M IP-la.
5.4 The Effect of M IP-la on M 07e Colony Formation
A second haemopoietic cell line, human megakaryocytic progenitor cell line M07e, 
was examined for its ability to respond to the inhibitory property of M IP-la. M07e 
cells are also a factor dependent cell line and they depend on rh GM-CSF for survival 
and growth. It has been reported by Aronica et al, that M IP-la can inhibit 
proliferation of these cells and that this effect is more pronounced when the cells are 
factor starved (Aronica et al 1995). This factor starvation may reduce the 
proliferative drive induced by GM-CSF, and thus allow M IP-la inhibitory effects to 
be more readily observed. Firstly, the potential of these cells to grow in soft agar was 
analysed the M07e cells were cultured for 4 days, and 18 hours prior to plating in 
agar, the cells were either re-fed or factor starved. The cells were then grown in soft 
agar in the presence or absence of 100 ng/ml m M IP-la and 100 ng/ml of rh GM-CSF 
for 7 days.
Similar to the FDCP-Mix colonies, a M 07e colony was defined as having between 20 
and 40 cells clustered together. An average of 110 M07e colonies were produced 
when 1 xlO M07e cells were plated and this number was reduced to 100 on the 
addition of 100 ng/ml of M IP-la, however, this was not significant (figure 5.3A).
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Figure 5.3 Colony Forming assay analysis of the effects of M IP-la on the production of 
M07e cells or factor starved M07e cells
M07e cells were cultured for 7 days in soft agar in the presence or absence of rm GM-CSF
(100 ng/ml) and M IP-la 100 ng/ml. M07e colonies were defined as having between 20-40
cells in a cluster. The average colony production (+ SEM) is shown for 5 plates. Results 
represent the mean of three replicate experiments. Students T-test were performed (* 1 = P < 
0.05, *2 = P < 0.01 and *3 = P < 0.001)
A) Normal M07e cell B) Factor starved M07e cell
H  Control □  Control
■  100 ng/ml M IP-la ■  100 ng/ml M IP-la
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This gives a cloning efficiency of 11% and this compares favourably to 10 % found 
by Mantel and Broxmeyer in 1995 (Mantel et al 1995). Furthermore, Broxmeyer et al 
observed that with the inclusion of a factor starvation step, the M07e cells become 
more responsive to M IP-la. However, upon factor starving the M 07e cells and 
plating 1000 cells in a soft agar assay (figure 5.3B), the overall colony number was 
reduced from 110 in non factor starved cells to 60 in factor starved cells. No 
inhibition of M07e colony formation was observed with the addition of 100 ng/ml of 
M IP-la in the factor starved conditions (figure 5.3B). These results are at odds with 
previously published data by Broxmeyer and Mantel, they demonstrated that M IP-la 
at 50 ng/ml could protect M07e cells from cell death, when exposed to an S-phase 
cell cytotoxic agent such as [H] Thymidine, and that this protective effect increases 
with the inclusion of a factor starvation step. As with the FDCP-Mix cell line, MIP- 
l a  could not inhibit the formation of M07e colonies. Therefore, these cells were 
deemed unsuitable as a model system for the inhibitory action of M IP-la, and it was 
decided to pursue the isolation of a highly enriched population of transiently 
engrafting stem cells.
5.5 Enrichment of CFU-A Stem Cells
5.5.1 Lineage Enrichment of Bone Marrow Cells
The incidence of CFU-A stem cells in normal bone marrow is estimated to be 
approximately 150-220/105 nucleated cells (Lorimore et al 1990). The aim is 
therefore to isolate a population of bone marrow cells that have a high cloning 
efficiency within the CFU-A assay. Cell separation techniques are based on both size 
and immunological approaches, these methods rely on diverse cell characteristics, 
ranging from cell density, cell surface antigen expression and differential sensitivity 
to cytotoxic agents.
As stated in the introduction, Boyum (1968,1983) originally described a one step 
centrifugal technique for the isolation of lymphocytes and mononuclear cells. Using 
this density gradient cell separation technique unfractionated bone marrow from 10- 
20 B6D2F-1 mice was firstly enriched for mononuclear cells, and then subsequently 
enriched using an indirect immunomagnetic bead selection, according to a previously 
described method by Hirayama et al (Hirayama and Ogawa 1992). Firstly, the cells
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were incubated with a cocktail of monoclonal antibodies specific for cell surface 
markers expressed on the mature cells which included: B 220 on B cells, CD 4, CD 5 
and CD 8 on T cells, Gr-1 and Mac-1 on myelomonocytic cells and Ter 119 on 
erythroid cells. The labelled cells were then mixed with sheep anti-rat IgG antibody 
conjugated to immunomagnetic beads and placed in a magnetic particle concentrator. 
The non-rosetting cells that were recovered from the negative immunomagnetic 
selection were designated as Lineage negative cells (lin‘), and northern blots 
confirmed the success of the lineage enrichment (data not shown). To investigate 
whether the density gradient and immunomagnetic selection could increase the 
incidence of CFU-A stem cells within this enriched cellular population, the plating 
efficiency of five hundred lin' cells were compared to 5x10 unfractionated bone 
marrow cells in the CFU-A assay (figure 5.4). Unfractionated bone marrow cells 
produce an average of 10 CFU-A colonies and this concurs with the number of CFU- 
A stem cells proposed to reside in the bone marrow by Lorimore (Lorimore et al 
1990). This enrichment technique increased the cloning efficiency from 0.2 %, for 
unfractionated bone marrow, to 4% for lineage negative enriched cells, a 20 fold 
enrichment. However, further enrichment of the CFU-A stem cells was required 
before it was possible to use these cells as a starting cellular population for the 
subtractive hybridisation.
5.5.2 Enrichment of Lineage Depleted Bone Marrow Cells with Sca-1 Antigen
As is the case with mature cells within the blood the progenitor and stem cells also 
express specific cell surface markers. The use of these specific markers enables one 
to isolate a further enriched population of CFU-A stem cells. To enrich for stem cells, 
several groups have used various cell surface markers that are expressed at various 
levels on more primitive cells. These included Thy-1.1, Sca-1, c-kit and CD34 
(Berman et al 1985, Spangrude et al 1988, Okada et al 1991, Morel et al 1996 and
Sato et al 1999). Sca-1 (stem cell antigen -1) is a glycosyl phosphatidylinositol 
(GPI)-anchored molecule that is expressed on a number of cell types including: 
peripheral lymphocytes, thymocytes and hematopoietic precursors and stem cells, as 
well as on non hematopoietic cells such as fibroblasts, kidney epithelial cells and 
osteoblasts (van de Rijn et al 1989). In this experiment a further enrichment was
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Fig 5.4
Figure 5.4 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony number by enriching for a subset of bone marrow defined by the lack 
of mature markers, lineage negative cells (Lin').
The cloning efficiency of unfractionated bone marrow and Lin' cells was calculated when 
5xl02 unfractionated bone marrow and 5xl02 Lin' cells were cultured for 11 days in the CFU- 
A assay. CFU-A colonies were defined as colonies greater or equal to 2 mm in size. This 
assay is a representative result from three replicate experiments. The efficiency of the lineage 
depletion was checked for mature cell markers via northen blotss (data not shown).
■  Cloning efficiency of 5xl02 Bone marrow cells
■  Cloning efficiency of 5xl02 Lineage minus cells
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attempted using a Sca-1 monoclonal antibody. After the pre-enrichment step in 
section 5.51, the lin' cells were labelled with either a monoclonal antibody to Sca-1 
(anti Ly-6A.2/E.l), stained with fluorescein isothiocyanate (FITC) conjugated goat 
anti-rat IgG or with an IgG isotype control antibody stained with FITC. The 
fluorescent staining of these lin' cells were compared to that of the isotype control 
treated cells on the FACS Star. The cells with high fluorescence intensity, as shown 
in top histogram in figure 4.1, were then sorted as Sca-1+/ Lin' cells. Furthermore, 
cells with low to negative Sca-1 staining were also collected and these cells represent 
a population of cells that are Sca-1'/ Lin'. The CFU-A activity of one hundred Sca-1+ 
/ Lin' and Sca-1' / Lin" cells were then compared with 5xl03 unfractionated bone 
marrow cells and 5x10 lin' cells. The isolation of Sca-1'/ Lin' cells did not improve 
the CFU-A yield however, cells that were positively stained with the Sca-1 antibody, 
the Sca-1 +/ Lin' cells, further enriched CFU-A numbers 3 fold producing a cloning 
efficiency of 12 % (Figure 5.5). Thus the addition of the Sca-1 enrichment step 
produced an overall 60-fold enrichment from unfractionated bone marrow.
5.5.3 Enrichment of Lineage Depleted Bone Marrow Cells with Sca-1 and 
Thy-1.1 Antigens
Berman et al observed that lineage depleted cells that expressed low but significant 
levels of a cell surface differentiation antigen Thy-1.1 could be used as an indicator 
for reconstituting bone marrow stem cells in mice (Berman and Basch 1985). Further 
evidence indicated that these Thy 1.1 lo/' Lin' cells were observed to be enriched in 
clonal progenitors for spleen colonies (CFU-S), thymic colonies (CFU-T), pre-B 
cultures and haemopoietic stem cells (Whitlock et al 1987). Spangrude et al 
identified a stem cell population, which is highly enriched in activity in various stem 
cell assays. These particular cells were depleted of lin+ cells, were positive for the 
Sca-1 antigen and had low or negative staining for the Thy-1.1 antigen. Spangrude 
observed that these cells represented approximately 0.05 % in total bone marrow from 
C57BL/Ka Thy-1.1 and that these cells contained haemopoietic stem cell activity, as 
limited numbers of these cells could repopulate T, B and myeloid lineages and lead to 
long term survival of lethally irradiated mice (Spangrude and Johnson 1990). 
Therefore, the Sca-1+/ Lin' cells were further enriched for cells that either do not 
express or cells that express a low level of the Thy-1.1 antigen by using a Thy-1.1
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Figure 5.5 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony number by further enriching lineage negative cells (Lin ) on the 
expression of Stem cell antigen -1 (Sca-1).
The cloning efficiency of unfractionated bone marrow, Lin' cells, Sca-1+/ Lin' and Sea-17 Lin 
cells was calculated for 5x10* unfractionated bone marrow, 5xl02 Lin' cells, lxlO2 Sca-17 
Lin' and Sea-17 Lin' cells that were cultured for 11 days in the CFU-A assay. CFU-A 
colonies were defined as colonies greater or equal to 2 mm in size. This assay is a 
representative result from three replicate experiments.
H  Cloning efficiency of 5x10* Bone marrow cells 
■  Cloning efficiency of 5xl02 Lineage minus cells
□  Cloning efficiency of 1 x 102 Sea-1 +/Lin' cells
□  Cloning efficiency of lxlO2 Sca-l'/Lin' cells
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phycoerythrin (PE) conjugated antibody. Thy 1.1 (CD90) is a GPI-anchored 
membrane glycoprotein of the Ig superfamily which is found on thymocytes, T 
lymphocytes, haemopoietic stem cells and some neurones (Ritter et al 1983). The 
lineage depleted (lin') cells were incubated either with IgG isotype control antibodies 
stained with FITC and PE, or an IgG monoclonal antibody to Sca-1 (anti Ly- 
6A.2/E.1), stained with FITC and a monoclonal antibody to Thy-1.1, stained with PE 
conjugated goat anti-rat IgG. The fluorescent staining of these cells were compared to 
that of the isotype control treated lin" cells on the FACS Star, and cells that were Sca- 
1+ / Thy 1.1 lo/' and Sca-1+ / Thy 1.1 + were collected (figure 4.2). The ability of these 
purified cellular populations to form CFU-A colonies was examined and the results 
can be observed in figure 5.6. One hundred Sca-1+ / Thy 1.1 + / Lin' cells did not 
increase the cloning efficiency over and above that displayed by Sca-1+ / Lin' cells 
within the CFU-A assay. However, the addition of 100 Sca-1+ / Thy 1.1 lo/' / Lin* cells 
to the CFU-A assay produced an average of 17.67 CFU-A colonies, which represents 
a cloning efficiency of 17.67 %. The cell sorting process leads to a reduction in cell 
viability therefore, to examine the actual cloning efficiency of the Sca-1+ / Thy 1.1 + / 
Lin' cells the viability was taken into account, this was performed by examining the 
uptake of a viability indicating dye, Napthalene black, by the enriched population 
cells. From Table 1, it can be observed that 19.26 % of the Sca-1+ / Thyl.l lo/' / Lin' 
cells took up the dye therefore within the enriched population there are only 80.74% 
of viable cells. This means that the actual cloning efficiency of these Sca-1+ / Thyl.l 
/ Lin' cells within the CFU-A assay is 21.98 %, and this produces a total 
enrichment factor of 109.9. This enrichment process was repeated and a cloning 
efficiency of 22 % was routinely obtained.
5.6 Inhibition of CFU-A Colony Formation of Sca-1+ / Thy-1.110 / Lin" Enriched 
Cells
To confirm that there was no loss of inhibitory response in these cells the inhibitory 
effect of M IP-la was examined. One hundred Sca-1+ / Thy-1.1 Io / Lin' cells were 
plated in the presence or absence of 100 ng/ml of M IP-la in a CFU-A assay. In figure 
5.7, it can be observed that the addition of M IP-la reduces CFU-A colony numbers 
from 17.56 to 3.55 a reduction of 79.88 %.
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Figure 5.6 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony number by further enriching Sca-1+/Lin‘ cells on the expression of 
Thy-1 antigen.
The cloning efficiency o f  unfractionated bone marrow, Lin' cells, S ea-1 T T hy-1.1 10 /L in' and S ea-17 
Thy 1.1 7 Lin' cells was calculated when 5x 10 3 un-fractionated bone marrow, 5x 10 : Lin' cells, 1 x 102 
Sca-1 /Thy-1.1 lo/L in  and Sca-17  Thy 1.1 7  Lin' cells were cultured for 11 days in the CFU-A assay. 
CFU-A colonies were defined as colonies greater than or equal to 2 mm in size. This assay is a 
representative result from three replicate experiments.
@ Cloning efficiency of 5xl03 Bone marrow cells
■  Cloning efficiency of 5xl02 Lineage minus cells
□  Cloning efficiency of 1 x 102 Sea-17Thy-1.110' /Lin' cells
□  Cloning efficiency of lxlO2 Sea-1/Thy-1.1 + / Lin' cells
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Table 1
Test Number of cells that Number of cells Total number %
number do not take up the dye that take up the of cells Viability
dye
1 250 49 299 83.61
2 265 77 342 77.48
3 265 60 325 81.54
Average 260 62 322 80.74
Table 1 Analysis of viability of the Sca-l+/Thy-l.l l0/Lin' cells by the exclusion or 
uptake of Napthalene Black
10 pi of Sca-l+/Thy-l.l lo/Lin' cells were spun down and resuspended in 7.5pl of PBS to this 
2.5pl of Napthalene Black was added and the cells were counted on a haemocytometer. The 
cells that took up the dye were counted as dead cells.
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5.7 Suitability of the Sca-1+ / Thyl.l lo/" / Lin" Cells as the Source for the 
Subtractive Hybridisation
o
The overall enrichment protocol reduced the total numbers of cells from 1.8 xlO in 
unfractionated bone marrow to 2-5 xlO4 in the final Sca-1+ / Thy-1.1 lo / Lin" 
population, these cells are highly enriched for CFU-A stem cells and M IP-la can 
almost completely inhibit the proliferation of these cells. These enriched cells 
produce a cloning efficiency of 22 % within the CFU-A assay, this means that there 
may be a possibility of contamination of the subtractive hybridisation from the other 
78 % of the cells that do not grow in the CFU-A assay. Morphological analysis of the 
residual 78 % of cells suggests that there is no evidence of a substantial contribution 
of mature cells to the enriched population and, the main constituent cell type of the 
enriched population was identified as blast cells (Table 2). These cells are primitive 
haemopoietic cells and characteristically display a high nuclear to cytoplasmic ratio, 
which can be observed in figure 5.8. As indicated by the cloning efficiency the 
majority of these blast cells do not produce colonies in the CFU-A assay suggesting 
that they may be out-with the phenotypic window which scores in the CFU-A assay 
(Table 2). Therefore, these particular blast cells are not CFU-A stem cells and as 
M IP-la can only inhibit CFU-S/A stem cells within the stem cell compartment it is 
unlikely that there will be an inhibitory signal induced in any of these cells within the 
finally enriched cellular population. The data in figure 5.9 provides further evidence 
that this cell population is indeed enriched for stem cells. Southern blot analysis (see 
methods section 4.27) of the abundance of a-actin, a house keeping gene, and CD34, 
a known stem cell marker, in the cDNA from Sca-1+ / Thyl.l lo/" / Lin" population was 
compared to that of cDNA from unfractionated bone marrow cells. There is an 
increase in CD34 expression within the cDNA from the Sca-1+ / Thyl .1 lo/" / Lin" cells 
compared to that of the bone marrow again indicating that these cells are primitive 
haemopoietic cells.
140
Fig 5.7
20n
Figure 5.7 Colony Forming Unit Agar (CFU-A) analysis of the effect of 100 ng/ml of 
M IP-la on the formation of the CFU-A colonies from Sea-14/Thy-1.1 lo/Lin‘ 
enriched cells.
Sca-l+/Thy-l.l lo/Lin' were cultured for 11 days in the presence of 100 ng/ml of M IP-la in 
the CFU-A assay. CFU-A colonies were defined as colonies greater or equal to 2 mm in size. 
The average colony production (+ SEM) is shown for 5 plates. Results represent the mean of 
three replicate experiments. Students T-test were performed 
(* = P <0.001)
□  lxlO2 Sca-l4/Thy-l.l lo/Lin'cells
H  1 x 102 Sea-1 +/Thy-1.1 l0/Lin' cells plus 100 ng/ml of MIP-1 a
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Table 2
Cell Type % of cells in
enriched population
Blast cells 87.5
Primitive Monocytoid 9.0
Cells
Primitive Myeloid Cells 3.5
Mature cells 0
Table 2 Cell morphological analysis of Sea-1 +/Thy-1.1 '7Lin‘ cells
Sca-l+/Thy-l.l l0/Lin' cells were isolated as described in the materials and methods and 
cytospins were prepared. The morphology of 500 cells was examined.
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Figure 5.8 Photographic analysis of the morphology of unffactionated bone marrow, 
lineage depleted cells and Sca-l+/Thy-l.l lo/Lin'
Bone marrow, lineage depleted and Sca-l+/Thy-l.l lo/Lin‘ were isolated and cytospins were 
prepared and photographed.
A) Shows the cell morphology of un-fractionated bone marrow
B) Shows the cell morphology of Sea-1+/ Thy-1.1 lo/Lin‘
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Fig 5.9
CD 34
fJ-Actin
Bone marrow Enriched Stem cells
Figure 5.9 Southern Blot Analysis of mCD34 Expression on Bone Marrow and 
Sca-l+/Thy-l.l '7Lirf Cells
The top row shows a blot hybridised with a probe for murine CD34 and the bottom panel 
shows the same blot stripped and reprobed for (3-actin. Column I is cDNA made from normal 
bone marrow and column 2 is cDNA from Sea- T /Thy-1.1 lo/Lin" cells.
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As M IP-la is a member of the C-C chemokine family and has functions other than 
inhibition of CFU-A/S stem cells, e.g. induction of chemotactic responses on a variety 
of blood cells, there is a concern over the possibility that signals other than the 
inhibitory signal produced by M IP-la may also be transduced in these Sca-1+ / 
Thyl.l lo/' / Lin' cells and therefore, may be detected by the subtractive hybridisation. 
In an attempt to overcome the possible problem, the cDNA made from RANTES 
(regulated upon activation normal T expressed and secreted) treated Sca-1+ / Thyl.l 
lo/7 Lin' cells was used as subtractive partner. RANTES treated cells were used as 
subtractive partner because RANTES is also a member of the C-C chemokine family 
and like M IP-la it also demonstrates chemotactic responses on a variety of mature 
blood cells (Rot et al 1992). Furthermore, no murine chemokine receptor has been 
identified that exclusively binds either RANTES or M IP-la and both chemokines 
have the ability to bind to the same receptors namely CCR 1, 3, 5 and D6. Therefore, 
the possible carry over of pro-inflammatory signals contaminating the subtractive 
hybridisation will be kept to a minimum by using RANTES treated cells as the 
subtractive partner. As well as these properties RANTES has a further advantage in 
that it does not inhibit stem cell proliferation and this means that the final cDNA 
isolated from the subtraction should be relatively specific for the inhibitory effect on 
CFU-A stem cells by M IP-la.
5.8 Subtractive Hybridisation
Cellular differentiation and developmental processes are associated with 
corresponding changes in messenger RNA within a particular cell type. Messages for 
genes relevant to specific developmental processes are thought to alter their 
abundance due to induction or repression of transcription. Several groups including 
ours have used subtractive hybridisation as a method for examining the alteration in 
gene expression in other situations (Wang and Brown 1998, Brady and Iscove 1993, 
Baird et al 1999). Subtractive hybridisation was used here to examine the induction 
and repression of gene transcripts that may be involved in M IP-la inhibition of CFU- 
A stem cells. However, it is necessary to realise that induction or repression of 
transcription may not be the only level of control used by M IP-la to inhibit the CFU- 
A stem cells.
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Indeed, phosphorylation or dephosphorylation of various cellular proteins may be an 
alternative means of control involved in M IP-la induced inhibition of CFU-A stem 
cells. However, these types of studies on stem cells are difficult to perform due to the 
limited numbers of stem cells and the inability to produce a homogenous stem cell 
population.
Therefore, although it is accepted that other controlling pathways may be involved in 
M IP-la inhibition of CFU-A stem cells, this part of this thesis is focused on isolating 
genes that are involved in the inhibitory pathway induced by M IP-la in CFU-A stem 
cells. To do this a PCR-based technique, subtractive hybridisation was used. In order 
to perform subtractive hybridisation efficiently an appropriate cellular population has 
to be isolated, in this case the cellular population is the enriched Sca-1+ / Thyl.l lo/' / 
Lin' cells. Dunlop et al observed that upon stimulation of CFU-A/S stem cells into 
cycle the addition of 100 ng/ml of M IP-la was sufficient to induce quiescence after 4 
hours (Dunlop et al 1992). Other studies within our group indicated that 100 ng/ml of 
M IP-la has been observed to produce a consistent inhibition of CFU-A colony 
formation. Furthermore, Maltman et al observed that M IP-la can induce 
transcription of the TGF-P gene after 4 hours; therefore the enriched Sca-1+/ Thy-1.1 " 
/l0/ lin' cells were incubated for 4 hours with 100 ng/ml M IP-la or RANTES. Each 
enrichment of CFU-A stem cells yields approximately 2-5 x 104 Sca-1+ / Thyl.l lo/' / 
Lin' cells, this small number of cells produces an insufficient amount of mRNA for 
northern blot analysis. Therefore, to overcome the problem of lack of mRNA, the 
generation of cDNA by oligo dT priming from the two mRNA populations was 
performed. Messenger RNA (mRNA) was isolated from these cells using an 
Invitrogen micro-fast track kit, as described in methods section 4.35.1, and cDNA was 
generated. The cDNA was then amplified via PCR to ensure there was sufficient 
material to perform the subtraction. The kinetics of PCR means that it will favour 
amplification of smaller DNA fragments, and thus in an attempt to overcome the size 
bias the cDNA was cleaved with a restriction enzyme, Alu-1. Alu-1 has a four base 
recognition site and therefore, will cut the cDNAs approximately every 44 (256) base 
pairs (Old 1989). This has the effect of reducing the size of the DNA molecules to 
between 200 bp and 1 kb and produces a population of cDNA that is a more 
representative of the RNA isolated. This particular restriction enzyme is a “flush end” 
cutter and therefore in order to perform subtractive hybridisation and PCR, specific
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double stranded oligonucleotide linkers were ligated onto the cDNA populations 
(figure 5.10). In an attempt to minimise the possibility of contamination by non­
specific driver sequences in the final subtractive product specific restriction sites were 
engineered into each of the distinct linkers. Single stranded primers from the double 
stranded linkers were used as PCR primers to allow the generation of large amounts 
of cDNA and this was used as the starting material for the subtraction using a 
modified method routinely used by Dr G Brady (Brady and Iscove 1993).
Three rounds of subtraction were performed using cDNA extracted from RANTES 
treated Sca-1+ / Thyl.l lo/' / Lin' enriched cells as the driver population, and cDNA 
from M IP-la treated Sca-1+ / Thyl.l lo/* / Lin' cells as the tracer population. This will 
produce cDNA fragments that are up regulated in primitive cells exposed to M IP-la. 
To confirm the success of the subtractive hybridisation it is normal to examine the 
cDNA populations for patterns of predictable cDNA alterations. In this case there are 
no identifiable candidate genes that will be up regulated upon M IP-la induced 
inhibition however, it is possible to screen for the removal of housekeeping genes to 
give an indication that the subtraction has at least removed common genes. As shown 
in figure 5.11, southern blot analysis examined the abundance of two housekeeping 
genes (3-actin and GAPDH. It can be observed, that on comparing the starting 
material with each subsequent round of subtraction that the third round of subtraction 
effectively removes both housekeeping genes. The final cDNA population was 
amplified by PCR and digested with Not-1. The recognition site for Not-1 had been 
previously engineered into the tracer specific linkers (figure 5.10). These fragments 
were then ligated into a pSK Bluescript vector and subsequent transformation of 
DH5a cells. Blue/white selection was performed on the transformed cells and from 
the resulting plates, 50 white colonies were picked and grown up in a 5 ml mini-prep 
culture overnight. A Quiagen mini prep kit was used to purify the plasmid DNA from 
the overnight cultures and diagnostic digests were performed to check for inserts 
within the plasmids. Sequence analysis was performed on 50 clones by comparing 
the sequences produced from the subtractive library with those of known genes and 
expressed sequence tags (EST’s) from non redundant and
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Fig 5.10
Pre subtractive hybridisation manipulations
Ligate on double stranded linkers to the blunt ended  
cD N A  from M I P - la  and R A N T ES enriched stem ce lls
M I P - la  treated tracer cD N  A R A N T ES treated driver cD N A
A: 5’ TA G  TCC GCG GCC GCA C A A  G A G  CAC A 3 ’ 
B: 3 ’ ATC AG G  CGC CGG CGT GTT CTC 5 ’
A: 5’ CGC G AG TGC AAG  CTT TA T CTA TCC C 3 ’ 
B : 3 ’ GCG CTC A C G  TTC G AA AT A G A T 5’
N ot 1 Site
A m plified  Stem cell 
Primer M IP -la
Hind Site
Phosphorylate with PNK, anneal 
and ligate to Alu-1 digested cD N A
R em ove non-ligated linkers 
on LMP agarose 
Size select 0.2-2kb A m plified  Stem cell 
Primer R A N T ES
Am plify linkered fragments from LMP agarose: 
(94oC , 1 min; 55oC , lm in; 72oC  1 min 30cycles)  
Perform subtraction
Figure 5.10 Schematic o f Manipulations o f the cDNA Populations before 
Subtractive Hybridisation was Performed.
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Fig 5.11
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Figure 5.11 Southern blot analysis of GAPDH and p-actin expression on starting 
cDNA (non subtracted material) and subtracted cDNA
The top row shows a blot hybridised with a probe for GAPDH and the bottom row 
shows the same blot stripped and reprobed for P-actin. Column 1 represents cDNA 
from Sca-lVThy-1.1 lo/Lm cells, non subtracted, columns 2, 3 and 4 represent cDNA 
that has been produced from three subsequent rounds of subtractive hybridisation. 
Briefly, this involved incubating two populations of Sca-l+/Thy-l.l lo/Lin' cells with 
either 100 ng/ml of M IP-la or RANTES for 4 hours. mRNA was isolated from these 
cells and the cDNA that was then produced was used to perform subtractive 
hybridisation as described in the materials and methods. (Rantes cDNA was used as 
the driver population and M IP-la as the tracer population) As there are no known 
sequences that will be up-regulated in the subtracted material the use of removal of 
common house keeping genes will give a rough indication that thus far the subtractive 
hybridisation has at least removed these common genes.
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EST databases using the basic logical alignment search tool (BLAST) search program 
(Altschul et al 1990a), (Table 3). Of the 50 clones sequenced there were 20 that did 
not produce a readable sequence. Although the removal of the common house 
keeping genes P-actin and GAPDH from the final round of subtraction was 
encouraging, the analysis of the 30 sequences suggested that the subtractive 
hybridisation had not worked efficiently. This may be due to the incomplete removal 
of shared sequences or contamination of the subtracted material with inappropriately 
amplified driver sequences. Genes that are fundamental for the every day functions of 
the cell were identified, for example Elongation factor-15 a gene involved in DNA 
replication and a human aldehyde reductase (Bohren et al 1989). Aldeyhde reductase 
is one of a number of cytosolic, monomeric oxidoreductases that catalyse the 
NADPH-dependant reduction of a wide variety of carbonyl compounds such as 
sugars, glucuronate as well as xenobiotic aldehydes and ketones (Wermuth 1985).
5.9 Summary
The enrichment process isolated a population of cells from bone marrow that were 
depleted of lineage positive cells and were stained highly for the Sca-1 antigen and 
low to negative Thyl.l antigen expression. These Sca-1+ / Thyl.l lo/* / Lin' cells have 
been observed to produce a cloning efficiency of 22 % in the CFU-A assay and the 
formation of these CFU-A colonies were almost completely inhibited by M IP-la. 
For the reasons explained in section 5.7, the cDNA extracted from this cellular 
population was used as for the subtractive hybridisation. The removal of the house 
keeping genes p-actin and GAPDH during the subtraction (figure 5.11) gave an initial 
indication that the subtraction had worked. However, the results outlined in table 3, 
suggested that the subtractive hybridisation has not effectively removed sequences 
that are shared between the driver and tracer populations.
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Table 3
Clone
Number
Identity Accession
Number
Length
(bp)
Journal if  
published
1,2 ,3  6, 
7,11,32, 
37,43
Stragene Lung Carcinoma 
sequence
937218 Homo sapiens cDNA  
clone
A A 134546 469 Genome Res 
6 807-828 1996
5 Mouse BAC-146N21 
Chromosome X contains 
idurinate-2-sulfatase gene
A C 002315 110079
4,8,9,16,
25,27,36,
41,45
H. sapiens seryl-tRNA 
Synthetase
X91257 1846 Eur.J. Biochem  
250 77-84 1997
12,40 Homo Sapiens 
Chromosome 5, PI clone 
1338G6 (LBNL H35) 
complete sequence
AC004502 79716 Unpublished
15 Human aldehyde reductase J04794 1132 J Biol Chem 
264 9547-9551 
1989
17,26,39,4
0
Elongation Factor -1 delta NM 001960 991 Biochem  
Biophys Acta 
1174 87-90 
1993
29 Homo sapiens BAC clone GS 
250A16 from 7p21-p22, 
complete sequence
AC005019 188362 Submitted
31 Zf72a09.rl Soares pineal 
gland N3HPG Homo sapiens 
cDNA clone
AA069743 526 Genome Res 6 
807-828 1996
35 Mus musculus adult 
C57BL/6J testis Mus 
musculus cDNA clone
AV047894 289 Unpublished
42 Rat Carbohydrate binding 
receptor gene
44 Homo sapiens chromosome 
16, BAC clone RPCI- 
11 1 9 2 K 1 8  complete 
sequence
AC 006075 169765 Unpublished
Table 4 Analysis of Sequences isolated from the subtractive hybridisation
Sequences produce from the subtractive library were analysed for homologies with known 
genes and expressed sequence tags (EST’s) from non redundant and EST databases using the 
basic logical alignment search tool (BLAST) search program (Altschul et al 1990a, b).
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CHAPTER 6
RESULTS 2 : The alteration of SCF and M-CSF concentration on the 
inhibition of CFU-A colony formation by MIP-la
6.1 Introduction
Unfortunately, as outlined in the previous chapter, the examination of gene expression 
induction or repression by M IP-la in CFU-A stem cells by subtractive hybridisation 
was unsuccessful. Therefore, it was decided to investigate the interaction of M IP-la 
and the CFU-A growth factors upon colony formation. The specific growth factors 
within the CFU-A assay produce the signals that allow the CFU-A stem cells to 
survive and thus differentiate into the CFU-A colonies. Upon the addition of M IP-la 
to a CFU-A assay it can be observed that the CFU-A colony formation is inhibited, 
suggesting that the M IP-la signalling pathway interacts with the other growth factor 
signalling pathways in some way thus preventing the formation of CFU-A colonies. 
Therefore, it was decided to investigate the possibility of interfering with the ability of 
M IP-la to inhibit the formation of CFU-A colonies by altering the concentration of 
each of the individual growth factors.
6.2 The Effects of Conditioned Media and Recombinant Growth Factors on 
CFU-A Colony Formation
With the use of conditioned media (CM) it is impossible to be certain what growth 
factors are being added to the assay system therefore, the replacement of CM with 
recombinant growth factors will rule out this uncertainty. Indeed, Pragnell and 
colleagues previously demonstrated that recombinant human M-CSF (6 ng/ml), 
recombinant murine GM-CSF (0.2 ng/ml) and recombinant murine SCF (12 ng/ml) 
can be used instead of CM for effective CFU-A assay development (Pragnell et al 
1994). However, before any alteration of recombinant growth factor concentrations 
were performed, it was deemed necessary to confirm that there was no difference in 
CFU-A colony production in CFU-A assays containing conditioned media or the 
above concentrations of recombinant growth factors. In the first experiment, 5000 
bone marrow cells per plate were added to a CFU-A assay containing 10 % L929 CM
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Figure 6.1 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony production by using conditioned media or recombinant growth factors
A CFU-A assay was set up containing either rm GM-CSF (0.2 ng/ml), rh M-CSF (6 ng/ml) 
and rm SCF at 12 ng/ml or 10% L 929 and 10 % AF-1.19T conditioned media. The average 
colony production ( + SEM) is shown for 5 plates. This assay is a representative result from 
three replicate experiments. Students T-test was performed (* 1 -  P < 0.05, *2 = P < 0.01 and 
*3 = P <0.001).
El Conditioned media (CM)
I  Recombinant growth factors
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and 10 % AF1 19T CM or 0.2 ng/ml rm GM-CSF, 6 ng/ml rh M-CSF and 12 ng/ml 
rm SCF as the source of growth factors. From figure 6.1, it can be observed that there 
is no significant difference between the CFU-A colony formation in either growth 
condition. Both conditioned media and recombinant growth factors produce 
approximately 8 CFU-A colonies per 5000 bone marrow cells. This figure is in 
agreement with previous work that has shown that the incidence of CFU-A in normal 
bone marrow is 150-220/105 (Lorimore eta l 1990).
Experiments were then set up to examine if  altering the source of growth factors had 
any effect on the ability of M IP-la to inhibit CFU-A colonies. M IP-la was added to 
the plates at 0.5, 1, 5, 10, 50 and 100 ng/ml and only 100 and 50 ng/ml of M IP-la 
produced a statistically significant inhibition of CFU-A colony formation under both 
growth conditions (P < 0.001) (Figure 6.2). The inhibition of CFU-A colony 
formation at these concentrations is in agreement with previous results within our 
group that indicated that M IP-la at 100 or 50 ng/ml reproducibly inhibit the 
formation of CFU-A colonies. Upon a further 7 days incubation the CFU-A colonies 
that were inhibited and had a diameter less than 2 mm (approx 0.2- 0.5 mm) were 
observed to grow and reach the characteristic CFU-A colony size, indicating that the 
reduction of CFU-A colonies was reversible. Furthermore, it can also be observed 
that no further inhibition occurs at M IP-la concentrations lower than 50 ng/ml (figure 
6.2). Therefore, these results indicate that the CFU-A assays containing CM or rGFs 
are functionally indistinguishable.
6.3 Tyrosine Kinase Signalling Growth Factors
SCF has a number of functions in the haemopoietic system. It has been reported to be 
a survival factor and on its own SCF has no proliferative effect on stem cells however, 
in combination with other growth factors it mediates extensive proliferation and 
expansion in cell numbers (Varas et al 1997). It plays an important role in 
megakaryopoiesis and erythropoiesis and it also appears to regulate the production, 
maintenance and differentiation of mast cells. Unlike SCF, macrophage colony 
stimulating factor (M-CSF) is a lineage specific growth factor which has been 
reported to play an essential role in the survival, proliferation, differentiation, and the 
maturation of the mononuclear phagocytic lineage (Fixe et al 1997). M-CSF and SCF 
are two of the three growth factors that are essential for the differentiation of CFU-A
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Figure 6.2 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production by using conditioned media or recombinant 
growth factors
M IP-la at 0.5, 1,5, 10, 50 and 100 ng/ml were added to the CFU-A assay containing either 
rm GM-CSF (0.2 ng/ml), rh M-CSF (6 ng/ml) and rm SCF at 12 ng/ml or 10 % L 929 and 
10% AF-1.19T conditioned media. The average colony production ( + SEM) is shown for 5 
plates. This assay is a representative result from three replicate experiments. Students T-test 
was performed (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001). Figure 6.2A contains the 
results from a CFU-A assay grown in conditioned media (10 % L  9 2 9  and 10 % AF-1.19T). 
Figure 6.2B contains the results from a CFU-A assay grown in recombinant growth factors 
(rm GM-CSF 0.2 ng/ml, rh M-CSF 6 ng/ml and 12 ng/ml of rm SCF).
□  CM or rGF ■  CM or rGF + 5 ng/ml MIP-1
■  CM or rGF + 100 ng/ml M IP-la ■  CM or rGF + 1 ng/ml M IP-la
□  CM or rGF + 50 ng/ml M IP-la ■  CM or rGF + 0.5 ng/ml M IP-la
□  CM or rGF + 10 ng/ml M IP-la
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stem cells into CFU-A colonies and they produce their various activities through the 
interaction with their specific receptors, c-fms and c-kit which are members of the 
type III receptor tyrosine kinase family. This family of cytokine receptors also 
includes flt3 and both of the receptors for platelet derived growth factor, PDGFR A 
and B. Each receptor is approximately 1000 amino acids in length, has five Ig-like 
domains in the extra cellular region, and contains a split catalytic domain in the 
cytoplasmic region that phosphorylates tyrosine residues in specific target proteins 
after activation of the receptor by its ligand (Sherr 1990). In this part of the project 
the concentration of SCF and M-CSF were individually altered in an attempt to 
examine the ability of the tyrosine kinase signalling pathway to interfere with the 
MIP-1 a  inhibitory pathway.
6.3.1 The Effects of SCF and M-CSF on CFU-A Colony Formation
The role of the tyrosine kinase signalling pathway and its ability to interact or 
interfere with the inhibition of CFU-A colony formation was examined by altering the 
concentration of rm SCF or rh M-CSF in the CFU-A assay, in the presence or absence 
of M IP-la. In the first experiment, the effect of the alteration of the rm SCF 
concentration was examined. Recombinant murine GM-CSF and rh M-CSF were 
added to the CFU-A assay at normal levels, 0.2 and 6 ng/ml, and SCF was either 
omitted or added at 0.0012, 0.012, 0.12, 1.2, 12 and 120 ng/ml (figure 6.3). The 
omission of rm SCF from the assay had the effect of significantly reducing the colony 
number from an average of 9.2 to an average of 2.8 CFU-A colonies (p < 0.001). 
Although these colonies have been scored as CFU-A colonies, it is possible that they 
are not CFU-A colonies and have arisen from the increased growth of committed 
progenitors such as CFU-GM. Granulocyte/ macrophage colony forming unit (CFU- 
GM) colonies are normally grown in agar assays containing between 0.1-10 ng/ml of 
GM-CSF, their incidence within the bone marrow has been previously reported to be 
between 100-240 / lxlO5 bone marrow cells (Broxmeyer et al 1991b). As the 
concentrations of rm GM-CSF used in the above experiment are at the lower range of 
the scale observed by Broxmeyer for the formation of these CFU-GM colonies this 
may explain the slight reduction in the observed number of CFU-GM colonies. 
However, it is also likely that the omission of rm SCF from the assay in figure 6.3 
would mean that within the assay there would not be sufficient growth factor activity 
to induce CFU-A stem cells to develop into their characteristic colony size.
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Fig 6.3
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Figure 6.3 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony production by increasing or reducing the SCF concentration within 
the assay
A CFU-A assay was set up with normal levels of rm GM-CSF (0.2 ng/ml), rh M-CSF (6 
ng/ml) and rm SCF at 0, 0.0012, 0.012, 0.12,1.2, 12 and 120 ng/ml. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing normal SCF levels (12 
ng/ml) to all the other concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
□  0 SCF
■  0.0012 ng/ml SCF
□  0.012 ng/ml SCF
□  0.12 ng/ml SCF
■  1.2 ng/ml SCF 
E3 12 ng/ml SCF
■  120 ng/ml SCF
157
Therefore, further investigation into the production of these colonies is needed to 
identify these colonies and ascertain their clonal cell of origin. Upon the addition of
1.2 pg/ml of SCF it can be observed in figure 6.3, that rm SCF can act synergistically 
with the other growth factors to significantly increase the colony number from an 
average of 2.8 to an average of 5.6 CFU-A colonies. The colony number is increased 
further to approximately 8.0 upon the addition of 0.012, 0.12 and 1.2 ng/ml of in SCF 
and a further increase in colony number to 9.2 is observed on the addition of 12 ng/ml 
of SCF. The further increment in concentration of SCF to 120 ng/ml had a surprising 
effect in that it reduced the colony size significantly and thus decreased the average 
CFU-A colony number to 4.6 (p < 0.01).
A similar experiment was set up to examine if the alteration in M-CSF concentration 
had a similar effect as the alteration of SCF concentration. In this experiment, rm 
GM-CSF and rm SCF are at normal levels whereas rh M-CSF was omitted or added at 
0.0006, 0.006, 0.06, 0.6, 6 and 60 ng/ml to the assay. The removal of M-CSF from 
the assay reduced the CFU-A colony number from 10.3 to 2.4 colonies (p < 0.001), as 
outlined in figure 6.4. This limited colony formation concurs with a previous study 
by Pragnell et al, they observed that M-CSF is essential for CFU-A colony formation 
(Pragnell et al 1988). The increase in M-CSF concentration in 10 fold increments 
from 0.6 pg/ml to 6 ng/ml produced an increase in CFU-A colony production in a 
dose dependant manner culminating in an average of 10.3 colonies being observed at 
6 ng/ml, the normal concentration of M-CSF. Upon a further increment in M-CSF 
concentration to, 60 ng/ml, a similar reduction in CFU-A colony formation to that 
observed at high doses of stem cell factor was observed to produce a decrease from 
10.4 to 6.5 (p < 0.001) as shown in figure 6.4. These results indicate that a 10-fold 
increase in either M-CSF or SCF concentration produces a reduction in the number of 
CFU-A colonies compared to control assays.
This reduction in CFU-A colony formation induced by high levels of M-CSF or SCF 
was reversible and appears similar to the reversible inhibition produced by M IP-la. 
Furthermore, this reduction is not due to a toxic effect of these growth factors as 
CFU-A colonies can be observed to grow in these high growth factor concentrations. 
M-CSF and SCF receptors are members of the tyrosine kinase receptor family 
therefore; the observed reduction in colony formation may be due to the activation of 
the same tyrosine kinase-signalling pathway by these separate growth factors.
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Fig 6.4
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Figure 6.4 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A 
colony production by increasing or reducing the rh M-CSF concentration 
within the assay
A CFU-A assay was set up with normal levels of rm GM-CSF (0.2 ng/ml), rm SCF (12 
ng/ml) and rh M-CSF at 0, 0.0006, 0.006, 0.06, 0.6, 6 and 60 ng/ml. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing normal M-CSF levels (6 
ng/ml) to all the other concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
□  0 M-CSF
■  0.0006 ng/ml M-CSF
□  0.006 ng/ml M-CSF
□  0.06 ng/ml M-CSF
■  0.6 ng/ml M-CSF 
□  6 ng/ml M-CSF
■  60 ng/ml M-CSF
159
6.3.2 The Effects of SCF and M-CSF on the Constituent Cells of the CFU-A 
Colonies
The effect of altering the SCF and M-CSF concentration on the production of the 
constituent cell types and their abundance within the CFU-A colonies was next 
examined (tables 4 and 5). This was performed by mixing unfractionated bone 
marrow cells with methylcellulose (#3230, -CSF-1 and -EPO), and layering this on 
top of a standard lower agar layer (section 4.15). Colonies were allowed to form for 
11 days at 37 °C in a humidified environment containing 10 % O2, 5 % CO2 and 85 % 
N2 and then normal and inhibited colonies were picked, washed and counted (Table 
4). It was observed that normal CFU-A colonies predominantly consist of 
macrophages, approximately 98 %, with a small number of granulocytes, normally 
neutrophils, and blast cells. The data presented in table 4 and 5 concurs with the 
findings of Pragnell et al, who previously reported that CFU-A colonies derived from 
mouse bone marrow are composed mainly of macrophages (90-95%). Furthermore, it 
also demonstrates that altering the rm SCF concentrations within the CFU-A assay 
has little effect on the constituent cells of the CFU-A colonies. On the addition of 100 
ng/ml of M IP-la to a normal CFU-A it can be observed that there is a non-significant 
reduction in the percentage of macrophages and a non-significant increase in the 
percentage of granulocytes in the inhibited CFU-A colonies. The data in table 4, also 
indicates that the addition of M IP-la to a CFU-A assays containing normal levels of 
each growth factor reduces the number of cells/colony from 21800 to 7000 cells. 
Interestingly in the CFU-A assays containing 120 ng/ml rm SCF, the number of cells/ 
colony is reduced from 21800 with 12 ng/ml to 16600 with 120 ng/ml and, upon the 
further addition of 100 ng/ml of M IP-la the number is further reduced to 4900 cells. 
Although the alteration in SCF concentration does not effect the proportions of the 
constituent cells of the CFU-A colonies it does as suggested by the results in table 4 
reduce the number of cells/colony.
A similar experiment was set up to examine the effects on the number and constituent 
cells of the CFU-A colonies in the alteration of rh M-CSF in the presence or absence 
of 100 ng/ml of M IP-la. From the data in table 5, it can be observed that there is a
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Table 4
Cell N um bers within CFU-A colonies
rm SCF 1.2 ng/ml 20400
rm SCF 1.2 ng/ml + M IP -la 5800
rm SCF 12 ng/ml 21800
rm SCF 12 ng/ml +  M IP -la 7000
rm SCF 120 ng/ml 16600
rm SCF 120 ng/ml +  M IP-1 a 4900
Differential counts 1500 cells)
M acrophages Granulocytes Othc
rm SCF 1.2 ng/ml 495 3 2
rm SCF 1.2 ng/ml + MIP-1 a 496 3 1
rm SCF 12 ng/ml 495 4 1
rm SCF 12 ng/ml + M IP -la 492 8 0
rm SCF 120 ng/ml 492 4 4
rm SCF 120 ng/ml + M IP -la 494 2 4
Table 4 Analysis of cell number and morphology of the cells within the CFU-A colonies 
containing 1.2, 12 and 120 ng/ml of rm SCF in the presence or absence of 100 
ng/ml MIP-la
CFU-A assays were set up containing a top layer of methylcellulose instead of the normal 
double agar assay. Three sets of 10 colonies were picked from plates containing 100 ng/ml 
MIP-la and three sets of 5 colonies from the plates that did not contain MIP-la. These cells 
were pooled, washed and either cytospins were prepared and stained with Giemsa for 
morphology analysis or cell numbers were counted.
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Table 5
Cell Num bers within CFU-A colonies
rh M-CSF 0.6 ng/ml 24600
rh M-CSF 0.6 ng/ml + M IP-1 a 9600
rh M-CSF 6 ng/ml 22850
rh M-CSF 6 ng/ml +  M IP -la 11200
rh M-CSF 60 ng/ml 20600
rh M-CSF 60 ng/ml +  M IP -la 8500
Differential counts (500 cells)
M acrophages G ranulocytes Others
rh M-CSF 0.6 ng/ml 495 3 2
rh M-CSF 0.6 ng/ml + M IP -la 490 8 2
rh M-CSF 6 ng/ml 490 5 5
rh M-CSF 6 ng/ml +  M IP -la 495 5 0
rh M-CSF 60 ng/ml 485 10 5
rh M-CSF 60 ng/ml +  M IP -la 479 15 6
Table 5 Analysis of cell number and morphology of the cells within the CFU-A 
colonies containing 0.6, 6 and 60 ng/ml of rh M-CSF in the presence or 
absence of 100 ng/ml MIP-la
CFU-A assays were set up containing a top layer of methylcellulose instead of the normal 
double agar assay. 10 colonies were picked from plates containing 100 ng/ml MIP-la and 5 
colonies from the plates that did not contain MIP-la. These cells were pooled, washed and 
either cytospins were prepared and stained by Giemsa for morphology analysis or cell 
numbers were counted.
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non-significant reduction in the number of cells within the colonies from 22850 with 
6 ng/ml to 20600 with 60 ng/ml. However, data from table 5 indicates that there is a 
reduction in the number of cells within the CFU-A colonies in assays containing 60 
ng/ml of rhM-CSF compared to assays containing 0.6 ng/ml of rhM-CSF. This 
therefore suggests that the alteration in rhM-CSF concentration is effecting the 
numbers of cells in each CFU-A colony. On the further addition of M IP-la there is a 
significant reduction in cell number to 11200 in normal assay conditions and 8500 
cells in assays containing a 10-fold increase in M-CSF concentration. These results 
indicate that although the increase in M-CSF reduces the overall cell numbers within 
the CFU-A colonies this reduction is not significant and, only upon the inclusion of 
M IP-la does this reduction in cell number become significant. On examining the 
composition of the CFU-A colonies it can be observed that 0.6 ng/ml rh M-CSF +/- 
100 ng/ml M IP-la does not alter the constituent cells of the CFU-A colony 
significantly from assays containing 6 ng/ml of rh M-CSF +/- 100 ng/ml M IP-la. 
However, on the addition of 60 ng/ml rh M-CSF +/- 100 ng/ml M IP-la it was 
observed that there is a significant increase in the number of granulocytes with a 
concurrent reduction in the number of macrophages. The observed decrease in CFU- 
A colonies at high levels of SCF and M-CSF was hypothesised to be due to the 
expression of an inhibitory factor such as M IP-la or alternatively, due to the 
induction of self renewal of the CFU-A stem cells at the expense of differentiation. A 
report by Baghestanian et al observed that SCF in combination with PMA can induce 
de novo expression of MIP-1(3 mRNA and M IP-la mRNA in a mast cell line (HMC- 
1) (Baghestanian et al 1997). Like SCF, M-CSF has also been reported to induce the 
expression of M IP-la and interestingly, Jarmin et al also observed that M IP-la and 
MEP-1(3 mRNA expression and a corresponding release of the M IP-la and MIP-1 (3 
proteins can be induced by GM-CSF in bone marrow macrophages (Maltman et al 
1996, Jarmin et al 1999). Furthermore, a more recent study has indicated that 
haemopoietic stem cells can also express M IP-la (Majka et al 1999). Therefore, if as 
proposed, high levels of M-CSF or SCF alone or in conjunction with GM-CSF may 
induce the expression of M IP-la within the constituent cells of the CFU-A colonies. 
If this were the case it might be expected that concentrations of M IP-la lower than 
previously observed within our group would induce inhibition of CFU-A colony 
formation.
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6.3.3 The Effects of SCF and M-CSF on M IP-la Inhibition of CFU-A Colony 
Formation
To examine if this observed reduction in CFU-A colony size was due to the induced 
expression of M IP-la by high levels of M-CSF or SCF, a CFU-A assay was set up to 
examine the effects of varying concentrations of rm SCF or rh M-CSF on a dose 
response of M IP-la inhibition. In figure 6.5, M IP-la at 0.5, 1, 5, 10, 50 and 100 
ng/ml was added to CFU-A assays containing normal levels of rm GM-CSF and rh 
M-CSF with rm SCF at 0.0012, 0.012 and 0.12, 1.2, 12, 120 ng/ml. M IP-la at 100 
and 50 ng/ml are the only concentrations that were observed to produce a statistically 
significant inhibition of CFU-A colony production at all of the SCF concentrations in 
figure 6.5 (p < 0.001). If as hypothesised that high levels of rm SCF are producing 
the reduction of CFU-A colonies by the induction of M IP-la, it would be expected 
that this increase in M IP-la expression in combination with the exogenously added 
M IP-la would produce an additive reduction in CFU-A colony formation. However, 
this does not appear to happen, indeed, quite the opposite occurs as high rm SCF 
concentration and non inhibitory concentrations of M IP-la increase the CFU-A 
colony formation over and above that of the control numbers, p < 0.05 and 0.01 
(figure 6.5f). Although M IP-la is predominantly known as an inhibitory molecule it 
has been observed to produce progenitor cell stimulatory effects in CFU-GM 
progenitor assays but not so far on CFU-A stem cells. Therefore, it is possible that at 
these lower concentrations of M IP-la in conjunction with high levels of rm SCF, that 
M IP-la is unable to act as a negative factor but somehow can act as a positive growth 
factor possibly through an alternative receptor who’s expression is regulated by SCF.
A similar experiment was set up to examine if the reduction in CFU-A colony 
formation in assays containing increased levels of rh M-CSF was through the 
induction of M IP-la expression. In figure 6.6 the effect of M IP-la at 0.5, 1, 5, 10, 
50 and 100 ng/ml can be observed, in assays containing rh M-CSF concentrations of 
0.0006, 0.006, 0.06, 0.6, 6 and 60 ng/ml. M IP-la significantly inhibits CFU-A 
colony formation at 100 and 50 ng/ml in all of the rh M-CSF concentrations, p < 
0.001.
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Figure 6.5 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production in the presence of 0.0012, 0.012, 0.12 ng/ml of rm 
SCF
M IP-la at 0.5, 1, 5, 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal 
levels of rm GM-CSF (0.2 ng/ml), rh M-CSF (6 ng/ml) and either 0.0012, 0.012, 0.12 ng/ml 
of rm SCF and these are represented in A, B and C respectively. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing control (No M IP-la) to all 
the other plates containing the various M IP-la concentrations (*1 = P < 0.05, *2 = P < 0.01 
and *3 = P < 0.001). Furthermore Students T-test were performed comparing each control to 
the 12ng/ml contol.
■  Control ■  5 ng/ml M IP-la
■  100 ng/ml M IP-la □  1 ng/ml M IP-la
□  50 ng/ml M IP-la □  0.5 ng/ml M IP-la
□  10 ng/ml M IP-la
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Figure 6.5 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production in the presence of 1.2, 12 and 120 ng/ml of rm SCF
M IP-la at 0.5, 1,5, 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal 
levels of rm GM-CSF (0.2 ng/ml), rh M-CSF (6 ng/ml) and either 1.2, 12 or 120 ng/ml of rm 
SCF and these are represented in D, E and F respectively. The average colony production ( + 
SEM) is shown for 5 plates. This assay is a representative result from three replicate 
experiments. Students T-test was performed comparing control (No M IP-la) to all the other 
plates containing the various M IP-la concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P 
< 0 .001).
I  Control
■  100 ng/ml M IP-la
□  50 ng/ml M IP-la
□  10 ng/ml M IP-la
■  5 ng/ml M IP-la 
□  1 ng/ml M IP-la
■  0.5 ng/ml M IP-la
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In figure 6.6C, it can be observed that M IP-la at 10, 5 and 1 ng/ml reduces the 
colony formation but this is not statistically significant. When rh M-CSF is added at 6 
ng/ml (normal levels) in (figure 6.6E) it can be seen that only 100 and 50 ng/ml MIP- 
l a  inhibit CFU-A colony formation (p < 0.001). On the further increment of M-CSF 
concentration to 60 ng/ml there is a reduction in CFU-A colonies from 11.4 to 7.0. If 
high levels of rh M-CSF were indeed inducing M IP-la expression within the CFU-A 
colonies, it would be expected that M IP-la concentrations less than 100 and 50 ng/ml 
would in combination with rh M-CSF induce M IP-la expression inhibit CFU-A 
colony formation. However, inhibition only occurs at 100 and 50 ng/ml of M IP-la (p 
< 0.001) and this suggests that rh M-CSF may not be inducing the expression of MIP- 
la . As was the case with SCF the hypothesised reduction in CFU-A colony numbers 
at concentrations of M IP-la not normally associated with inhibition in assays 
containing high levels of M-CSF did not occur. In fact similar to the observed 
activity with high SCF, non-inhibitory concentrations of M IP-la increased the 
formation of CFU-A colonies over and above that of the control numbers, p < 0.05 
and 0.01, see discussion. As mentioned above M IP-la has been previously reported 
to act as a growth stimulator for granulocyte macrophage progenitor cells and a 
similar stimulatory activity for M IP-la was also reported by Broxmeyer et al. They 
observed that M IP-la could enhance the colony formation of a subset of myeloid 
progenitor cells, CFU-M colony forming unit macrophage, in the presence of 0.6 
ng/ml M-CSF (Broxmeyer et al 1999). As previously discussed, it is the various 
growth factors within each assay that induce the formation of the specific colonies via 
the survival, proliferation and differentiation of their clonal stem/progenitor cells. 
Therefore, it may be possible that by altering the concentrations of the CFU-A growth 
factors that the growth conditions may favour the formation of maturer progenitor cell 
colonies. Alternatively high levels of SCF or M-CSF may alone or in combination 
with GM-CSF increase the levels of M IP-la receptor and upon the interaction with 
M IP-la this may lead to the increase formation of CFU-A colonies, see discussion.
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Figure 6.6 Colony Forming Unit Agar (CFU-A) analysis of the effect of MIP-1 a  on the 
CFU-A colony production in the presence of 0.0006, 0.006 and 0.06 ng/ml of 
rh M-CSF
M IP-la at 0.5, 1,5, 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal 
levels of rm GM-CSF (0.2 ng/ml), (12 ng/ml) rm SCF and rh M-CSF at 0.0006, 0.006, 0.06
ng/ml and these are represented in A, B and C respectively. The average colony production (
+ SEM) is shown for 5 plates. This assay is a representative result from three replicate 
experiments. Students T-test was performed comparing control (No M IP-la) to all the other 
plates containing the various M IP-la concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P 
<0.001)..
□  Control B 5 ng/ml M IP-la
B 100 ng/ml M IP-la B 1 ng/ml M IP-la
□  50 ng/ml M IP-la ®  0.5 ng/ml M IP-la
□  10 ng/ml M IP-la
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Fig 6.6
Figure 6.6 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production in the presence of 0.6, 6 and 60 ng/ml of rh M-CSF
M IP-la at 0.5, 1,5, 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal 
levels of rm GM-CSF (0.2ng/ml), (12 ng/ml) of rm SCF and rh M-CSF at 0.6, 6 and 60 ng/ml 
and these are represented in D, E and F respectively. The average colony production ( + 
SEM) is shown for 5 plates. This assay is a representative result from three replicate 
experiments. Students T-test was performed comparing control (No M IP-la) to all the other 
plates containing the various M IP-la concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P
< 0 .001).
□ Control ■ 5 ng/ml M IP-la
■ 100 ng/ml M IP-la □ 1 ng/ml M IP-la
□ 50 ng/ml M IP-la ■ 0.5 ng/ml M IP-la
□ 10 ng/ml M IP-la
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6.3.4 The Effects of a Neutralising M IP-la Antibody on CFU-A Colony 
Formation
To further assess the possibility that the cells within the CFU-A colony could be 
producing M IP-la in response to high levels of SCF or M-CSF the effect of the 
addition of a M IP-la neutralising antibody to CFU-A assays was examined. A CFU- 
A assay was therefore, set up containing normal levels of rm GM-CSF, rh M-CSF, rm 
SCF at 1.2, 12, 120 ng/ml in the presence or absence of 100 ng/ml of M IP-la and 
5|ig/ml of the M IP-la neutralising antibody (Figure 6.7). At control levels of SCF 
(12 ng/ml) and 1.2 ng/ml an average of 9.8 and 10.3 colonies were produced. In the 
assays containing 120 ng/ml of SCF a slight reduction in colony number from 9.8 to 
8.6 was observed however, this is not significant when compered to control levels. If 
as previously suggested, that high levels of SCF can induce M IP-la expression the 
addition of a M IP-la neutralising antibody should lead to an increase in colony 
number, see figure 6.7C. Although there is a slight increase in colony number this is 
not significant. M IP-la at 100 ng/ml reduced colony number significantly to 1.0, 1.3, 
or 0 (p < 0.001) in assays containing 1.2, 12 and 120 ng/ml of rm SCF. On the 
addition of the neutralising antibody to the assay containing 12 and 1.2 ng/ml of SCF 
the inhibition of CFU-A colony formation was reversed. However, the neutralising 
antibody did not return the CFU-A colony number back to the control levels in the 
assay containing 100 ng/ml of M IP-la and 120 ng/ml SCF (p <0.05). From these 
results it seems likely that high levels of SCF do not induce the expression of M IP-la 
however, as the antibody used above is a M IP-la neutralising antibody this does not 
rule out the possible induction of other inhibitory molecules by high levels of SCF.
A similar experiment using the same M IP-la neutralising antibody was set up to 
examine whether M-CSF might induce M IP-la expression in the cells of the CFU-A 
colony. Figure 6.8, shows a CFU-A assay containing normal levels of rm GM-CSF 
and rm SCF with the addition 0.6, 6 and 60 ng/ml of rh M-CSF. As well as these 
growth factors 100 ng/ml of M IP-la and 5 pg/ml anti M IP-la antibody were added
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Fig 6.7
Figure 6.7 Colony Forming Unit Agar (CFU-A) analysis of the effect of anti -M IP-la 
antibodies on the size of the CFU-A colonies
Unfractionated bone marrow was plated in a CFU-A assay containing 1.2, 12 and 120 ng/ml 
rm SCF and these are represented in A, B and C respectively. The effects of M IP-la at 100 
ng/ml and of an anti-MIP-la antibody at 5 pg/ml on the size and number of the colonies were 
examined. The average colony production (+ SEM) is shown for 5 plates. This assay is a 
representative result from three replicate experiments. Students T-test was performed 
comparing control (normal bone marrow) to all the other plates containing the various MIP- 
1 a  concentrations (* 1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
I  Normal bone marrow
I  Normal bone marrow 5 pg/ml of anti -M IP-la antibody 
□  Normal bone marrow and 100 ng/ml of M IP-la
01 Normal bone marrow 100 ng/ml of M IP-la plus 5 pg/ml of anti -M IP-la antibody
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Figure 6.8 Colony Forming Unit Agar (CFU-A) analysis of the effect of anti-MIP-la 
antibodies on the size of the CFU-A colonies
Unfractionated bone marrow was plated in a CFU-A assay containing 0.6, 6, 60 ng/ml rh M- 
CSF and these are represented in A, B and C respectively. The effects of M IP-la at 100 
ng/ml and of anti-MIP-la antibody at 5 pg/ml on the size and number of the colonies were 
examined. The average colony production (+ SEM) is shown for 5 plates. This assay is a 
representative result from three replicate experiments Students T-test was performed 
comparing control (normal bone marrow) to all the other plates containing the various MIP- 
la  concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
□  Normal bone marrow
■  Normal bone marrow 5 pg/ml of anti -M IP-la antibody
□  Normal bone marrow and 100 ng/ml of M IP-la
O Normal bone marrow 100 ng/ml of M IP-la plus 5 pg/ml of anti -M IP-la antibody
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to the assay. In all M-CSF concentrations 0.6, 6 and 60 ng/ml an average of 
approximately 10 colonies were produced, surprisingly no reduction in colony 
number was observed with high levels of M-CSF. These results are inconsistent with 
what has been previously observed, see figures 6.4 and 6.6. On the addition of the 
neutralising antibody there was a slight decrease in colonies in 0.6 and 60 ng/ml, 
neither effect is however statistically significant.
M IP-la at 100 ng/ml reduced colony number to 1 or 0 (p < 0.001) and this was 
returned back to control levels for 0.6, 6 and 60 ng/ml of M-CSF (see figure 6.8). 
Furthermore, the inability of the neutralising antibody added to normal bone marrow 
to increase the CFU-A colony number over and above the level produced without the 
antibody in normal bone marrow suggests that high M-CSF may not induce the 
expression of MIP-1 a.
6.3.5 The Effects of SCF and M-CSF on CFU-A Colony Formation from 
Normal or M IP-la Null Mice Bone Marrow
In a further attempt to examine the expression of M IP-la by high levels of SCF and 
M-CSF a CFU-A assay was set up comparing the CFU-A colony production from 
unfractionated bone marrow of a M IP-la null mouse and a normal mouse, using 
various M-CSF and SCF concentrations. Figures 6.9 and 6.10, indicate that there is 
no significant difference in the number of CFU-A colonies produced by either bone 
marrow in any of the SCF or M-CSF concentrations and that M IP-la can inhibit 
CFU-A colony production in both types of bone marrow equally well. However, it 
can be observed that again the higher levels of both rm SCF and rh M-CSF do reduce 
the average CFU-A colony number. If M IP-la was expressed within the CFU-A 
colony in the assay containing 120 ng/ml SCF it might be expected that the bone 
marrow from the M IP-la null mouse would produce more CFU-A colonies than the 
normal mouse. From figure 6.9C, a small increase in CFU-A numbers is observed but 
this is not significant again indicating that the high level of SCF or M-CSF do not 
produce the reduction in CFU-A colony formation by increasing the production of 
M IP-la. It should be noted that as there is a great deal of redundancy within the 
chemokine family, and growth factors in general, it is possible that the inability of 
these cells to express M IP-la may be overcome by another inhibitory molecule
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Figure 6.9 Comparison of the potential of bone marrow from a M IP-la null mouse and a 
normal mouse to form CFU-A colonies in CFU-A assays containing 1.2, 12 and 
120 ng/ml of rm SCF and in the absence and presence of 100 ng/ml of M IP-la
Unfractionated bone marrow from a M IP-la null mouse or a normal mouse was plated in a 
CFU-A assay containing 1.2, 12 and 120 ng/ml rm SCF in the presence or absence of 100 
ng/ml of M IP-la and can be observed in A, B and C respectively. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing control (normal bone 
marrow) to all the other plates containing the various M IP-la concentrations (*1 = P < 0.05, 
*2 = P < 0.01 and *3 = P < 0.001).
□  Normal bone marrow
I  Normal bone marrow and 100 ng/ml of M IP-la
□  Bone marrow from a M IP-la Null mouse
□  Bone marrow from a M IP-la Null mouse and 100 ng/ml of M IP-la
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Fig 6.10
Figure 6.10 Comparison of the potential of bone marrow from a M IP-la null mouse and a 
normal mouse to form CFU-A colonies in CFU-A assays containing 0.6, 6 and 
60 ng/ml of rh M-CSF and in the absence and presence of 100 ng/ml of M IP-la
Unfractionated bone marrow from a M IP-la null mouse or a normal mouse was plated in a 
CFU-A assay containing 0.6, 6 and 60 ng/ml rh M-CSF in the presence or absence of 100 
ng/ml of M IP-la and these are represented in A, B and C respectively. The average colony 
production (+ SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing control (normal bone 
marrow) to all the other plates containing the various M IP-la concentrations (*1 = P < 0.05, 
*2 = P < 0.01 and *3 = P <0.001)
H Normal bone marrow
I  Normal bone marrow and 100 ng/ml of M IP-la
□  Bone marrow from a M IP-la Null mouse
□  Bone marrow from a M IP-la Null mouse and 100 ng/ml of M IP-la
175
taking its place eg MIP-lp or TGF-p. Further analysis of the expression of these 
other two inhibitory molecules is needed before firm conclusions can be reached.
6.3.6 The Effect of SCF on M IP-la Expression in Monocytic Cell Lines
To further clarify the possible expression of M IP-la by the CFU-A colonies, the 
possible induction of M IP-la expression by SCF was examined in two monocytic cell 
lines, RAW and J774.2 cells. Monocytic cell lines were chosen due to the lack of 
macrophage cell lines and because monocytes are the precursor cells of macrophages.
Macrophages are the predominant cell type within the CFU-A colonies, see table 4, 
therefore it is possible that if SCF can induce the expression of M IP-la within CFU- 
A colonies it will occur in these cells or their precursors. These cell lines were 
incubated for 48 hours in the presence or absence of 120 ng/ml of rm SCF and, 
samples of the conditioned media were removed at 0, 16, 24 and 48 hours and 
analysed for M IP-la expression by ELISA. The baseline expression of M IP-la in 
J774.2 and RAW cells is 5 and 42.8 ng/ml respectively. After 48 hours the expression 
of M IP-la induced by rm SCF rose to 120 ng/ml in J774.2 cells and in 164 ng/ml 
RAW cells, (figure 6.11). However, this increase in the level of M IP-la expression 
was not significantly different to that observed in cells treated with endotoxin free 
PBS, the same PBS used to reconstitute the rm SCF. Therefore, in this particular 
assay rm SCF does not induce the expression of M IP-la in RAW or J774.2 cells over 
the levels induced by endotoxin free PBS.
6.3.7 The Effect of SCF on M IP-la Expression in Bone Marrow Macrophages 
(BMM)
Using cell lines has its advantages however, it is not ideal therefore in an attempt to 
produce a situation that was nearer the conditions within the CFU-A colony, the 
analysis of M IP-la production by bone marrow macrophages stimulated with rm SCF 
was examined. The expression of M IP-la increased from 0 ng/ml at 0 hours to 300 
ng/ml after 48 hours in untreated cells and this was also the case with cells treated 
with endotoxin free PBS (Figure 6.12). Bone marrow macrophages that were treated
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Figure 6.11 Analysis of the expression of M IP-la by J774.2 and RAW cells upon 
stimulation with rm SCF
The expression of M IP-la protein by ELISA was examined in J774.2 and RAW cells 
stimulated with rm SCF reconstituted in endotoxin free PBS and PBS for 48 hours and these 
are represented in A and B respectively. Samples were taken at 0, 16, 24 and 48 hours and 
analysed. Results represent a single experiment. The y-axis is the concentration of MIP-1 a
in ng/ml.
B  0 hours PBS H  0 hours rm SCF
■  16 hours PBS □  16 hours rm SCF
□  24 hours PBS ■  24 hours rm SCF
□  48 hours PBS D 48 hours rm SCF
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Figure 6.12 Analysis of the expression of M IP-la by bone marrow macrophages cells 
upon stimulation with rm SCF
Bone marrow macrophage cells were made as described in the materials and methods. The 
bone marrow macrophages were either untreated or stimulated with rm SCF reconstituted in 
endotoxin free PBS and PBS for 48 hours and these are represented in A, B and C 
respectively. Samples were taken at 0, 16, 24 and 48 hours and analysed for the expression of 
M IP-la protein by ELISA. Results represent a single experiment. The y-axis is the 
concentration of M IP-la in ng/ml.
■  0 hours 
I  16 hours
□  24 hours
□  48 hours
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with rm SCF reconstituted in endotoxin free PBS produced the same level of M IP-la 
as the other two treatments. As with the cell lines it seems that bone marrow 
macrophages do not express M IP-la after stimulation with rm SCF.
In a final attempt to clarify whether 120 ng/ml SCF can induce expression of M IP-la, 
total RNA was produced from un-stimulated bone marrow macrophages (BMM), 
BMM that were stimulated with endotoxin free PBS, or rm SCF reconstituted in 
endotoxin free PBS or GM-CSF. GM-CSF treated BMM were used as a positive 
control as Jarmin et al previously observed that GM-CSF induces M IP-la expression 
in BMM (Jarmin et al 1999). 20 fig of total RNA was run on a gel and then 
immobilised onto a Hybond N membrane and was probed for the expression of MIP- 
l a  using a radiolabelled M IP-la specific probe (see methods section 4.2.3). The blot 
was then stripped and re-probed for the presence of P-actin as shown in figure 6.13. 
In lane 1, M IP-la mRNA is expressed highly in the presence of GM-CSF as 
previously observed by Jarmin et al. This results also indicates that the treatment of 
bone marrow macrophages with rm SCF, lane 4, produces no increase in the 
expression of M IP-la over the levels observed with bone marrow macrophages 
stimulated with PBS (lane 3) control or no treatment (lane 2). Therefore, the evidence 
indicates that whilst 120 ng/ml of SCF reduces CFU-A colony number it does not 
induce the expression of M IP-la in CFU-A stem cells or the constituent cells of the 
CFU-A colony however this does not rule out the possibility of induction of other 
inhibitory growth factors other than M IP-la. These further experiments indicate that 
SCF does not induce the expression of M IP-la.
6.3.8 Summary
In the above sections the alteration of the concentration of M-CSF and SCF had no 
effect on the M IP-la induced inhibition of CFU-A colony formation. However, upon 
increasing the concentration of both these growth factors it was observed that this had 
the effect of reducing the numbers of CFU-A colonies. This was hypothesised to be 
due to the increase in M IP-la expression by the constituent cells of the CFU-A 
colony however, experiments using M IP-la null mice and M IP-la neutralising 
antibodies indicated that this was not the case. The inability of bone marrow
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Figure 6.13 Northern blot analysis of Bone marrow macrophage expression of M IP-la 
RNA upon stimulation with endotoxin free PBS or SCF
Bone marrow macrophages were made as described in the materials and methods. The bone 
marrow macrophages were either untreated or stimulated for 48 hours with endotoxin free 
PBS or rm SCF.
The upper panel is a northern blot of M IP-la RNA expression by bone marrow macrophages. 
Lane 1 is a positive control that contains RNA from bone marrow macrophages stimulated 
with GM-CSF. Lane 2 contains RNA form un-stimulated bone marrow macrophages. Lane 3 
contains RNA form bone marrow macrophages stimulated PBS and finally lane 4 contains 
RNA form bone marrow macrophages stimulated 100 ng/ml rm SCF. This blot was then 
stripped and reprobed for P-actin and this is represented by the lower panel.
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macrophages to produce M IP-la on incubation with SCF also provided further 
evidence to suggest that SCF did not reduce the CFU-A colony number by increasing 
the expression of M IP-la. However, it is feasible that the activation of the tyrosine 
kinase signalling pathway by these growth factors may induce the expression of 
another inhibitory molecule such as MIP-lp or TGF-p. Therefore, further work is 
needed to further characterise this reduction in CFU-A colonies observed at high 
levels of both M-CSF and SCF.
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CHAPTER 7
RESULTS 3 : The alteration of GM-CSF concentration on the 
inhibition of CFU-A colony formation by MIP-la
7.1 Introduction
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a haemopoietic 
growth factor that stimulates the proliferation and differentiation of immature 
haemopoietic cells and regulates the functional activities of mature granulocytes, and 
macrophages, in-vitro and in-vivo (Kwon and Sckamato 1996). There are many cell 
types that have been reported to produce GM-CSF, these include haemopoietic cells 
such as T lymphocytes, macrophages, mast cells, B lymphocytes and natural killer 
cells (Nimer and Uchida 1995). Molecular cloning studies have indicated that the 
human and murine GM-CSF receptors are heterodimeric and are composed of an 
alpha (a) sub-unit, which binds to GM-CSF with low affinity, and a beta (p) sub-unit 
which is involved in signal transduction (Matsuguchi et al 1997). In humans the p 
sub-unit has no detectable binding affinity for GM-CSF, but forms a high affinity 
GM-CSF receptor with the a-sub-unit and both sub-units are members of the type-I 
cytokine receptor sub family (Gearing et al 1989, Hayashida et al 1990). Mice and 
humans have unique a-sub-units for the GM-CSF receptor however, they share the pc 
sub-unit with receptors for interleukin-3 (IL-3) and IL-5. In contrast to the human 
system, the mouse has two p sub-units, Pc and piu (Itoh et al 1990, Hayashida et al 
1990) and like the human Pc, the mouse Pc is the common P sub-unit for mouse IL-3, 
GM-CSF and IL-5 receptors. Although Piu, has an extensive sequence homology 
with mouse Pc, Pil3 does not form high affinity receptors with the a  sub-units of 
murine IL-5 or GM-CSF. However, both pc and piu interact equally well with 
mouse IL-3 a  sub-unit in the presence of IL-3 to form high affinity IL-3 receptors 
(Hara et al 1992). In this part of the project the GM-CSF concentration was altered in 
an attempt to examine the ability of the p common signalling pathway to interact with 
the M IP-la inhibitory pathway.
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7.2 GM-CSF a Beta Common (pc) Signalling Growth Factor
7.2.1 The Effects of GM-CSF on CFU-A Colony Formation
GM-CSF is one of the main growth factors used to induce CFU-A colony formation. 
It was originally produced and added to the assay in the form of conditioned medium 
from AF1 19T cells. These cells are a NRK (rat fibroblast) cell line and produce GM- 
CSF after being transformed with the malignant hystiocytosis sarcoma virus (MHSV) 
(Franz et al 1989). As with M-CSF and SCF, the effects on CFU-A colony 
production were examined by altering the concentration of GM-CSF within the CFU- 
A assay. In the first experiment, rm SCF was added at 12 ng/ml and rh M-CSF at 6 
ng/ml whereas, rm GM-CSF was either omitted or included at 0.0002, 0.002, 0.02, 
0.2, 2 and 20 ng/ml. From the data in figure 7.1, it can be observed that with the 
omission of rm GM-CSF the CFU-A stem cells cannot produce CFU-A colonies. 
This is not surprising as GM-CSF is involved in the differentiation of 
monocyte/macrophage lineage and macrophages are the predominant cell type within 
the CFU-A colony. It was observed that with the omission of rm GM-CSF, a number 
of small colonies were produced (less than 0.5 mm in diameter) and these colonies did 
not show the characteristic morphology or size of CFU-A colonies. Further 
investigation is needed to examine the identity of these colonies, indeed, an ideal 
experiment would be picking these colonies out and staining them to identify the 
constuituent cells, however time restaints meant that these experiments were not 
performed. Alternatively it is possible that the lower concentration of GM-CSF may 
not allow the formation of CFU-A colonies by day eleven, and that by increasing the 
incubation time of the assay that CFU-A colony formation may occur at similar levels 
to controls. The addition of rm GM-CSF at 0.2 pg/ml did not allow CFU-A colonies 
to form, it was only after the addition of 2 pg/ml of rm GM-CSF that CFU-A colonies 
appeared giving an average of 3.4 colonies (p < 0.001). This number of CFU-A 
colonies was subsequently increased to 7.5, 9.4, 7.8 and 10 in the assays containing, 
0.02, 0.2, 2 and 20 respectively.
7.2.2 The Effect of GM-CSF on the Constituent Cells of the CFU-A Colonies
The analysis of the effect of altering GM-CSF concentration on the cell types and
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Fig 7.1
Figure 7.1 Colony Forming Unit Agar (CFU-A) analysis of the effect on the CFU-A colony 
production by increasing or reducing the rm GM-CSF concentration within the 
assay
A CFU-A assay was set up with normal levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and 
varying concentrations of rm GM-CSF. The average colony production ( + SEM) is shown 
for 5 plates. This assay is a representative result from three replicate experiments. Students 
T-test was performed comparing normal GM-CSF levels (0.2ng/ml) to all the other 
concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
□  0 GM-CSF ■  0.2 ng/ml GM-CSF
■  0.0002 ng/ml GM-CSF □  2 ng/ml GM-CSF
□  0.002 ng/ml GM-CSF B 20 ng/ml GM-CSF
□  0.02 ng/ml GM-CSF
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Table 6
Cell Num bers within CFU-A colonies
rm GM-CSF 0.02 ng/ml 19800
rm GM-CSF 0.02 ng/ml +  M IP -la 4400
rm GM-CSF 0.2 ng/ml 23200
rm GM-CSF 0.2 ng/ml +  M IP -la 6500
rm GM-CSF 2 ng/ml 24800
rm GM-CSF 2 ng/ml +  M IP -la 6900
Differential counts 1500 cells')
M acroDhages G ranulocytes Othc
rm GM-CSF 0.02 ng/ml 494 4 2
rm GM-CSF 0.02 ng/ml + M IP -la 498 0 2
rm GM-CSF 0.2 ng/ml 490 5 5
rm GM-CSF 0.2 ng/ml +  M IP -la 498 0 2
rm GM-CSF 2 ng/ml 476 22 2
rm GM-CSF 2 ng/ml +  M IP -la 487 11 2
Table 6 Analysis of cell number and morphology of the cells within the CFU-A 
colonies containing 0.02, 0.2 and 2 ng/ml of rm GM-CSF in the presence or 
absence of 100 ng/ml MIP-la
CFU-A assays were set up containing a top layer of methylcellulose instead of the normal 
double agar assay. 10 colonies were picked from plates containing 100 ng/ml MIP-la and 5 
colonies from the plates that did not contain MIP-la. These cells were washed and either 
cytospins were prepared and stained by Giemsa for morphology analysis or cell numbers were 
counted.
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numbers within the CFU-A colonies was next examined. The results in table 6 
indicate that the colonies are predominantly made up of macrophages. The only 
noticeable alteration in colony make up is an increase in granulocytes from 1 % in a 
normal CFU-A assay to 4.4 % in a CFU-A assay incubated with 2 ng/ml rm GM-CSF. 
Interestingly, the percentage of granulocytes in each CFU-A colony was subsequently 
reduced upon the further addition of 100 ng/ml of M IP-la, from 4.4% to 2.2%. 
These results suggest that the increase in GM-CSF alters the constituent cells in the 
CFU-A colonies. The analysis of cell numbers within the CFU-A colonies indicate 
that there is a small reduction in cell numbers in colonies incubated in 0.2 ng/ml rm 
GM-CSF compared to that of 0.02 ng/ml of GM-CSF, 23200 to 19800. However, the 
opposite effect occurs upon adding 2 ng/ml of rm GM-CSF as this produces an 
increase in the constituent cells from 23200 to 24800. Furthermore, with the 
inclusion of 100 ng/ml of M IP-la to each of the assays containing the various GM- 
CSF concentrations, it can be observed that there is an overall reduction in cell 
number by approximately 4 fold when compared to that of control CFU-A plates, see 
table 6.
7.2.3 The Effect of GM-CSF on M IP-la Inhibition of CFU-A Colony 
Formation
In an attempt to investigate if altering the GM-CSF concentration could interfere with 
the inhibition of CFU-A colony formation by M IP-la, the above GM-CSF titration 
was repeated with the inclusion of M IP-la at concentrations ranging from 0.5 ng/ml 
to 100 ng/ml. At the normal levels of GM-CSF, 0.2 ng/ml figure 7.2C, it was 
observed that M IP-la had the ability to inhibit CFU-A colony formation at 100 
ng/ml. Although M IP-la could also induce a statistically significant inhibition of 
CFU-A colony formation at 50 ng/ml, it was observed that M IP-la was not as 
effective at inducing inhibition at this concentration compared to 100 ng/ml (p < 
0.001). This was also true for CFU-A assays containing 2 and 20 ng/ml of GM-CSF. 
Within the assay containing 0.002 ng/ml of rm GM-CSF, it was observed that M IP-la 
could produce inhibition of CFU-A colonies at concentrations as low as 5 ng/ml, p < 
0.05, figure 7.2A. This indicates that it may be possible to enhance the ability of 
M IP-la to inhibit the formation of CFU-A colony formation by reducing the GM- 
CSF concentration. Alternatively, this reduction in CFU-A colony numbers may be
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Figure 7.2 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production in the presence of 0.002, 0.02 and 0.2 ng/ml of rm 
GM-CSF
M IP -la  at 0.5, 1 ,5 , 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal levels o f  
rh M -CSF (6 ng/ml), rm SCF (12 ng/ml) and either 0.002, 0.02 or 0.2 ng/ml o f  rm GM -CSF and these 
are represented in A, B and C respectively. The average colony production ( + SEM ) is shown for 5 
plates. This assay is a representative result from three replicate experiments. Students T-test was 
performed com paring controls to all the other M IP -la  concentrations (*1 = P < 0.05, *2 -  P < 0.01 and 
*3 = P < 0.001).
I  Control H  5 ng/ml M IP - la  D  10 ng/ml M IP - la
I  100 ng/ml M IP - la  D 1 ng/ml M IP - la  □  0.5 ng/ml M IP - la
□  50 ng/ml M IP - la
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Figure 7.2 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production in the presence of 2 and 20 ng/ml of rm GM-CSF
M IP-la at 0.5, 1,5, 10, 50 and 100 ng/ml was added to the CFU-A assay containing normal 
levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and either 2 or 20 ng/ml of rm GM-CSF 
and these are represented in D and E respectively. The average colony production ( + SEM) 
is shown for 5 plates. This assay is a representative result from three replicate experiments. 
Students T-test was performed comparing controls to all the other M IP-la concentrations (*1 
= P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
H  Control 
■  100 ng/ml M IP-la
□  50 ng/ml M IP-la
□  10 ng/ml M IP-la
■  5 ng/ml M IP-la
■  1 ng/ml M IP-la
■  0.5 ng/ml M IP-la
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due to this low level of GM-CSF not being able to support a similar level of survival, 
differentiation and proliferation needed for the formation of CFU-A colonies as 
observed in control assays. Indeed, on examining control CFU-A assays prior to day 
11, small colonies that do not display the characteristic size of CFU-A colonies are 
observed and upon further incubation these colonies develop into CFU-A colonies. 
This has been proposed to be due to the inability of the growth factors to induce the 
normal levels of survival, differentiation and proliferation of the CFU-A stem cells in 
this smaller time scale. If this is the case it may explain the apparent ability of MIP- 
l a  to inhibit CFU-A colony formation in CFU-A assays containing 0.002 ng/ml of 
GM-CSF. Further studies examining the effect of increasing the incubation time to 
day 14 or 20 may indicate that the low levels of GM-CSF are insufficient to allow 
formation of CFU-A colonies by day 11.
On further analysis of the CFU-A colonies produced in the above assay, an alternative 
colony morphology was observed in the assays containing 2 or 20 ng/ml of GM-CSF 
and 50 ng/ml of M IP-la. These colonies were of similar size to normal CFU-A 
colonies, greater than or equal to 2 mm in diameter; however, they appeared to have a 
more defined edge than normal colonies. On staining CFU-A assays containing 
various GM-CSF concentrations with INT, and examining the plates from the side 
instead of from above, the colonies grown in 0.02, 0.2, 2 or 20 ng/ml GM-CSF, 
appear to be flat and are slightly embedded in the top layer of agar. Furthermore in 
assays containing 0.02, 0.2, 2 or 20 ng/ml GM-CSF +100 ng/ml of M IP-la, another 
colony morphology can be observed, see figure 7.3 and 7.4. On examining the 
colonies from 2 and 20 ng/ml GM-CSF in the presence of 50 ng/ml of M IP-la 
compared to that of either no M IP-la or indeed 100 ng/ml of M IP-la, it was 
observed that these conditions resulted in another different colony shape. These 
colonies formed in the assay containing 2 or 20 ng/ml GM-CSF + 50 ng/ml of MIP- 
l a  are similar in size to control CFU-A colonies. However, this is where the 
similarities stop, these alternative colonies are embedded in the two layers of the 
assay and from the side the colonies appear almost spherical, they also have a densely 
stained central region, a lighter stained exterior region and a densely stained outer 
edge.
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Size > 2mm
Normal CFU-A colony
0.2 ng/ml GM-CSF
Size > 2mm
I---------------------
B
Odd CFU-A colony
2 ng/ml GM-CSF 
+ 50ng/ml M IP -la
Size = 0.2 mm
Inhibited CFU-A colony
0.2 ng/ml GM-CSF 
+ 100 ng/ml M IP -la
Figure 7.3 Photographic analysis of CFU-A colonies
Photographs o f  CFU-A colonies were produced as described in materials and methods. The CFU-A
colonies were stained with I NT and incubated overnight
A) Shows a photograph o f  a normal CFU-A colony produced in a CFU-A assay containing 0.2 ng/ml 
rm GM -CSF. Similar colonies are produced in assays containing 0.02, 2 and 20 ng/ml GM -CSF. 
The colony is greater than or equal to 2mm in size.
B) Shows a photograph o f an odd shaped CFU-A colony produced in a CFU-A assay containing 2 
ng/ml rm GM -CSF + M IP - la  50 ng/ml. Similar colonies are produced in assays containing 20 
ng/ml rm GM -CSF + M IP - la  50 ng/ml or 2 ng/ml rm G M -CSF + rh HCC-1 l|ig /m l or 20 ng/ml 
rm GM -CSF + rh HCC-1 1 (J.g/ml. The colony is greater than or equal to 2mm in size.
C) Shows a photograph o f  an inhibited CFU-A colony produced in a CFU-A assay containing 0.2 
ng/ml rm GM -CSF + M IP - la  at 100 ng/ml. Similar colonies are produced in assays containing 
0.02, 2 and 20 ng/ml GM -CSF. The colony is less than 2 mm in size.
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Figure 7.4 Photographic analysis o f  CFU-A colonies
Photographs o f  CFU-A colonies were produced as described in materials and methods. The CFU-A
colonies were stained with May and G runwald and Giemsa.
A) Shows a photograph o f the side view o f  a plate that shows a representative colony shape which is 
produced in a CFU-A assay containing 0.2 ng/ml rm GM -CSF. Similar colonies are produced
in assays containing 0.02, 2 and 20 ng/ml GM -CSF
B) Shows a photograph o f  the side view o f  a plate that shows a representative colony shape which is 
produced in a CFU-A assay containing 0.2 ng/ml rm GM -CSF + 100 ng/ml M IP -la . Sim ilar 
colonies are produced in assays containing 0.02, 2 and 20 ng/ml GM -CSF
C) Shows a photograph o f  the side view o f  a plate that shows a representative colony shape which is
produced in a CFU-A assay containing 20 ng/ml rm GM -CSF + 50 ng/ml o f  M IP -la . Sim ilar 
colonies are produced in assays containing 2 ng/m lGM -CSF + 50 ng/ml o f  M IP - la
D) Shows a photograph o f the side view o f  a plate that shows a representative colony shape which is
produced in a CFU-A assay containing 20 ng/ml rm GM -CSF + 1 |!g/ml o f  HCC-1. S im ilar 
colonies are produced in assays containing 2 ng/m lGM -CSF + 1 pg/m l o f  HCC-1.
GM-CSF 0.2 ng/ml
GM-CSF 0.2 ng/ml + 100 ng/ml M IP-la
GM-CSF 20 ng/ml + M IP-la 50 ng/ml
GM-CSF 20 ng/ml + HCC-1 ljlg/ml
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Jarmin et al previously observed that incubating bone marrow derived macrophages 
with GM-CSF induces the expression of various chemokines e.g. M IP-la, MIP-lp, 
JE and MARC. Furthermore, they also observed that 10 ng/ml of GM-CSF could 
induce the expression of CCR-1 mRNA expression after 4 hours. Indeed, on analysis 
of surface expression of this receptor they observed a 130 % increase in CCR-1 
expression from 20000 to 46000 receptors on bone marrow derived macrophages after 
incubation with GM-CSF. M IP-la has been observed by a number of groups to be 
one of a number of chemokines that has the ability to interact with CCR-1 (Gao et al 
1995, Post et al 1996). On this basis, it was hypothesised that the production of these 
alternatively shaped colonies in the current experiment may be due to the increased 
expression of CCR-1 by high levels of GM-CSF and the subsequent interaction with 
MIP-1 a. From table 6, it can be observed that there is a 4 fold increase in granulocyte 
numbers in CFU-A assays containing 2 ng/ml GMCSF and this is reduced to a 2 fold 
increase upon the inclusion of 100 ng/ml M IP-la compared to that of a normal CFU- 
A conditions. Therefore, it is feasible that CFU-A colonies grown in 2 or 20 ng/ml of 
rm GM-CSF + 50 ng/ml M IP-la may have an increased number of granulocytes 
compared to that of CFU-A colonies grown in 0.2 ng/ml + 50 ng/ml M IP-la. If so, 
this suggests that maybe the alteration in granulocyte numbers within these alternative 
colonies may be involved in their formation. It has been previously observed that 
CFU-GM colonies have a compact centre consisting largely of neutrophils and a 
dispersed halo of macrophages. Therefore, it is possible that the increase in 
granulocytes in these alternative CFU-A colonies occurs in the central region, if so 
this may explain the appearance of the tight central region. Furthermore, the 
increased level of GM-CSF may induce the expression of CCR1 on these 
granulocytes, and upon their interaction with M IP-la, these granulocytes may 
become activated and produce a number of different cytokines or chemokines that 
may act to repel the macrophages from the centre of the colony. If this were to occur, 
this would explain the appearance of the leading edge observed in these colonies, see 
discussion.
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7.2.4 Examination of the Alternative Colony Shape
Graham et al produced a variant of M IP-la, which they designated HepMut due to its 
inability to bind to heparin. Functional analysis of HepMut indicated that it had 
retained the stem cell inhibitory property associated with the parent molecule 
however, it has an impaired ability to induce monocyte shape change or locomotion 
and did not show any detectable binding to the chemokine receptor CCR-1 (Graham 
et al 1996). In an attempt to examine the hypothesis that CCR-1 may be involved in 
the production of these alternative shaped colonies, an experiment comparing the 
effects of M IP-la and HepMut on the CFU-A colony formation in assays with altered 
GM-CSF concentrations was set up, (see figure 7.5). M IP-la at 100 and 50 ng/ml 
could significantly inhibit the formation of CFU-A colonies at all the GM-CSF 
concentrations tested, p < 0.001. As well as the observed inhibition by M IP-la, 
HepMut at 100 ng/ml was able to inhibit the formation of CFU-A colonies 
significantly at 0.02 and 0.2 (P < 0.001). Although, HepMut did inhibit the CFU-A 
proliferation in the assays containing 2 ng/ml rm GM-CSF, this proved not to be 
statistically significant. HepMut could not significantly inhibit CFU-A formation at 
50 ng/ml in any of the GM-CSF concentrations and like wise M IP-la and HepMut 
did not produce any inhibition at concentrations lower than 50 ng/ml in any of the 
assays. On analysis of the morphology of the colonies, it was observed that the 
HepMut colonies were similar to the colonies observed in the control plates, and that 
they did not resemble the alternative shaped colonies produced in 2 or 20 ng/ml GM- 
CSF + 50 ng/ml M IP-la assays. Both M IP-la and HepMut have been observed to 
inhibit the formation of CFU-A colonies however, only M IP-la can induce the 
production of the alternative colonies suggesting that the inhibitory property of MIP- 
1 a  does not play a part in the creation of these alternative colonies. As HepMut can 
not bind to CCR-1 and can not produce these alternative colonies this may suggest 
that the formation of these colonies is due to the interaction between M IP-la and 
CCR-1. Furthermore, these results indicate that the interaction between CCR1 and 
M IP-la may be involved in the activation of an alternative signalling pathway other 
than the pathway used to produce the inhibition of the CFU-A colonies.
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Figure 7.5 Colony Forming Unit Agar (CFU-A) analysis of the effect of HepMut a non 
heparin binding variant of M IP-la on the CFU-A colony production in the 
presence of 0.02, 0.2 and 2 ng/ml of rm GM-CSF
HepMut and M IP-la at 10, 50 and 100 ng/ml was added to the CFU-A assay containing 
normal levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and either 0.02, 0.2 or 20 ng/ml of 
rm GM-CSF and these are represented in A, B and C respectively. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing controls to all the treatments 
(*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
I  Control
H  100 ng/ml M IP-la
□  100 ng/ml HepMut
□  50 ng/ml M IP-la
■  50 ng/ml HepMut 
19 10 ng/ml M IP-la
■  10 ng/ml HepMut
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Figure 7.6 Colony Forming Unit Agar (CFU-A) analysis of the effect of mMCP-3 a CCR- 
1 ligand on the CFU-A colony production in the presence of 0.02, 0.2 and 2 
ng/ml of rm GM-CSF
MCP-3 and M IP-la at 10, 50 and 100 ng/ml was added to the CFU-A assay containing 
normal levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and either 0.02, 0.2 or 2 ng/ml of 
rm GM-CSF and these are represented in A, B and C respectively. The average colony 
production ( + SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing controls to all the treatments 
(*1 = P < 0.05, *2 = P < 0.01 and *3 = P <0.001)
B Control B 50 ng/ml MCP-3 B  10 ng/ml MCP-3
B 100 ng/ml M IP-la □  50 ng/ml M IP-la
□  100 ng/ml MCP-3 □  10 ng/ml M IP-la
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7.2.5 The Effects of High Levels of GM-CSF and other CCR-1 Ligands on 
CFU-A Colony Formation
In a further attempt to examine the role of CCR1 in the formation of these alternative 
colonies at high GM-CSF concentration and 50 ng/ml of M IP-la, the effects of two 
other CCR-1 ligands were examined, neither of which have been previously shown to 
inhibit CFU-A colony formation. The data in figure 7.6 indicates, that M IP-la at 100 
and 50 ng/ml can inhibit the CFU-A colony formation at all GM-CSF concentrations, 
(p <0.001 and p < 0.05), see figure 7.6. However, rm MCP-3 can not inhibit CFU-A 
colony formation at 100, 50 or 10 ng/ml and did not induce the formation of the 
alternatively shaped colonies (data not shown).
Tsou et al using a panel of cloned chemokine receptors revealed that rh HCC-1 could 
bind to and induce signalling through hCCR-1 (Tsou et al 1998). With a few 
exceptions most human chemokines that signal through a particular human chemokine 
receptor have been observed to signal through its murine counterpart. To date no 
murine homologue of the human HCC-1 has been identified therefore, the human 
protein was used to examine the potential for hHCC-1 to produce these alternative 
shaped colonies. This was examined by the addition of rh HCC-1 to a CFU-A assay 
containing various concentrations of GM-CSF, (figure7.7). In this assay it was 
observed that again M IP-la could inhibit CFU-A colonies at 100 and 50 ng/ml and 
although 100 ng/ml of rh HCC-1 could reduce the number of CFU-A colonies 
produced at all GM-CSF concentrations this was not statistically significant, (figure 
7.7). Furthermore, on examination of the morphology of the colonies under the 
conditions where the alternatively shaped colony morphology was produced it was 
observed that hHCC-1 could not induce the formation of these alternative shaped 
colonies. Human HCC-1 has been observed to compete with rm M IP-la for binding 
to mCCR-1 transfected cell lines with a markedly reduced affinity (IC50 = 93 nM 
compared to that of 1.3 nM for M IP-la), and hHCC-1 is also 100 fold less efficient at 
inducing chemotaxis compared to mM IP-la in freshly isolated human monocytes 
(Tsou et al 1998). Therefore, it is possible that higher concentrations of rh HCC-1 
may in fact produce the formation of these alternatively shaped colonies. In figure 
7.8, a CFU-A assay was set up containing 20 ng/ml GM-CSF with the addition of 
100, 50 ng/ml of M IP-la, 1 pg/ml of rm RANTES, rm MCP-3 or rh HCC-1. M IP-la 
as expected inhibited the colony formation at 100 and 50 ng/ml and the alternative
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Figure 7.7 Colony Forming Unit Agar (CFU-A) analysis of the effect of hHCC-1 a CCR-1 
ligand on the CFU-A colony production in the presence of 0.02, 0.2 and 2 
ng/ml of rm GM-CSF
HCC-1 and M IP-la at 10, 50 and 100 ng/ml was added to the CFU-A assay containing 
normal levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and either 0.02, 0.2 or 2 ng/ml of 
rm GM-CSF and these are represented in A, B and C respectively. The average colony 
production (+ SEM) is shown for 5 plates. This assay is a representative result from three 
replicate experiments. Students T-test was performed comparing controls to all the treatments 
( * 1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
H  Control I  50 ng/ml M IP - la  H  10 ng/ml HCC-1
■  100 ng/ml M IP - la  ■  50 ng/ml HCC-1
D  100 ng/ml HCC-1 I  10 ng/ml M IP - la
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Figure 7.8 Colony Forming Unit Agar (CFU-A) analysis of the effect of mMIP-1 a, 
mMCP-3, hHCC-1 and RANTES on the CFU-A colony production in the 
presence 20 ng/ml of rm GM-CSF
M IP-la was added to the assay to give a final concentration of 50 or 100 ng/ml whereas the 
other CCR-1 ligands had a final concentration of 1 pg/ml. The CFU-A assay contains normal 
levels of rh M-CSF (6 ng/ml), rm SCF (12 ng/ml) and 20 ng/ml of rm GM-CSF. (100 fold 
higher than normal levels of 0.2 ng/ml). The average colony production (+ SEM) is shown 
for 5 plates. This assay is a representative result from two replicate experiments. Students T- 
test was performed comparing controls to all the treatments (*1 = P < 0.05, *2 = P < 0.01 and 
*3 = P <0.001).
El Control 
■  100 ng/ml M IP-la 
□  50 ng/ml M IP-la
□  1 pg/ml RANTES 
■  1 pg/ml MCP-3
□  1 pg/ml HCC-1
colony shape was observed at 50 ng/ml (p < 0.001). Murine RANTES and mMCP-3, 
at 1 pg/ml, did not inhibit CFU-A colony formation nor did they produce the 
alternatively shaped colonies. On searching the literature there is a limited amount of 
binding affinity data relevant to the interaction of these murine ligands with mCCR-1 
however, there is data to suggest that rm RANTES is a low affinity ligand for mCCR- 
1, if this is also true for mMCP-3 and rh HCC-1 this may explain why low 
concentrations of these CCR-1 ligands do not induce the formation of the alternative 
colonies. If this is the case, the addition of a substantially higher concentration of 
both chemokines will enable these low affinity ligands to interact with mCCR-1, 
ruling out the low affinity of these ligands as an explanation of why they do not 
induce the formation of these alternative shaped colonies. Unlike rm RANTES and 
rm MCP-3, the addition of 1 pg/ml of rh HCC-1 to the CFU-A assay produced a small 
but statistically significant inhibition of CFU-A colony formation (p < 0.05). This 
suggests that rh HCC-1 can inhibit CFU-A colony formation and that this high 
concentration may be needed to allow a weak interaction with an unknown inhibitory 
receptor. However, it is also possible that this reduction in CFU-A colonies is due to 
the very high concentration of rhHCC-1 being toxic to either the CFU-A stem cells or 
the mature cells of the CFU-A colony. Alternatively, the formation of these 
alternative colonies could be due to a non-specific interaction with this high level of 
hHCC-1. On the analysis of the colony shape it was observed that the colonies 
produced in high levels of rh HCC-1 were similar in shape to that observed with 2 or 
20 ng/ml GM-CSF + 50 ng/ml of M IP-la, see figure 7.3 and 7.4.
Therefore, from the above observations it seems that the appearance of these 
alternative shaped colonies may be due initially to the increased expression of CCR-1 
by high levels of GM-CSF and the subsequent interaction between this receptor and 
some of its ligands. Interestingly, M IP-la and rh HCC-1 could not only induce the 
formation of these alternative shaped colonies they were also observed to inhibit the 
formation of CFU-A colonies. Therefore, it may be that the interaction between two 
different signalling pathways induced through distinct receptors may play a role in the 
formation of these alternatively shaped colonies.
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7.2.6 CCR1 and its possible role in the Alternative Colony Shape
In chapter 9, total RNA produced from lineage depleted bone marrow cells, 
previously expanded by treatment with rm SCF and rh IL-11 for 6 days, were 
examined for the expression of CC chemokine receptors. It was observed that CCR-1 
was up-regulated at the RNA level in lineage depleted expanded bone marrow cells 
compared to non expanded lineage depleted bone marrow cells, (figure 9.6). If this 
up regulation of CCR-1 transcripts is the same at the protein level, and if  as 
hypothesised CCR-1 is involved in the production of these alternative colonies, it 
would be expected that plating these expanded CFU-A stem cells in a normal CFU-A 
assay in the presence of M IP-la would produce these alternative shaped colonies. To 
examine if this was the case, expanded stem cells were plated in a CFU- A assay 
containing a titration of M IP-la and compared to non expanded stem cells, in the 
presence or absence of high levels of GM-CSF. In this experiment the expanded 
CFU-A colonies appeared to have a defined edge and looked similar to the alternative 
shaped colonies referred to before, at all concentrations of M IP-la used except 
lOOng/ml (data not shown). Therefore, it seems that the expansion of CFU-A stem 
cells can produce conditions that allow the formation of colonies that are similar to 
the alternatively shaped colonies produced in 2 or 20 ng/ml GM-CSF + 50 ng/ml of 
M IP-la. All the evidence thus far seems to point to a link between the formation of 
these alternative shaped colonies and the interaction of M IP-la with the chemokine 
receptor CCR-1. The analysis of the ability of bone marrow from CCR-1 null mice to 
produce these alternative colonies would provide conclusive evidence that CCR-1 is 
the predominant receptor involved in this process. However, within the time scale of 
this project this type of experiment could not be performed.
7.2.7 Summary
In summary, the decrease in GM-CSF concentration reduces the formation of the 
CFU-A colonies confirming that GM-CSF is an essential growth factor for the 
production of CFU-A colonies. The addition of M IP-la to assays containing low 
levels of GM-CSF was observed to reduce the number of CFU-A colonies produced. 
This may be inhibition but more probably is due to the lack of differentiation of the 
CFU-A stem cells as discussed above. The increase in GM-CSF concentration within 
the CFU-A assays had no effect on the inhibition of the formation of CFU-A colonies
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by M IP-la however, it was observed that there was an increase in the number of 
neutrophils within the CFU-A colonies. Although increased levels of GM-CSF did 
not interfere with the inhibition of the CFU-A colony formation by M IP-la it did 
however, alter the colony shape and this was observed in assays containing 2 and 20 
ng/ml of GM-CSF + 50 ng/ml of M IP-la. The data presented above suggests that the 
formation of these alternative colonies involves the interaction between the increased 
levels of CCR1 and M IP-la, see discussion.
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CHAPTER 8
RESULTS 4 : The effect of the addition of gpl30 signalling proteins 
on the ability of MIP-la to inhibit CFU-A colony 
formation
8.1 Introduction
Interleukin-11 (IL-11) was first cloned from a primate bone marrow derived stromal 
cell line PU34, as a factor that stimulated proliferation of an IL-6 dependant 
plasmacytoma cell line (Paul et al 1990). The human and murine IL-11 receptors 
have been identified and share 82 % sequence homology and they have two 
independent sub-units, a ligand binding sub-unit and a signal-transducing sub-unit. 
The signalling sub-unit, gpl30, is not unique to the IL-11 receptor and is a 
characteristic feature of a family of cytokines that have been identified by their ability 
to use this particular sub-unit to induce a signal within the cell. Oncostatin M, ciliary 
neurotrophic factors (CNTF), interleukin-6 (IL-6) and leukaemia inhibitory factor 
(LIF), are further examples of members of this family (Taga and Kishimoto 1997). 
IL-6 can support the growth and differentiation of both granulocyte-macrophage and 
megakaryocyte progenitors (Kimura et al 1990, Hirano et al 1996). Furthermore, IL- 
6 has been observed to induce murine multi-lineage cells to exit G0 and enter cell 
cycle, where they can be acted upon by various growth factors e.g. IL-3 (Mushashi et 
al 1991). Leukaemia inhibitory factor can also act in combination with IL-3 and these 
growth factors were observed to enhance the survival and proliferative response of 
primitive blast cells. Thus, IL-11, IL-6 and LIF have been implicated as stimulatory 
proteins for early hematopoietic stem/progenitor cells, and all signal through the 
gpl30 signalling pathway. Therefore, IL-6, IL-11 and LIF were individually added to 
the CFU-A assay in an attempt to examine the ability of the gp 130-signalling pathway 
to interact with the M IP-la inhibitory pathway.
8.2 Glycoprotein 130 (gp-130) Signalling Cytokines
8.2.1 The Effect of IL-11 and IL-6 on CFU-A Colony Formation
In the first experiment, the effect of IL-11 and IL-6 on the formation of CFU-A 
colonies was examined. Various concentrations of rh IL-11 and rh IL-6, ranging from
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500 pg/ml to 100 ng/ml, were added to a CFU-A assay containing 12 ng/ml of rm 
SCF, 6 ng/ml of rh M-CSF and 0.2 ng/ml of rm GM-CSF. The addition of 0.5 ng/ml 
of rh IL-11 produced an increase in CFU-A colony numbers however this was not 
statistically significant. Upon the further increment of rh IL-11 concentration to 1 or 
5 ng/ml, no further increase or decrease in colony numbers was observed, (figure 8.1). 
However, the addition of 100, 50 and 10 ng/ml of rhIL-11 reduced the CFU-A colony 
numbers from 9.47 to 4.8, 6.0 and 4.9 respectively (p<0.001). Unlike rh IL-11, the 
addition of 0.5 ng/ml of rh IL-6 to a CFU-A assay did not produce an increase in 
CFU-A colonies, and on the subsequent increase of rh IL-6 concentration to 1 ng/ml 
no alteration in colony numbers was observed. However, on the addition of 5, 10, 50 
and 100 ng/ml of rh IL-6, a decrease in CFU-A colony numbers was observed from 
6.25 to 3.8, 1.3, 0.8 and 0.6 respectively, p < 0.05 and p < 0.001 (figure 8.2). These 
results indicate that both rh IL-11 and rh IL-6 have the effect of reducing the 
formation of CFU-A colonies and that rh IL-6 is more effective than rh IL-11.
8.2.2 The Effect of IL-11 and IL-6 on M IP-la Inhibition of CFU-A Colonies
To examine the effect of rh IL-11 and rh IL-6 on the inhibition of the CFU-A stem 
cells by M IP-la, a subsequent assay containing a titration of rh IL-11 or rh IL-6 and 
M IP-la at 1, 10 and 100 ng/ml was set up. In figure 8.3, it can be observed that 100 
ng/ml of M IP-la can not only significantly inhibit the formation of CFU-A colonies 
in the absence of rh IL-11, it can also significantly inhibit the formation of CFU-A 
colonies in the presence of the various concentrations of rh IL-11. No further 
inhibition of CFU-A colonies were observed at concentrations lower than 100 ng/ml 
of rm M IP-la. With the inclusion of 100 ng/ml rm M IP-la in the CFU-A assays 
containing 0.5, 1, 5, 10, 50 and 100 ng/ml of rh IL-6, it can be observed that the 
formation of CFU-A colonies is totally inhibited (p < 0.001) in all concentrations of 
rh IL-6 (figure 8.4). Interestingly, in CFU-A assays containing 50, 10 and 5 ng/ml of 
rh IL-6, the inhibition of CFU-A colonies also occurred at 10 ng/ml of rm M IP-la. 
This is a concentration of rm M IP-la that does not normally induce inhibition of 
CFU-A colony formation, therefore, it seems that rh IL-6 and rm M IP-la are having 
an additive effect in reducing the formation of CFU-A colonies.
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Fig 8.1
Figure 8. 1 Colony Forming Unit Agar (CFU-A) analysis of the effect of Interleukin-11 
on the CFU-A colony production
Interleukin-11 at 0.5, 1,5, 10, 50 and 100 ng/ml was added to a normal CFU-A assay 
containing 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml rm GM-CSF. The average 
colony production ( + SEM) is shown for 5 plates. This assay is a representative result from 
three replicate experiments. Students T-test was performed comparing controls to all the 
treatments (* 1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
□  Control ■  5 ng/ml rh IL-11
■  100 ng/ml rh IL-11 M 1 ng/ml rh IL-11
□  50 ng/ml rh IL-11 ■  0.5 ng/ml rh IL-11
D 10 ng/ml rh IL-11
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Figure 8. 2 Colony Forming Unit Agar (CFU-A) analysis of the effect of Interleukin-6 on 
the CFU-A colony production
Interleukin-6 at 0.5, 1, 5, 10, 50 and 100 ng/ml was added to a normal CFU-A assay 
containing 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml rm GM-CSF. The average 
colony production (+ SEM) is shown for 5 plates. This assay is a representative result from 
three replicate experiments. Students T-test was performed comparing controls to all the 
treatments (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
Si Control 
■  100 ng/ml IL-6
□  50 ng/ml IL-6
□  10 ng/ml IL-6
■  5 ng/ml IL-6 
B  1 ng/ml IL-6 
B  0.5 ng/ml IL-6
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Figure 8.3 Colony Forming Unit Agar (CFU-A) analysis of the effect of Interleukin-11 
at 0.5, 1,5, 10, 50 and 100 ng/ml on the inhibitory effect of M IP-la in a 
CFU-A assay
A CFU-A assay was set up that contained 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml 
rm GM-CSF + M IP-la at 1, 10 and 100 ng/ml. This assay was set up in the absence {A} or 
the presence of Interleukin-11 at 100 and 50 {B}, 10 and 5 {C}, 1 and 0.5 ng/ml {D}. The 
average colony production (+ SEM) is shown for 5 plates. This assay is a representative result 
from three replicate experiments. Students T-test was performed comparing controls to all 
the treatments (* 1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
I  Control 
■  100 ng/ml M IP-la
□  10 ng/ml M IP-la
□  1 ng/ml M IP-la
■  100, 50, 10, 5, 1 and 0.5ng/ml IL-11
□  100, 50, 10, 5, 1 and 0.5ng/ml IL-11 + 100 ng/ml M IP-la
■  100, 50, 10, 5, 1 and 0.5ng/ml IL-11 + 10 ng/ml M IP-la
□  100, 50, 10, 5, 1 and 0.5ng/ml IL-11 + 1 ng/ml M IP-la
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Figure 8.4 Colony Forming Unit Agar (CFU-A) analysis of the effect of Interleukin-6 at 
0.5, 1, 5, 10, 50 and 100 ng/ml on the inhibitory effect of M IP-la in a CFU-A 
assay
A CFU-A assay was set up that contained 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml 
rm GM-CSF + M IP-la at 1, 10 and 100 ng/ml. This assay was set up in the absence {A} or 
the presence of Interleukin-6 at 100 and 50 {B}, 10 and 5 {C}, 1 and 0.5 ng/ml {D}. The 
average colony production (+ SEM) is shown for 5 plates. This assay is a representative result 
from three replicate experiments. Students T-test was performed comparing controls to all 
the treatments (*1 = P < 0.05, *2 -  P < 0.01 and *3 = P < 0.001)
■  Control 
I  100 ng/ml M IP - la  
D  10 ng/ml M IP - la  
E l 1 ng/ml M IP - la
■  100, 50, 10, 5, 1 and 0.5ng/ml IL-6
□  100, 50, 10, 5, 1 and 0.5ng/ml IL-6 + 100 ng/ml M IP - la
■  100, 50, 10, 5, 1 and0 .5ng/m l IL-6 + 10 ng/ml M IP -la
□  100,50, 10, 5, 1 and 0.5ng/ml IL-6 + 1 ng/ml M IP - la
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8.2.3 The Effect of LIF on CFU-A Colony Formation
In an attempt to see if the apparent reduction in CFU-A colonies was shared by all the 
gpl30 signalling cytokines, a titration of Leukaemia Inhibitory Factor (LIF) in the 
presence or absence of rm M IP-la at 1, 10 or 100 ng/ml was set up. Figure 8.5 and
8.6 both indicate that rh LIF has no effect on normal colony production or inhibition 
of CFU-A colonies when it is added to a CFU-A assay. McKinstry et al observed that 
isolated LTRC, STRC and progenitor cells from bone marrow can not bind 
radiolabelled LIF suggesting that LIF receptors are not found on these cells 
(Mckinstry et al 1997). This may explain why rh LIF has no effect on the formation 
or inhibition of CFU-A colonies. The inhibition of CFU-A stem cells by rh IL-11 and 
rh IL-6, is not a property that has been normally associated with either of these 
cytokines and thus, further analysis was performed to examine what is occurring in 
these assays.
8.2.4 The Effect of IL -ll and IL-6 on the Constituent Cells of the CFU-A 
Colonies
In order to examine the effects of rh IL-11 and rh IL-6 further, a CFU-A assay was set 
up to examine the effects on the number and types of cells in each CFU-A colony in 
the presence or absence of 100 ng/ml of M IP-la (table 7 and 8). Upon the addition of 
10 ng/ml and 100 ng/ml of rh IL -ll, the number of cells within the CFU-A colonies 
are reduced from 20000 to 18800 and 16400 respectively. Upon the addition of 100 
ng/ml of rm M IP-la, it was observed that there was a further reduction in the number 
of cells within each colony to 7750 and 5800. In a control CFU-A assay, it can also 
be observed that the colonies predominantly consist of macrophages (approximately 
98 %) with a small number of granulocytes, predominantly neutrophils, and blast 
cells. However, on the addition of 100 ng/ml of rh IL-11, there is an increase in the 
number of granulocytes observed in the CFU-A colonies from 0.4 to 4 % with a 
similar decrease in the number of macrophages. In similar assays containing rh IL-6, 
instead of rh IL-11, it can be seen that on the addition of 10 ng/ml and 100 ng/ml of rh 
IL-6 the number of cells within the CFU-A colonies are reduced from 20000 to 16400 
and 10400 respectively. Furthermore, upon the addition of 100 ng/ml of rm M IP-la
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Fig 8.5
Figure 8.5 Colony Forming Unit Agar (CFU-A) analysis of the effect of Leukaemia 
Inhibitory Factor on the CFU-A colony production
Leukaemia Inhibitory Factor at 0.5, 1,5, 10, 50 and 100 ng/ml was added to a normal CFU-A 
assay containing 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml rm GM-CSF. The 
average colony production (+ SEM) is shown for 5 plates. This assay is a representative result 
from three replicate experiments. Students T-test was performed comparing controls to all 
the treatments (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
IB Control 
■  100 ng/ml LIF 
□  50 ng/ml LIF 
El 10 ng/ml LIF
H 5 ng/ml LIF 
□  1 ng/ml LIF 
■  0.5 ng/ml LIF
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Figure 8.6 Colony Forming Unit Agar (CFU-A) analysis of the effect of LIF at 0.5, 1, 5,
10, 50 and 100 ng/ml on the inhibitory effect of M IP-la in a CFU-A assay
A CFU-A assay was set up that contained 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml 
rm GM-CSF + M IP-la at 1, 10 and 100 ng/ml. This assay was set up in the absence {A} or 
the presence of LIF at 100 and 50 {B}, 10 and 5 {C}, 1 and 0.5 ng/ml {D}. The average 
colony production (+ SEM) is shown for 5 plates. This assay is a representative result from 
three replicate experiments. Students T-test was performed comparing controls to all the 
treatments (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001).
H  Control 
■  100 ng/ml M IP-la 
□  10 ng/ml M IP-la 
E0 1 ng/ml M IP-la
■  100, 50, 10, 5, 1 and 0.5ng/ml LIF
□  100, 50, 10, 5, 1 and 0.5ng/ml LIF + 100 ng/ml M IP-la
■  100, 50, 10, 5, 1 and 0.5ng/ml LIF + 10 ng/ml M IP-la
□  100, 50, 10, 5, 1 and 0.5ng/ml LIF + 1 ng/ml M IP-la
2 1 0
Table 7
Cell Num bers within CFU-A colonies
Normal 20000
100 ng/ml M IP -la 5500
rh IL -ll 1 0 0 ng/ml 16400
rh IL -ll 1 0 0 ng/ml + M IP -la 5800
rh IL -ll 10 ng/ml 18800
rh IL -ll 10 ng/ml + M IP -la 7750
rh IL -ll 1 ng/ml 24500
rh IL -ll 1 ng/ml + M IP -la 7100
Differential counts (500 cells')
M acrophages G ranulocytes Others
Normal 498 2 0
100 ng/ml M IP -la 490 5 5
rh IL -ll 100 ng/ml 480 20 0
rh IL -ll 100 ng/ml + M IP -la 482 17 1
rh IL -ll 10 ng/ml 492 4 4
rh IL -ll 10 ng/ml +  M IP -la 495 5 0
rh IL -ll 1 ng/ml 498 2 0
rh IL -ll 1 ng/ml + M IP -la 499 1 0
Table 7 Analysis of cell number and morphology of the cells within the CFU-A 
colonies containing 1, 10 or 100 ng/ml of Interleukin-11 in the presence or 
absence of 100 ng/ml MIP-la
CFU-A assays were set up containing a top layer of methylcellulose instead of the normal 
double agar assay. 10 colonies were picked from plates containing 100 ng/ml MIP-la and 5 
colonies from the plates that did not contain MIP-la. These cells were washed and either 
cytospins were prepared slides and stained by Giemsa for morphology analysis or cell 
numbers were counted.
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Table 8
Cell Num bers within CFU-A colonies
Normal 20000
100 ng/ml M IP -la 5500
rh IL-6 100 ng/ml 10400
rh IL-6 100 ng/ml + M IP -la 6700
rhIL-6 10 ng/ml 16400
rh IL-6 10 ng/ml + M IP -la 12550
rh IL-6 1 ng/ml 22500
rh IL-6 1 ng/ml +  M IP -la 9000
Differential counts 1500 cells!
MacroDhaoes Granulocvtes Othei
Normal 498 2 0
100 ng/ml M IP -la 490 5 5
rh IL-6 100 ng/ml 300 150 50
rh IL-6 100 ng/ml +  M IP -la 425 25 50
rh IL-6 10 ng/ml 390 9 1
rh IL-6 10 ng/ml + M IP-1 a 370 30 0
rh IL-6 1 ng/ml 493 7 0
rh IL-6 1 ng/ml +  M IP -la 450 50 0
Table 8 Analysis of cell number and morphology of the cells within the CFU-A
colonies containing 1,10 and 100 ng/ml of Interleukin-6 in the presence or 
absence of 100 ng/ml MIP-la
CFU-A assays were set up containing a top layer of methylcellulose instead of the normal 
double agar assay. 10 colonies were picked from plates containing 100 ng/ml MIP-la and 5 
colonies from the plates that did not contain MIP-la. These cells were washed and either 
cytospins were prepared slides and stained by Giemsa for morphology analysis or cell 
numbers were counted.
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it was observed that the number of cells was further reduced within each colony to 
12550 and 6700. It can also be seen that with the inclusion of 100 ng/ml of rh IL-6 in 
the CFU-A assays, there is an increase in the number of granulocytes observed in the 
CFU-A colonies from 0.4 to 30 %, an increase in the number of blast cells from 0 to 
10 % and a subsequent decrease in the number of macrophages from 99.6 % to 60 %. 
The alteration of the constituent cells of the CFU-A colonies upon the addition of rh 
IL-11 and rh IL-6 suggest that these cytokines are, in some way, interacting with the 
CFU-A stem cells and maybe altering their ability to differentiate along the pathways 
that normally lead to the formation of CFU-A colonies. The alteration in granulocytes 
with rhIL-11 and blast cell number with rhIL-6 has not been observed in any of the 
previous assays that were examining the alteration of growth factor concentrations. 
Blast cells are primitive haemopoietic cells and characteristically display a high 
nuclear to cytoplasmic ratio and this morphology is shared by stem cells. Therefore, 
as suggested from the data in table 8, it seems that rh IL-6 may in fact be increasing 
the number of blast cells in these colonies by increasing the level of the stem cell 
renewal with a concomitant decrease in differentiation. This would explain the 
alteration in the constituent cells of the CFU-A colony, and may also explain the 
apparent reduction in CFU-A colony numbers at high levels of hIL-6, see discussion. 
The replating ability of the CFU-A colonies that contained an increased number of 
blast cells was performed, however the data was inconclusive, data not shown.
8.3 Summary
In summary, the overall trend produced with the inclusion of rh IL-6 in the CFU-A 
assay is similar to the results with rh IL-ll in that both cytokines at the higher 
concentrations reduced/ inhibited the number of CFU-A colonies. At lower 
concentrations of both these cytokines, the reduction or inhibition in CFU-A numbers 
is not as clear. Unlike rh IL -ll, rh IL-6 can enhance the ability of rm M IP-la to 
reduce CFU-A colony formation as 10 ng/ml of rm M IP-la was observed to induce a 
significant reduction in CFU-A colony number. This concentration of rm M IP-la is 
not normally associated with the reduction in CFU-A colony formation, therefore, it 
seems that rh IL-6 can interact with rm M IP-la and induce an additive reduction in 
CFU-A colony numbers. Alternatively the decrease in colony formation may be due 
to IL-6 and IL-11 acting upon the progeny of the CFU-A stem cell, e.g CFU-GM or 
CFU-G, in such a way that they stimulate the formation of neutrophils from these
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progenitor cells. There are a number of reasons why this may occur and these are 
discussed later in section 10.3.1. Recombinant human IL-11 and rh IL-6 also have the 
ability to alter the constituent cells of the CFU-A colony and again IL-6 has a more 
prominent effect than IL -ll. Interestingly, these abilities of rh IL -ll and rh IL-6 to 
affect the inhibition of CFU-A colonies and the constituent cells of the colonies is not 
a function that is shared by all gpl30 signalling cytokines. Indeed, rh LIF does not 
share the activities of IL-11 or IL-6 observed above and this may be due to the lack of 
LIFRa sub-units expressed on the CFU-A stem cells.
8.4 Overall Summary of the Effects of CFU-A Growth Conditions on M IP-la  
Inhibition of CFU-A Colony Formation
Overall, it can be observed in these studies that rm SCF, rh M-CSF and rm GM-CSF 
are essential for the formation of CFU-A colonies. An increase or reduction in the 
stimulus through the tyrosine kinase and the (3 common signalling pathways by rh M- 
CSF/rm SCF and rm GM-CSF respectively, appear to minimally interfere with the 
inhibition of CFU-A colony formation by rm M IP-la. However, high concentrations 
of SCF and MCSF in the presence of low M IP-la concentrations were observed to 
increase CFU-A colony numbers. Furthermore, an increase in concentration of rm 
GM-CSF in the presence of rm M IP-la was observed to induce the formation of an 
alternative colony shape that may be induced through the activation of a signalling 
pathway through the chemokine receptor CCR-1. Upon the addition of gpl30 
signalling cytokines to the CFU-A assay, it was observed that rh IL-6 and rh IL-ll 
could reduce the number of CFU-A colonies produced and rh IL-6, but not rhIL-11, 
was observed to further reduce the colony number with the addition of rm M IP-la. 
Recombinant human LIF had no effect on colony number or inhibition by M IP-la 
and this maybe due to the level of receptor expression. The inability of rm SCF, rh 
M-CSF, rh IL-11 and rh LIF to interfere with rm M IP-la induced inhibition may be 
due to the CFU-A assay being an inappropriate system to analyse the effect of MIP- 
1 a  on the inhibition of the proliferation of CFU-A stem cells. The CFU-A assay by 
definition is examining the differentiation of CFU-A stem cells into CFU-A colonies 
and therefore, it may be possible to interfere with the inhibitory effect of M IP-la in a 
proliferation-based assay. Such a proliferation-based assay is described and examined 
in the chapter 9.
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CHAPTER 9
RESULTS 5 : Ex-Vivo Expansion
9.1 Introduction
In the previous chapters, the alterations in the growth factor concentration were 
observed to have a limited ability to interfere with the inhibition of CFU-A colony 
formation by MEP-la. This may be because there is a limited interaction between the 
growth promoting signalling and inhibitory signalling pathways, but it may also be 
due to the inappropriateness of the CFU-A assay. The CFU-A assay by definition 
examines the differentiation of CFU-A stem cells into CFU-A colonies. Therefore, it 
is possible that the role of rm SCF, rm GM-CSF and rh M-CSF is to prevent cell 
death, and upon doing so they allow the differentiation of the CFU-A stem cells and 
thus play a minimal role in the direct proliferation of the CFU-A stem cells. If this is 
the case, the effect of altering the growth factor concentrations on M IP-la responses 
may be easier to see in a short trem proliferative assay e.g ex-vivo expansion assay..
Cytokine treatment of murine bone marrow has been observed to be an alternative 
source of transiently engrafting haemopoietic stem cells but not primitive 
haemopoietic stem cells for transplantation after myeloablative therapy (Peters et al 
1996, Varas et al 1998). The characterisation of numerous cytokines involved in the 
control of haemopoiesis and, their potential use in ex-vivo cultures to expand stem and 
progenitor cells has established these growth factors not only as candidates for use in 
expanding cells prior to transplantation but also for gene therapy (Bernard et al 1994). 
In ex-vivo culture systems, combinations of synergistic growth factors are needed to 
provide signals that allow the stem cells to survive and proliferate. IL-3 and SCF 
have been observed to act as survival factors for dormant murine haemopoietic 
progenitor and stem cells (Katayama et al 1993, Bodine et al 1989). As well as acting 
as a survival factor, SCF in combination with IL-6, IL-11 and G-CSF has the ability 
to shorten the time that these cells spend in Go (Tsuji et al 1991). Prior to the cloning 
of SCF, the most potent combination of synergising growth factors was IL-3 and IL-6 
(Bodine et al 1989) however, with the identification and inclusion of SCF in these 
expansion protocols an even greater expansion of stem and progenitor cells could be 
produced (Bodine et al 1992). Fit 3 ligand, signals through its receptor Flk 2, which
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is a member of the tyrosine kinase family, is another early acting cytokine (Zeigler et 
al 1994). Similar to SCF, Fit 3 has been observed to produce strong synergy when 
combined with ligands that signal through the hematopoietin family of receptors (G- 
CSF, GM-CSF, IL-3, IL-6, IL-11 and IL-12) (Haylock et al 1997, Kobari et al 1998). 
A less potent synergy was found when Flt3 was used in combination with growth 
factors that signal through other members of the tyrosine kinase family, eg SCF or M- 
CSF. Therefore, the activation of a tyrosine kinase receptor pathway along with the 
activation of a hematopoietin receptor pathway, by their several ligands, produces a 
larger expansion of stem and progenitor cells compared to the activation of two 
similar receptor signalling pathways.
9.2 Ex-vivo Expansion
9.2.1 Expansion of CFU-A Stem Cells
Holyoake et al previously optimised the ex-vivo culture conditions that allowed the 
amplification of murine transiently engrafting stem cells, as measured by the CFU-A 
assay (Holyoake et al 1996). Using a variety of single growth factors or a 
combination of growth factors, they observed that the most impressive amplification 
was consistently obtained with rm SCF and rh IL-11 at 18 and 100 ng/ml respectively. 
To confirm this a number of expansion experiments were performed, 2 x 105 
unfractionated murine bone marrow cells were cultured in a-MEM supplemented 
with 25 % DHS and grown in 35 mm petri dishes for 6 days in the presence of various 
single growth factors or combinations of these growth factors. These ex-vivo 
expansion experiments have been repeated several times and the results of one is 
outlined in figures 9.1 and 9.2. CFU-A colony production was enumerated before and 
after the expansion and the amplification factor was derived using this equation:
Number of cells of normal bone marrow plated Number of CFU-A colonies in expanded bone marrow
Number of cells of expanded bone marrow plated Number of CFU-A colonies in normal bone marrow
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Fig 9.1
Amplification factor
Figure 9.1 Colony Forming Unit Analysis of the expansion of CFU-A stem cells by 
various single growth factors and combinations of growth factors
Unfractionated bone marrow was cultured for 6 days in a-MEM media. Cytokines were 
added either singly or in combination at the start of the culture. mSCF at 18 ng/ml, rhIL-11 
100 ng/ml, rmM IP-la 100 ng/ml, mSCF and rhIL-11 or rm SCF, rh IL-11 and rmMIP-la. 
Unfractionated bone marrow or expanded cells were plated in CFU-A assay that contained 6 
ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml rm GM-CSF. The amplification factor is 
shown for each treatment. This assay is a representative result from five replicate 
experiments.
I  Medium B  M IP-la 100 ng/ml
B  SCF 18 ng/ml B  SCF 18 ng/ml and IL-11 100 ng/ml
□  IL-ll 100 ng/ml E3 SCF 18 ng/ml, IL-11 100 ng/ml and 100 ng/ml M IP-la
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Fig 9.2
Figure 9.2 Morphological analysis o f expanded CFU-A colonies by photography
Photographs o f  CFU-A colonies were produced as described in materials and methods. The CFU-A 
colonies were stained with 1NT and incubated overnight. This assay contains the normal 
concentrations o f  the three basic growth factors within the CFU-A assay 12 ng/ml rm SCF, 6 ng/ml rh 
M-CSF and 0.2 ng/ml rm GM -CSF.
Plate 4
SC F.Ib-11 ,M1P-1 
18,100,100 ng/mi 
5x10e2
Plate 7 
MIP-1 a 
100 ng/ml 
5x10e2
Plate 6 
SCF 
18 ngtri 
5x10e2
Plate 1
Control
5xl0e3
Plate 5 
IL-ll  
lOOng'ni 
5x10e2
Plate 2 
Media 
5x10e2
Plate 3
SCF & I d  1 
18 &100 ngtnl 
5x10e2
The plate 1 is the control CFU-A assay containing unfractionated non expanded cells plated at a final 
concentration o f  5000 cells / plate.
In the top row plate 2 contains cells grown for 6 days in media alone and plated at a final concentration 
o f 500 cells / plate.
The plate 3 contains cells grown for 6 days in 18 ng/ml o f mSCF and 100 ng/ml rhlL-1 land plated at a 
final concentration o f  500 cells / plate.
The plate 4 contains cells grown for 6 days in 18 ng/ml o f  rm SCF and 100 ng/ml o f  rh IL -11 and 100 
ng/ml M IP - la  and plated at a final concentration o f  500 cells / plate.
In the lower row the plate 5contains cells grown for 6 days in 100 ng/ml rh IL -11 plated at a final 
concentration o f  500 cells / plate.
The plate 6 contains cells grown for 6 days in 18 ng/ml o f  rm SCF and plated at a final concentration o f  
500 cells / plate.
The plate 7 contains cells grown for 6 days in 100 ng/ml o f  M IP - la  and plated at a final concentration 
o f  500 cells / plate.
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The incubation of unfractionated bone marrow in a-MEM alone or with rh IL -ll or 
rm M IP-la could not produce any significant amplification of CFU-A stem cell 
numbers. The only single growth factor to produce an amplification of CFU-A 
numbers was rm SCF; however, the amplification was never as great as that observed 
with the combination of SCF and IL-11. The effect of the addition of rm M IP-la to 
the expansion of CFU-A stem cells numbers by rm SCF and rh IL-11 was examined 
next. M IP-la has been shown to have bi-directional effects (i.e. stimulatory or 
inhibitory) depending on the maturation stage of the target population, this is also the 
case for TGF-fh The further addition of 100 ng/ml of rm M IP-la a concentration 
known to inhibit CFU-A colony production in soft agar assays, to the expansion 
cocktail of rm SCF and rh IL -ll produced no positive or negative effects on the 
amplification of CFU-A numbers (figure 9.1). This result indicated that the 
synergistic activity of rm SCF and rh IL -ll could somehow interfere with the 
inhibitory activity of M IP-la. Alternatively it is possible that the action of SCF or 
IL -ll on the constituent cells of the bone marrow induce the production of another 
factor/s that interfere with the M IP-la inhibition of CFU-A colony formation. The 
prepartion of conditioned media form the expanded bone marrow and the examination 
of its effect to interfere with M IP-la inhibtion of CFU-A colony formation would be 
an ideal experiment to analyse this effect, however due to time restraints this was not 
examined.
9.2.2 The Effects of Various Sources of SCF on the Expansion of CFU-A Stem 
Cells
The SCF used in these expansion experiments was in medium conditioned by CHO 
cells expressing soluble kit ligand (Anderson et al 1990). Due to the possibility that 
unknown factors within the conditioned media could be producing this expansion by 
synergising with SCF, the expansion of CFU-A stem cells using recombinant human 
and murine SCF + rh IL-11 was compared to the combination of CM SCF and IL-11. 
In figure 9.3, it can be observed that human SCF in combination with IL-11 produced 
a small amplification of CFU-A numbers, whereas rm SCF/IL-11 and CM SCF/IL-11 
could produce an approximately 40-fold amplification in CFU-A stem cells. This 
inability of cross species activity has been observed before for SCF. These results 
suggest that the impurities that may exist within the CM do not enhance the expansion 
of CFU-A stem cells by SCF and IL-11, in fact they may slightly reduce it. Therefore,
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Fig 9.3
Amplification factor
Figure 9.3 Colony Forming Unit Agar analysis of the expansion of CFU-A stem cells rh 
IL-ll and various sources of SCF
Unfractionated bone marrow was cultured for 6 days in a-MEM media. Combinations of 
rmSCF 18 ng/ml +IL-11 100 ng/ml, rhSCF 18 ng/ml +IL-11 100 ng/ml and conditioned 
media SCF 18 ng/ml +IL-11 100 ng/ml were added at the start of the culture. Expanded cells 
were plated in CFU-A assay that contained 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 
ng/ml rm GM-CSF. Conditioned media is from CHO cells (Anderson et al 1990). The 
amplification factor is shown for each treatment. This assay is a representative result from 
five replicate experiments.
□  rm SCF + IL-ll 
■  rh SCF + IL-ll
□  cm SCF + IL-ll
2 2 0
it seems that the amplification in CFU-A stem cells observed in these experiment is 
likely to be due the synergism between SCF and IL-11, (figure 9.3).
9.2.3 The Effect of M IP-la on the Expansion of CFU-A Stem Cells
The ability of the synergistic combination of SCF and IL-11 to interfere with the MIP- 
l a  induced inhibitory pathway was further analysed in figure 9.4. A CFU-A assay 
was set up to examine the effects of a dose response of M IP-la on the inhibition of 
formation of CFU-A colonies from normal bone marrow and expanded bone marrow. 
Bone marrow cells were incubated for 6 days with SCF and IL-11, the expanded cells 
were then harvested, washed and plated in a CFU-A assay in the presence of 0.5, 1, 5, 
10, 50 and 100 ng/ml of M IP-la and compared to a CFU-A assay using non 
expanded bone marrow. From the results in figure 9.4, it can be observed that only 
M IP-la at 100 and 50 ng/ml can inhibit the formation of CFU-A colonies from 
normal bone marrow. However, on the analysis of the inhibition of CFU-A colony 
formation by M IP-la on expanded bone marrow cells, it can be observed that 50 
ng/ml of M IP-la can not induce inhibition of CFU-A colony formation. Also MIP- 
l a  at 100 ng/ml can only reduce the formation of CFU-A colonies by 70 % compared 
to that of 100 % in the normal CFU-A assay. These results further indicate that the 
expansion of bone marrow with rm SCF and rh IL-11 can somehow interfere with the 
inhibitory property of rm M IP-la. Interestingly, the morphology of the CFU-A 
colonies produced from the expanded bone marrow in CFU-A assays containing 0.5, 
1,5, 10 and 50 ng/ml of M IP-la were similar to the alternative colonies described in 
section 7.2.3.
9.2.4 The Effect of TGF-p on the Expanded CFU-A Stem Cells
M IP-la is not the only molecule that has been observed to inhibit the formation of 
CFU-A colonies, TGF-P has also been observed to possess inhibitory properties with 
respect to CFU-A colony formation. Therefore, a further experiment was set up to see 
if the expansion of bone marrow by rm SCF and rh IL -ll could render the CFU-A 
stem cells unresponsive towards TGF-p. Bone marrow cells were expanded, as 
previously described, and 5000 normal bone marrow cells/plate or 500 expanded bone 
marrow cells /plate were grown in the CFU-A assay in the presence and absence of 
either M IP-la or TGF-p at 100 ng/ml. From figure 9.5, it can be observed that both
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Figure 9.4 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la on the 
CFU-A colony production of normal and expanded bone marrow
Bone marrow was expanded for 6 days by incubating with 18 ng/ml of rmSCF and rhlOO 
ng/ml of IL-11, washed and counted. 5000 normal bone marrow cells and 500 expanded bone 
marrow cells were plated in a CFU-A assay containing M IP-la at 0.5, 1,5, 10, 50 and 100 
ng/ml and rm GM-CSF (0.2 ng/ml), rh M-CSF (6 ng/ml) and 12 ng/ml of rm SCF and these 
are represented in A and B respectively. The average colony production ( + SEM) is shown 
for 5 plates. This assay is a representative result from three replicate experiments. Students 
T-test was performed comparing control (normal bone marrow) to all the other plates 
containing the various M IP-la concentrations (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 
0 .001).
□  Control H  5 ng/ml M IP-la
■  100 ng/ml M IP-la □  1 ng/ml M IP-la
□  50 ng/ml M IP-la ■  0.5 ng/ml M IP-la
□  10 ng/ml M IP-la
2 2 2
Fig 9.5
Figure 9.5 Colony Forming Unit Agar (CFU-A) analysis of the effect of M IP-la and 
TGF-P on CFU-A stem cells that have been expanded by mSCF and rhIL-11 
treatment.
CFU-A stem cells were routinely expanded by incubating unfractionated bone marrow cells 
in 18 ng/ml of m SCF and 100 ng/ml of rh IL-11. The effect of 100 ng/ml of M IP-la and 
TGF-P (two known inhibitors of CFU-A colonies) on the CFU-A formation was examined in 
a CFU-A assay containing 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml rm GM-CSF. 
The average colony production (+ SEM) is shown for 5 plates. This assay is a representative 
result from three replicate experiments. Students T-test was performed comparing controls to 
all the treatments (*1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
H  Expanded bone marrow 
■  Expanded cells 100 ng/ml M IP-la 
B  Expanded cells 100 ng/ml TGF-p
f l  Control
B  100 ng/ml M IP-la 
□  100 ng/ml TGF-P
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M IP-la and TGF-p can inhibit the formation of normal CFU-A colonies equally (p <
0.001). However, M IP-la was not as effective at inhibiting the formation of CFU-A 
colonies in assays using expanded bone marrow cells. M IP-la could only inhibit 20 
% of the CFU-A colony formation in assays using expanded bone marrow compared 
to that of 90 % in assays using normal bone marrow. TGF-p can however, inhibit the 
formation of CFU-A colonies from expanded stem cells. From these results, TGF-p 
can be observed to inhibit the formation of CFU-A colonies in both normal and 
expanded bone marrow therefore, the expansion of stem cells by rm SCF and rh IL-11 
in some way is specifically interfering with the inhibitory action of M IP-la.
9.2.5 Receptor Expression of Lineage Depleted Normal and Expanded Bone 
Marrow Cells
It was hypothesised that this inability of M IP-la to inhibit CFU-A colony formation 
after the expansion of CFU-A stem cells by rm SCF and rh IL-11 may be due to down 
regulation of the M IP-la inhibitory receptor. Therefore, the expression of messenger 
RNA for the various known M IP-la receptors was examined in a lineage-depleted 
population of normal and expanded bone marrow. Lineage depletion was performed 
on normal and expanded bone marrow cells in an attempt to produce a more 
comparable cellular population. Bone marrow and expanded CFU-A stem cells were 
firstly depleted of cells that expressed the mature lineage markers B220, Gr-1, 
Ter 119, CD4, CD5 and CD8, and then total RNA was isolated from these lineage 
negative cells. 20 pg of total RNA from both cell samples were separated on an 
agarose gel and then immobilised on Hybond N membranes. These RNA populations 
were then examined for the expression of four CC chemokine receptors namely CCR-
1, CCR-3, CCR-5 and D6. The message for CCR-3 and D6 receptors could not be 
detected by this method however, as observed in figure 9.6, both CCR-1 and 5 could 
be detected in both lineage depleted populations, the expression of P-actin, the house 
keeping gene, was used as a loading control. Two bands of 2.8 kb and 3.7 kb were 
detected when both populations were probed for CCR-5 expression and these sizes 
compare favourably to that of 3.1 and 4 kb that was initially reported by Meyer et al 
(Meyer et al 1996). The results from figure 9.6, indicate that CCR-5 levels are 
unaltered in the expanded bone marrow lineage negative population.
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Fig 9.6
CCR-5
P-Actin
Figure 9.6 Northern blot analysis of the expression of chemokine receptors CCR-1, 5 
and D6 after the expansion of CFU-A stem cells.
Bone marrow and expanded cells were firstly enriched for lineage negative populations. This 
was to ensure that both populations were similar to each other in cell types. 20 |ig of total 
RNA from each lin' population was immobilised on each blot. The expression of CCR-1, 5 
and D6 along with (3-actin was examined; CCR3 and D6 could not be detected. This blot was 
stripped and reprobed after each hybridisation and the levels of loading were checked via 
ethidium bromide staining on the gel.
Column 1 shows RNA from lin' enriched bone marrow cells 
Column 2 shows RNA from lin' enriched expanded cells
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However, on the examination of CCR-1 receptor expression, it was observed that the 
levels of its mRNA were slightly increased in the expanded stem cells compared to 
the lineage depleted bone marrow cells. Two bands of 3.0 and 2.4 kb were observed 
after the blot was stripped and reprobed for CCR-1 expression. Gao et al identified 
three different specific mRNA bands in mouse leukocytes, which corresponded to 
mCCR-1, the major band was 2.4 kb, whereas the two minor bands were 3.7 and 6.0 
kb. They suggested that the major 2.4 kb band appears as a broad band and therefore, 
it maybe made up of a collection of mRNA species (Gao et al 1995). The broad band 
may explain the isolation of the 3.0 kb band in figure 9.6, and the inability to detect 
the other minor bands maybe due to the isolation of RNA from different cellular 
populations. As described earlier in section 7.2.3, CFU-A colonies produced from 
expanded bone marrow and treated with rm M IP-la were observed to display the 
alternative shape that was initially identified with high levels of rm GM-CSF. The 
formation of these alternative colonies and the increase in CCR-1 expression levels 
upon expansion of the bone marrow provides further evidence that CCR-1 may be 
involved in the formation of these alternatively shaped CFU-A colonies.
9.2.6 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Analysis of 
CCR-3 and D6 Expression in Lineage Depleted Normal and Expanded 
Bone Marrow Cells
As indicated above northern blot analysis failed to reveal detectable expression of 
mRNA for the M IP-la receptors CCR-3 and D6. The highly sensitive technique of 
reverse transcriptase polymerase chain reaction (RT-PCR) was therefore, used in an 
attempt to examine the expression of these receptors in lineage depleted bone marrow 
and expanded bone marrow. 1 pg of total RNA from each sample was used and the 
results are shown in figure 9.7, p-actin was used as a positive control and can be 
detected in both populations as a 247 bp band. The CCR-3 and D6 primers (section 
3.13) used in the PCR reaction define fragments of 280 and 380 base pairs 
respectively. Although, the P-actin controls are uneven, it does indicate that CCR-3 
and D6 can only be detected in the lineage depleted RNA from bone marrow and not 
in the lineage depleted RNA from the expanded stem cells, (figure 9.7). These results 
suggest that if the down regulation of the protein levels of D6 and CCR-3 are similar
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Fig 9.7
- / + RT Controls BM Lin- RNA Expanded Lin- RNA
1 2 3 4 5 6  1 2 3 4 5 6  1 2 3 4 5 6
(3-actin p-actin
Figure 9.7 RT-PCR analysis of the expression of chemokine receptors CCR- 3 and D6 
after the expansion of CFU-A stem cells
A master mix was made and split into + RT and - RT and reverse transcribed. A further PCR 
master mix was made up and divided up equally before the addition of + RT, -RT, no RNA or 
the different RNA samples and this was amplified up via 30 cycles of PCR as described in the 
materials and methods, lpg of RNA was used from lineage enriched bone marrow and 
expanded cells. The primers that were used in the PCR reaction for CCR-3 and D6 will 
recognise bands of 280bp and 380bp respectively.
+ /- R T B on e M a rro w E x p a n d ed  C ells
Lane 1 (3-actin no RNA (3-actin no RNA (3-actin no RNA
Lane 2 (3-actin RNA (3-actin RNA (3-actin RNA
Lane 3 D6 no RNA D6 no RNA D6 no RNA
Lane 4 D6 RNA D6RNA D6 RNA
Lane 5 CCR-3 no RNA CCR-3 no RNA CCR-3 no RNA
Lane 6 CCR-3 RNA CCR-3 RNA CCR-3 RNA
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to the RNA levels that either of these receptors may be the M IP-la inhibitory 
receptor (see section 9.2.7 and in the discussion).
9.2.7 CCR-3 and D6 as possible Candidates for the Inhibitory Receptor
Both D6 and CCR-3 were down regulated when CFU-A stem cells are expanded and, 
as these expanded stem cells are unresponsive to M IP-la it may be that either D6 or 
CCR-3 are in fact the inhibitory receptor. Recent work within our group comparing 
the inhibition of CFU-A colony formation using normal and D6 null mice bone 
marrow by M IP-la, indicated that D6 is not the receptor that is responsible for the 
inhibitory activity of M IP-la. As CCR3 null mice have yet to be made available, the 
analysis of the effect of M IP-la on CFU-A colony formation from CCR3 bone 
marrow could not be performed. Therefore, a further experiment was set up to 
examine the role of CCR3 in M IP-la inhibition of CFU-A colony formation. Murine 
Eotaxin does not inhibit CFU-A colony formation, Ottersbach personal 
communication, and displays a higher affinity for CCR3 than mM IP-la, Nibbs 
personal communication. Therefore in an assay containing both Eotaxin and MIP- 
la ,  Eotaxin will prevent M IP-la from binding to CCR-3 and thus producing an 
inhibitory signal, that is if CCR-3 is in fact the inhibitory receptor used by M IP-la. 
A CFU-A assay was performed containing a ten fold higher concentration of eotaxin 
(1 fig/ml) than M IP-la (100 ng/ml). Eotaxin at ljig/ml could not inhibit CFU-A 
colony formation and M IP-la alone or in the presence of 1 jog/ml of Eotaxin could 
still inhibit CFU-A colony formation (figure 9.8). Therefore, these experiments 
indicate that M IP-la must be inducing its inhibitory activity through a receptor other 
than CCR-3.
9.2.8 Summary
In summary, the expansion of bone marrow cells with rm SCF and rh IL-11 interferes 
with the ability of rm M IP-la, but not rm TGF-P, to inhibit the proliferation and 
formation of CFU-A colonies. On analysis of M IP-la receptor expression on rm SCF 
and rh IL-11 expanded stem cells it was also observed that CCR-3 and D6 receptor
228
Fig 9.8
</>
<ZJ
•P p
Co
15-,
©3 1 0 -0
U
<1
u
o>
iS
a
5 -
0
Figure 9.8 Colony Forming Unit Agar (CFU-A) analysis of the effect of Eotaxin and 
M IP-la on the formation of CFU-A colonies
A CFU-A assay was set up that contained 6 ng/ml rh M-CSF, 12 ng/ml rm SCF and 0.2 ng/ml 
rm GM-CSF. To this was added either nothing, lOOng/ml of M IP-la, 1 jug/ml Eotaxin or 
lOOng/ml of M IP-la and 1 jig/ml Eotaxin. The average colony production ( + SEM) is shown 
for 5 plates. This is a single experiment. Students T-test was performed comparing controls 
to all the treatments (* 1 = P < 0.05, *2 = P < 0.01 and *3 = P < 0.001)
Q Control
■  100 ng/ml M IP-la
□  100 ng/ml MIP-1 a  + 1 jig/ml Eotaxin
□  1 pg/ml Eotaxin
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levels were down regulated whereas, CCR-5 levels were unchanged and CCR-1 is up 
regulated. These results indicate that the expansion of CFU-A stem cells by rm SCF 
and rh IL -ll not only renders the CFU-A stem cells unresponsive to the inhibitory 
effect of M IP-la, it also down regulates the expression of CCR-3 and D6 and up 
regulates the expression of CCR-1. These effects produced by expanding bone 
marrow by cytokine treatment may therefore, alter the response of the cells within the 
expanded population to the various chemokines.
10.0 DISCUSSION
10.1 Introduction
Our group is interested in chemokines, especially M IP-la and its role as a 
haemopoietic stem cell inhibitor. M IP-la was originally purified and characterised as 
a stem cell inhibitor, within our group, and further studies have indicated possible 
mechanisms for regulating the levels of M IP-la in-vivo (Graham et al 1990, Maltman 
et al 1993 and 1996, Jarmin et al 1999). Although there has been a rapid expansion 
of the chemokine field in recent years, including the identification of various M IP-la 
receptors, this has not enhanced our understanding of how M IP-la induces the 
inhibition of CFU-A stem cell proliferation. Therefore, in this thesis I have attempted 
to examine how M IP-la exerts its inhibitory activity at the molecular level, and 
whether altering the CFU-A growth factor concentrations could interfere with the 
M IP-la induced inhibition of CFU-A colony formation.
From the results described in chapter 5, it can be concluded that the subtractive 
hybridisation was unsuccessful. Indeed, the two stem cell lines that were examined 
were deemed inappropriate for the study of M IP-la inhibition, and the analysis of the 
cDNA isolated from the subtractive hybridisation indicated that the subtraction had 
not efficiently removed common genes. This therefore led to a change of direction 
aimed at examining if it was possible to interfere with M IP-la inhibition of CFU-A 
colony formation by altering the CFU-A growth conditions and to attempt to infer 
from these results, modes of actions for M IP-la.
10.2 CFU-A Growth Factor Alteration
10.2.1 The Effect of Omission of SCF on CFU-A Colony Formation
Before investigating the effect of growth factor concentration on M IP-la inhibition of 
CFU-A colony formation, it was deemed necessary to firstly examine the effect of 
growth factor concentration on the formation of CFU-A colonies themselves. In the 
first experiment, the omission of SCF from the CFU-A assay was observed to produce 
a low level of CFU-A colony formation, compared to that of assays containing normal
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levels of SCF (figure 6.3). This result confirmed the previous observation by Pragnell 
et al, who observed that, as well as GM-CSF and M-CSF, SCF is needed for optimal 
CFU-A colony growth (Pragnell et al 1994). Other studies examining the colony 
formation of human or murine haemopoietic stem and progenitor cells, have reported 
that SCF on its own has limited ability to induce colony formation. However, in 
combination with various growth factors SCF has been reported to increase the 
number and size of progenitor colonies (Broxmeyer et al 1991a, b, McNiece et al 
1991a, b). These studies suggested that SCF enhances the proliferative response of 
progenitor cells to the other growth factors in the assays. Therefore, if this were the 
role that SCF plays within the CFU-A assay, this would explain the reduction in 
colony formation observed in figure 6.3 upon the omission of SCF. It is also possible 
that another function of SCF may explain the reduction in colony formation observed 
in figure 6.3. SCF has been observed to act as a survival factor for various cell types 
such as NK cells, mast cells, myelomonocytic cell lines and both human and murine 
stem and progenitor cells (Carson et al 1994, Gommerman and Berger 1998, Borge et 
al 1997, Li et al 1994). Therefore, it may be that within the context of the CFU-A 
assay, SCF functions to promote the survival of the CFU-A stem cells. However, as a 
small number of CFU-A colonies are produced in the absence of SCF, it may be that 
SCF is not acting as a survival factor and its main activity may be to enhance the 
proliferative response to other growth factors within the CFU-A assay. Although it is 
possible that GM-CSF or M-CSF may induce CFU-A stem cell survival in the 
absence of SCF, it is also feasible that the colonies observed in the CFU-A assays, in 
the absence of SCF, may have arisen from the increased growth of progenitor cells. 
Indeed, McNiece et al reported that M-CSF promoted the proliferation of a subset of 
HPP-CFC progenitors known as HPP-CFC-3 cells (McNiece et al 1988). Therefore, 
it may be that the interaction of M-CSF and GM-CSF in these CFU-A assays induces 
the growth of these colonies, such that they display CFU-A characteristics. However, 
further studies are needed to examine the origin of these colonies produced in the 
CFU-A assays in the absence of SCF.
10.2.2 The Effect of Altering SCF Levels on CFU-A Colony Formation
The reduction of SCF concentration from 12 ng/ml in ten fold steps has minimal 
effects on CFU-A colony formation, until the SCF concentration was reduced to 1.2
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pg/ml, where CFU-A colony formation was reduced by 50% (figure 6.3). As 
mentioned in section 10.2.1, this may be explained by the decrease in SCFs ability to 
induce cell survival or even due to the reduction in synergistic interactions with the 
other CFU-A growth factors.
Interestingly, it was observed that a 10-fold increase in SCF above normal 
concentrations reduced the level of CFU-A colony formation (figure 6.3). Analysis of 
the constituent cells of the CFU-A colonies produced in assays containing high levels 
of SCF, indicated that high levels of SCF decreased the number of cells in the CFU-A 
colonies and also slightly increased the number of blast cells contained in these 
colonies (Table 4). Although SCF has been observed to display a limited ability to 
stimulate colony formation, a study by Metcalf et al observed that SCF could 
stimulate colony formation from bone marrow cells, but only at 1000 fold higher 
concentration than observed with other colony stimulating factors. Further analysis of 
these colonies indicated that they were small and contained anywhere in the region of 
50-800 cells, and could be described as either blast, immature granulocytic or mature 
granulocytic colonies (Metcalf et al 1991a). This report provides evidence to suggest 
that high levels of SCF may support the formation of blast, immature granulocytic or 
mature granulocytic type of colonies within the CFU-A assays. Alternatively, the 
high levels of SCF may interact with the progenitor cells within the developing CFU- 
A colony and this may alter the constituent cells of the CFU-A colony. These 
hypothetical situations may explain the smaller colonies within the CFU-A assays that 
display a similar appearance to M IP-la inhibited CFU-A colonies. Another report by 
Broxmeyer and colleagues suggested that, as the combination of GM-CSF and SCF 
increased the size of normal CFU-GM colonies compared to GM-CSF alone, SCF 
might serve to promote renewal and expansion of responsive progenitor cells within 
CFU-GM colonies (Broxmeyer et al 1991b). Therefore, it is possible that the high 
levels of SCF may produce a signal that can induce renewal of the CFU-A stem cells 
at the expense of differentiation, and this may account for the small increase in blast 
cells, and the decrease in CFU-A colony numbers observed in table 4. In an attempt 
to examine this possible self-renewal effect further, CFU-A colonies grown in the 
various SCF concentrations were picked and replated in a secondary CFU-A assay. 
The results from these assays were inconclusive, therefore, further analysis is needed 
to examine if high levels of SCF can reduce the CFU-A colony size by increasing 
self-renewal of the CFU-A stem cells at the expense of differentiation.
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Alternatively, it was proposed that the reduction in the cellular content of the CFU-A 
colonies and the reduction in their colony numbers, as observed in table 4 and figures
6.3 and 6.5f, were due to the increase in expression of a growth inhibitor either 
directly or indirectly by the high levels of SCF. The mature cells within the bone 
marrow or the CFU-A colonies are not the only potential source of inhibitory 
molecules, as a recent study indicated that haemopoietic stem and progenitor cells 
also produce M IP-la (Majka et al 1999). Therefore, it is possible that the bone 
marrow stroma cells, the mature blood cells or the progenitor cells can act as the 
source of inhibitory cytokines. However, experiments using a M IP-la neutralising 
antibody, and bone marrow from M IP-la null mice, indicated that the high levels of 
SCF did not produce the reduction in CFU-A colony number by increasing the 
production in M IP-la (figure 6.7 and 6.9). Furthermore, expression studies also 
indicated that high levels of SCF could not induce M IP-la expression in monocytic 
cell lines or bone marrow macrophages (figures 6.11, 6.12 and 6.13). Although these 
studies indicate that SCF does not reduce the CFU-A colony numbers, by increasing 
the expression of M IP-la, it does not rule out the possibility that SCF may increase 
the expression of other growth inhibitory molecules such as TGF-p, TNF-a, IFN-a or 
MIP-ip. Therefore, further work is needed to examine the role of this high level of 
SCF in the reduction of CFU-A colony formation
Interestingly, SCF has also been observed to promote the production of IL-6 from 
mast cells, and a more recent study indicated that SCF could induce the expression of 
IL-6 in bone marrow stromal cells (Lu-Kuo et al 1996, Rougier et al 1998). IL-6 in 
combination with SCF has been observed to stimulate the production of blast cell 
colonies and granulocytic colonies (Tsuji et al 1991). Furthermore, data presented in 
table 8 also indicates that the addition of IL-6 to a CFU-A assay alters the constituent 
cells of the CFU-A colonies. Therefore, if SCF can induce the production of IL-6 in 
the bone marrow cells, it is feasible that the interaction of IL-6 and the CFU-A growth 
factors may alter the constituent cells of the CFU-A colonies, in such a way that they 
appear smaller. Alternatively as IL-6, M-CSF and GM-CSF, in combination with 
SCF, can support the formation of HPP-CFC colonies (Kreigler et al 1994). It is 
therefore possible that the combination of these growth factors may lead to the 
preferential production HPP-CFC colonies at the expense of CFU-A colonies.
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As discussed above, there are several possible mechanisms that could have led to the 
reduction in the CFU-A colony formation in the assays containing high levels of SCF, 
and there are several experiments that could be performed to examine this effect 
further. The role of inhibitory molecules or growth factors in the reduction of the 
CFU-A colony formation could be analysed by adding specific neutralising antibodies 
to these growth factors or inhibitors to a CFU-A assay. A similar experiment using 
bone marrow from the null mice of growth factors suggested to be involved in the 
reduction of CFU-A colony numbers at high SCF concentrations (e.g. M IP-la, IL-6), 
may also indicate whether these factors play a role in the decreased colony formation 
in assays containing high levels of SCF.
10.2.3 The Effect of Altering SCF on M IP-la Activity
Reducing or increasing the concentration of SCF had no obvious effects on the overall 
ability of M IP-la to inhibit the formation of CFU-A colonies (figure 6.5). Thus it 
appears that the SCF signalling pathway minimally interacts with the MIP- 
l a  inhibitory signalling pathway.
Although the alteration of SCF concentration had no effect on M IP-la inhibition of 
CFU-A colony formation, high concentrations of SCF in the presence of low 
concentrations of M IP-la had a stimulatory effect on the numbers of CFU-A colonies 
(figure 6.5f). Despite this being the first report of M IP-la stimulatory effects on 
CFU-A colony formation, stimulation of haemopoietic cells is not a new phenomenon 
for M IP-la. Indeed, Keller et al previously reported that M IP-la can stimulate 
progenitor colony growth, and this stimulatory activity is dependent upon the 
particular maturation stage of the stem/progenitor cell and the growth conditions 
(Keller et al 1994). Furthermore, Broxmeyer et al also reported that M IP-la in 
combination with GM-CSF could enhance the colony growth of murine CFU-GM 
progenitors in normal mice (Broxmeyer et al 1989, 1990). Upon further examination 
of these effects, using bone marrow from CCR1 null mice, it was observed that MIP- 
l a  did not enhance the growth of these CFU-GM progenitors, suggesting that the 
interaction between M IP-la and CCR1 is essential for the growth promoting 
activities observed in the previous study (Broxmeyer et al 1999). As the interaction 
of M IP-la and CCR-1 has been observed to play a stimulatory role in CFU-GM
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colony formation, it is possible that this interaction may also stimulate CFU-A colony 
formation. Indeed, Jarmin et al reported that GM-CSF induces the production of 
CCR1 in bone marrow macrophages (Jarmin et al 1999). If high levels of SCF alone 
or in combination with GM-CSF can induce CCR1 expression on the CFU-A stem 
cells, it may be possible that the interaction of M IP-la and CCR1 is involved in this 
growth promotion of the CFU-A colonies. Alternatively, CCR1 levels may be 
increased on the bone marrow progenitor cells, and upon the interaction with M IP-la, 
this may induce progenitor colony growth to such an extent that these colonies display 
similar size characteristics as CFU-A colonies.
The models suggested above, do not explain why this increase in CFU-A colony 
numbers only occurs at low M IP-la concentrations. However, there are a number of 
possible reasons why this may occur. It may be due to different signalling through the 
different M IP-la receptors, such as CCR1 and the as yet unidentified M IP-la 
inhibitory receptor. Indeed, low concentrations of chemotaxins have been observed to 
induce the characteristic feature of cell motility, whereas, high concentrations can 
induce the release of pro-inflammatory mediators, and this has been observed to be 
due to differential use of G-proteins (Haribabu et al 1999). This suggests that 
different concentrations of chemotaxins may activate different signalling pathways 
and this may explain the observation that high concentrations of M IP-la inhibit CFU- 
A proliferation, whereas low concentrations are stimulatory in the presence of high 
SCF concentrations.
Interestingly, a report by Richardson et al indicated a further level of complexity in 
chemokine signalling. They observed that signalling through CXCR1 by IL-8 could 
cross desensitise the signalling potential through CCR1 (Richardson et al 2000). 
These reports described above, provide evidence that may be used to hypothesise on 
how M IP-la can exert different growth activities. Furthermore, our group has 
observed that concentrations of M IP-la lower than 50 ng/ml do not have the ability to 
inhibit CFU-A colony formation, suggesting the existence of an inhibitory 
concentration threshold that needs to be reached to activate the inhibitory signalling 
pathway. If upon activating this pathway, it has the effect of cross desensitising other 
M IP-la signalling pathways, this may explain why high levels of M IP-la only 
inhibit CFU-A formation and do not promote CFU-A colony growth. This
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hypothetical situation may also explain the CFU-A growth promotion in CFU-A 
assays containing high levels of SCF or M-CSF, and low concentrations of M IP-la. 
In these assays, the high levels of SCF or M-CSF alone or in combination with GM- 
CSF, may increase the levels of CCR1, a chemokine receptor previously observed to 
be involved in growth promotion (Broxmeyer et al 1999). The addition of low 
amounts of M IP-la, which do not exceed the concentration threshold and thus do not 
activate the inhibitory signalling pathway, will bind to the increased levels of CCR1 
and may lead to the observed increase in CFU-A colonies.
Further analysis of this growth stimulation is needed to examine whether this effect is 
regulated through the interaction of M IP-la and CCR1. The role of CCR1 in the 
stimulation of these CFU-A colonies could be examined by the analysis of CFU-A 
colony formation from CCR1 null bone marrow. Alternatively, the use of a CCR1 
antibody may also indicate that CCR1 is involved in the observed growth stimulation.
10.2.4 The Effect of Altering M-CSF Levels on CFU-A Colony Formation
Interestingly, the removal of M-CSF from the CFU-A assays produced a similar low 
level of CFU-A colony production, as observed in CFU-A assays containing no SCF 
(figure 6.4). The result of CFU-A colony formation in the absence of M-CSF concurs 
with a previous report by Pragnell et al, who observed that antisera to M-CSF was 
effective at inhibiting the production of CFU-A colonies by 92% (Pragnell et al 
1988). These observations therefore suggest that M-CSF is an essential growth factor 
for CFU-A colony formation. A report by Horiguchi indicated that GM-CSF could 
induce the production of M-CSF mRNA and protein in monocytes (Horiguchi et al 
1987). Therefore the residual level of CFU-A colony formation observed in figure
6.4 might be due to the induction of M-CSF in the bone marrow cells by GM-CSF. 
The reduction of M-CSF concentration in 10 fold steps from 6ng/ml to 6pg/ml was 
observed to produce a step wise reduction in CFU-A colony numbers, further 
indicating the importance of M-CSF in the formation of the CFU-A colonies (figure 
6.4).
Similar to the high SCF concentrations, the increased levels of M-CSF were observed 
to reduce CFU-A colony formation, therefore, suggesting that this common
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observation related to the fact that both of these growth factors signal through 
receptors that are members of the tyrosine kinase family. It was proposed that high 
levels of M-CSF produced its effects in a similar way to high levels of SCF. 
Therefore, the examination of the replating ability of CFU-A colonies, grown in high 
M-CSF, was performed. However, similar to assay containing high levels of SCF, the 
data produced was inconclusive and therefore, further replating experiments are 
needed to examine the potential role if any of high levels of M-CSF in self renewal of 
CFU-A stem cells. Alternatively, it was proposed that this reduction in colony 
formation, observed in high M-CSF concentrations, was due to the production of an 
inhibitory cytokine. Indeed, M-CSF is capable of inducing the expression of M IP-la 
in bone marrow macrophages Jarmin, personal communication. Furthermore, M-CSF 
has also been observed to induce the expression of several growth factors, cytokines 
and inhibitory molecules such as IL-6, G-CSF, GM-CSF, M-CSF, IFN and IL-8 from 
human monocytes (Motoyoshi et al 1989, Kamdar e t  al 1997, Warren e t  al 1986, 
Hashimoto e t  al 1996). M-CSF has also been reported to induce the expression of 
TNF-a and increase mRNA levels of TGF-pl (Sakurai et al 1994, Wu et al 1997). 
Therefore, it is possible that high levels of M-CSF may produce the reduction in 
CFU-A colonies by the direct induction of expression of growth inhibitors. 
Alternatively, M-CSF may act on the various cell types within the bone marrow to 
induce the expression of other cytokines, who may be able to induce the expression of 
inhibitory molecules. Studies using M IP-la neutralising antibodies and bone marrow 
from M IP-la null mice indicated, that this reduction in CFU-A colony numbers in 
high M-CSF conditions was not due to the increased production of M IP-la (figure 
6.8 and 6.10). Although these studies indicate that high levels of M-CSF do not 
increase the expression of M IP-la, it does not rule out the possibility of high levels of 
M-CSF inducing the production of other inhibitory molecules.
10.2.5 The Effect of Altering M-CSF Levels on M IP-la Activity
Similar to the alteration in SCF concentration, reducing or increasing the 
concentration of M-CSF had no obvious effects on the overall ability of M IP-la to 
inhibit the formation of CFU-A colonies (figure 6.6). Pragnell previously reported 
data that CFU-A colonies are predominantly made up of macrophages (Pragnell et al 
1994) and this was confirmed by data reported in table 5. Similar to high levels of
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SCF, high levels of M-CSF were observed to reduce the CFU-A colony formation, 
and in conjunction with low levels of M IP-la, high levels of M-CSF have been 
shown to stimulate CFU-A colony formation. This data therefore suggested that these 
similar effects observed with SCF and M-CSF may be produced via similar signalling 
pathways.
The further analysis of the role M-CSF plays in the CFU-A assays would be similar to 
the ones suggested in sections 10.2.2 and 10.2.3. The ability of M-CSF to reduce 
CFU-A colonies, by the induction of expression of other growth regulators, could be 
examined by the incorporation of neutralising antibodies to these factors within the 
CFU-A assays. Alternatively, using bone marrow from these growth regulator null 
mice similar experiments could be performed. Furthermore, in section 10.2.4 it was 
suggested that GM-CSF could induce the expression of M-CSF, this effect may 
explain the CFU-A colony formation in the absence of M-CSF. This effect could be 
analysed further by the examination of CFU-A colony formation from the bone 
marrow of op/op mice in the absence of M-CSF.
10.2.6 The Effect of Alterating GM-CSF Levels on CFU-A Colony Formation 
and MIP-1 a  Activity
The omission of GM-CSF from the CFU-A assays results in the inability of CFU-A 
stem cells to produce colonies indicating that GM-CSF is essential for the formation 
of CFU-A colonies (figure 7.1). Furthermore, the essential role of GM-CSF was 
confirmed upon the observation that 1000 fold lower than normal levels of GM-CSF 
could not promote CFU-A colony formation, and CFU-A colonies were produced 
only after a further 10 fold increase in GM-CSF concentration. Similar to SCF and 
M-CSF, the alteration of GM-CSF concentration displayed a minimal affect on the 
inhibitory activity of M IP-la therefore suggesting that GM-CSF, like SCF and M- 
CSF, signalling pathways are limited in their interaction with the M IP-la inhibitory 
signalling pathways.
Upon analysis of CFU-A assays containing 10 and 100 fold normal GM-CSF 
concentrations in the presence of 50 ng/ml of M IP-la, an interesting alternative 
colony shape was consistently observed. These colonies are similar in size to normal
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CFU-A colonies, however, they displayed a more defined edge compared to the 
normal CFU-A colonies (figure 7.3 A and B). On further analysis of the assay plates 
containing the alternative colonies, it was observed that these alternative colonies 
appeared half-spherical in shape and, unlike normal colonies, were embedded in the 
two layers of the CFU-A assay. Furthermore, these alternative colonies have a 
defined central region, and what appears to be a leading edge of cells, that may be 
produced by cells moving away from the central area (figure 7.4 C and D). Jarmin et 
al reported that GM-CSF and IL-3 could enhance the expression of CCR1 on the 
surface of bone marrow macrophages (Jarmin et al 1999). Interestingly, a possible 
role for CCR1 in growth promotion was observed by Broxmeyer et al who reported 
that CCR1 is the receptor that is involved in the stimulation of CFU-GM colony 
formation by M IP-la (Broxmeyer et al 1999). Therefore, it may be possible that the 
interaction of M IP-la with the increased levels of CCR1, induced by high levels of 
GM-CSF, may be involved in this alternative CFU-A colony shape.
In an attempt to examine if CCR1 was involved in the formation of these alternative 
colonies, HepMut (a variant of M IP-la) was added to CFU-A assays containing high 
levels of GM-CSF. Graham et al previously reported that HepMut was as potent as 
M IP-la at inhibiting CFU-A colony formation, however, unlike M IP-la, it could not 
bindtoCC Rl (Graham et al 1996). Although HepMut was observed to inhibit CFU- 
A colony formation (figure 7.5), it did not produce the alternatively shaped colonies, 
suggesting that CCR1 is involved in the formation of the alternative colonies (data not 
shown). Further analysis of other CCR1 ligands revealed that RANTES and MCP-3 
were unable to induce the formation of these alternative colonies. However high 
levels of HCC-1 were observed to induce the formation of these alternative colonies 
as well as inhibit the formation of CFU-A colonies (figure 7.8). The inability of the 
CCR1 ligands RANTES and MCP-3 to induce the formation of these alternative 
colonies suggests that M IP-la and HCC-1 somehow specifically induce the formation 
of these alternative colonies. This may be through an unknown CC chemokine 
receptor that is restricted to interact with M IP-la and HCC-1, and is up regulated by 
GM-CSF. However, further evidence to suggest that CCR1 is involved in the 
formation of these alternative colonies is described in chapter 9. The expansion of 
bone marrow with SCF and IL-11 for 6 days was observed to increase the expression 
of CCR1 (figure 9.6). Upon the incubation of these expanded cells in a CFU-A assay
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containing M IP-la, it was observed that the alternative colonies were produced at all 
concentrations except 100 ng/ml of M IP-la (data not shown). This provided further 
evidence to suggest that the interaction of M IP-la with the possible increased levels 
of CCR1, due to GM-CSF treatment, may be involved in the formation of these 
alternative colonies.
In a further attempt to understand how these alternative colonies are formed, an 
analysis of the constituent cells of these alternative CFU-A colonies was performed 
and the results in table 6, indicate that similar to normal CFU-A colonies, these 
alternative colonies predominantly consist of macrophages. However, interestingly 
the alternative colonies have a 4 % increase in the number of granulocytes compared 
to the normal CFU-A colonies when incubated in 10 x the normal levels of GM-CSF. 
Previous characterisation of CFU-GM colonies indicated that they have a tight central 
area consisting of neutrophils surrounded by a halo of macrophages. If as suggested 
by analysis of CFU-GM colonies the increase in granulocytes occurs at the central 
region of these alternative CFU-A colonies, this may explain the appearance of a 
defined central area (figure 7.4C and D). These centrally located granulocytes may 
also be the key to the other characteristic feature of these colonies i.e. the leading 
edge of cells that appear to be moving away from the centre of the colony. Indeed, a 
recent study by Cheng et al demonstrated that GM-CSF could induce the expression 
of CCR-1 on neutrophils (Cheng et al 2001). Therefore it may be possible that the 
stimulation of these granulocytes by M IP-la, through CCR1, enables these cells to 
produce some factor that repels the macrophages from the central region of these 
colonies and this in turn may lead to the formation of the outer edge of these 
alternative colonies. Chemokines are generally accepted as molecules that can induce 
movement of various types of leukocytes, whether it is random movement (which is 
referred to as chemokinesis) or controlled movement through a concentration gradient 
(which is known as chemotaxis). Until recently, chemokines have never been shown 
to induce cellular repulsion however, Poznansky et al observed that high 
concentrations of SDF-1 can induce the repulsion of T cells in-vitro and in-vivo 
(Poznansky et al 2000). They referred to this cell movement away from a high 
concentration of chemotactic agent as “chemofugetaxis”.
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From the various studies described above, a possible model for the generation of the 
alternative colonies is suggested below. Firstly, the high levels of GM-CSF are 
proposed to induce the expression of CCR1 on the centrally located granulocytic cells 
of the CFU-A colony. Upon the interaction of M IP-la with these increased levels of 
CCR1, it is proposed that this induces these cells to produce a repelling factor, e.g. 
SDF-1. This may therefore produce a high local concentration, which upon 
interaction with CXCR4 bearing cells (predominantly macrophages in CFU-A 
colonies), induces these cells to move away from this high local concentration. SDF- 
1 has been observed to chemoattract neutrophils, monocytes and T cells (Oberlin et al 
1996), and with the recent observation that SDF-1 can repel T cells it may be feasible 
that this repellent property may be seen with other SDF-1 receptor expressing cells. 
Therefore, it is possible that SDF-1 or some other repelling factor is involved in the 
movement of cells and thus may explain the appearance of the alternative colonies. 
Indeed, the highly stained central region may consist of cells that are CXCR4 negative 
and thus are not repelled, whereas the highly stained outer edge may consist of 
CXCR4 positive cells that have moved away from the high local concentration in the 
central area of the colony.
To test the above hypothesis, it would be prudent to design experiments to analyse the 
various roles that the suggested factors play in the formation of these alternative 
colonies. There are a number of experiments that can examine the individual roles of 
these factors. Indeed neutralising antibodies to SDF-1 could examine its possible role 
in the repulsion of the cells in these colonies. Alternatively, the basis for these 
colonies could be examined by investigating the CFU-A colony formation from the 
bone marrow of CCR1 null mice. These experiments would hopefully clarify the 
roles that CCR1 and SDF-1 play in the formation of these alternative colonies. 
Furthermore the role the constituent cells play in the formation of the alternatively 
shaped colonies may be examined by staining them with esterases to examine the 
localisation of the neutrophils and macrophages within these colonies.
10.3 The Effects of the Addition of gpl30 Cytokines to the CFU-A Assay
Glycoprotein 130 cytokines are not required for the formation of CFU-A colonies 
however upon the addition of IL-11 or IL-6 to a CFU-A assay, it was observed that 
both of these cytokines could reduce the formation of CFU-A colonies. Although IL-
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6 and IL-11 have never been reported to inhibit the formation of CFU-A colonies, or 
indeed the formation of any stem or progenitor colonies, it is possible that they can 
either inhibit the formation of CFU-A colonies directly or via the expression of an 
inhibitory molecule. Further analysis of the colonies grown in IL-6 and IL-11 
revealed that high levels of IL-11 and IL-6 both increased the number of granulocytes 
within the colonies, and also that high levels of IL-6 increased the number of blast 
cells within the CFU-A colonies (Table 7 and 8). This therefore suggested that the 
combination of the CFU-A growth factors and IL-6 or IL-11 altered the differentiation 
of CFU-A stem cells, thus producing smaller colonies. Interleukin-6 in combination 
with SCF has been observed to induce the formation of blast cell colonies, HPP-CFC 
colonies and CFU-GM colonies (Krcigler et al 1994, Sui et al 1995). Similar to IL-6, 
IL-11 can support granulocyte/macrophage colonies, and furthermore, the 
administration of IL-11 to mice has been observed to increase the numbers and 
cycling rate of CFU-GM and CFU-GEMM (Musashi et al 1991, Hangoc et al 1993).
As indicated in table 8, the addition of IL-6 to CFU-A assays increases the number of 
blast cells within the CFU-A colonies. It was hypothesised that these blast cells may 
be CFU-A stem cells, however, on the analysis of the replating potential of these blast 
cells it was observed that they do not produce secondary CFU-A colonies (data not 
shown). This indicated that although the high levels of IL-6 induced an increase in 
blast cells within the CFU-A colonies, they are not CFU-A stem cells and thus, further 
analysis is needed to identify these blast cells.
The addition of a further gpl30 signalling cytokine leukaemia inhibitory factor (LIF) 
to the CFU-A assay had no effect on colony numbers or M IP-la inhibition. This 
inability of LIF to affect CFU-A colony formation may be explained by the 
observation that short term repopulating cells, which contain CFU-A stem cells, do 
not have the ability to bind radiolabelled LIF, suggesting that these cells do not have 
LIF receptors (McKinstry et al 1997). A contradictory study by Imamura et al the 
observed that SCF and LIF expanded the number of transiently engrafting stem cells 
from bone marrow, suggesting that these cells did in fact express LIF receptors 
(Imamura et al 1996). However, it is possible that this increase in transiently 
engrafting stem cell amplification is due to the expansion of pre-CFU-A stem cells 
and not due to a direct amplification of the CFU-A stem cells themselves.
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10.3.1 The Effect of IL-11 and IL-6 on M IP-la Inhibition of CFU-A Colony 
Formation
Upon the inclusion of various concentrations of M IP-la to CFU-A assays containing 
IL-6, it was observed that M IP-la at 10 ng/ml, a concentration not normally 
associated with inhibition of CFU-A colony formation, could inhibit CFU-A colony 
formation in assays containing IL-6. It is possible that this is a direct inhibitory effect 
of M IP-la in these assays. However, a study by Fahey et al observed that 100 ng/ml 
of M IP-la induced the expression of 1 ng/ml of IL-6 from cultured macrophages after 
6 hours, therefore, indicating that it is entirely feasible that the further reduction in the 
colony formation is due to an additive effect of the exogenously added IL-6 and the 
endogenously induced IL-6 (Fahey et al 1992). Interestingly as mentioned earlier 
SCF has also been observed to induce IL-6 expression in bone marrow stroma 
therefore it is possible that, in combination with M IP-la, SCF also increases the 
production of IL-6 from the bone marrow cells (Rougier et al 1998). On analysis of 
the replating ability of CFU-A colonies grown in high
Further analysis is needed to examine whether the reduction in CFU-A colonies 
observed in assays containing IL-6 and M IP-la is through the induction of M IP-la 
by IL-6 or due to the induction of IL-6 by M IP-la. The analysis of the CFU-A 
colony forming potential of bone marrow from M IP-la and IL-6 null mice plated in 
assays containing IL-6 and/or M IP-la may clarify these observations. Alternatively, 
M IP-la neutralising antibodies would also clarify this matter.
10.4 Ex-vivo Expansion
As described in the sections above, CFU-A growth factors had no effect on M IP-la 
inhibition of CFU-A colonies. Therefore, in a further attempt to examine the effect of 
growth factors on the inhibition of proliferation by M IP-la an assay, unlike the CFU- 
A assay, which allows the differentiation of CFU-A stem cells into CFU-A colonies, 
was needed.
The ex-vivo expansion of stem cells is an assay system where cocktails of growth 
factors induce the expansion of various stem cell populations prior to transplantation.
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It was initially thought that this expansion was due to self-renewal of the various stem 
cell populations, however, expansion protocols invariably lead to an increase in 
mature cell numbers and a decrease in LTR ability, indicating that the increase in cell 
number is likely not to be via self-renewal of stem cells.
Numerous ex-vivo expansion studies have been performed using various combinations 
of growth factors. Indeed Bodine et al reported that various combinations of growth 
factors can induce the expansion of CFU-S stem cells in-vitro, and upon the addition 
of M IP-la, the increase in CFU-S numbers was reduced (Bodine et al 1991). 
Similarly, Holyoake et al also observed that the combination of growth factors, such 
as SCF and IL-11, could amplify the transiently engrafting stem cells (CFU-A) by 50 
fold. However, unlike the Bodine study, the addition of M IP-la to the expansion 
protocol did not decrease or further increase the CFU-A numbers (Holyoake et al 
1996).
In this thesis, SCF and IL-11 were observed to amplify the CFU-A numbers by 30 
fold and similar to the report by Holyoake et al, the addition of M IP-la to the 
expansion protocol did not reduce or increase this level of expansion (figure 9.1). The 
effect of M IP-la on the formation of CFU-A colonies from normal and expanded 
bone marrow was next examined. After 6 days of expansion in SCF and IL-11, the 
potential of M IP-la to inhibit the colony formation was assessed. Unlike the 80 % 
inhibition observed upon the addition of M IP-la to normal bone marrow, M IP-la 
could only reduce the CFU-A colony formation by 10-20% using expanded bone 
marrow. This indicated that the expansion of bone marrow with SCF and IL-11 was 
interfering with the inhibitory properties of M IP-la. To investigate if this effect was 
specific to M IP-la, the ability of TGF-p, a previously reported inhibitor of CFU-A 
colony formation (Maltman et al 1996), to inhibit CFU-A colony formation from 
expanded bone marrow was analysed. After a 6 day expansion of bone marrow with 
SCF and IL-11, TGF-p was observed to inhibit the formation of CFU-A colonies from 
the expanded bone marrow (figure 9.5) to a similar degree, as observed with normal 
bone marrow. This indicated that the expansion of the CFU-A stem cells by SCF and 
IL-11 somehow interfered with the inhibitory activity of M IP-la and this was 
proposed to be due to the down regulation of M IP-la receptors. Alternatively, SCF 
or IL-11, alone or together, may indirectly regulate the expression of chemokine
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receptors by inducing the expression of other cytokines that can reduce or down 
regulate the expression of the MEP-la receptors. Indeed TNF-a, IL-1, IFN, IL-10, 
IL-12 and IL-16 are a few of the cytokines that have been reported to regulate the 
expression of M IP-la receptors. As SCF can induce the expression of IL-1 and TNF- 
a, it is possible that the indirect action of SCF may result in the reduction in receptor 
levels.
Ex-vivo expansion protocols have been observed to increase the numbers of mature 
cells, therefore, prior to the examination of the expression of mRNA for the known 
M IP-la receptors CCR1, CCR3 and D6, a lineage depletion of both the expanded and 
non expanded cellular populations was performed. The inclusion of a lineage 
depletion step will produce a more comparable starting cellular population. 
Expression of messenger RNA for the known M IP-la receptors was examined and it 
was observed that CCR1 was up regulated whilst CCR3 and D6 were down regulated 
in the lineage depleted expanded bone marrow compared to the lineage depleted non 
expanded bone marrow. These results suggested that maybe CCR3 and D6 are 
involved in the inhibition of CFU-A stem cells (figure 9.7). However, unpublished 
data within our group using bone marrow from D6 null mice indicated that M IP-la 
can still inhibit the formation of CFU-A colonies, therefore suggesting that D6 is not 
involved in M IP-la inhibition of CFU-A colony formation. Data from figure 9.8 
indicates that a high excess of eotaxin cannot stop M IP-la inhibiting CFU-A colony 
formation thus demonstrating that CCR3 is unlikely the receptor involved in the 
inhibition of CFU-A stem cells (figure 9.8). Thus although CCR3 and D6 are all 
down regulated none of them account for the inhibitory activity of M IP-la thus 
further studies are needed to identify for this M IP-la inhibitory receptor. However to 
rule out CCR3 as the inhibitory receptor the analysis of bone marrow from CCR3 null 
mice in the CFU-A assay is needed.
10.5 Summary
M IP-la is a member of a group of pro-inflammatory molecules known as 
chemokines, the various members of which display a multitude of activities including 
development, angiogenesis and regulation of specific leukocyte trafficking (Streiter et 
al 1995, Sozzani et al 1997). Furthermore M IP-la has been observed to be involved
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in various inflammatory diseases such as EAE and asthma. However the main 
activity that this thesis is concerned with is M IP-la’s ability to inhibit the 
proliferation of the transient engrafting stem cells, namely the CFU-S and CFU-A 
stem cells. This is of particular interest as it has been estimated that in steady state 
conditions, it is likely that the majority of haemopoietic function is regulated at the 
level of the transiently engrafting stem cells with little input from the primitive long 
term repopulating cells. Therefore, it is likely that the transient engrafting stem cells, 
the target of M IP-la, may be more in need of regular growth control. Although this 
may be the case there is a lack of reports investigating how M IP-la exerts its 
inhibitory activity, therefore this thesis was undertaken to investigate if altering the 
CFU-A growth conditions would interfere with M IP-la inhibition of CFU-A colony 
formation, and thus allow us to infer modes of action of M IP-la.
In-vitro stem and progenitor assays by definition identify a particular stem or 
progenitor cell by the formation of mature cell colonies, however, there are aspects of 
these assays that are not fully understood. Within these assays it is not known what 
effect the varied cellular populations within the bone marrow play in the colony 
formation or indeed, the exact role of the various growth factors have in the formation 
of these colonies . All we know for certain is that the various stem/progenitor cells 
will differentiate into their respective colonies in assays conatining specific growth 
conditions.
The data presented in this thesis confirmed that CFU-A stem cells require SCF, M- 
CSF and GM-CSF to produce their characteristic colonies and that M IP-la inhibits 
the formation of these colonies. Furthermore the alteration of SCF, M-CSF and GM- 
CSF concentration and the addition of IL-11 or LIF to the assay had minimal effects 
on the inhibition of the CFU-A colony formation by M IP-la. Although the addition 
of IL-6 to the CFU-A assay seemed to increase the inhibitory activity of M IP-la , it is 
possible that this effect may be due to the altered differentiation of the CFU-A stem 
cells as suggested by the increase in neutrophils and blast cells, (table 8).
Although the alteration of growth factor concentration did not interfere with thre 
inhibitory activity of M IP-la, it did however interact with other M IP-la signalling 
pathways. Indeed high lebvels of SCF and M-CSF, in the presence of low levels of
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M IP-la were observed to produce an increase in CFU-A colony formation. 
Furthermore the combination of high levels of GM-CSF and 50ng/ml of M IP-la lead 
to the production of an alternatively shaped CFU-A colonies. These effects were 
hypothesised to be due to the interaction of M IP-la and one of its receptors CCR-1. 
Indeed, Broxmeyer et al observed that CCR-1 is involved in the growth of CFU-GM 
progenitors (Broxmeyer et al 1999), therefore it may also be involved in the increase 
in the CFU-A colony formatiom. Futhermore GM-CSF has been observed to increase 
the expression of CCR-1 on macrophages (Jarmin et al 1999), therefore the analysis 
of CCR-1 null mice bone marrow in these assays is needed to examine the role, if any, 
that CCR-1 plays in these observations.
There are other interesting observations that merit further investigartion, indeed, it 
was observed that upon the removal of either SCF, M-CSF or GM-CSF from the 
CFU-A assay that various sized colonies were formed. The clonal origin of these 
colonies is uncertain, however, in assays containing either no SCF or no M-CSF 
colonies that displayed similar size characteristics to CFU-A colonies were observed. 
It is entiorely feasible that these colonies are CFU-A colonies as Pragnell previously 
observed that M-CSF and GM-CSF are sufficient fir CFU-A colony formation 
(Pragnell et al 1994). Furthemore GM-CSF has been observed to induce M-CSF 
expression in bone marrow cells, it is feasible that this makes up for the omission of 
M-CSf and results in CFU-A colony formation (Horiguchi et al 1987).
One other area worthy of further investigation is the effect the expansion of bone 
marrow by SCF and IL-11 treatment has on the CFU-A stem cells. Indeed, ex-vivo 
expansion of bone marrow not only altered the chemokine receptor levels, it also 
aided the formation of the alternative colony shape and reduced the effectiveness of 
M IP-la at inhibiting CFU-A colony formation .
These results indicate that in the context of the CFU-A assay the M IP-la inhibitory 
signalling pathway is robust and may only minimally interact with the CFU-A growth 
factors, IL-11 or LIF signalling pathways. However data also suggests that a different 
M IP-la signalling pathway may interact with the tyrosine kinase signalling pathways, 
leading to an increase in CFU-A colony growth. Although growth factor signalling 
pathways in the CFU-A assays cannot interfere with M IP-la inhibitory signalling 
pathway that is not the case in ex-vivo expansion assays. This suggest that the
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interaction of the growth factors signalling pathways and M IP-la signalling 
pathways are dependent on the assay type and possibly the particular function the 
growth factors have in the particular assays. In altering the growth conditions of the 
CFU-A assay we have attempted to interfere with M IP-la inhibitory induced 
signalling, it is noted that these types of experiments may not be the best model to use 
However it is possible that they may aid to direct further analysis of signalling 
interactions via other methods such as proteomics.
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